COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE. FIELD OF THE INVENTION The present invention relates to compounds, compositions containing them, and their use for treating medical disorders where it is desirable to modulate the activity of hormone-sensitive lipase. BACKGROUND OF THE INVENTION The overall energy homeostasis of a mammalian system requires a high degree of regulation to ensure the availability of the appropriate substrate at the appropriate time. Plasma glucose levels rise during the post-prandial state, to return to pre-prandial levels within 2-3 hours. During these 2-3 hours, insulin promotes glucose uptake by skeletal muscle and adipose tissue and decreases the release of free fatty acids (FFA) from adipocytes, to ensure that the two substrates do not compete with each other. When plasma glucose levels fall, an elevation in plasma FFA is necessary to switch from glucose to fat utilization by the various tissues. In individuals with insulin resistance, FFA levels do not fall in response to insulin, as they do in normal individuals, preventing the normal utilization of glucose by skeletal muscle, adipose and liver. Furthermore, there is a negative correlation between insulin sensitivity and plasma FFA levels. Hormone-sensitive lipase (HSL) is an enzyme, expressed primarily in adipocytes, that catalyses the conversion of triglycerides to glycerol and fatty acids. It is through the regulation of this enzyme that the levels of circulating FFA are modulated. Insulin leads to the inactiva-tion of HSL with a subsequent fall in plasma FFA levels during the post-prandial state, followed by the activation of the enzyme when the insulin concentration falls and catecholamines rise during the post-absorptive period. The activation of HSL leads to an increase in plasma FFA, as they become the main source of energy during fasting. The activation inactivation of HSL is primarily mediated through the cAMP-protein kinase A and AMP-dependent kinase pathways. There are compounds like nicotinic acid and its derivatives, that decrease the activation of HSL via these pathways and cause a decrease in lipolysis that leads to a reduction in the FFA levels. These drugs have a beneficial effect in the utilization of glucose and in the normalization of the excess triglyceride synthesis seen in patients with elevated FFA. However, since these pathways are used by other processes in the body, these drugs have severe side effects. We have found compounds that specifically inhibit the lipolytic activity of HSL and lead to a decrease in plasma FFA levels. These compounds can be used to treat disorders where a decreased level of plasma FFA is desired, such as insulin resistance, syndrome X, dyslipi-demia, abnormalities of lipoprotein metabolism. One object of the present invention is to provide compounds and pharmaceutical compositions that inhibit the lipolytic activity of HSL. A further object is to provide compounds which have good pharmaceutical properties such as solubility, bioavailability etc. DEFINITIONS The following is a detailed definition of the terms used to describe the compounds of the invention. "Halogen" designates an atom selected from the group consisting of F, CI, Br and I. The term "C1-6-ralkyl" in the present context designates a saturated, branched or straight hydrocarbon group having from 1 to 6 carbon atoms. Representative examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, neopentyl, tert-pentyl, n-hexyl, isohexyl and the like. The term "C1-6-alkyl" in the present context designates a saturated, branched or straight hydrocarbon group having from 2 to 6 carbon atoms. Representative examples include, but are not limited to, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, n-hexyl, isohexyl and the like. The term "C1-6-alkoxy"in the present context designates a group -O-C1-6-alkyl wherein C1-6alkyl is as defined above. Representative examples include, but are not limited to, methoxy, eth-oxy, n-propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy,tert-butoxy, n-pentoxy, isopen-toxy, neopentoxy, terf-pentoxy, n-hexoxy, isohexoxy and the like. The term "C3-C6alkoxy" in the present context designates a group -O-C1-6-alkyl wherein C3-8-alkyl is a saturated, branched or straight hydrocarbon group having from 3-6 carbon atoms. Representative examples of C1-6-alkoxy include, but are not limited to, n-propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, isopentoxy, neopentoxy, tert-pentoxy, n-hexoxy, isohexoxy and the like. The term "C2-6-alkenyl" as used herein, represent an olefinically unsaturated branched or straight hydrocarbon group having from 2 to 6 carbon atoms and at least one double bond. Examples of such groups include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, allyl, iso-propenyl, 1,3-butadienyl, 1-butenyl, hexenyl, pentenyl and the like. The term "C1-6o-cycloalkyl" as used herein represents a saturated mono-, bi-, tri- or spirocar-bocyclic group having from 3 to 10 carbon atoms. Representative examples are cyclopropyl, cyclobutyl, cyclopentyl, cydohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, bicy-do[3.2.1]octyl, spiro[4.5]decyl, norpinyl, norbonyl, norcaryl, adamantyl and the like. The term "C1-6-heterocydyr as used herein represents a saturated 3 to 8 membered ring containing one or more heteroatoms selected from nitrogen, oxygen and sulfur. Representative examples are pyrrolidyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, aziridinyl, tetrahydrofuranyl and the like. The term "aryl" as used herein represents a carbocyclic aromatic ring system being either monocydic, bicyclic, or polycyclic, such as phenyl, biphenyl, naphthyl, anthracenyl, phenan-threnyl, fluorenyl, indenyl, pentaienyl, azulenyl, biphenylenyl and the like. Aryl is also intended to include the partially hydrogenated derivatives of the carbocyclic aromatic systems enumerated above. Non-iimiting examples of such partially hydrogenated derivatives are 1,2,3,4-tetrahydronaphthyl, 1,4-dihydronaphthyl and the like. The term "aryioxy" as used herein represents an aryl which is linked via an oxygen atom, e.g. phenoxy, 1-naphthyloxy, 2-naphthyloxy and the like. The term "heteroaryl" as used herein represents a heterocyclic aromatic ring system containing one or more heteroatoms selected from nitrogen, oxygen and sulfur such as furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, isoxazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyI, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyI, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyi, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyI, tetrazolyl, thiadiazinyl, indolyl, isoindolyl, benzofuranyi, benzothiophenyl (thianaphthenyl), indazolyl, benzimidazolyl, benzthiazolyl, ben-zisothiazolyl, benzoxazolyl, benzisaxazolyl, purinyl, quinazolinyl, quinolizinyl, quinolinyl, iso-quinolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, azepinyl, diazepinyl, acridinyl and the like. Heteroaryl is also intended to include the partially hydrogenated derivatives of the heterocyclic systems enumerated above. Non-limiting examples of such partially hydrogenated derivatives are 2,3-dihydrobenzofuranyl, 3,4-dihydroisoquinolinyl, pyrrolinyl, pyra-zolinyl, indolinyl, oxazolidinyl, oxazolinyl, oxazepinyl and the like. The term "perhalomethyl" as used herein designates a methyl moiety substituted with three halogen atoms. Non-limiting examples of perhalomethyl are CF3, CCI3,and CF2CI. The term "perhalomethoxy" as used herein designates a perhalomethyl linked via an oxygen atom, e.g. -0-CF3, -O-CCI3, and -0-CF2CI The term "ring system" as used herein includes aromatic as well as non-aromatic ring moieties, which may be monocyclic, bicyclic or polycyclic, and they encompass moieties with zero, one or more hetereatoms selected from nitrogen, oxygen and sulphur. Non-limiting examples of such ring systems are aryl, C3-6-heterocyclyl and heteroaryl. The term "heterocyclic system" as used herein includes aromatic as well as non-aromatic ring moieties, which may be monocyclic, bicyclic or polycyclic, and containing in their ring structure one or more heteroatoms selected from nitrogen, oxygen and sulfur. Non-limiting examples of such heterocyclic systems are C3-6-heterocyclyl and heteroaryl. Certain of the above defined terms may occur more than once in the structural formulae, and upon such occurrence each term shall be defined independently of the other. The term "optionally substituted" as used herein means that the groups in question are either unsubstituted or substituted with one or more of the substituents specified. When the groups in question are substituted with more than one substituentthe substituents may be the same or different. The term "optionally covalently bound" as used herein means that the substituents in question are either not covalently bound to each other or the substituents are directly connected to each other by a covalent bond. A non-limiting example of such optionally covalently bound substituents is -NR1R2 wherein R1 is ethyl and R2 is propyl which provided that the substituents, ethyl and propyl, are optionally covalently bound may be ethyl-propyl-amino, 1-piperidyl, 3-methyM-pyrrolidyI or2,3-dimethyI-1-azetidyl. The term "hydrolysable group" as used herein means a group which can be hydrolysed at certain chemical conditions, i.e. an internal covalent bond in the group can be cleaved to give two compounds. A hydrolysable group does not have to be hydrolysed during carrying out the present invention. For instance, the hydrolysable group -C(=X)-L. can be hydrolysed to give the products -C(=X)OH and HL, which means that the covalent bond between -C(X) and L is cleaved. Examples of hydrolysable groups are carbamates, esters and amides. The terms "disease", "condition" and "disorder" as used herein are used interchangeably to specifiy a state of a patient which is not the normal physiological state of man. The term "treatment" as used herein means the management and care of a patient having developed a disease, condition or disorder, as well as the management and care of an individual at risk of developing the disease, condition or disorder prior to the clinical onset of said disease, condition or disorder. The purpose of treatment is to combat the disease, condition or disorder, as well as to to combat the development of the disease, condition or disorder. Treatment includes the administration of the active compounds to prevent or delay the onset of the symptoms or complications and to eliminate or control the disease, condition or disorder as well as to alleviate the symptoms or complications associated with the disease, condition or disorder. The term "effective amount" as used herein means a dosage which is sufficient in order for the treatment of the patient to be effective compared with no treatment. The term "modulate" as used herein means to influence, i.e. to modulate a parameter means to influence that parameter in a desired way. Examples are to modulate insulin secretion from beta cells and to modulate the plasma level of free fatty acids. The term "medicament" as used herein means a pharmaceutical composition suitable for administration of the pharmaceutically active compound to a patient. The term " pharmaceutically acceptable" as used herein means suited for normal pharmaceutical applications, i.e. giving rise to no adverse events in patients etc. DESCRIPTION OF THE INVENTION The present invention relates to compounds of the general formula II wherein R1 is selected from Chalkyl, C2-C6-alkenyl and C3-10-cycloalkyl, each of which is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano and nitro; and R2 is selected from C2-C6-alkyl, C2-6-aIkenyl, aryl, heteroaryl, C2-C6-heterocyclyl and C3-10-cycloalkyl, each of which is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C2-C6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C2-C6-heterocyclyl and C3-1o-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C2-C6-alkyl, C2-5-alkenyl, aryl, heteroaryl, C3-6-heterocyclyl and C2-C6-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C2-C6-alkyl, C26-alkenyl, aryl, heteroaryl, C3-10heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C2-C6-alkyl, C2-C6alkenyl, aryl, heteroaryl, C2-C6-heterocydyl and C3-10cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C2-C6-alkyl, C2-C6-alkenyl, aryl, heteroaryl, C2-C6-heterocyclyl and C2-C6o-cycioalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C2-C6-alkyl, C2-6-alkenyI, aryl, heteroaryl, C2-C6-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Chalkyl, C2-6-alkenyl, aryl, heteroaryl, C1-6-heterocyciyl and C3. 10-cycloaIkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Chalkyl, C1-6-alkenyl, aryl, heteroaryl, C1-6-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C1-6-alkyl, C1-6-alkenyl, perhalomethyl and perhalomethoxy; and wherein R2 is optionally covalently bound to R1 by an ether, thioether, C-C or C-N bond, to form a ring system with the N-atom to which R1 and R2 are bound; and R3 is selected from hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, C2-6-aIkenyI, aryl, heteroaryl, C3. 8-heterocyclyl and C1-6o-cycloalkyl, each of which is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C1-6-alkyl, C2-C6-alkenyl, aryl, heteroaryl, C1-6-heterocyclyl and C3-1o-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, C2-C6-alkenyl, aryl, heteroaryl, C1-6-heterocyclyl and C3_1D-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C1-6-alkyl, C2-6-alkenyl, aryi, heteroaryl, C1-6-heterocyclyl and C1-6o-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3_8-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C1-6-alkyl, C1-6-alkenyl, aryl, heteroaryl, C3-8-h6terocyclyl and C3_1o-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-6-heterocyclyI and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C1-6-alkyl, C2-C6«alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C1-6o-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, C1-6-alkenyl, aryl, heteroaryl, C1-6-heterocyclyl and C1-6o-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C1-6-alkyl, C2-6-alkenyl, perhalomethyl and perhalomethoxy; and X is O or S; or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, mixture of stereoisomers including a racemic mixture, or polymorphs. In an aspect of the invention, compounds are of the general formula III wherein R1a and R28 are independently selected from C1-6-alkyl, C2-C6-alkenyl, aryl, heteroaryl, C1-6-heterocyclyl, and C1-1o-cycloalkyl, each of which is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C1-6-alkyl, C1-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyt, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6alkyl, C2-8-alkenyl, aryl, heteroaryl, C3-8 heterocyclyl and C1-6o-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano and nitro, C1-6 alkyl, C2_6-alkenyI, aryl, heteroaryl, C1-6-heterocyclyl and C1-6o-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Chalkyl, C2-C6-aIkenyl, aryl, heteroaryl, C1-6-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, perhalomethyl and perha-lomethoxy; and wherein R1a is optionally covalently bound to R2a by an ether, thioether, C-C or C-N bond, to form a ring system with the N-atom to which R1a and R23 are bound; and R4*, R53, R53 and R7a are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C1-6-alkyl, C2-C6-aIkenyI, aryl, heteroaryl, C1-6-heterocyclyl and C3-10-cycloalkyl, each of which is optionally substituted by one or more substituents selected from hydroxy, sulfanyl, sulfo, oxo, amino, cyano, nitro, C1_6-alkyl, C1-6-alkenyl, aryl, heteroaryl, C1-6-heterocyclyl and C1-6o-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C1-6-heterocyclyl and C1-6o-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, perhalomethyl and perhalomethoxy; and A1a is N or C-R8a; A23 is N or C-R9a; A3a is N or C-R10a; A48 is N or C-R11a; and A5a is N or O R12a; and wherein R8a, R9a, R10a, R11a and R12a are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C3-8-alkyl, Cu-alkenyl, aryl, heteroaryl, C3-8-heterocyctyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl,, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyc!yl and C3-10-cycloaIkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C3-8alkyl, C2-C8-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C3-8-alkyl, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10rcycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C3-8-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-8cpcycloatkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, perha-lomethyl and perhalomethoxy. In one embodiment, the invention is concerned with compounds of formula (III), wherein R2a is phenyl, optionally substituted by halogen or methyl. In! another embodiment, the invention in concerned with compounds of formula (III), wherein R1a is selected from methyl and ethyl, optionally substituted by one or more halogen. In another embodiment, the invention in concerned with compounds of formula (III), wherein R1a and R23 are covalently bound so as to form a ring system with the N-atom to which they are bound, wherein said ring system is a piperidine, piperazine, morpholine, or thiomor- pholine. In another embodiment, the invention in concerned with compounds of formula (III), wherein R4a, R53, R6a and R7a are independently selected from hydrogen, F, CI, C3-8-alkyl, C3-8-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perha- lomethyl. In another embodiment, the invention in concerned with compounds of formula (III), wherein A1a, A23, A3a, A43 and A53 are independently selected from N, CH, CF, C-Cl and C-CF3. In an aspect of the invention, compounds are of the general formula IV wherein R1b and R25 are independently selected from C3-8-alkyl, C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloaikyl, each of which may optionally be substituted with one or more substituents selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl,, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3_8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl andC3-10-cycloalkyi, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, Cn-e-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-aikyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocydyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy; wherein R1b is optionally covalently bound to R2" by an ether, thioether, C-C or ON bond, to form a ring system with the N-atom to which R1b and R2b are bound; R4t and R6b are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, suifo, C1-6-alkyl, C2-C6-alkenylI aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocycIyl and C3-10-cycloalkyis optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C2-C6-alkenyl, aryl, heteroaryl, C3-8rheterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, C1-6-alkyl, perhalomethyl and perhalomethoxy; R4b and R7b are independently selected from hydrogen, hydroxy, suifanyl, halogen, amino, cyano, nitro, sulfo, C3-8alkyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, suifanyl, amino, sulfo, C1-6-alkyI, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, suifanyl, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C2_6-alkenyI, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, suifanyl, sulfo, C1-6-alkyI, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, suifanyl, oxo, halogen, amino, cyano, nitro, C1-6-alkyI, perhalomethyl and perhalomethoxy; and wherein R8b, R9*, R10b, R11b and R12b are selected from hydrogen, hydroxy, suifanyl, halogen, amino, cyano, nitro, sulfo, C1-6-alkyI, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, suifanyl, amino, sulfo, C3-8-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, suifanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, suifanyl, amino, sulfo, C1-6-alkyl, C3-8alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, suifanyl, oxo, halogen, amino, cyano, nitro, C3-8-alkyl, perhalomethyl and perhalomethoxy; wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R4b, R5b, R6b, R7b, R8b, R9b, R10b, R11b and R12b. In one embodiment, the invention is concerned with compounds of formula IV, wherein Ra is phenyl, optionally substituted by halogen. In another embodiment, the invention is concerned with compounds of the general formula IV, wherein Rlb is selected from methyl and ethyl, optionally substituted by one or more halogen. In another embodiment, the invention is concerned with compounds of the general formula IV, wherein R1b and R2b are covalently bound so as to form a ring system with the N-atorn to which they are bound, wherein the ring system is a piperidine, piperazine, morpholine, or thiomorpholine. In another embodiment, the invention is concerned with compounds of the general formula IV, wherein R4b, R56, R6b and R7* are independently selected from hydrogen, F, CI, C3-8-alkyl, C1-6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)-rOH, hydroxy, amino and perhalomethyl. In another embodiment, the invention is concerned with compounds of the general formula IV, wherein A1b, Aa, A3", A46 and A5b are independently selected from N, CH and CF. In an aspect of the invention, compounds are of the general formula V wherein R40, R5c, R60, R7c and Rte are independently selected from hydrogen, hydroxy, sul-fanyl, amino, halogen, cyano, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, C1-6-alkyl. C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyi, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8rheterocyclyi and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyI, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perha-lomethoxy; and R9c, R10c, R11ct R12c and R13c are independently selected from hydrogen, sulfanyl, amino, halogen, cyano, nitro, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloaikyl, wherein each of sulfanyl, amino, sulfo, C3-8-alkyl,, C1-6-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalky), C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyi may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl. C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl- C1-6alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycioalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3_10-cycloalkyl, perhalomethyl and perha-lomethoxy; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R40, R5c, R6c, R7c and R30; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9c, R10c, R11c, R12c and R13c; and at least one of R40, R5c, R60, R7c, R8cf R9c, R10c, R11c, R12c and R13c are different from hydrogen. In one embodiment, the invention is concerned with compounds of formula V, wherein R90, R10c, R11c, R12c and R13c are selected from H and F. In another embodiment, the invention is concerned with compounds of the general formula V, wherein R40, R5c, R6c, R7c and R4tc are independently selected from hydrogen, F, CI, C1-6-alkyl, C1-6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0);rNH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. In another embodiment, the invention is concerned with compounds of the general formula V, where there are no covalent bonds between any of the substituents R9c, R10c, R11c, R12c and R13c. In another embodiment, the invention is concerned with compounds of the general formula V, where there are no covalent bonds between any of the substituents R40, R5c, R6c, R7c and R8c. In an aspect of the invention, compounds are of the general formula VI wherein R4* and R5d are independently selected from hydrogen, hydroxy, suifanyl, amino, C2. 8-alkyl, C1-6-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, suifanyl, amino, C2-6-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, suifanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, suifanyl, amino, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, suifanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-8crcycloalkyl, wherein each of the hydroxy, suifanyl, amino, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, suifanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkylf C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycIoalkyl, perhalomethyl and perhalomethoxy: and R6d, R7d, R4t1, R9*, R10d, R11d, R12d, R13d and R14d are independently selected from hydrogen, hydroxy, suifanyl, halogen, amino, cyano, nitro, sulfo, C2-C8-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyI, wherein each of hydroxy, suifanyl, amino, suifo, C1-6-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10- cycioalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-6-aIkenyI, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C1-6-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-8i0-cycloalky( may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C1-6-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocycfyl and C3-10-cycioalkyi may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8alkyl, C1-6-alkoxy, C2-C8-aIkenyl, aryl, heteroaryl, C3-8-heterocycIyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R4*, R5*, R4t. R7d, Red and R9d; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R10d, Rl1d, R12d, R13d and R14d. In one embodiment, the invention is concerned with compounds of the general formula VI, wherein R4t6 and R5d are H. In another embodiment, the invention is concerned with compounds of the general formula VI, wherein R6d, R7d, Rad and R9are selected from the group consisting of hydrogen, F, CI, Chalkyl, d-6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2s -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. In another embodiment, the invention is concerned with compounds of the general formula VI, wherein R10d, R11d, R12d, R13d and R14d are selected from the group consisting of hydrogen, F, CI, C3-8-alkyl, C3-8-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2l -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. In another embodiment, the invention is concerned with compounds of the general formula VI, wherein there are no covalent bonds between any of the substituents R4δH R5d, Red, R7d, RM and R9d. In another embodiment, the invention is concerned with compounds of the general formula VI, wherein there are no covalent bonds between any of the substituents R10d, R11d, R12df R13d and R14d. wherein R46 is selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, Chalky), C1-6-alkoxy, C2-C8-alkeny!, aryl, heteroaryl, C3-10rheterocyclyl and C3-10-cycloalkyl, wherein each of C2-C8-alkyl, C2_6-alkenyI, aryl, heteroaryl, C3-10-heterocyclyl and C3-10-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo,C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyl, perha-lomethyl and perhalomethoxy: and R5e is selected from hydrogen, F, cyano, C3-8-alkyl, C3-8-alkoxy, C2-C6-aikenyi, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of C1-6-alkyl, C3-8-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3_10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8heterocyclyl, and Cs-to-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C3-8-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3_8-heterocyclyl, and C3-8urcycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl,, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may op- tionally be substituted with one or more substituents independently selected from hydroxy, suffanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8-alkoxy, C3-8-alkenyi, aryl, heteroaryl, C3-8-heterocyclyl, C3-8a-cycloalkyl, perhalomethyl and perhalomethoxy; wherein R46 and R56 may be covalently bound to each other by a C-0 bond. In one embodiment, the invention is concerned with compounds of the general formula VII, wherein R46 or R56 is selected from the group consisting of wherein R66, R7e, R88, R9e and R10e are independently selected from hydrogen, hydroxy, sul-fanyi, sulfo, halogen, amino, cyano, nitro, C3-8alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyciyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, C1-6-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8-alkoxy, C2-C6-alkenyl, .. aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C3-8-alkyl, C3-8-alkoxy, C2-C6-aikenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycioalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C1-6-alkoxy, C3-8alkenyl. In another embodiment, the invention is concerned with compounds of the general formula VII, wherein R46 or R5e is selected from the group consisting of wherein R66, R7e, R88, R98 and R108 are independently selected from hydrogen, hydroxy, suifanyl, sulfo, halogen, amino, cyano, nitro, C3-8-alkyl, C3-8-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, suifanyl, sulfo, amino, C3-8 alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocydyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, suifanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, suifanyl, sulfo, amino, Chalkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, suifanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyI, C1-6-alkoxy and C2-C8-aIkenyl. In another embodiment the invention is concerned with compounds of the general formula VII, wherein at least one of the substituents R6e, R7e, R8e, R9e and R10e are selected from the group consisting of F and perhalomethyl. In another embodiment, the invention is concerned with compounds of the general formula VII, wherein R48 and R5e are connected by a C-0 bond to form the compound . wherein R11e is selected from hydrogen, hydroxy, suifanyl, amino, sulfo, C1-6-alkyl, C3-8-alkoxy, C1-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, suifanyl, amino, sulfo, C1-6-alkylt C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, CM-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, suifanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and dMo-cycloalkyl, wherein each of the hydroxy, suifanyl, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C1-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, suifanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8j-heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, suifanyl, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6- alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C3-8alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloaikyl, perhalomethyl and perhalomethoxy; and R12e is selected from hydrogen, F, CI, C1-6-alkyl, C1-6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2l -NH-S(=0)2rOH, hydroxy, amino and perhalomethyl. wherein R4f, Rm, R6*, R7f, Rw and R10f are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, d-6-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10 cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8rheterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6 alkyl, Ci.6-alkoxy, C2„6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, Cn-e-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: with the proviso that R4f and R5f are not both methoxy, and Rw is selected from hydrogen, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8 heterocyclyl and C3-10-cycloalkyl, wherein each of sulfo, C3-8alkyl, C3-8-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8heterocyclyl and C3-iQ-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkylf C3-8alkoxy, C2-C8-alkenyl, aryl, heteroaryl, Cwrheterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and Ca.io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1_6-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycioalkyl, perhalomethyl and perhalomethoxy; wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R4tf R5*, R6f, R7f and Rw; and wherein there may optionally be a covalent bond between R9* and R10f. In one embodiment, the invention is concerned with compounds of the general formula VIII, wherein R9f and R10f are covalently bound so as to form a ring system with the C-atom to which they are bound. In another embodiment, the invention is concerned with compounds of the general formula VIII, wherein said ring system is a cycloalkyl, phenyl, heteroaryl, piperidine, piperazine, mor- pholine, orthiomorpholine. In another embodiment, the invention is concerned with compounds of the general formula VIM, wherein R4f and Rw are connected by a C-O bond to form the compound wherein R11f is selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloaIkyI, wherein each of hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C3-8-alkoxy, C3-8-alkenyl, aryl, het- eroaryl, C3-8-heterocyclyl and C3-10-cycloalkyi may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyi, oxo, halogen, amino, cyano, nitro, sulfo, C3-8alkyl, C3-8alkoxy, C2-6-alkenyI, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, perhalomethyl and perhalomethoxy; and R17f is selected from hydrogen, F, CI, C3-8-alkyl, 1-6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)rNH2, -NH-S(=0)rOH, hydroxy, amino and perhalomethyl; and wherein there may optionally be a covalent bond between R9f and R10f. In an aspect of the Invention, compounds are of the general formula IX wherein R49, R59, R69, R79, Rag, R", R109 and R11g are independently selected from hydrogen, hydroxy, sulfanyi, halogen, amino, cyano, nitro, C3-8-alkyl, C1-6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of Chalkyl, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3_10-cycloalkyl may optionally be substituted with one or more substituents independent/y selected from hydroxy, sulfanyi, oxo, halogen, amino, cyano, nitro, sulfo, Chalkyl, C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyi, amino, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyi, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-1D-cycloalkyl, wherein each of the hydroxy, sulfanyi, amino, sulfo, C3-8-alkyl, C1-6-alkoxy, C3-8-alkenyl, aryl. heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyi, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocydyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: and R129 is selected from the group consisting of-C(=0=, -C(=0)NH-, -CHr, -CH2CH2-, -CHR15fl-, -CH2CHR159-, -CHR159-CH2-, -NH-, -NR159-, -NHC(O)-, -NR159-C(=0)-, -0-, -S-, -S(=OK -S(=0)r; wherein R159 is selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, ni-tro, C1-6-alkyl, C3-8-alkoxy, C2-C6alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl. wherein each of hydroxy, suffanyf, suffo, amino, C1-6-alkyl, C1-6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocydyl and Cs.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, CWalkyl, C3-8-alkoxy, C2-C6-alkenyl, perhalomethyl and perhalomethoxy, and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R49, R5g, R60, R79 and R15g; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R8g, R", R109f R11fl and R15g; and R13fl is selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, C3-8-alkyl, Ci_ 6-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-8Krcycloalkyl, wherein each of C3-8-alkyl, C2-8aJkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C2_6-alkenyi, aryl, heteroaryl, C3-8-heterocyclylr and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1. 6-aIkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8rheterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8afkyl, C1-6-alkoxy, C2-C6«alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-10-heterocydyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: and R14fl is selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, C2-6-alkyl, d-s-alkoxy, C3-8alkenyl, aryl, heteroaryl, heterocyclyl and C3-10-cycloalkyl, wherein each of C2-C8-alkyl. C2-C6-alkenyl, aryl, heteroaryl, C1-6-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C2_8-alkenyl, aryl, heteroaryl, C3-8heterocyciyi, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, d-6-alkoxy, C1-6alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, d-r-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C1-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyI, perhalomethyl and perha-lomethoxy: and wherein R13g and R14g may optionally be covalently bound to each other. in one embodiment, the invention is concerned with compounds of the general formula IX, wherein R139 and R149 are covalently bound so as to form a ring system with the N-atom to which they are bound. In another embodiment, the invention is concerned with compounds of the general formula IX, wherein said ring system is a piperidine, piperazine, morpholine, orthiomorpholine. In another embodiment, the invention is concerned with compounds of the general formula IX, wherein there are no covalent bonds between any of the substituents R4°, R5g, R6g, R?B and R15g. In another embodiment, the invention is concerned with compounds of the general formula IX, wherein there are no covalent bonds between any of the substituents R89, R99, R109, R11g and R159. In another embodiment, the invention is concerned with compounds of the general formula IX, wherein R49, R59, R6g, R7g, R8g, R", R109, R11g are selected from the group consisting of hydrogen, F, CI, C1-6-alkyl, C1-6-alkoxy, -C(=0)NH2l -NHC(=0)-OH, -S(=0)rNH2, -NH-S(=0)2- OH, hydroxy, amino and perhalomethyl. In an aspect of the invention, compounds are of the general formula X wherein R4h and R5th are independently selected from cyano, C3-8-alkyl, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of C1-6-alkyl, C2-C6-aikenyl, aryl, heteroaryl, C3-8-heterocyclyl and Cs.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and 03.10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-C6~alkenyl, aryl, heteroaryl, C3-s-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyI, C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: and R6h, R7h, Rah, R9*, R10h, R12h, R14h and R15h are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, C3-8-alkyl, C3-8-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and (Vio-cycloalkyl. wherein each of C3-8-alkyl, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo,.halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkylf C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocydyl and C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: and R11h and R13h are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, perhalomethyl, perhalomethoxy, C3-8-alkyl, methoxy, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of sulfanyl, amino, C2-C6-alkyl, C1-6-alkoxy, C3-8e-alkenyl, aryl, heteroaryl, Cwheterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-C6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl, andC3-10-cycloalkyl- wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R4h, R4t. R6h, R™ R8h, R9h; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R10h, R11h, R12h, R13h, R14h and R15h. In.one embodiment, the invention is concerned with compounds of the general formula X, wherein R6h, R7*, R8h, R9h, R10h, R12h and R14h are selected from the group consisting of hydrogen, F, CI, C1-6-alkyl, C3-8alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. In another embodiment, the invention is concerned with compounds of the general formula X, wherein there are no covalent bonds between R4h, R5h, R6h, R7*1, R8h and R9h. In another embodiment, the invention is concerned with compounds of the general formula X, wherein there are no covalent bonds between R10h, R11h, R12h, R13h, R14h and R15h. In another embodiment, the invention is concerned with compounds of the general formula X, wherein R15h is hydrogen. In another embodiment, the invention is concerned with compounds of the general formula X, wherein R11h and R13h are selected from the group consisting of hydrogen, F, CI, C2-C6-aIkyl, methoxy, C3-8-alkoxy, -NHC(=0-OHI -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. In an aspect of the invention, compounds are of the general formula XI Rs is selected from hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C3-8-alkyl, C1-6-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyciyl and C3-10-cycloalkyl, wherein each of C1-6-alkyl, C3-8-alkoxy, C2-C6alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8rheterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl,, C3-8-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocydyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: and R51, R71, R4t, R9i, R10i, R14i and R15 are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C3-8-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyi and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C3-8-alkyli C1-6-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may op- tionally be substituted with one or more substituents independently selected from hydroxy, sulfanyi, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C3-8alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyi, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C1-6-alkenyl, aryl, heteroaryl, C3-8-heterocycfyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyi, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C6alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3_10-cycloalky[, perhalomethyl and pertia-lomethoxy: and R111 and R13i are independently selected from hydrogen, hydroxy, sulfanyi, sulfo, halogen, amino, cyano, nitro, C3-8-allcyl, methoxy, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of sulfanyi, sulfo, C3-8-alkyl, C3-8alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyi, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-ic-cycloalkyI, wherein each of the hydroxy, sulfanyi, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2_6-aIkenyl, aryl, heteroaryl, C3-rheterocydyI, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyi, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C3-8-alkenyl, aryl, . heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: and R12 is selected from hydrogen, hydroxy, sulfanyi, sulfo, halogen, amino, cyano, nitro, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyi, sulfo, amino, C1-6-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyi, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyi, amino, sulfo, C1-6-alkyl, C3-8-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyi, oxo, F, amino, cyano, nitro, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, perhalomethyl and perhalomethoxy. In one embodiment, the invention is concerned with compounds of the general formula XI, wherein R61, Rr', R81 and R9i are selected from the group consisting of hydrogen, F, CI,C1-6- alkyl,. C3-8alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2l -NH-S(=0)2-OH, hydraxy, amino and perhalomethyi. In another embodiment, tine invention is concerned with compounds of the general formula XI, wherein R10i, R11i, R12, R13i and R14i are selected from the group consisting of hydrogen, F, CI, C1-6-alkyl, C3-8-alkoxy, -C(=0)NH2- -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0);rOH, hydroxy, amino and perhalomethyi. In another embodiment, the invention is concerned with compounds of the general formula XI, wherein R1S is hydrogen. In another embodiment, the invention is concerned with compounds of the general formula XI, wherein R10i, R11i, R12i( R1*, R141 and R15i are selected from the group consisting of H, F and methyl. wherein R4*, Rg, R6j, R7*, R8j, R4t1 and R10j are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C1-6-alkyl, C1-6-alkoxy, C3-8-alkenyl, aryl, het-eroaryl, C3-8-heterocyclyl and C3-10ncycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C3-8-alkyl, C3-8-alkoxy, C3-8-aikenyl, aryl, heteroaryl, C-3-8a-rheterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-6-alkenylf aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocydyl, and C3.io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl. C1-6-alkoxy, C3-8alkenyi, aryl, heteroaryl, C3-8-heterocyclyl and C3-10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalkyl, C3-8-alkoxy, C3-8-alkeny!, aryl, heteroaryl, C3-8-heterocyciyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, ni- tro, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: and wherein there may optionally be a covalent bond between the substituents R6J and R71; and wherein there may optionally be a covalent bond between R5 and R8i; and R11iand R12J are independently selected from cyano, C3-8-alkyl, C3-8alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of C1-6-alkyl, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl andC3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C3-8-alkoxy, C2-B-alkenyl, aryl, heteroaryl, pδH-heterocyclyl, and C3-10-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyI, C3-8alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, perhalomethyl and perhalomethoxy; and with the proviso that R9j and R10i are both hydrogen, there may optionally be a covalent bond connecting R11jand R12i. In one embodiment, the invention is concerned with compounds of the general formula XII, wherein Ffi, Rg, R6j and R71 are selected from the group consisting of hydrogen, F, CI, C3-8-alkyl, C3-8-alkoxy, -C(=0)NH2l -NHC(=0)-OH, -S(=0)rNH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. In another embodiment, the invention is concerned with compounds of the genera! formula XII, wherein at least one of the substituents R4i, R5j, R6j and R71 are different from hydrogen. In another embodiment the invention is concerned with compounds of the general formula XII, wherein R8i is covalently bound to R5. In an aspect of the invention, compounds are of the general formula XIII wherein R4k is selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C3-8-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6alkyl, C1-6-alkoxy, C2-6-aIkenyl, aryl, heteroaryl, C3-8heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8alkoxy, C2-6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyc!yl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-to-cycloalkyl, perhaiomethyl and perhalomethoxy: and R5kis selected from hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C3-8-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocydyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C3-8-alkyl, C3-8-alkoxy, C3-8alkenyl, aryl, heteroaryl, C3-8-heterocycly! andC3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8-alkoxy, C2-C6-alkenyI, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C3-8alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyciyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-10- heterocydyl and CsMo-cycloalkyl, perhalomethyl and perhalomethoxy: with the proviso that when R4* is hydrogen, then R5kis not C(=0)N(Me)2; and R4t R7", R8q, R9kf R10k, R11k, R13k and R14k are independently selected from hydrogen, hydroxy, suifanyl, sulfo, halogen, amino, cyano, nitre, C3-8alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryi, C3-8rheterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, suifanyl, sulfo, amino, C1-6-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryi, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, suifanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalkyl, C1-6-alkoxy, C2-C8-alkenyl, aryl, heteroaryi, C1-6-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, suifanyl, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C3-8-alkenyl, aryl, heteroaryi, C3-8-heterocyclyl, and C3-10-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, suifanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryi, C3-8-heterocyclyl and C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: and R12k is selected from hydrogen, hydroxy, suifanyl, sulfo, halogen, cyano, nitro, C3-8-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryi, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, suifanyl, sulfo, amino, C1-6-alkyl, C1-6-alkoxy, C3-8-alkenyl, aryl, heteroaryi, C1-6-heterocyclyl and d-10-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, suifanyl, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryi, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, suifanyl, amino, sutfo, C3-8-alkyl, C1-6-alkoxy, C2-C6*alkenyl, aryl, heteroaryi, C3-s-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, suifanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci.6-alkyl, C1-6-alkoxy, C1-6-alkenyl, aryl, heteroaryi, C1-6-heterocyclyl and C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: and wherein there may optionally be a covalent bond between any of the substituents selected from the group consisting of R4k, R5k, R7" and R8k; and wherein there may optionally be a covalent bond between R5kand any one of the substituents R7* and R8k; and wherein there may optionally be one or more covalent bonds between R10\ R11k, R12k, R13k and R14k. In one embodiment, the invention is concerned with compounds of the general formula XIII, wherein the substituents R4** and R5k are connected by a covalent bond. In another embodiment, the invention is concerned with compounds of the general formula XIII, wherein the substituents R5kand R8k are connected by a covalent bond. In another embodiment, the invention is concerned with compounds of the general formula XIII, wherein the substituents R10k and R11k are connected by a covalent bond. In another embodiment, the invention is concerned with compounds of the general formula XIII, wherein the substituents R12k and R13k are connected by a covalent bond. In another embodiment, the invention is concerned with compounds of the general formula XIII, wherein R6k, R™, R8k and R5kkare selected from the group consisting of hydrogen, F, CI, hydroxy, amino, methyl, methoxy, ethoxy and perhalomethyl. In another embodiment, the invention is concerned with compounds of the general formula XIII, wherein R10k, R11\ R12k, R13k and R14k are selected from the group consisting of hydro- gen, F, CI, C3-8-alkyl,, C3-8-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. wherein R1 is Ci.e-alkylF C2-C6-alkenyl or C3-10-cycloalkyl, each of which is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano and nitro; and R2 is C1-6-alkyl, C3-8-alkenyl, arylf heteroaryl, C3-8-heterocyclyl, or C3-10-cycloalkyl, each of which is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, C3-8-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3. 10-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, C1-6-alkyl, C2-C6- alkenyl, aryl, heteroaryl, C3-8-heterocydyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, C1-6alkyl, C3-8alkenyl, aryl, heteroaryl, C3-s-heterocyclyi and C3-10-cycloalkyi, wherein each of hydroxy, sulfanyl, amino, Chalkyl, C2-C6-alkenyl, aryi, heteroaryl, C3-8-heterocyclyl and C3-810-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, perha-lomethyl and perhaiomethoxy; with the proviso that when R1 and R2 are identical they are not methyl or benzyl; and R2 is optionally covalently bound to R1 by an ether, thioether or C-C bond, to form a ring system with the N-atom to which R1 and R2 are bound; and R9, RQ!, R8!, R9(, R10' and R11] are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C3-8-alkyl, C1-6-alkoxy, C2-6-aIkeny!, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, Cve-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-10-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cswrheterocyclyi, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, suifo,C1. 8-aikyl, C1-6-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, perhalomethyl and perhaiomethoxy: and R41 and R71 are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C3-8-alkyl, methoxy, C3-6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C34-heterocyclyl and C3-10-cycloalkyl, wherein each of sulfanyl, sulfo, amino, C3-8-alkyl, C3-alkoxy, C2-C6-aikenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8alkoxy, C2-ralkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8rheterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8alkyl, C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocydyl and C3-10-cycloalkyl, perhalomethyl and perhaiomethoxy: and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R41, Ra, R61, R71, Rai, R91, R101 and R111. In one embodiment, the invention is concerned with compounds of the general formula XIV, wherein R1 and R2 are covalently bound so as to form a ring system with the N-atom to which they are bound. In another embodiment, the invention is concerned with compounds of the general formula XIV, wherein said ring system is a piperidine, piperazine, morpholine, or thiomorpholine. In another embodiment, the invention is concerned with compounds of the general formula XIV, wherein there are no covalent bonds between R1 and R2. In another embodiment, the invention is concerned with compounds of the general formula XIV, wherein there are no covalent bonds between R8' and any of the substituents selected from the group consisting of R9i, R101, R111. In another embodiment, the invention is concerned with compounds of the general formula XIV, wherein there are no covalent bonds between R81 and any of the substituents selected from the group consisting of R4!, R51, R61 and R71. In another embodiment, the invention is concerned with compounds of the general formula XIV, wherein there are no covalent bonds between any of the substituents R41, R51, R61, R71, R81, R91, R101 and R111. In another embodiment, the invention is concerned with compounds of the general formula XIV, wherein R4', R51, R61 and R7i are selected from the group consisting of hydrogen, F, CI, C3-8-alkyl, C3-8-alkoxy, -C(=0)NH2f -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. In an aspect of the invention, compounds are of the general formula XV wherein R4"1 is selected from hydrogen, sulfo, C3-8-alkyl, C2-C6-alkenyII aryl, heteroaryl, C3-8-heterocydyl and C3-10-cycloalkyl, wherein each of sulfo, C3-8-alkyl, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, ni-tro, sulfo, C3-8-alkyl, C3-8-alkoxy, C3-8-afkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-C8-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from 'hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalkyl, C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cs-a-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C8-alkenyir aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perha-lomethoxy: and R5m, R6m, R7m, R8m, R9"1, R10m, R11m, R12m, R13m, R14m, R15mand R16m are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C3-8-alkyl, C1-6-alkoxy, C2-C6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyI and C3-10-cycloaIkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl,, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyI, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalkyl, C1-6-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo,C1-6-alkyl,C1-6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of RAm, R5™, R6m, R7m and R8m; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9"1, R10m, R11m, R12m, R13m, R14m, R15mand R16m. In one embodiment, the invention is concerned with compounds of the general formula XV, wherein there are no covalent bonds between any of the substituents selected from the group consisting of R5*, R6ro, R7m and R8m. In another embodiment the invention is concerned with compounds of the general formula XV, wherein there are no covalent bonds between any of the substituents R9m, R10m, R11m, R12m and R13m. In another embodiment, the invention is concerned with compounds of the general formula XV, wherein there are no covalent bonds between any of the substituents R14m, R15mand R16m. In another embodiment, the invention is concerned with compounds of the general formula XV, wherein R4m is covalently bound to R6m. In another embodiment, the invention is concerned with compounds of the general formula XV, wherein R5m, RBm, R7m, R8m, R9"1, R10m, R11m, R12m, R13m and R14mare selected from the group consisting of hydrogen, F, CI, C3-8-alkyl, C1-6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, - S(=0);rNH2l -NH-S(=0)rOH, hydroxy, amino and perhalomethyl. In another embodiment, the invention is concerned with compounds of the general formula XV, wherein R14m, R15m and R16m are selected from the group consisting of hydrogen, F, CI, C3-8-alkyt, C1-6-alkoxy, -C(=0)NH2, -NHC(=OK-H, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. In an aspect of the invention, compounds are of the general formula XVI wherein R4" is selected from hydrogen, sulfo, C2-C8-alkyl, C1-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of sulfo, C2-C6-alkyIt C3-8alkenyl, aryl, heteroaryl, Csn-heterocyclyl and C3.io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, C-14-alkyl, C3-8-alkoxy, C2_6-alkenyI, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-C6alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3_10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C1-6-alkoxy, C3-8alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-crcycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C3-8alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C6-aIkenyl, aryl, heteroaryl, C3-8-hetero-cyclyl, C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10"cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyI, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy; and Z is selected from S, S(=0) and S(=0)2; and R5n, R6", R7n, R8n, R9n, R10n, R11n, R12n, R13n and R14n are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C3-8-alkyl, C1-6-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C3-8-alkyl, C3-8-alkoxy, C3-8alkenyl, aryl, heteroaryl, C3-8-heterocydyl and C3-icrcycloa!kyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfa, Ct_6-alkyl, C1-6 alkoxy, C2-C6-alkenylr aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8-alkoxy, C2-6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, perha-lomethyl and perhalomethoxy: and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R4", R5n, R6n, R7n and R8nf; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R10n, R11n, R12n and R14n; and at least one of the substituents R5n, R6n, R7n, R8n, R9n, R10n, R11n, R12n, R13n and RUn are different from hydrogen. In one embodiment, the invention is concerned with compounds of the general formula XVI, wherein there are no covalent bonds between any of the substituents R5n, R6n, R7n and R8n. In another embodiment, the invention is concerned with compounds of the general formula XVI, wherein there are no covalent bonds between any of the substituents R10n, R11n, R12n. In another embodiment, the invention is concerned with compounds of the general formula XVI, wherein R14nis not covalently bound to any other substituent selected from the group consisting of R4n, R5n, R6n,. R7n, R8n, R10n, R11n, R12n. In another embodiment, the invention is concerned with compounds of the general formula XVI, wherein R4n is covalently bound to R6n. In another embodiment, the invention is concerned with compounds of the general formula XVI, wherein R5n, RBn, R7n and R8" are independently selected from the group consisting of hydrogen, F, CI, C3-8alkyl, C3-8-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)rNH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. In another embodiment, the invention is concerned with compounds of the general formula XVI, wherein R14nis selected from the group consisting of hydrogen, F, CI, C3-8-alkyl, d-c-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)rOH, hydroxy, amino and perhalomethyl. wherein R20 is selected from sutfo, C1-6-alkyl, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyt and C3-10-cycloalkyl, each of which may optionally be substituted with one or more substitu-ents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3.io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-s-heterocyclylf and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1_6-alkyl, C1-6«alkoxy, C2-C8-alkenyI, aryl, heteroaryl, C3-8-heterocyclyl, C3. icrcycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3_10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8-alkoxy, C2_6-aikenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C3-8-alkoxy, G2δHalkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalkyl, C1-6alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhaiomethoxy; with the proviso that R20 is not methyl; and R40, R5D, R60 and R70 are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C3-8-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8r heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3 8-alkyl, C3-8alkoxy, C2-C6alkenylt,aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: and A10 is N or C-R60; A20 is N or OR90; A30 is N or C-R100; A40 is N or C-R110; and A50 is N or C-R12°; and wherein R8°, R90, R100, R110 and R120 are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C2-C8-alkenyl, aryl, heteroaryl, C3-8r heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, G2-e-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C2-C6-alkenyl, aryl, heteroaryl, C3_B-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl,, C2-6-alkenyI, aryl, heteroaryl, C3-8-heterocydyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, C3-8-alkyl, perhalomethyl and perhalomethoxy; with the proviso that when A10, A20, A3°, A40 and A50 are all CH, and R40, R50, R60 and R7D are all hydrogen, then R20 is not phenyl; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R40, R5°, R60, R70, R80, R90, R10D, R110 and R120 In one embodiment, the invention is concerned with compounds of the general formula XVII, wherein there are no covalent bonds between any of the substituents R40, R50, R60 and R7°. In another embodiment, the invention is concerned with compounds of the general formula XVII, wherein there are no covalent bonds between any of the substituents A10, A20, A30, A40 and A50. In another embodiment, the invention is concerned with compounds of the general formula XVII, wherein R5kis selected from the group consisting of cycloalkyl, phenyl, piperidine, piperazine, morpholine, thiomorpholine and heteroaryl. In another embodiment, the invention is concerned with compounds of the general formula XVII, wherein R40, R50, R8° and R70 are independently selected from the group consisting of hydrogen, F, CI, C3-8-alkyl, C3-8-afkoxy, -C(=0)NH2) -NIHC(=0)-OH, -S(=0}2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. In an aspect of the invention, compounds are of the general formula XVIII (XVII I) wherein R4p is selected from hydrogen, sulfo, C2-C8-alkyl, C2-C6-alkenyI, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of sulfo, C2-C6-alkyl, C2-C6a!kenyl, aryl, heteroaryl, C3-8heterocyclyl andC3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, C1-6-alkyI, C1-6-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8rheterocyclyl, and C3-10-cycloalkyl,wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C1-6-alkoxy, C3-8-alkenyf, aryl, heteroaryl, C3-8-heterocyclyl, C3. lo-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-8crcycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8alkoxy, C2-C6-alkenyI, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalkyl, C3-8alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalkyl, C3-8alkoxy, C2-C6-alkenylI aryl, heteroaryl, C3-8-heterocyclyl, C3-10rcycloaIkyl, perhalomethyl and perhalomethoxy: and R5p, R6p, R7p and R8p are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, F, amino, cyano, C3-8-alkyl, C1-6-aIkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, C1-6-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocycIyl and C3-10-cycloaIkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-aIkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocydyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-C6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl,C3-10-cycloalkyl, perhalomethyl and perhalomethoxy; and R9p, R10p, R11p, R12p, R13p, R14p, R15pand R1Bp are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C3-8-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C3-8-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8rheterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-6alkenyi, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R5p, R6p and R7p; and wherein there may optionally be a covalent bond between R4p and R5p so as to form a chromen ring system; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9p, R10p, R11p, R12p, R13p, R14p, R15pand R16p; and E is selected from the group consisting of -0-, -S-, -S(=0)-, -S(=0)r, -NR17p- and -CR17pR18p-;and wherein R17p and R18p are independently selected from hydrogen, hydroxy, sulfanyi, sulfo, halogen, amino, cyano, nitro, C3-8-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyi, sulfo, amino, C3-8-alkyl, C3-8alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C1-6-heterocyclyl and C3-10-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyi, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3_8-heterocyclyl, and C3-8icrcycloalkyl, wherein each of the hydroxy, sulfanyi, amino, sulfo, C1. 6-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyi, oxo, halogen, amino, cyano, nitro, sulfo, Chalkyl, C3-8alkoxy, C3-8alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloaikyl, wherein each of the hydroxy, sulfanyi, amino, sulfo, C1-6-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyi, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyi, amino, sulfo, C3-8-alkyl, C3-8-alkoxy, C3-8alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and p3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyi, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyc!yl, C3-10-cycloaIkyl, perhalomethyl and perhalomethoxy. In one embodiment, the invention is concerned with compounds of the general formula XVIII, wherein E is selected from the group consisting of-O and -CR17pR18p-. In another embodiment, the invention is concerned with compounds of the general formula XVIII, wherein R4p and R5p are connected by a covalent bond so as to form said chromen ring system. In another embodiment, the invention is concerned with compounds of the general formula XVIII, wherein R4p and R59 are connected by a covalent bond so as to form the chromen ring system wherein R19p is selected from the group consisting of hydrogen, hydroxy, sulfanyl, sulfa, halogen, amino, cyano, nitro, C3-8-alkyl, C1-6-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, suffo, amino, Chalkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfa, C3-8-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyI, perhalomethyl and perhalomethoxy. In another embodiment, the invention is concerned with compounds of the general formula XVlll, wherein R4p is selected from the group consisting of wherein R20p, R21p, R229, R23* and R24p are independently selected from hydrogen, hydroxy, sulfanyl, sulfa, halogen, amino, cyano, nitro, C3-8-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, CM-heterocyclyl and C3_10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfa, amino, C1-6-alkyl, C3-8-alkoxy, C3-8-alkenyi, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfa, oxo, halogen, amino, cyano, nitro, sulfa, C3-8-alkyl, C3-8-alkoxy, C2-C6-alkenyl, perhalomethyl and perhalomethoxy. In another embodiment, the invention is concerned with compounds of the general formula XVlll, wherein there are no covalent bonds between any of the substituents R4p, R5p, R6p, R7p and R8p. In another embodiment, the invention is concerned with compounds of the general formula XVIII, wherein there are no covalent bonds between any of the substituents R9p, R10p, R11p, R12p( R13p, R14p, R15pandR16p. in another embodiment, the invention is concerned with compounds of the general formula XVIII, wherein R10p and R11p are connected by a covalent bond. In another embodiment, the invention is concerned with compounds of the general formula XVIII, wherein R9p, R10p/R11p, R12p, R13p, R14p, R15pand R16p are independently selected from hydrogen, F, CI, C3-8alkyl, C3-8alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0);rNH2, -NH-S(=0)r OH, hydroxy, amino and perhalomethyl. In another embodiment, the invention is concerned with compounds of the general formula XVIII, wherein R5**, R6p, R7p and R8p are independently selected from hydrogen, F, CI, C1-6- alkyl, C3-8-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. wherein R4*, RBq, R7q, R5kR10q, R11q, R12q, R13q, R14q, R15q, R16q, R17q,and R18q are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, Chalkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyi and C3-8icrcycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C3-8-alkyl, C2-C8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocycIyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8alkyl, C3-8alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8r heterocyctyl, C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C1-6-alkenyl, aryl, heteroaryl, rheterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-aikyl, C1-6-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C1-6-alkenyl, aryl, heteroaryl, C3-8-heterocydyl, and d-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C1-6-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: and R5kand R5kkare independently selected from hydrogen, hydroxy, sulfanyl, sulfo, F, Br, amino, cyano, nitro, C1-6-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C1-6-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-C6-alkenyI, aryl, heteroaryl, C3-8-heterocyclyl, and d-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and d-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, d-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C1-6-alkenyl, aryl, heteroaryl, C1-6-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R4", R5q, R6q, R7q and RBq; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9q, R10q, R11q, R12q, R13q, R14q, R15q, R16q, R17q and R1Bq. In one embodiment, the invention is concerned with compounds of the general formula XIX, wherein R4q and R6q are connected by a covalent bond. in another embodiment, the invention is concerned with compounds of the general formula XIX, wherein R4k is selected from the group consisting of substituted heteroaryl and substituted C3-8-heterocyclyl. In another embodiment, the invention is concerned with compounds of the general formula XIX, wherein R5k is selected from the group consisting of wherein R19q, R20q, R21q, R22* and R23q are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C3-8-alkyl, C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C3-8-alkyl,, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocydyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8-alkoxy, C3-8alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkylf wherein each of hydroxy, sulfanyl, sulfo, amino, Chalkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyI, C1_6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C3-8-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3. 10-cycloalkyl, perhalomethyl and perhalomethoxy. In another embodiment, the invention is concerned with compounds of the general formula XIX, wherein there are no covalent bonds between any of the substituents R4q, R5q, R6q, R7q and R8q. In another embodiment, the invention is concerned with compounds of the general formula XIX, wherein there are no covalent bonds between any of the substituents R9q, R10q, R11q, R12q, R13q, R14q, R15q' R16q, R17q and R18q. In another embodiment, the invention is concerned with compounds of the general formula XIX, wherein R10p and R11p are connected by a cbvalent bond. In another embodiment, the invention is concerned with compounds of the general formula XIX, wherein R11p and R13p are connected by a covalent bond. In another embodiment, the invention is concerned with compounds of the general formula XIX, wherein R4t R10q, R11q, R12q, R13q, R14q, R15q, R16q, R17q and R18q are independently selected from hydrogen, F, CI, C3-8-alkyl, C3-8-alkoxy, -C(=0)NH2| -NHC(=0)-OH, -S(=0)2-NH2, -NH«S(=0)2-OH, hydroxy, amino and perhalomethyl. In another embodiment, the invention is concerned with compounds of the general formula XIX, wherein R4t. R10q, R11q, R12q, R14q, R15q, R16q, R17q and R1Bq are all hydrogen or F. In another embodiment the invention is concerned with compounds of the general formula XIX, wherein R59, R6q, R7q and R8q are independently selected from hydrogen, F, CI, C3-8-alkyl, C1-6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. wherein R4t is selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C3-8alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloaIkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C3-8-alkyl,, C3-8-alkoxy, C3-8-alkenyl, aryl, het-eroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3_10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C6-aIkenyI, aryl, heteroaryl, C3-8-heterocyclyl, C3- 10-cycloalkyl, perhaiomethyl and perhalomethoxy: provided that R4ris not methyl or phenyl; and R4t R6r, R7r( R4t. R4tf R10r, R11rf R12r, R13r, R14r, R15r, R18r, R17r and R18r are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, F, amino, cyano, nitro, C3-8-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloaIkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Ci-ralkyl, C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, Cwrheterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C1-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Ct-6-alkyI, C1-6-alkoxy, C2-C6-aIkenyl, aryl, heteroaryl, C3-8-heterocydyl, and C3-10-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyl, perhaiomethyl and perhalomethoxy: and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R5r, R6r, R7r and R8r; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9r, R10r, R11r, R12r, R13r, R14r, R15r, R16r, R17r and R1Br. In one embodiment, the invention is concerned with compounds of the general formula XX, wherein R4t and R51" are connected by a covalent bond. In another embodiment, the invention is concerned with compounds of the general formula XX, wherein R4r is selected from the group consisting of substituted heteroaryl and substituted C3-8-heterocyclyl. wherein R19r, R2r, R21r, R2b and R2b are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C3-8-alkyl, C3-8alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3.B~heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, C3-8alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-C6-alkenyI, aryl, heteroaryl, C3-8-heterocyciyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Chalkyl, C3-8alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, Chalkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyI, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C1-6-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8heterocyclyl, C3-10-cycloalkyl, perha-lomethyl and perhalomethoxy. In another embodiment, the invention is concerned with compounds of the general formula XX, wherein there are no covalent bonds between any of the substituents R5r, R61", R7r and R8r. In another embodiment, the invention is concerned with compounds of the general formula XX, wherein there are no covalent bonds between any of the substituents R4t. R?0r, R11r, R12r, R13rf R14r, R15rand R16r. In another embodiment, the invention is concerned with compounds of the general formula XX, wherein R10r and R11r are connected by a covalent bond. In another embodiment, the invention is concerned with compounds of the general formula XX, wherein R11r and R13r are connected by a covalent bond. In another embodiment, the invention is concerned with compounds of the general formula XX, wherein R9r, R10r, R11r, R12r, R13r, R14r, R15r, R16r, R17r and R1Br are independently selected from hydrogen, F, CI, C1-6alkyl, C3-8-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH- S(=0)?-OH, hydroxy, amino and perhaiomethyl. In another embodiment, the invention is concerned with compounds of the general formula XX, wherein R9r, R10r, R11r, R12r, R14r, R15r, R16r, R17r and R18r are all hydrogen or F. In another embodiment, the invention is concerned with compounds of the general formula XX, wherein R5r, R8r, R7r and R4t are independently selected from hydrogen, F, CI, C3-8-alkyl, C3-8-alkoxy, -C(=0)NHa, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)rOH, hydroxy, amino and perhalomethyl. In an aspect of the invention, compounds are of the general formula XXI wherein A1s is N or C-R17s; A25 is N or C-R18s; A35 is N or C-R19s; A4s is N or C-R205; and A56 is N or C-R21s; and wherein R17!\ R1Bs, R19s, R205 and R21s are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C3-8alkyl, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl andC3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C2-C6-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl and C3-8K,-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C1-6-alkyI, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, C3-8alkyl, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-8o-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C2-C6alkenyl, aryl, heteroaryl, C3-8-heterocyclyl andC3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, C3-8-alkyl, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, C1-6-alkyl, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy; and R5s, R6s, R7$ and R8s are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, F, amino, cyano, nitro, C1-6-alkyl, C1-6-alkoxy, C2-C6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl and d-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalkyl, C1-6-alkoxy, C2-C6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3_110rcycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyI, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, d-6-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: and R98, R10s, R11s, R12s, R13s, R14s, R15s and R16s are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, F, amino, cyano, nitro, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, C1-6-alkoxy, C2-C6-aIkenyl, aryl, heteroaryl, CδHs-heterocyclyl and C3-10-cycioalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyIf wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalkyl, C1-6-alkoxy, C2-C8-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: and E is selected from the group consisting of -0-, -S-, -S(=0)-, -S(=0)2-, -NR225- and -CR22δH235-;and wherein R228 and R238 are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C1-6-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, C2-C8-alkoxy, C1-6-a'kenyl, aryl, heteroaryl, C1-6-heterocyclyl and dMo-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci.6-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyI, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d- e-alkyl, C1-6-alkoxy, C2-6-aIkenyl, aryl, heteroaryl, C3-8-heterocyciyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nrtro, sulfo, C3-8-alkyl, C3-8-alkoxy, C3-8alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R58, R68, R7s and R88; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R98, R10s, R1ls, R12s, R13s, R14s, R15s, R16s, R18s. R19s, R206, R218, R228 and R238. In one embodiment, the invention is concerned with compounds of the general formula XXI, wherein E is selected from the group consisting of -O and -CR22δH238-. In another embodiment, the invention is concerned with compounds of the general formula XXI, wherein there are no covalent bonds between any of the substituents R5*, R68, R76 and R88. in another embodiment, the invention is concerned with compounds of the general formula XXI, wherein R58, R6s, R7s and RBs are independently selected from the group consisting of hydrogen, F, CI, C1-6-alkyl, C3-8-alkoxy, -C(=0)NH2l -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0-2- OH, hydroxy, amino and perhalomethyl. In another embodiment, the invention is concerned with compounds of the general formula XXI, wherein there is a covalent bond between R10s and R11s. In another embodiment, the invention is concerned with compounds of the general formula XXI, wherein there is a covalent bond between R13s and R228. In another embodiment, the invention is concerned with compounds of the general formula XXI, wherein R9s, R10s, R118, R12s, R13s, R14s, R15s and R16s are all hydrogen or F. In an aspect of the invention, compounds are of the general formula XXII wherein E is selected from the group consisting of -O-, -S-, -S(=0)-, -S(=0)r. -NR18t- and -CR18tR19t-; and R41, R5t, R4t. R71, Rat, R91, R10t, R11t, R12t, R13t, R14t, R15t, R16t, R17t, R18t and R19t are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, nitro, Chalkyl, C3-8 alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, C1-6-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C1-6-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3. 8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, Ci*-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Ci.6-alkyl, C3-8alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C3-8alkoxy, C2-C6-alkenylt aryl, heteroaryl, C3-8-heterocyclyl, and C3-icrcycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, C3-8-alkyl,, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy, with the proviso that R4t and Ra are not both methyl; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R4t, R10t, R11t, R12t, R13t, R14t, R15t, R16t, R17t,R18t and R19t. In one embodiment, the invention is concerned with compounds of the general rormuia AAH, wherein E is selected from the group consisting of -O, -S-, -S(=0)-, -S(=0)r and -CR18tR19t-. In another embodiment, the invention is concerned with compounds of the general formula XXII, wherein R1Bt is hydrogen or F. in another embodiment, the invention is concerned with compounds of the general formula XXII, wherein R10t, R12t, R4t and R4t are all hydrogen. In another embodiment, the invention is concerned with compounds of the general formula XXII, wherein Rm, R7*, Rw and R91 are independently selected from the group consisting of hydrogen, F, CI, C3-8-alkyl, C1-6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)r OH, hydroxy, amino and perhalomethyl. In another embodiment, the invention is concerned with compounds of the general formula XXII, wherein there is a covalent bond between R11t and R13t. In another embodiment, the invention is concerned with compounds of the general formula XXII, wherein there is a covalent bond between R13t and R19t. In another embodiment, the invention is concerned with compounds of the general formula XXII, wherein R10t, R11t, R12t, R13t, R14\ R15t, R16t and R17t are all hydrogen or F. wherein R4u, R50, R6u, R7u, R6u, R9", R10u, R11u, R12u, R13u, R14u and R15u are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C1-6-alkoxy, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cyc!oalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C3-8-alkyl, C1-6-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3_8-heterocyciyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C3-8-alkenyi, aryl, heteroaryl, C3-8-heterocyclyl, andC3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, ni-tro, sulfo, C1-6-alkyl, C1a6-alkaxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-aikyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8alkyl, C3-8-alkoxy, C2_6-aIkenyl, aryl, heteroaryl, C3-8 heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: with the proviso that R4u, R5u and R6u are not all hydrogen; and E is selected from the group consisting of -0-, -S-, -S(=0)-, -S(=0)r, -NR16u- and -CR1BuR17u-; wherein R1Su and R17u are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C3-8-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-nrcycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, C3-8-alkoxy, C2-C6-alkenyI, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1. e-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-8Mo-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, Cswrheterocyclyi, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalkyl, C3-8-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R4u, R5u and R6u; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R8u, R9u, R10u and R11u; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R12u, R13u, R14u, R15u, R16u and R17u. In one embodiment, the invention is concerned with compounds of the general formula XXIII, wherein E is selected from the group consisting of -O-, -S-, -S(=0)-l -S(=0)2- and -CR1BuR17u-. In another embodiment, the invention is concerned with compounds of the general formula XXIII, wherein R17u is hydrogen or F. In another embodiment, the invention is concerned with compounds of the general formula XXIII, wherein there are no covalent bonds between any of the substituents R8u, R9u, R10u and R11u. In another embodiment, the invention is concerned with compounds of the general formula XXIII, wherein R8u, R9", R10u and R11u are independently selected from the group consisting of hydrogen, F, CI, C3-8-alkyl, C3-8-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)r OH, hydroxy, amino and perhalomethyL In another embodiment, the invention is concerned with compounds of the general formula XXIII, wherein there is a covalent bond between R12u land R13u. In another embodiment, the invention is concerned with compounds of the general formula XXIII, wherein R12u, R13u, R14u and R15u are all selected from the group consisting of hydrogen, F, methyl and Chalkyl. In an aspect of the invention, compounds are of the general formula XXIVa-b C1-6-alkylf C1-6-aIkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C3-8-alkyl, C3-8-alkoxy, Ca-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, ni-tro, sulfo, C3-8alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C1-6-alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C1-6alkoxy, C2-C8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycioalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalkyl, C1-6-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocycIyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3_icrcycioalkyl, perhalomethyl and perhalometboxy; with the proviso that none of the substituents R4v, R5v and R6* are benzothiazolyl or benzooxazolyl; and E is selected from the group consisting of -0-, -S-, -S(=Oh -S(=0)r, -NR19v- and -CR19vR20v-; and wherein R19v and R20* are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C3-8-alkyl, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3. 10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C3-8-alkyl, C3-8alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyI, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8-alkyl, C3-8alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-10-cycloaIkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be a covalent bond between the substituents R7v and R8v or between the substituents R9v and R10v; and wherein there may optionally be a covalent bond between R6v and a substituent selected from R8v and R9*; and wherein there may be a covalent bond between any of the substituents selected from the group consisting of R4v, R5kand R6*; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R11v, R12v, R13v, R14v, R15v, R16v, R17v, R18v, R19v and R20*. In one embodiment, the invention is concerned with compounds of the general formula XXIV, wherein E is selected from the group consisting of -0-, -S-, -$(=0)-, -S(=0)2- and -CR19vR20v- In another embodiment, the invention is concerned with compounds of the general formula XXIV, wherein R4t°v is hydrogen or F. In another embodiment, the invention is concerned with compounds of the general formula XXIV, wherein there are no covalent bonds between any of the substituents R4v, R5kand R6v. In another embodiment, the invention is concerned with compounds of the general formula XXIV, wherein there are no covalent bonds between any of the substituents R7v, R8v, R9v and R10v. In another embodiment, the invention is concerned with compounds of the general formula XXIV, wherein there are no covalent bonds between a substituent selected from the group consisting of R4v, R5v and R6v and a substituent selected from the group consisting of R7v, R8v, R9v and R10v. In another embodiment, the invention is concerned with compounds of the general formula XXIV, wherein R7v, R8q, RSv and R10v are independently selected from the group consisting of hydrogen, F, CI, d-ralkyl, C3-8-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)rNH2, -NH-S(=0)r OH, hydroxy, amino and perhalomethyl. In another embodiment, the invention is concerned with compounds of the general formula XXIV, wherein there is a covalent bond between R12v and R13v. In another embodiment, the invention is concerned with compounds of the general formula XXIV, wherein R11v, R12v, R13v, R14v, R15v, R16v, R17v and R18v are all hydrogen or F. In an aspect of the invention, compounds are of the general formula XXV wherein R4* Is selected from hydrogen, hydroxy, amino, sulfo, C3-8-alkyl, C2_6-alkenyI, aryl, heteroaryl, C3-8-heterocyclyl and C3-10rcycloalkyI, wherein each of hydroxy, amino, sulfo, C2-C8-alkyl, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, C1-6-alkyl, C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycioalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1-6-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3.1(rcycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, C3-8-alkyl, C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C41. 6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, C3-8-alkyl, C1-6-alkoxy, C2-C8-alkenyI, aryl, heteroaryl, C3_8-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: with the proviso that R4w is not methyl, morpholine or a 2-chromen derivative; and Z is selected from S, S(=0) and S(=0)2; and R5", R6", R7w, R6w, R9w, R10w, R11w, R12w, R13w, R14w, R15w and R16w are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C1-6-alkyl, C3-8-alkoxy, C2-6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyI, wherein each of hydroxy, sulfanyl, sulfo, amino, C3-8-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl,heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8alkyl, C3-8-alkoxy, C3-8-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C3-8-alkyl, C3-8-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8 heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C3-8 alkyl, C1-6-alkoxyf C2.4ralkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-8alkyl, perha-lomethyl and perhalomethoxy: and E is selected from the group consisting of -0-, -S-, -S(=0)-, -S(=0)r, -NR17w- and -CR17wR18w-; and wherein R17w and R18w are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C1-6-alkyl, C1-6-alkoxy, C3-8-e-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C3-8-alkyl, C3-8alkoxy, C3-8-e-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycIoalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-6-alkyl, C3-8-alkoxy, C2-C6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Ci. methyI)-2-pyrimidoi (0.49 g, 3.00 mmol), 4-morpholinecarbonyl chloride (0.45 g, 3.00 mmol) and 1,4-diazabicyclo[2.2.2]octane (0.51 g, 3.00 mmol) in N,N-dimethylformamide (15 ml) was stirred at room temperature for 2 hours. Water was added and the solution was extracted twice with dichloromethane. The combined organic layers were dried over sodium sulphate, filtered and evaporated in vacuo. The residue was purified by flash column chromatography (Si02, ethyl acetate:heptane (30:70 -» 50:50)) yielding the title compound (0.66 g, 80% yield) as a white solid. 1H NMR (300MHz, CDCl3): £3.57-3.81 (m, 8H), 7.57 (d, 1H), 8.97 (d, 1H).; HPLC-MS (Method A): mfz^ 300. (M+Na); Rt = 2.36 min. Example 252 Methyl-phenyl-carbamic acid 3-nitn>pyridin-2-yI ester A solution of 2-hydroxy-3-nitropyridine (0.42 g, 3.00 mmol), 1-methyl-3-(methyl-phenyl-caitamoyf)-3H-imidazol-1-ium iodide (1.03 g, 3.00 mmol) and triethylamine (0.42 ml, 3.00 mmol) in acetonitrile (15 m!) was stirred at room temperature for 3 days. The solvent was evaporated in vacuo and the residue was purified by flash column chromatography (Si02, ethyl acetate;heptane (40:60)) yielding the title compound (0.41 g, 50% yield) as a yellow solid. 1H NMR (300MHz, CDCI3): £3.41 + 3.58 (2 x br.s, 3H), 7.30 (m, 1H), 7.42 (m, 5H), 8.45 (br.d, 1H), 8.49 (br.s, 1H); HPLC-MS (Method A): mlz = 296 (M+Na); Rt = 3.22 min. Example 253 Methyl-phenyl-carbamic acid 5-chloro-pyridin-2-yI ester A solution of 5-chloro-2-pyridol (0.39 g, 3.00 mmol), 1-methyl-3-(methyl-phenyl-carbamoyl)-3H-imidazol-1-ium iodide (1.03 g, 3.00 mmol) and triethylamine (0.42 ml, 3.00 mmol) in acetonitrile (15 ml) was stirred at room temperature for 3 days. The solvent was evaporated in vacuo and the residue was purified by flash column chromatography (Si02, ethyl ace-tate:heptane (30:70)) yielding the title compound (0.78 g, 99% yield) as a white solid. 1H NMR (300MHz, CDCl3): 53.44 (br.s, 3H), 7.00 (br.s, 1H), 7.27 (m, 1H), 7.39 (m, 4H), 7.69 (d, 1H), 8.30 (d, 1H); HPLC-MS (Method A): mlz = 285 (M+Na); Rt = 3.47 min. Example 254 Methyl-phenyl-carbamic acid 5-(2-nitro-phenyl)-pyrimidin-2-yl ester A solution of 5-(2-nitrophenyl)-pyrimidin-2-ol (0.35 g, 1.61 mmol), 1-methyl-3-(methyl-phenyl-carbamoyI)-3tf-imidazol-1-ium iodide (0.55 g, 1.61 mmol). and triethylamine (0.22 ml, 1.61 mmol) in acetonitrile (15 ml) was heated at 50 °C for 18 hours. The solvent was evaporated in vacuo and the residue was purified by flash column chromatography (Si02, ethyl ace-tateiheptane (50:50)) yielding the title compound (0.18 g, 32% yield) as a yellow oil. 1H NMR (300MHz, CDCI3): £3.47 (br.s, 3H), 7.29 (m, 1H), 7.40 (m, 5H), 7.63 (dt, 1H), 7.72 (dt, 1H), 8.10 (d, 1H), 8.61 (br.s, 2H); HPLC-MS (Method A): mlz = 351 (M+H), 373 (M+Na), 723 (2M+Na).; Rt = 3.65 min. Example 255 Methyl-phenyi-carbamic acid 5-trifluoromethyI-pyridin-2-yl ester A solution of 2-hydroxy-5-(trifluoromethyI)pyridine (0.49 g, 3.00 mmol), 1-methyI-3-(methyl-phenyl-carbamoyI)-3H-imidazol-1-ium iodide (1.03 g, 3.00 mmol) and triethylamine (0.42 ml, 3.00 mmol) in acetonitrile (15 ml) was stirred at room temperature for 18 hours. The solvent was evaporated in vacuo and the residue was purified by flash column chromatography (Si02) ethyl acetate:heptane (15:85)) yielding the title compound (0.59 g, 66% yield) as a white solid. 1H NMR (300MHz, CDCI3): £3.43 (br.s, 3H), 7.23 (br.s, 1H), 7.28 (m, 1H)r 7.37 (m, 4H), 7.94 (br.d, 1H), 8.62 (br.s, 1H); HPLC-MS (Method A): m/z= 319 (M+Na); Rt = 3.85 min. Example 256 Methyl-phenyi-carbamic acid 3-chloro-5-trifluoromethyl-pyridin-2-yI ester A solution of 3-chloro-5-(trifluoromethyI)"2-pyridinol (0.59 g, 3.00 mmol), 1-methyI-3-(methyl-phenyl-carbamoyI)-3H-imidazol-1-ium iodide (1.03 g, 3.00 mmol) and triethylamine (0.42 ml, 3.00 mmol) in acetonitrile (15 ml) was stirred at room temperature for 18 hours. The solvent was evaporated in vacuo and the residue was purified by flash column chromatography (Si02, ethyl acetate:heptane (15:85)) yielding the title compound (146 mg, 15% yield) as a white solid. 1H NMR (300MHz, CDCI3): £3.43 (br.s, 3H), 7.30 (m, 1H), 7.40 (d, 4H), 8.00 (br.s, 1H), 8.52 (br.s, 1H).; HPLC-MS (Method A): mfz = 353 (M+Na); Rt = 4.29. min. Example 257 Methyl-phenyi-carbamic acid 5-nitro-3-trifluoromethyl-pyridin-2-yl ester A solution of 2-hydroxy-5-nitro-3-(trifluoromethyl)pyridine (0,36 g, 1.73 mmol), N-methyl-N-phenylcarbamoyl chloride (0.44 g, 2.59 mmol) and 1,4-diazabicyclo[2.2.2]octane (0.29 g, 2.59 mmol) in tetrahydrofuran (15 ml), was stirred at room temperature for 18 hours. The solvent was evaporated in vacuo and the. residue was purified by flash column chromatography (Si02, ethyl acetate:heptane (15:85)) yielding the title compound (0.55 g, 92% yield) as an orange solid.. 1H NMR (300MHz, CDCI3): (53.46 (br.s, 3H), 7.23-7.46 (m, 5H), 8.70 (br.s, 1H), 9.37 (br.s, 1H); HPLC-MS (Method A): mlz = 364 (M+H); Rt = 4.08 min. Example 258 (3-Chloro-phenyI)-methyl-carbamic acid 4-trifluoromethyl-pyrimidin-2-yl ester At 0 °C diphosgene (0.99 g, 5.00 mmol) was added to a stirred solution of 4-trifluoromethyI-2-hydroxypyrimidine (1.64 g, 10.0 mmol) in tetrahydrofuran (25 ml). The cooling bath was removed and stirring was continued at room temperature for 1 hour. (3-ChIorophenyI)-methylamine (0,35 g, 2.50 mmot) was added to one-fourth of the solution. After stirring overnight at room temperature the solvent was evaporated In vacuo and the residue was purified by flash column chromatography (Si02( ethyl acetate:heptane (20:80)) followed by preparative HPLC, yielding the title compound (332 mg, 40%) as a colourless oil. 1H NMR (300MHz, CDCI3): S3.45 (br.s, 3H), 7.23-7.44 (m, 4H), 7.56 (d, 1H), 8.94 (d, 1H); HPLC-MS (Method A): m/z= 354 (M+H); Rt = 4.03 min. Example 259 Methyl-m-tolyl-carbamic acid 4-trifluoromethyl-pyrimidin-2-yl ester At 0 °C diphosgene (0.99 g, 5.00 mmol) was added to a stirred solution of 4-trifluoromethyI-2-hydroxypyrimidine (1.64 g, 10.0 mmol) in tetrahydrofuran (25 ml). The cooling bath was removed and stirring was continued at room temperature for 1 hour. Methykn-tolyl-amine (0,30 g, 2.50 mmol) was added to one-fourth of the solution. After stirring overnight at room temperature the solvent was evaporated in vacuo and the residue was purified by flash column chromatography (Si02, ethyl acetate:heptane (20:80)) followed by preparative HPLC, yielding the title compound (51 mg, 7%) as a colourless oil. 1H NMR (300MHz, CDCi3): 52.37 (s, 3H). 3.42 (br.s, 3H), 7.07-7.31 (m, 4H)f 7.52 (br.s, 1H), 8.92 (br.s, 1H); HPLC-MS (Method A): mlz = 334 (M+Na); Rt = 3.92 min. Example 260 Morpholine-4-carboxylic acid 4-trifluoromethyl-pyrimidin-2-yl ester A solution of 4-trifluoromethyl-2-hydroxypyrimidine (0.49 g, 3.00 mmol), 4-morpholinecarbonyl chloride (0.45 g, 3.00 mmol) and 1,4-diazabicyclo[2.2.2]octane (0.34 g, 3.00 mmol) in dimethylformamide (15 ml) was stirred at room temperature for 1 hour. Water and brine were added and the solution was extracted twice with dichloromethane. The combined organic layers were dried over sodium sulphate, filtered and evaporated in vacuo. The residue was purified by flash column chromatography (Si02, ethyl acetate:heptane (30:70 -* 50:50)) yielding the title compound (0.66 g, 80% yield) as. a white solid. 'H NMR (300MHz, CDCI3): 53.45 (br.s, 3H), 7.23-7.44 (m, 4H), 7.56 (d, 1H), 8.94 (d, 1H); HPLC-MS (Method A): mlz = 354 (M+H); Rt =. 4.03 min. Example 261 Methyl-phenyl-carbamic acid 4,5-dichloro-pyridazin-3-yl ester A solution of 4,5-dichloro-3-hydroxypyridazine (0.49 g, 3.00 mmol), Af-methyl-W-phenylcarbamoyl chloride (0.51 g, 3.00 mmol) and triethylamine (0.42 ml, 3.00 mmol) in tet-rahydrofuran (15 ml) was stirred at room temperature for 3 days. The solvent was evaporated in vacuo and the residue was purified by flash column chromatography (Si02j ethyl acetate:heptane (20:80)) yielding the title compound (0.12 g, 14% yield) as a white solid. 1H NMR (300MHz, CDCI3): 53.50 (s, 3H), 7.18-7.32 (m. 5H), 7.63 (s, 1H); HPLC-MS (Method A): mlz = 320 (M+Na); Rt = 2.91 min. Example 262 Methyl-phenyl-carbamic acid 5-benzoylamino-pyridin-2-yI ester A solution of N-(6-hydroxy-pyridin-3-yl)-benzamide (0.64 g, 3.00 mmol), A/-methyl-/V-phenylcarbamoyl chloride (0.51 g, 3.00 mmol) and 1,4-diazabicyclo[2.2.2]octane (0.34 g, 3.00 mmol) in dimethylformamide (15 ml) was stirred at room temperature for 1 hour. Water was added and the precipitates were collected by suction. The solids were dissolved in di-chloromethane and the solution was dried over sodium sulphate, filtered and evaporated in vacuo. The residue was dissolved in ethyl acetate and filtered over a short pad of silica. Evaporation of the solvent in vacuo yielded the title compound (0.70 g, 68% yield) as a thick oil. 1H NMR (300MHz, CDCI3): £3.40 (br.s, 3H), 6.90 (br.s, 1H), 7.26 (m, 1H), 7.31-7.44 (m, 6H), 7.50 (m, 1H), 7.88 (d, 2H), 8.08 (dd, 1H)( 8.37 (d, 1H)f 8.79 (br.s, 1H); HPLC-MS (Method A): mlz = 348 (M+H); Rt = 3.49 min. Example 263 Methyl-phenyl-carbamic acid 5-(cyclohexanecarbonyI-amino)-pyridin-2-yl ester A solution of cyclohexanecarboxylic acid (6-hydroxy-pyridin-3-yI)-amide (0.66 g, 3.00 mmol), N-methyl-A/-phenylcarbamoyl chloride (0.51 g, 3.00 mmol) and 1,4-diazabicycio[2.2.2]octane (0.34 g, 3.00 mmol) in dimethylformamide (20 ml) was stirred at room temperature for 18 hours. Water was added and the precipitates were collected by suction. The solids were dissolved in dichloromethane and the solution was dried over sodium sulphate, filtered and evaporated in vacuo. The residue was crystallised from ethyl acetate:heptane yielding the title compound (0.75 g, 71% yield) as a slightly coloured solid. 1H NMR (300MHz, CDCI3): 51.18-1.33 (m, 3H), 1.42-1.59 (m, 2H), 1.60 (m, 1H), 1.77-1.94 (m, 4H), 2.20 (m, 1H), 3.45 (br.s, 3H), 6.91 (br.s, 1H), 7.28 (m, 1H), 7.39 (m, 4H), 7.94 (br.s, 1H)( 8.00 (dd, 1H), 8.20 (d, 1H); HPLC-MS (Method A): mlz = 354 (M+H); Rt = 3.74 rnin. Example 264 Methyl-phenyl-carbamic acid 4,4-dimethyI-2,6-dioxo-3,4,5)6-tetrahydro-2H-[1 ^bipyridinyl-e1-yl ester A solution of e'-hydroxy-4,4-dimethyl-4,5-dihydro-SH-tl^lbipyridinyl-^e-dione (0.70 g, 3.00 mmol), /V-methyl-N-phenylcarbamoyl chloride (0.51 g, 3.00 mmo!) and 1,4-diazabi-cyclo[2.2.2]octane (0.34 g, 3.00 mmol) in dimethylformamide (20 ml) was stirred at room temperature for 18 hours. Water was added and the precipitates were collected by suction and subsequently dried in a vacuum oven yielding the title compound (0,75 g, 71% yield) as a white solid. 1H NMR (300MHz, CDCI3): oxylic acid 4-(54rifluoromethyl-pyridin-2-yioxy)phenyl ester The hydrochloride of the title compound was prepared from 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyl chloroformate and 1-(2-thienyIethy[)piperazine, white crystals, yield 62 %; m.p. 236 - 237 °C; 1H NMR (DMSO-cf6): 511.51 (br s, 1H), 8.61 - 8.54 (br m, 1H), 7.48 -7.17 (m, 6H), 7.06 - 6.89 (m, 2H), 4.4 - 3.9 (br, 2H), 3.9 - 2.6 (br m, 15.5 H ~ 12H + water); HPLC-MS: m/z = 478 (M+H); IR (KBr): v 1714 (C=0) cm-1. Example 279 (General procedure 15) 4-(1-PhenyIethyI)piperazine-1-carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yIoxy)phenyl ester The crude hydrochloride of the title compound was prepared from 4-(5-trifluoromethyi-pyridin-2-yIoxy)-phenyl chloroformate and l~(1-phenylethyl)piperazine. Trituration with water, filtering and drying of the residue gave white crystals, yield 31 %; m.p. 242 °C; 1H NMR (DMSO-ofe): S11.56 (br s, 1H), 8.61 - 8.52 (br m, 1H), 8.30. - 8.19 (dd-like m, 1H), 7.77 - 7.31 (br. m, 5H), 7.31 - 7.13 (m, 5H), 4.60 - 3.27 (br m, 6H + water), 3.27 - 2.57 (br, 3H), 1.73 (br d, 3H); IR (KBr): v 1712 (C=0) cm"1. Example 280 (General procedure 15) 4-Octylpiperazine-1-carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)phenyl ester The crude hydrochloride of the title compound was prepared from4-(5-trifluoromethyl-pyiidin-2-yloxy)-phenyl chloroformate and 1-(1-phenylethyl)piperazine. Trituration with water, filtering and drying of the residue gave white crystals, yield 31 %; m.p. 244-245 °C; 1H NMR (DMSO-cfe): 511-16 (br s, 1H), 8.61 - 8.57 (br m, 1H), 8.30 - 8.20 (dd-like mT 1H)f 7.32 - 7.18 (m, 5H), 4.39 - 3.96 (br, 2H), 3,77 - 3.38 (br, 4H), 3.25 - 2.88 (br, 4H), 1.84 -1.58 (br, 2H), 1.42 - 1.12 (br s, 10H), 0.87 (br t, 3H); IR (KBr): v 1731,1713 (C=0) cm"1. Example 281 (General procedure 15) 4-(3-Dimethylamino-propyl)-piperazine-1 -carboxylic acid 4«(5"trifluoromethyl-pyridin-2-yloxy)- phenyl ester The crude hydrochloride of the title compound was prepared from 4-(5-trifluorornethyl-pyridin-2-yloxy)-phenyI chloroformate and 1-(3-dimethylaminopropyl)piperazine. A suspension of the product in ether was stirred with an excess of HCI in ether and the precipitate was washed with ether and dried to give the dihydrochloride of the title compound as white crystals, m.p. 292 - 293 °C; 'H NMR (DMSO-cf6): S11.35 (br s, 1H), 10.46. (br s, 1H), 8.61 - 8.52 (br m, 1H), 8.31 - 8.17 (m, 1H), 7.35 - 7.16 (m, 5H), 4.45 - 4.00 (br, 2H), 3.80 - 3.45 (br, 4H), 3.30 - 3.01 (br, 6H), 2.78 (br s, 6H), 2.31 - 2.07 (br, 2H); lR (KBr): v 1731, 1713 (C=0) cm-1. Example 282 (General procedure 15) 4-Pyrimidin-2-yI-piperazine-1 -carboxylic acid 4-(5-trifluoromethyI-pyridin-2-yioxy)-phenyI ester The hydrochloride of the title compound was prepared from 4-(5-trifiuoromethyI-pyridin-2-yloxy)-phenyl chloroformate and 1-(pyrimidin-2-yI)piperazine. The crude product was dried in vacuo at 50 °C for 80 min and extracted with ether. The ether phase was evaporated and the residue was purified by flash chromatography on silica eluted with ethyl acetate - heptane 1:1 to give the title compound as white needles. Yield 14 %; m.p. 120-121 °C; 1H NMR (DMSO-af6): £8.61 - 8.56 (br, 1H), 8.41 (d, J = 4.8 Hz, 2H)f 8.29 - 8.20 (dd-like, 1H), 7.31 - 7.20 (m, 5H), 6,69 (Hike m, J - 4.8 Hz, 1H), 3.94 - 3.78 (br s, 4H), 3.78 - 3.45 (br d, 4H); HPLC-MS: m/z = 446 (M+H); lR (KBr): v 1719 (C=0) cm"1. Example 283 (General procedure 15) 4-CycIopropylmethyl-piperazine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI ester The hydrochloride of the title compound was prepared from 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyl chloroformate and 1-cyclopropyIpiperazine, yield 62 %. Recrystallisation from 0.2 M HCI gave white, crystals, m.p. 238 - 239 °C; 1H NMR (DMSO-cfe): 611.51 (br s, 1H), 8.61 - 8.55 (m, 1H), 8.30 - 8.20 ( m, dd, 1H), 7.32 - 7.19 (m, d+s, 5H), 4.44 - 4.00 (br, 2H), 3.80 - 3.40 (br m, 4H), 3.29 - 2.93 (br m, 4H), 1.28 - 1.05 (br m, 1H), 0.75 - 0.58 (m, 2H), 0.50 - 0.35 (m, 2H).IR (KBr): v 1730, 1713 (C=0) cm"1. Example 284 (General procedure 15) 4-Methyl-1,4-diazepane-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yIoxy)phenyl ester The hydrochloride of the title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate and 1-methylhomopiperazine; white crystals, m.p. 210 - 211 °C; 1H NMR (DMSO-d6): 511.27 (br s, 1H), 8.61 - 8,54 (m, 1H), 8.30 - 8.20 (dd-Iike m, 1H). 7.34 - 7.18 (m, 5H), 4.13 - 3.08 (br, 11H, 8H + water), 2.80 (br s, 3H), 2.47 -1.98 (br m, 2H); IR (KBr): v 1723, 1711 (C=0) cm"1. Example 285. (General procedure 15) 4-Phenethyl-piperazine-1-carboxylic acid 4-(5-trifluorornethyI-pyridin-2-yloxy)-phenyI ester The hydrochloride of the title compound was prepared from 4-(5-trifluoromethy!-pyridin-2-y!oxy)-phenyI chloroformate and 1-phenethylpiperazine, yield 54 %. Recrystallisation from 99% EtOH gave white crystals, m.p. 245 - 247 °C; 1H NMR (DMSOcf6): 8 11.72 (br, 1H), 8.63 - 8.53 (br, 1H), 8.31 - 8.19 (dd-Iike m, 1H), 7.44 - 7.16 (m, 10H), 4.44 - 4.01 (br, 2H), 3.83.-3.45 (br, 4H), 3.45 - 2.95 (br, ~8H, 6H + water); IR (KBr): v 1713 (C=0) cm-1. Example 286 (General procedure 15) 4-Pyridin-2-ylmethyl-piperazine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI ester The hydrochloride of the title compound was prepared from 4-(5-trifiuoromethyl-pyridin-2-yloxy)-phenyl chloroformate and 1-pyridin-2-yImethyl-piperazine. White crystals, yield 64 %; m.p. 189 - 190 °C; 1H NMR (DMSO-d6): 58.72 - 8.63 (m, 1H), 8.60 - 8.55 (br, 1H), 8.29 -8.20 (dd-Iike, 1H), 8.02 - 7.90 (m( 1H). 7.80 - 7.65 (m, 1H)r 7.56 - 7.45 (m. 1H)f 7.31- 7.22 (m, 5H), 4.52 (br. s, 2H), 4.06 - 3.68 (br s, 4H), 3.68 - 2.93 (br, 4H + NH + water); HPLC-MS: m/z = 459 (M+H); IR (KBr): v 1717 (C=0) cm"1. Example 287 (General procedure 15) 4-Pyridin-3-y)methyl-piperazine-1 -carboxylic acid 4-(5-trif luoromethyl-pyridin-2-yloxy)-phenyl ester The hydrochloride of the title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate and 1-pyridin-3-ylmethyl-piperazine. Trituration with water, filtering and drying of the residue gave white crystals. 1H NMR (DMSO-cfe): £8.78 - 8.51 (m, 3H), 8.30 - 8.18 (dd-Iike, 1H), 8.12 - 8.00 (br d, 1H), 7.57 -7.46 (m, 1H), 7.32 - 7.17 (m, 5H), 4.65 - 4.11 (br, 2H), 4.11 - 2.78 (br m, 6H + water); HPLC-MS: m/z = 459 (M+H); IR (KBr): v 1723 (00) cm"1. Example 288 (General procedure 15) 4-(3-Phenylpropyl)piperazine-1 -carboxylic acid 4-(54rifluoromethyl-pyridin«2-yloxy)-phenyI ester The hydrochloride, of the title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate and 1-(3-phenylpropyl)piperazine, yield 68 %. m.p. 235 - 238 °C; 1H NMR(DMSO-d6): 5 11.51 (br, 1H), 8.61 -8.55.(br, 1H), 8.29 - 8.20 (dd-like m, 1H)f 7.38 - 7.16 (m, 10H), 4.38 - 3.96 (br, 2H), 3.83 - 3.40 (br, 4H), 3.30 - 2.91 (br, 4H), 2.75 - 2.57 (Hike m, 2H), 2.20 -1.94 (m, 2H); IR (KBr): v 1715 (C=0) cm"1. Example 289 (General procedure 15) 4-(4-PhenylbutyI)piperazine-1-carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI ester The hydrochloride of the title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate and 1-(4-phenyIbutyI)piperazine, yield 71 %. m.p. 232 - 234 °C; 1H NMR (DMSO-cf6): tf 11.32 (br s, 1H), 8.61 - 8.55 (br, 1H), 8.29- 8.20. (dd-like m, 1H), 7.36 - 7.13 (m, 10H), 4.4Q - 3-97 (br, 2H), 3.81 - 3.39 (br m, 4H), 3.26 - 2.91 (br, 4H), 2.71 - 2.55 (t-like m, 2H)f 1.88 -1.51 (br m, 4H); IR (KBr): v 1728,1713 (C=0) cm"1. Example 290 (General procedure 15) 4-Benzyl-1,4-diazepane-1-carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester The hydrochloride of the title, compound was prepared from 4-(5-trifluoromethyl«pyridin-2-yloxy)-phenyl chloroformate and 1-benzyIhomopiperazine, crude yield 70 %. 0.20 g Of the crude product was heated with 3 ml of water, cooled at 0 °C, the precipitate filtered off and dried; m.p. 231 - 233 °C; 1H NMR (DMSO-of6): 811.38 (br s, 1H), 8.62 - 8.55 (br, 1 H)r 8.30 -8.20 (dd-like m, 1H), 7.76 - 7.60 (br, 2H), 7.52- 7.41 (br m, 3H), 7.32 - 7.19 (m. 5H), 4.38 (br s, 2H), 4.18 - 3.01 (br m, 8H + water), 2.6 - Z0 (brf 2H + DMSO); IR (KBr): v 1726,1710 (C=0) cm"1. Example 291 (General procedure 15) 4-(3,4-DichlorophenyI)piperazine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)phenyI ester The hydrochloride of the title compound was prepared from 4-(5-trifluoromethy!-pyridin-2-yloxy)-phenyl chloroformate and 1-(3,4-dichlorophenyl)piperazine. The crude product was partitioned between dichlorormethane and 2 M aqueous sodium carbonate. The organic layer was washed with water, dried and evaporated. The residue was triturated with ethyl acetate - heptane (1:4) and the precipitate was collected by filtration and dried to give the title compound as white crystals. Yield 28 %; m.p. 115 -116 °C; 1H NMR (DMSO-cf6): 8 8.61 -8.55 (br, 1H), 8.30 - 8.20 (dd-like, 1H), 7.48 - 7.40 (d-Iike,1H), 7.31 - 7.16 (m, 6H), 7.04 - 6.94 (dd-like, 1H), 3.83 - 3.47 (br m, 4H), 3.36 - 3.24 (br s, 4H + water); HPLC-MS: m/z = 512 (M+H); IR (KBr): v 1724,1706 cm"1. Example 292 (General procedure 15) 4-(4-Fluorophenyt)piperazine-1 -carboxylic acid 4-(5-trifluoromethyI-pyridin-2-yloxy)phenyl ester The hydrochloride of the title compound was prepared from 4-(5~trifluoromethyI-pyridin-2-yloxy)-phenyl chloroformate and 1-(4-fluoropheny()piperazine. White crystals, yield 20 %; m.p. 131-132 °C; 1H NMR (DMSO-cf6): 8 8.61 - 8.53 (br, 1H), 8.30 - 8.19 (dd-like, 1H), 7.33 -7.17 (m, 5H), 7.17 - 6.95 (m, 4H), 3.85 - 3.47 (br d, 4H), 3.25 - 3.07 (br m, 4H); HPLC-MS: m/z = 462 (M+H); IR (KBr): v 1739,1714 cm'1. Example 293 (General procedure 15) 4-(2-ChlorophenyI)piperazine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)phenyl ester The the hydrochloride of title compound was prepared from 4-(5-trifluoromethyi-pyridin-2-yloxy)-phenyl chloroformate and 1-(2-chlorophenyl)piperazine. Drying in vacuo at 50 °C for 3Yz h gave the title compound; 1H NMR (DMSO-of6): £8.61 - 8.55 (br, 1H), 8.29 - 8.20 (dd-like, 1H), 7.53-7.41 (m, 1H), 7.39 - 7.17 (m, 7H), 7.14 - 7.03 (m, 1H), 4.58 (br s, NH + water), 3.85 - 3.55 (br m, 4H), 3.12 - 2.99 (br m, 4H); HPLOMS: m/z = 478 (M+H); IR (KBr): v 1733(C=0)cm- Example 294 (General procedure 15) (2-Dimethylamino-ethyl)methyicarbamic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester The hydrochloride of the title compound was prepared from 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyl chloroformate and N,N,N'-trimethyIethylenediamine; m.p. 139 -140 °C; 1H NMR (MeOH-de): 8 8.45 - 8.38 (br, 1H), 8.15 - 8.05 (dd-!ike m, 1H), 7.31 - 7.11 (m, 5H), 3.84 - 3.73 (br m, 2H), 3.54 - 3.38 (br m, 3H), 3.19 (br s, 2H)f 2.99 (br s, 6H); traces of impurities at 3.9 (br) and 3.1 (br); lR (KBr): v 2695, 1705 cm 1 (C=0) cm"1. Example 295 (General procedure 15) 4-Methylpiperazine-1~carboxyIic acid 4-chIorophenyl ester The hydrochloride of the title compound was prepared from 4-chlorophenyI chloroformate and 1-methy!piperazinef yield 81 %. White crystals, m.p. 237 - 240 DC; 1H NMR (DMSO-of6): 4»4-dimethyl-piperidine-2,6-dione (0.60 g, 2.55 mmol), N-methyl-N-phenylcarbamoyI chloride (0.48 g, 2.81 mmol) and 1,4-diazabicyclo-[2,2,2]octane (0.31 g, 2.81 mmol) in dichloromethane (25 mL) was stirred at room temperature for 15 minutes. The solvent was evaporated in vacuo and the residue was purified by flash column chromatography (Si02l ethyl acetate:heptane 50:50), yielding the title compound as a white solid. 1H NMR (300MHz, CDCI3): 8 = 1.22 (s, 6H), 2.65 (s, 4H), 3.44 (br.s, 3H), 7.28-7.48 (m, 5H), 8.68 (br.s, 2H); HPLC-MS (Method A): m/z = 369 (M+H)+; Rt = 3.45 min. Example 369 Methyl-phenyl-carbamic acid 5-bromo-pyrimidin-2-yI ester A mixture of 4-bromo-2-hydroxypyrimidine (0.96. g, 5.49 mmol), N-methyl-N-phenylcarbamoyl chloride (1.02 g, 6.04 mmol) and 1 ,4-diazabicyclo[2,2,2]octane (0.68. g, 6.04 mmol) in dry tet-rahydrofuran (15mL) was stirred at room temperature for 1 hour. Dichloromethane was added and the solution was extracted twice with water. The organic layer was dried over sodium sulphate, filtered and evaporated in vacuo yielding the title compound (170 g, 100% yield) as a white solid. 1H NMR (300MHz, CDCI3): 8 = 3.43 (br.s, 3H), 7.27 (m, 1H), 7.38 (m, 4H), 8.68 (br.s, 2H); HPLC-MS (Method A): m/z = 330 and 332 (M+H)+; Rt = 3.33 min. Example 370 Methyl-phenyl-carbamic acid 5-[(6-chloro-pyridine-3-carbonyI)-amino]-pyridin-2-yl ester A mixture of 4-chIoro-N-(6-hydroxy-pyridin-3-y!)-nicotinamide (0.56 g, 2.25 mmol), N-methyl-N-phenylcarbamoyl chloride (0.51 g, 3.00. mmol) and 1,4-diazabicyclo[2,2,2]octane (0.67 g, 6.00 mmol) in dry tetrahydrofuran (15mL) was stirred at room temperature for 1 hour. Dichloromethane was added and the solution was extracted twice with water. The organic layer was dried over sodium sulphate, filtered and evaporated in vacuo. The residue was purified by flash column chromatography (Si02, ethyl acetate;heptane 70:30) followed by crystallised from ethyl acetate:heptane, yielding the title compound (44 mg, 5% yield) HPLC-MS (Method A): m/z = 383 (M+H)+; Rt = 3.40 min. Example 371 Methyl-phenyl-carbamic acid 5-(2,2-dimethyl-propylcarbamoyl)-pyridin-2-yl ester A solution of N-(2,2-dimethyl-propyI)-6-hydroxy-nicotinamide (0.50 g, 2.40 mmol), N-methyl-N-phenylcarbamoyl chloride (0.41 g, 2.40 mmol) and 1,4-diazabicyclo[2,2,2]octane (0.27 g, 2.40 mmol) in tetrahydrofuran (15 mL) was stirred at room temperature for 3 hours. The solvent was evaporated in vacuo and the residue was purified by flash column chromatography (first column: Si02, dichloromethane:ethyl acetate 95:5, second column: Si02) ethyl acetate), yielding the title compound (0.43 g, 52% yield). 1H NMR (300MHz, CDCI3): 5 = 0.97 (s, 9H), 3.26 (d, 2H), 3.44 (br.s, 3H), 6.26 (br.s, 1H), 7.08 (br.s, 1H), 7.29 (m, 1H), 7.39 (m, 4H), 8.13 (br.d, 1H), 8.70 (br.s, 1H); HPLC-MS (Method A): m/z = 383 (M+H)+; Rt = 3.40 min. Example 372 [Methyl-phenyl-carbamic add 6-(3,4-clichloro-phenoxy)-pyridazin-3-yl ester A solution of 6-(3,4t4-thiomorpholine-4-carboxylic acid 4-(5-trifIuoromethyI-pyridin-2-yIoxy)-phenyl ester The title compound was prepared from 4-(5-trifluoromethyI-pyridin-2-yIoxy)-phenyI chloroformate and thiomorpholine 1-oxide and purified by flash chromatography (ethyl acetate), yield 37%. White crystals, m.p. 156 -157 °C; 1H NMR (CDCI3) .£8.47 - 8.40 (s-like, 1H), 7.94 -7.87 (dd-Iike, 1H), 7.24 - 7.13 (m, 4H), 7.06 - 6.99 (d-like), 4.31 - 3.91 (m, 4H), 2.97 - 2.87 -2.75 (m, 2H + 2H); IR (KBr): v 1710 (C=0) cm'1. Example 441 (General procedure 18) 4-(2,4-Dimethoxypheny[)-piperazine-1 -carboxyiic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)- phenyl ester The title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate and 1-(2,4-dimethoxyphenyl)-piperazine. Purified by flash chromatography (ethyl acetate - heptane 1:4), yield 69%. White crystals, m.p. 98-99 °C; HPLC-MS: m/z = 504 (M+1) at Rt = 4.0 min.; IR (KBr): v 1733,1712 (C=0) cm'1. Example 442 (General procedure 15) 5-Benzyl-2,5-diazabicycIo[2.2. 1 ]heptane-2-carboxylic acid 4-(5-trifluoromethylpyridin-2- yloxy)-phenyI ester The hydrochloride of the title compound was prepared from 4-(5-trifluoromethyI-pyridtn-2-yIoxy)-phenyl chloroformate and 2-benzyl-2,5-diazabicyclo[2.2.1]heptane. The crude product was converted to the free base and further purified by flash chromatography (ethyl acetate -heptane 1:4), yield 16 %. White crystals, m.p. 114-115 °C; HPLC-MS: m/z: 470 (M+1) at Rt = 2.6 min.; IR (KBr): v 1718 (C=0) cm'1. Example 443 (General procedure 10) 4-Aminomethyl-piperidine-1-carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester The title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate and 4-aminomethylpiperidine. The crude product was purified by preparative HPLC (Method C) (32%, off-white crystals). HPLC-MS m/z = 396.1 (M+1), Rt: 2.65 min. purity: 86%. Example 444 (General procedure 10) 4-Pyrimidin-2-yl-piperazine-1-carboxylic acid 4-(5-chloro-pyridin-2-yloxy)-phenyl ester The' title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate and 1-(2-pyrimidinyI)-piperazine, two equivalent of diisopropylethyiamine was added. The crude product was obtained by filtration of the reaction mixture. The crude product was washed with diethyl ether and subjected to column chromatography, ethyl acetate/heptane (1:3) (18%, white crystals). HPLC-MS m/z = 412.1 (M+1), Rt: 4.12 min. Example 445 (General procedure 12) 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 4-(4,4-dirnethyl-2,6-dioxo-piperidin-1 -yl)- phenyl ester The title compound was prepared from 4-(4,4-dimethyl-2,6"dioxo-piperidin-1-yI)-phenyI chloroformate and 1-cyclopropylmethyI-piperazine, preparative HPLC (Method C) (45%, off-white crystals). HPLC-MS m/z = 400.3 (M+1), Rt 1.83 min. Example 446 (General procedure 12) 4-(4-Methoxy-benzyI)-piperazine-1 -carboxylic acid 4-(4,4-dimethyI-2,6-dioxo-piperidin-1-yI)- phenyl ester The title compound was prepared from 4-(4I4-dimethyI-2,6-dioxo-piperidin-1*yI)-phenyI chloroformate and 1-(4-methoxybenzy!)-piperazine, preparative HPLC (Method C) (54%, white crystals). HPLC-MS m/z = 466.3 (M+1), Rt: 2.26 min. Example 447 (General procedure 12) 4-Pyridin-3-ylmethyI-piperazine-1-carboxyIic acid 4-(4,4-dimethyl-2J6-dioxo-piperidin-1 -yl)- phenyl ester The title compound was prepared from 4-(4,4-dimethyI-2,6-dioxo-piperidin-1-y!)-phenyl chloroformate and 1-pyridin-3-ylmethyl-piperazine, hydrochloride, preparative HPLC (Method C) (75%, colourless oil). HPLC-MS m/z = 437.2 (M+1), Rt: 1.70 min. Example 448 (General procedure 12) 4-(4-Methoxy-benzyI)-piperazine-1-carboxyIic acid 4-(2-cyclohexyI-acetylamino)-phenyl ester The title compound was prepared from 4-(2-cyclohexyl-acetyIamino)-phenyI chloroformate and 1-(4-methoxybenzyl)-piperazine, preparative HPLC (Method C) (49%, white crystals). HPLC-MS m/z = 466.3 (M+1), Rt: 2.85 min. Example 449 (General procedure 12) 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 4-(2-cycIohexyl-acetylamino)-phenyl ester The title compound was prepared from 4-(2-cyclohexyl-acetylamino)-phenyI chloroformate and 1-cyclopropylmethyl-piperazine, preparative HPLC (methode C (60%, off-white crystals). HPLC-MS m/z = 400.3 (M+1), Rt: 2.42 min. Example 450 (General procedure 12) 4-Pyrid»n-3-ylmethyl-piperazine-1-carboxylic acid 4-(2-cyclohexyl-acetylamino)-phenyl ester The title compound was prepared from 4-(2-cyclohexyl-acetyiamino)-phenyl chioroformate and 1-pyridin-3-ylmethyl-piperazine, hydrochloride, preparative HPLC (method© C) (64%, white crystals). HPLC-MS m/z = 437.4 (M+1), Rfc 2.38 min. Example 451 (General procedure 14) Methyl-phenyl-carbamic acid 4-(2-cyclohexyl-ethyIsulfamoyI)-phenyl ester The title compound was prepared from N-(2-cyclohexyI-ethyI)-4-hydroxy-benzenesulfonarnide and N-methyl-N-phenyl carbamoylchloride, preparative HPLC (Method C) (14%, light yellow oil). HPLC-MS m/z = 417.3 (M+1), Rt: 4.89 min. Example 452 (General procedure 14) Methyl-phenyl-carbamic acid 4-(3-methyI-butylsulfamoyl)-phenyI ester The title compound was prepared from 4-hydroxy-N-(3-methyl-butyl)-benzenesulfonamide and N-methyl-N-phenyl carbamoylchloride, preparative HPLC (Method C) (11%, light yellow oil). HPLC-MS m/z = 377.2 (M+1), Rt: 4.32 min. Example 453 (General procedure 12) (6-Methoxy-pyridin-2-yl)-methyl-carbamicacid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester The crude product was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI chioroformate and and 2-methoxy-6-methylaminopyridine. The reaction mixture was evaporated to dryness, dissolved in dichloromethane (100 ml) and extracted with a aqueous phosphate buffer, pH 7. The aqueous phase was extracted with dichloromethane (100 ml x 2) and the combined organic phases were dryed and evaporated to dryness. The product was subjected to flash chromatography, ethyl acetate/heptane (1:7) to give the titlew product (86%, white crystals). HPLC-MS m/z = 420.4 (M+1), Rt 5.23 min. Example 454 (General procedure 12) 4-Benamidazol-1-yI-piperidine-1-carboxyfc ester The crude product was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chlorofor- mate and l-piperidine-4-yl-IH-benzimidazoIe, 5 equivalent of diisopropylamine was added, preparative HPLC (method C) (23%, colourless crystals). HPLC-MS m/z = 483.3 (M+1), Rt: 3.14. min. Example 455 (General procedure 12) 4-Hydroxymethyl-piperidine-1-carboxylic acid 4-(2-cyclohexyI-acetylamino)-phenyI ester The title compound was prepared from 4-(2-cyclohexyl-acetylamino)-phenyI chloroformate and 4-hydroxymethyI-piperidine, praeparative HPLC (Method C) (37%, off-white crystals). HPLC-MS m/z = 375.2 (M+1), Rt: 3.41 min. Example 456 (General procedure 12) 4-(4-Amino-phenyI)-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-y!oxy)-pheny] ester The title compound was prepared from 4-(5-trifluoromethyI-pyridin-2-yIoxy)-phenyl chloroformate and 4-(4-aminophenyl)piperidine, hydrochloride, praeparative HPLC (Method C) (30%, light yellow crystals). HPLC-MS m/z = 458.2 (M+1), Rt: 3.42 min. Example 457 (General procedure 12) 4-(Methy!-pyridin-3-ylmethyl-amino)-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin- 2-yIoxy)-phenyl ester The title compound was prepared from 4-(5-trifIuoromethyl-pyridin-2-yIoxy)-phenyl chloroformate and methyl-piperidin-4-yI-pyridin-3-ylmethyl-amine, hydrochloride, praeparative HPLC. (Method C) (31%, orange oil). HPLC-MS m/z = 487.1 (M+1), Rt: 2.64 min. Example 458 (Genera! procedure 12) 4-(2-Oxo-pyrrolidin-1 -yl)-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)- phenyl ester The title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate and 1-piperidin-4-yI-pyrrolidine-2-one, hydrochloride, praeparative HPLC (Method C) (55%, semi-crystaline oil). HPLC-MS m/z = 450.1 (M+1), Rt: 3.81 min. Example 459 (General procedure 12) 4-(MethyI-phenethyl-amino)-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yIoxy)- phenyl ester The title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI chlorofor-mate and methyI-phenethyl-piperidin-4-yI-amine, hydrochloride, prasparative HPLC (Method C) (37%, colourless oil). HPLC-MS m/z = 500.1 (M+1), Rt: 3.26 min. Example 460 4-[(Benzyl-ethyI-amino)-methyl]-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester Benzyl-ethyl-piperidin-4-yImethyI-amine (1.42 mmol) was dissolved in dichloromethane. 4-(5-Trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate (1.42 mmol, 0.451 g) (prepared from the corresponding phenol by conventional methods) was added at room temperature. The reaction mixture was stirred overnight and evaporated to dryness. The crude product was subjected to column chromatography, ethyl acetate/heptane (1:3) -+ Triethylamine/ethyl acetate 1:9). The fractions containing the title product, was evaporated to dryness and HCI (g) in ethyl acetate was added and stirred for 16 hours. The solution was evaporated to dryness and dryed in vacoum for 16 h. to give the title product. (58%, light yellow crystals). HPLC-MS m/z = 514.1 (M+1), Rt: 3.27 min. Example 461 (General procedure 12) 4-[Methyl-phenethyI-amino)-methy!]-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yIoxy)-phenyI ester The title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate and methyl-phenethyl-piperidin-4-ylmethyl-amine, hydrochloride, 5 equivalent of diiso-propylamine was added, praeparative HPLC (Method C) (46%, colourless crystals). HPLC-MS m/z = 514.1 (M+1), Rt: 3.31 min. Example 462 (General procedure 12) 4-[(CyclohexyI-methyl-amino)-methyl]«piperidine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester The title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chlorofor-mate and cyclohexyI-methyl-piperidine-4-ylmethyI-amine, hydrochloride, 5 equivalent of diisopropylamine was added, prasparative HPLC (Method C). (43%, white crystals). HPLC-MS m/z = 492.3 (M+1), Rt 3.22 min. Example 463 (General procedure 12) 4-[(Ethyl-pyridin-4-ylmethyl-amino)-methyI]-piperidine-1 -carboxylic acid 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyi ester The title compound was prepared from 4-(5-trifIuoromethyl-pyridin-2-yloxy)-pheny! chlorofor-mate and ethyI-piperidin-4-ylmethyI-pyridin-4-ylmethyl-amine, hydrochloride, 5 equivalent of diisopropylamine was added, prasparative HPLC (Method C) (25%, off-white crystals). HPLC-MS m/z = 515.2 (M+1), Rt: 2.77 min. Example 464 (General procedure 12) 4-[(Benzyl-methyl-amino)-methyI]-piperidine-1 -carboxylic acid 4-(5-trifluoromethyI-pyridin-2- yloxy)-phenyl ester The title compound was prepared from 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyl chlorofor-mate and benzyl-methyl-piperidin-4-ylmethyl-amine, hydrochloride, 5 equivalent of diisopropylamine was added, praaparative HPLC (Method C) (56%, colourless crystals). HPLC-MS m/z = 500.2 (M+1), Rt: 3.18 min. Example 465 (General procedure 12) 4-[(Methyl-pyrldin-3-ylmethyl-amino)-methyI]-piperidine-1 -carboxylic acid 4~(5-trifluoromethyI-pyridin-2-yloxy)-phenyl ester The title compound was prepared from 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyl chlorofor-mate and methyl-piperidine-4-ylmethyl-pyridine«4-ylmethyl-amine, hydrochloride, 5 equivalent of diisopropylamine was added, praeparative HPLC (Method C) (36%, colourless crystals). HPLC-MS m/z = 501.1 (M+1), Rt: 2.74 min. Example 466 (General procedure 12) 4-(1,3-Dihydro-isoindol-2-ylmethyl)-piperidine-1-carboxylic acid 4-(5-trifluoromethyI-pyridin-2- yloxy)-phenyl ester The title compound was prepared from 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyl chlorofor-mate and 2-piperidin-4-yImethyl-2f3-dihydro-1H-isoindole, hydrochloride, 5 equivalent of diisopropylamine was added, prseparative HPLC (Method C) (63%, colourless crystals). HPLC-MS m/z = 498.1 (M+1),. Rt: 3.07 min. Example 467 4-BenzotriazoM -yl-piperidine-1 -carboxylic acid 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyl ester The title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yIoxy)-phenyI chlorofor-mate and 1-piperidin-4-yMH-benzotriazolef hydrochloride, 5 equivalent of diisopropylamine was added, preparative HPLC (Method C) (7%, colourless crystals). HPLC-MS m/z = 506.2 (M+1), Rt 4.56 min. Example 468 (General procedure 12) 4-[(CyclopropylmethyI-amino)-methyI]-piperidine-1-carboxylicacid 4-(5-trifluoromthyI-pyridin-2-yIoxy)-phenyI ester CyclopropylmethyI-piperidine-4-ylmethyi-amine (0.65 mmol, 110 mg) was dissolve in di-chloromethane. 4-(5-trifIuoromethyI-pyridin-2-yloxy)-phenyl chloroformate (0.65 mmol, 0.208 g) (prepared from the corresponding phenol by conventional methods) was added at - 15 °C for 15 min and stired at room temperature overnight and evaporated to dryness. The crude product was purified by preparative HPLC (Method C) (16%, colourless crystals). HPLC-MS m/z = 450.1 (M+1), Rt: 2.98 min. Example 469 (General procedure 12) 4-[Methyl-(2-pyridin-2-yl-ethyl)-amino]»piperidine-1 -carboxyfic add 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyl ester The title product was prepared from methyl-piperidin-4-yl-(2-pyridin-2-yl-ethyl)"amine and 4-(5-trifluoromethyl-pyridin"2-y}oxy)-phenyl chloroformate, 5 equivalent of diisopropylamine was added, preparative HPLC (method C) (48%, colourless oil). HPLC-MS m/z = 501.1 (M+1), Rt: 2.77 min. Example 470 (General procedure 12) 4-(CyclohexyI-methyI-amino)-piperidine-1 -carboxylic acid 4-(5-trifluoromethyI-pyridin«2- y!oxy)-phenyl ester The title product was prepared from cyclohexyI-methyl-piperidin-4-yl-amine, dihydrochloride and 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI chloroformate, 2 equivalent of diisopro-pylamine; dimethylformamide/ tetrahydrofuran (2:1). The reaction mixture was evaporated to dryness and the crude product extracted with ethyl acetate from an aqueous HCI solution saturated with sodium chloride, pH 1-2. The title product was crystallized from ethyl acetate during evaporation of the solvent, filtered and dryed in vacoum (45%, white crystals). HPLC-MS m/z = 478.2 (M+1), Rt: 3.10 min. Example 471 (General procedure 12) 4-(IsopropyI-methyI-amino)-piperidine-1 -carboxylic acid 4-(5-trifIuoromethyl-pyridin-2-yIoxy)- phenyl ester The title product was prepared from isopropyl-methyl-piperidin-4-yi-amine, dihydrochloride and 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate; dimethylformamide as solvent, preparative HPLC (method C) (77%, light yellow oil). HPLC-MS m/z = 438.3 (M+1), Rt: 2.77 min. Example 472 (General procedure 12) (4-Methoxy-phenyl)-methyl-carbamic acid 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyI ester The title product was prepared from N-methyl-p-anisidine and 4-(5-trifluoromethyl-pyrldin-2-yloxy)-phenyl chloroformate, preparative HPLC (method C) (61%, off-white crystals). HPLC-MS m/z = 419.2 (M+1), Rt: 4,67 min. Example 473 (General procedure 12) (2-Methoxy-phenyl)-methyl-carbamic add 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester The title product was prepared from 2-methoxy-N-methylamine and 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate, preparative HPLC (method C) (63%, colourless oil). HPLC-MS m/z = 419.2 (M+1), Rt 4.75 min. Example 474 (General procedure 12) (2-Cart3amoyl-chIoro-phenyI)-methyI-carbamic phenyl ester. The title product was prepared from 5-chloro-2-(methyIamino)-benzamide and 4-(5- trifluoromethyI-pyridin-2~yloxy)-phenyI chloroformate, preparative HPLC (method C) (31%, light yellow oil). HPLC-MS m/z = 466.1 (M+1), Rt: 3.99 min. Example 475 (General procedure 12) (2-CarbamoyI-phenyI)-methyI-carbamic acid 4«(5-trifluoromethyI-pyridin-2-yloxy)-phenyI ester The title product was prepared from 2-(methylamino)benzamide and 4-(5-trifIuoromethyI-pyridin-2-yloxy)-phenyI chloroformate, preparative HPLC (method C) (57%, light yellow oil). HPLC-MS m/z = 454.2 (M+Na), Rt: 3.66 min. Example 476 (General procedure 12) (2-Chloro-phenyI)-methyl-carbamic acid 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyl ester The title product was prepared from 2-chlor-N-methylani!ine and 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate, preparative HPLC (method C) (48%, light yellow oil). HPLC-MS m/z = 423.1 (M+1), Rt: 4.98 min. Example 477 (General procedure 12) (2,4-Difluoro-phenyl)-methy!-carbamic acid 4-(5-trifIuoromethyI-pyridin-2»yloxy)-phenyl ester The title product was prepared from 2,4-difluouro-N-methyIaniIine and 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate, preparative HPLC (method C) (37%, white crystals). HPLC-MS m/z = 425.1 (M+1), Rt: 4.90 min. Example 478 (General procedure 12) Methyl-(2-trifluoromethoxy-phenyI)-carbamic acid 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyl ester The title product was prepared from N-methyl-2-(trifluoromethoxy)-aniline and 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate, preparative HPLC (method C) (49%, colourless oil). HPLC-MS m/z = 473.2 (M+1), Rt 5.18 min. Example 479 (General procedure 13) Methyl-phenyl-carbamic acid 4-(1,1,3,3-tetramethyI-butylcarbamoyI)-phenyI ester The title product was prepared from tert-octylamine and 4-(methyI-pheny!-carbamoyIoxy)-benzoic acid 2,5-dioxo-pyrroiidin-1-yl ester, preparative HPLC. (method C) (26%, white crystals). HPLC-MS m/z = 383.5. (M+1), Rt: 4.67 min. Example 480 (General procedure 13) Methyl-phenyl-carbamic acid 4-[(2-dimethyIamino-ethyI)-methyl-carbamoyl]-phenyl ester The title product was prepared from N.NX-trimethylethylendiamine and 4-(methyl-phenyl-carbamoyloxy)-benzoic acid 2,5-dioxo-pyrroIidin-1-yl ester, preparative HPLC (method C) (2%, colourless oil!). HPLC-MS m/z = 356.2 (M+1)f Rt: 2.17 min. Example 481 (General procedure 13) Methyl-phenyl-carbamic acid 4-(cyclopropyImethyI-carbamoyI)-phenyI ester The title product was prepared from cyclopropylmethylamine and 4-(methy!-phenyl-carbamoyloxy)-benzoic acid 2,5-dioxo-pyrroIidin-1-yl ester. The crude product was used without further purification (100%, semi-crystal oil). HPLC-MS m/z = 325.1 (M+1), Rt: 3.40 min. Example 482 (General procedure 13) Methyl-phenyl-carbamic acid 4-(methyl-pyridin-3-ylmethyl-carbamoyl)-phenyI ester The title product was prepared from methyl-pyridin-3-ylmethyI-amine and 4-(methyl-phenyI-carbamoyloxy)-benzoic acid 2,5-dioxo-pyrroIidin-1-yI ester. The crude product was subjected to preparative HPLC (method C) (48%, clear colourless oil). HPLC-MS m/z = 376.2 (M+1), Rt: 2.37 min. Example 483 (General procedure 13) Methyl-phenyl-carbamic acid 4-[(1H-benzimidazoI-2-ylmethyl)-carbamoyl]-phenyI ester The title product was prepared from 0(1 H-benzimidazol-2-yI)-methyIamine and 4-(methyI- phenyl-carbamoyloxy)-benzoic acid 2,5-dioxo-pyrroiidin-1-yl ester. The crude product was subjected to preparative HPLC (method C) (8%, off-white crystals). HPLC-MS m/z = 401.1 (M+1), Rt: 2.56 min. Example 484 (General procedure 13) Methyl-phenyl-carbamic acid 4-[2-(4-chloro-pheny!)-ethylcarbamoyl3-phenyI ester The title product was prepared from 2-(4-chIoro-phenyI)-ethyIamine and 4-(methyl-phenyI-carbamoyloxy)-benzoic acid 2,5-dioxo-pyrrolidin-1-yl ester. The crude product was subjected to preparative HPLC (method C) (39%, off-white crystals). HPLC-MS m/z = 409.2 (M+1), Rt: 4.27 min. Example 485 4-Cyclopropy)methyI-piperazine-1 -carboxylic acid 4-(3,3-dimethyl-butylcarbamoyI)-phenyl ester The title product was prepared from 1-cycIopropyImethyIpiperazine (0.35 mmol) dissolved in dichloromethane (5 ml). 4-(3,3-dimethyl-butyIcarbamoyi)-phenyl chloroformate (0.35 mmol) was added at room temperature. The reaction mixture was stirred for 16 h and evaporated to . -dryness and subjected to preparative HPLC (metod C) (5%, white crystals). HPLC-MS m/z = 388.2 (M+1), Rt: 2.43 min. Example 486 4-Hydroxymethy!-piperidine-1-carboxylic acid 4-(3,3-dimethyl-butylcarbamoyI)-phenyI ester ester The title product was prepared from 4-hydroxymethyIpiperidtne (0,35 mmol) was dissolved in dichloromethane (5 ml). Diisopropylethylamine (0.35 mmol was added together with 4-(3,3-dimethyl-butylcarbamoyl)-phenyl chloroformate (0.35 mmol) at room temperature. The reaction mixture was stirred for 16 h and evaporated to dryness and subjected to preparative HPLC (metod C). (25%, white crystals). HPLC-MS m/z = 363.3 (M+1), Rt 3.27 min. Example 487 4-Pyridin-3-ylmethyl-piperazine-1-carboxylic acid 4-(3,3-dimethyl-butylcarbamoyl)-phenyl ester The title product was prepared from 1-pyridin-3-yImethyl-piperazine was dissolved in di-chloromethane (5 ml). 4-(3,3-DimethyI-butylcarbamoyl)-phenyl chloroformate (0.35 mmol) was added at room temperature. The reaction mixture was stirred for 16 h and evaporated to dryness and subjected to preparative HPLC (metod C) (88%, light yellow oil).. HPLC-MS m/z = 425.4 (M+1),Rt 2.33 min. Example 488 4-(4-Methoxy-benzyI)-piperazine-1-carboxyiicacid 4»(313-dimethyI-butyIcarbamoyI)-pheny! ester The title product was. prepared from 1-(4-methoxy-benzyI)-piperazine (0.35 mmol) was dissolved in dichloromethane (5 ml). 4-(3,3-Dimethyl-butylcarbamoyl)-phenyl chloroformate (0.35 mmo!) was added at room temperature. The reaction mixture was stirred for 16 h and evaporated to dryness and subjected to preparative HPLC (metod C). (54%, colourless semi-crystaline oil). HPLC-MS m/z = 454.3 (M+1), Rt: 2.78 min. Example 489 4-(2-Pyridin-2-yl-acetyI)-piperazine-lK^rbo^ ester a) Piperazine-I^dicarboxylicacid tert-butyl ester 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester (General procedure 18) The title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yIoxy)-phenyl chloroformate and 1-tert-butoxycarbonyl-piperazin, yield 59% (recrystallized from EtOAc - heptane 1:1). White crystals, m.p. 165 -166 °C; 1H NMR (CDCI3) D 8.45 - 8.42 (m, 1H), 7.92 - 7.87 (m, dd-like, 1H), 7.21 - 7.12 (AB-system, 4H), 7.03 - 6.98 (m, d-iike, 1H), 3.72 - 3.45 (br mf 8H), 1.49 (s, 9H); 13C-NMR (CDCI3) Q (ref. CDCI3 77.00 ppm):165,71,154.56,153.51,150.21,148.34, 145.43 (q, J= 4.4 Hz), 136.701 (q, J = 3 Hz), 123.65 (q, J= 271.5 Hz), 122.86,122.24,121.62 (q, J = 33 Hz), 11.20, 80.32,44.38,43.78,44.6 - 42.3 (br), 28.36 ppm; IR (KBr) p 1722 (CO), 1691(C=0)cnrb) Piperazin&-1-carboxylic acid 4-(5-trifluoromethyl-pyridirh2-yloxy)-phenyl ester hydrochloride Piperazine-1,4-dicarboxyIic acid tert-butyl ester 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester (0.12 g, 0.26 mmol) was stirred at 100 °Cfor 10 min in a mixture of ethanol (3 ml) and concentrated hydrochloric acid (1 ml). The solvent was removed in vacuum. The residue was stirred with toluene (10 ml) and evaporated, then stirred with ethanol and evaporated to dryness to give white crystals (0.10 g). Recrystallization from absolute ethanol gave the title compound. White crystals, 0.068 g (65%); m.p. 279 - 282 °C (decomp.); 1H-NMR (DMSO) q 9.62 (br, 2H, NH2+), 8.61 - 8.55 (m, 1H), 8.29 - 8.21 (m, dd-Iike, 1H), 7.30 - 7.20 (m, 5H), 3.86 and 3.70 (br s, 4H), 3.19 (br s, 4H); 13C-NMR (DMSO) □ (ref DMSO 39.50 ppm): 165.51,152.71,149.98,148.04, 145.20 (J = 4.4 Hz), 137.62 (J = 3.7 Hz), 123.87 (J = 271.5 Hz), 123.11,123.39, 120.39 (J = 32.2Hz), 111.80,42.15 and a broad signal partly overlapping with the DMSO signal. IR (KBr) □ 1731,1709(0=0) cm"1. c) 4-(2-Pyridin-2-yl-acetyI)-piperazine-1-carboxytic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-pheny! ester Triethylamine (0.026 ml) was added to a stirred solution of (pyridin-2-yI)acetic acid hydrochloride (0.033 g, 0.19 mmol) in DMF (2.5 ml) at 0 DC. 1-Hydroxy-benzotriazole containing 8% of water (0.034 g) and then 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.044 g) was added and the mixture was stirred for 50 min. Piperazine-1-carboxyIic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI ester hydrochloride (0.070 g) in a mixture of DMF (1 ml) and triethylamine (0.032 ml) was added and stirring was continued over night at room temperature. The solvent was removed in vacuum and the residue was partitioned between dichloro-methane (10 ml) and water (10 ml). The organic phase was washed with water (10 ml), dried over sodium sulfate, filtered and evaporated. The residue was triturated with ether-petroleumsether 1:1 and the (2 + 1 ml). The residue was dried to give the title compound. White solid, m.p. 143 -146 °C; HPLC-MS m/z: IR (KBr) D 1732 (C=0), 1643 (C=0). Example 490 (General procedure 15) 4-(2-Pyridin-4-yl-ethyl)-piperazine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester The hydrochloride of the title compound was prepared from 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyl chloroformate and 1-(4-pyridin-2-yI-ethyI)-piperazine. White crystals, m.p. 268 - 271 °C (decomp); IR (KBr) □ 2680, 2579, 2456 (N+-H), 1731,1713 (C=0) cm-1; HPLC-MS m/z: 473 (M+H) Rt = 2.3 min. Example 491 Methyl-phenyl-carbamic acid 5-amino-pyridin-2-yI ester A solution of methyl-phenyl-carbamic acid 5-nitro-pyridin-2-yl ester (10.41 g, 38.1 mmol) in tet-rahydrofuran (100 mL) was hydrogenated in a Parr apparatus with wet 5% palladium on carbon and 20 psi hydrogen pressure. After 2 hours the solution was filtered over a short pad of Celite, washed thoroughly with ethyl acetate and evaporated in vacuo, yielding title compound (9.51 g, 103% yield) as a thick oil, which solidified upon standing. 1H NMR (300MHz, CDCl3): 5 = 3.40 (br.s, 3H), 3.70 (br.s, 2H), 6.80 (br.d, 1H), 6.97 (dd, 1H), 7.22 (m, 1H), 7.36 (m, 4H), 7.72 (d, 1H); HPLC-MS (Method A): m/z = 244 (M+H)+; Rt = 2.28 min. Example 492 Methyl-phenyl-carbamic acid 5-benzenesu]fonylamino-pyridin-2-yl ester. Benzenesuiphonyl chloride (0.18 g, 1.00 mmol), dissolved in a small amount of dichloro-methane, was added dropwise to a stirred solution of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (0.24 g, 1.00 mmol) and triethylamine (0.10 g, 1.00 mmol) in dichloromethane (10 mL). After stirring for 4 hours the solution was extracted with water and evaporated in vacuo. The residue was purified by flash column chromatography (Si02l ethyl acetate:heptane 40:60 followed by 50:50) yielding the title compound (108 mg, 23% yield) as a white solid. 1H NMR (300MHzr CDCI3): 5 = 3.46 (br.s, 3H), 6.82 (br.s, 1H), 7.24-7.52 (m, 9H), 7.63 (m, 3H), 7.84 (br.s, 1H); HPLC-MS (Method A): m/z = 384 (M+H)+; Rt = 3.26 min. Example 493 3,3-DimethyI^[6-(methykphenyk^^ A solution of methyl-phenyl-carbamic acid 5-amino-pyriditv2-yl ester (243 mg, 1.00 mmol) and 3,3-dimethylglutaric anhydride (142 mg, 1.00 mmol) in dichloromethane (10 mL) was stirred at room temperature for 48 hours. Evaporation of the solvent yielded the title compound as a thick oil. HPLC-MS (Method A): m/z = 386 (M+H)+; R( = 2.76 min. Example 494 Piperidine-1-carboxylic acid 4J4-dimethyI-2)6-dioxo-3,4,5,6-tetrahydro-2H-[1 ^bipyridinyl-e-yl 1-PiperidinecarbonyI chloride (63 microL, 0.50 mrnol) was added to a solution of B'-hydroxy^,^ dimethyl^.S^lihydrc^SH-tl^^ipyridinyl-^e-dione (117 mg, 0.50 mmol) and DABCO (56 mg, 0.50 mmol) in dimethylformamide (10 mL). After stirring for 1 hour at room temperature water was added and the solution was extracted twice with dichloromethane. The combined organic layers were dried over sodium sulphate, filtered and evaporated in vacuo. The residue was crystallised from ethyl acetate:heptane yielding the title compound (0.12 g, 69% yield) as a white solid. 1H NMR (300MHz, CDCI3): 5 = 1.21 (s, 6H), 1.64 (s( 6H), 2.69 (s, 4H), 3.53 (m, 2H), 3.63 (m, 2H), 7.22 (df 1H), 7.49 (dd, 1H), 8.09 (d, 1H); HPLC-MS (Method A): m/z = 346 (M+H)+; Rt = 3.12 min. Example 495 2,2-Dimethyl-N-[6-(methy!-phenyl-carbamoyloxy)-pyridin-3-yI]-succinamicacid A solution of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (0.49 g, 2.00 mmol) and 2,2-dimethylsuccinic anhydride (0.26 g, 2.00 mmol) in dichloromethane (10 mL) was stirred at room temperature overnight Evaporation of the solvent in vacuo yielded the title compound. HPLC-MS (Method A): m/z = 372 (M+H)+; Rt = 2.84 min. Example 496 Methyl-phenyl-carbamic add 5-(3l3-dimethyl-2l5-dioxo-pyrroIidin-1-y()-pyridin-2-y[ ester A mixture of thionyl chloride (0.726 mL, 10.00 mmol) and 2,2-dimethyI-N-[6-(methyl-phenyl-carbamoyloxy)-pyridin"3-yI]-succinamic acid (0.74 g, 2.00 mmol) in dichloromethane (25 mL) was stirred at room temperature for 18 hours. The solvent and excess thionyl chloride were evaporated in vacuo. The crude product was redissolved in dichloromethane (25 mL) and pyridine (316 mg, 4.00 mmol) was added. The solution was extracted with water, dried over sodium sulphate, filtered and evaporated in vacuo. The residue was purified by flash column chromatography (SiO* ethyl acetaterheptane 50:50), yielding the title compound (490 mg, 69% yield) as a white solid. 1H NMR (300MHz, CDCI3): S = 1.43 (s, 6H), 2.74 (sf 2H), 3.45 (br.s, 3H), 7.14 (br.s, 1H), 7.26 (m, 1 H)f 7.38 (m, 4H), 7.76 (br.d, 1H), 8.39. (s, 1H); HPLC-MS (Method A): m/z = 354 (M+H)+; Rt = 3.35 min. Example 497 Methyl-phenyl-carbamic acid 5-[3,3-dimethyI-5-(4-methyI-piperazin-1 -yI)-5-oxo-pentanoy!amino]-pyridin-2-yI ester Thionyl chloride (56 microL, 0.78 mmol) was added to a stirred solution of 3,3-dimethyl-4-[6-(methyl-phenyi-rarbamoyloxy)-pyridin-3-ylcarbamoy!]-butyric acid (0.15 g, 0.39 mmol) in di-chloromethane (5 mL) and 2 drops of dimethylformamide. After stirring for 10 minutes N-methylpiperazine (1. mL) was added and stirring was continued for 2 hours. The solvent was evaporated in vacuo. The residue was redissolved in dichloromethane and extracted with water, dried over sodium sulphate, filtered and evaporated in vacuo. The crude product was purified by filtration over a short column (Si02, ethyl acetate followed by acetone) yielding the title compound (93 mg, 51% yield) as a thick oil. 1H NMR (300MHz, CDCI3): 5 = 1.11 (s, 6H), 2.32 (s, 3H), 2.43 (m, 8H), 3.42 (br.s, 3H), 3.61 (m, 2H), 3.74 (m, 2H), 7.00 (br.s, 1H), 7.38 (dt 4H), 8.21 (dd, 1H), 8.47 (d, 1H)f 10.90 (s, 1H); HPLC-MS (Method A): mfe = 468 (M+H)+; Rt = 2.20 min. Example 498 Methyl-phenyl-carbamic acid 5-[3,3-dime^ ester Thionylchloride (237 microL, 3.27 mmol) was added to a stirred solution of 3,3-dimethy!-4«[6-(methyl-phenyl-carbamoyIoxy)-pyridin-3-ylcarbamoyl]-butyric acid (0,63 g, 1.63 mmol) in dichloromethane (10 mL). After stirring for 10 minutes the solution was divided into 4 equal portions of acid chloride. To one portion was added 2-aminopyridine (0.5 mL) and after stirring for 2 hours at room temperature the crude product was purified by flash column chromatography (SiOa, ethyl acetate followed by ethyl acetate:acetone 90:10), yielding the title compound (105 mg, 56% yield). 1H NMR (300MHz, CDCl3): 8 = 1.09 (s, 6H)f 2.36 (s, 2H), 2,38 (s, 2H), 3.44. (br.s, 3H), 6.95 (br.s, 1H), 7.26 (m, 2H), 7.38 (m, 4H), 8.05 (dd, 1H), 8.10 (dt, 1H), 8.30 (m, 2H), 8.67 (d, 1H); HPLC-MS (Method A): mfe = 462 (M+H)+; Rt = 2.52 min. Example 499 Methyl-phenyi-rarbamic add 5-@^ yl ester Thionylchloride (237 microL, 3.27. mmol) was added to a stirred solution of 3,3-dimethyl-4-[5- (methyl-phenyi-rarbamoyloxy)-pyridin-3-ylcaft^ acid (0.63 g, 1.63 mmol) in di- chloromethane (10 mL). After stirring for 10 minutes the. solution was divided into 4 equal portions of acid chloride. To one portion was added morpholine (0.5 mL) and after stirring for 2 hours at room temperature the crude product was purified by flash column chromatography (Si02), yielding the title compound (117 mg, 63% yield). 1H NMR (300MHz, CDCI3): 5= 1.11 (s, 6H), 2.44 (s, 4H), 3.42 (br.s, 3H), 3.59 (m, 2H), 3.70 (m, 6H), 7.00 (br.s, 1H), 7.24 (m, 1H), 7.38 (d, 4H), 8.21 (dd, 1H), 8.45 (d, 1H), 10.76 (s, 1H); HPLC-MS (Method A): m/z = 455 (M+H)+; Rt = 2.87 min. Example 500 Methyl-phenyl-carbamic acid 5-[4«(2-dimethyIamino-ethyIcarbamoyl)-3)3-dimethy!-butyrylamino]-pyridin-2-yl ester Thionylchloride (237 microL, 3.27 mmol) was added to a stirred solution of 3r3-dimethyl-4-[6-(methyl-phenyl-carbamoyloxy)-pyridin-3-ylcarbamoyI]-butyric acid (0.63 g, 1.63 mmol) in di-chloromethane (10 mL). After stirring for 10 minutes the solution was divided into 4 equal portions of acid chloride. To one portion was added N.N-dimethylethylenediamine (0.5 mL) and after stirring for 2 hours at room temperature the crude product was purified by flash column chromatography (Si02), yielding the title compound (74 mg, 39% yield). 1H NMR (300MHz, CDCI3): 5 = 1.10 (s, 6H), 2.22 (s, 2H), 2.27 (s, 6H), 2.44 (m, 4H), 3.37 (m, 2H), 3.43 (br.s, 3H), 6.60 (br.t, 1H), 7.00 (br.s, 1H), 7.25 (m, 1H), 7.38 (d, 4H), 8.21 (dd, 1H), 8.46 (d, 1H), 10.70 (s, 1H); HPLC-MS (Method A): m/z = 456 (M+H)+; Rt = 1.93 min. Example 501 (General procedure 12) 4-[Methyl-(2-pyridin-4-yI-ethyl)-amino]-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI ester The title product was prepared from methyI-piperidine-4-yl-(2-pyridin-4-yl-ethyl)-amine and 4-(5-trifluoramethyl-pyridin-2-yloxy)-phenyl chloroformate, 3 equivalent of diisopropylamine was added, preparative HPLC (method C) (15%, colourless oil). HPLC-MS m/z = 501.4 (M+1), Rt 2.04 min. Example 502 (General procedure 12) 4-(Cyclopropyl«pyridin-4-ylmethyl-amino)-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl- pyridin-2-yloxy)-phenyl ester The title product was prepared from cyclopropyl-piperidine«4-yl-pyridin-4-ylmethyl-amine and 4-(5-trifIuoromethyI-pyridin-2-yIoxy)-phenyI chloroformate, 3 equivalent of diisopropylamine was added, solvent: dimethylformamide. The crude reaction mixture was evaporated without addition of acetic acid, preparative HPLC (method C) (19%, yellow oil). HPLC-MS m/z = (M+1), Rt:2.82min. Example 503 (General procedure 12) 4-[Cyclopropyl-(2-fluoro-benzyl)-amino]-piperidine-1-carboxyIicacid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester The title product was prepared from cyclopropyl-(2-fluoro-benzy[)-piperidin-4-yI-amine and 4-(5-trifIuoromethyI-pyridin-2-yloxy)-phenyl chloroformate, 3 equivalent of diisopropylamine was added, solvent; dimethylformamide. The crude reaction mixture was evaporated without addition of acetic acid, preparative HPLC (method C) (60%, colourless oil). HPLC-MS m/z = (M+1), Rt:3.02min. Example 504 (General procedure 12) 4-(Cyclopropyl-pyridin-3-ylmethyl«amino)-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yIoxy)-phenyI ester The title product was prepared from cyclopropyl-piperidin-4-yl-pyridin-3-ylmethyl-amine and 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI chloroformate, 3 equivalent of diisopropylamine was. added, solvent: dimethylformamide. The crude reaction mixture was evaporated without addition of acetic acid, preparative HPLC (method C) (26%, light brown solid). HPLC-MS m/z = (M+1) 513.3, Rt: 2.64 min. Example 505 (General procedure 12) 4-(Cyclopropylmethyl-pyridin-3-ylmethyl-amino)-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl"pyridin-2-yloxy)-phenyl ester The title product was prepared from cyclopropylmetiiyl-piperidin-4-yl-pyridin-3-ylmethyl-amine and 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate, 3 equivalent of diisopropylamine was added, solvent dimethylformamide. The crude reaction mixture was evaporated without addition of acetic acid, preparative HPLC (method C) (47%, off-white solid. HPLC-MS m/z = (M+1) 513.3, Rt: 2.70 min. Example 506 (General procedure 12) 4-(C^clopropylmethyl-pyridin-3-y!methy!-amino)-piperidine-1 -carboxylic acid 4-(5-trif!uoromethyl~pyridin-2-yloxy)-phenyl ester The title product was prepared from cyclopropyImethyI-piperidin-4-yl-pyridin-4-ylmethy!-amine and 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI chloroformate, 3 equivalent of diiso-propylamine was added, solvent: dimethylformamide. The crude reaction mixture was evaporated without addition of acetic acid, preparative HPLC (method C) (22%, off-white solid. HPLC-MS m/z = (M+1) 513.3, Rt: 2.70 min. Example 507 (General procedure 12) 4-(4-Hydroxy-piperidin-1-ylmethyI)-piperidine-1-carboxyIicacid4-(5-trifiuoromethyl-pyridin«2-yloxy)-phenyl ester The title product was prepared from 1-piperidin-4-yimethyl-piperidine-4-ol (released form the correspondent hydrochloride by a standard procedure) and 4-(5-trifluoromethyI-pyridin-2-ybxy)-phenyl chloroformate, preparative HPLC (method C) (reaction performed in a mixture of dichloromethane and dimethylformamide). 1.7 M HCI in ethyl acetate was added to the pooled fractions containing the title product, and the fractions was evaporated to dryness (92%, white solid. HPLC-MS m/z = (M+1) 480.4, Rt: 2.38 min. Example 508 (General procedure 11) 4-{3-[1 -(2-Hydroxy-ethyi)-piperidin-4-yi]-propyI}-piperidine-1 -carboxylic acid 4-(5- trifluoromethyl-pyridin-2-yioxy)-phenyl ester The title product was prepared from 2-[4-(3-piperidin-4-yl-propy!)-piperidin-1-yr|-ethanol and 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate. The reaction mixture was evaporated, diethyl ether (30 ml) was added and the title product isolated by filtration, washed with diethyl ether and ried to give (67%, white solid. HPLC-MS m/z = (M+1) 536.2, Rt: 3.39 min. Example 509 (General procedure 12) 4-(2-PyrroIidin-1 -yl-ethyl}-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)- phenyl ester The title product was prepared from 2-[4-(3-piperidin-4-yI-propyI)-piperidin-1-yI3-ethanoI and 4-(5-trifluoromethyI-pyrJdin-2-yloxy)-phenyl chloroformate, preparative HPLC (method C). 1.7 M HCI in ethyl acetate was added to the pooled fractions containing the title product, and the fractions was evaporated to dryness (65%, white solid). HPLC-MS m/z = (M+1) 464.1, Rt: 2.99 min. Example 510 (General procedure 16) Methyl-o-tolyl-carbamic acid 4-iodo-pyrazol-1-yl ester The title compound was prepared from 1-hydroxy-4-iodopyrazole and methy!-o-tolylamine. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (40%, oil). HPLC-MS : mfz = 380.1 (M+23); Rt = 4.05 min. Example 511 (General procedure 16) Methyl-m-tolyl-carbamic acid 4-iodo-pyrazoM-yI ester The title compound was prepared from 1-hydroxy-4-iodopyrazole and methyl-m-tolylamine. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (44%, oil). HPLC-MS : mfz = 380.1 (M+23); Rt = 4.13 min. Example 512 (General procedure 16) Methyl-p-tolyl-carbamic acid 4-iodo-pyrazol-l-yI ester The title compound was prepared from 1-hydroxy-4-iodopyrazole and methyl-p-tolylamine. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (55%, oil). HPLC-MS : mfz = 380.1 (M+23); Rt = 4.13 min. Example 513 (General procedure 16) (3-Chloro-phenyI)-methyl-carbamic acid 4-iodo-pyrazoI-1-yl ester The title compound was prepared from 1-hydroxy-4-iodopyrazole and 3-chlorophenyl-methylamine. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (54%, oil). HPLC-MS : mlz = 399.9 (M+23); R* = 4.28 min. Example 514 (General procedure 16) (3-Fluoro-phenyI)-methyl-carbamic acid 4-iodo-pyrazoM-yl ester The title compound was prepared from 1-hydroxy»4-iodopyrazoIe and 3-fIuorophenyl-methylamine. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (51%, oil). HPLC-MS : mlz = 384.0 (M+23); Rt = 4.00 min. Example 515 (General procedure 16) 4-(3-TrifluoromethyI-pyridin-2-yl)-piperazine-1-carboxyIic acid 4-iodo-pyrazol-1-yI ester The title compound was prepared from 1-hydroxy-4-iodopyrazoie and 1-(3-trifluoromethylpyridin-2-yI)piperazine. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (13%, oil). HPLC-MS : mlz = 468.1 (M+1); Rt = 4.38 min. Example 516 (General procedure 16) 2f6-Dimethyl-morpholine-4-carboxylic acid 4-iodo-pyrazoI-1~yI ester The title compound was prepared from 1-hydroxy-4~iodopyrazoIe and 2,6-dimethyImorphoIin. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (11%, oil). HPLOMS: mlz = 374.0 (M+23); Rt = 3.24 min. Example 517 (General procedure 16) Thiomorpholine-4-carboxylic acid 4-iodo-pyrazoM-yI ester The title compound was prepared from 1-hydroxy-4-iodopyrazole and thiomorpholin. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (27%, oil). HPLC-MS: m!z= 340.0 (M+1); Rt = 3.22 min. Example 518 (General procedure 16) 3r5-DimethyI-morpholine-4-carboxyIic acid 4-iodo-pyrazol-1-yi ester The title compound was prepared from 1-hydroxy-4~iodopyrazole and 3,5-dimethylmorphoiin. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (15%, oil). HPLC-MS : m/z= 352.0 (M+1); Rt = 3.17 min. Example 519 (General procedure 16) Piperidine-1-carboxy!ic acid 4-iodo-pyrazoI-1-yl ester The title compound was prepared from 1-hydroxy-4-iodopyrazoIe and piperidine. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (46%, oil). HPLC-MS : mlz = 322.0 (M+1); Rt = 3.38 min. Example 520 (Genera! procedure 16) Methy!-o-tolyl-carbamic acid 2-chloro-imidazo!-1-yI ester The title compound was prepared from 1-hydroxy-2-chloroimidazole, hydrochloride and methyl-o-tolyiamine. The crude product was purified by preparative HPLC (Gilson) (4%, red oil). HPLC-MS : mlz = 266.0 (M); Rt = 3.28 min. Example 521 (General procedure 16) (3-Fluoro-phenyl)-methyl-carbamic acid 2-chloro-imidazoM-yl ester The title compound was prepared from 1-hydroxy-2-chloroimidazole, hydrochloride and 3-fluorophenyl-methylamine. The crude product was purified by preparative HPLC (Gilson) (2%, oil). HPLC-MS : mlz = 270.1 (M); Rt = 3.08 min. Example 522 Methyl-phenyl-carbamic acid 4-iodo-phenyl ester To a solution of 4-iodophenol (30 mmol) in CH2CI2 (100 mL) was added N-methyl-N-phenylcarbamoyi chloride (27 mmol) and diisopropylethylamine (60 mmol) at room temperature.. The reaction mixture was stirred for 16 hours at rt, added CH2CI2 (20 mL) and washed with aqueous citric acid (5%), aqueous Na2C03 and brine. The organic phase was dried (MgS04) and evaporated to give the crude product which was purified by FC (Quad flash 40 EtOAc-Heptane) to give 6.55 g (69%) of the. title compound as light brown crystals. 1H NMR (300MHz; CDCI3): 8 3.38 (brs, 3H), 6.88 (d, 2H), 7.22-7,46 (m, 5H), 7.62 (d, 2H); HPLC-MS : mlz = 354.0 (M+1); Rt = 4.54. min. Example 523 (General procedure 20) Methyl-phenyl-carbamic acid 4,-trifluoromethyl-biphenyl-4-yI ester The title compound was prepared from methyl-phenyl-carbamic acid 4-iodo-phenyl ester and 4-trifluoromethylphenyIboronic acid. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane 1:9) (42%, light brown crystals). HPLC-MS : mlz = 372.1 (M+1); Rt = 5.19 min. Example 524 (General procedure 20) Methyl-phenyl-carbamic acid 4,-trifluoromethoxy-biphenyI-4-yi ester The title compound was prepared from methyl-phenyl-carbamic acid 4-iodo-phenyl ester and 4-trifIuoromethoxyphenylboronic acid. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane 1:9) (17%, brown oil). HPLC-MS : m/z= 388.1 (M+1); Rt= 5.27 min. Example 525 (General procedure 20) Methyl-phenyl-carbamic acid 4-pyridin-3-yl-phenyl ester The title compound was prepared from methyl-phenyl-carbamic acid 4-iodo-phenyl ester and pyridine-3-boronic acid. The crude product was purified by preparative HPLC (Gilson) (5%, brown oil). 1H NMR (300MHz; CDCI3): 8 3.46 (br s, 3H), 7.29-7.46 (m, 7H), 7.61 (d, 2H), 7.88 (dd, 1H), 8.41 (d, 1H), 8.78 (d, 1H); HPLC-MS : mlz = 305.1 (M+1); Rt = 2.99 min. Example 526 (General procedure 20) Methyl-phenyl-carbamic acid 4-(5-chloro-thiophen-2-yI)-phenyl ester The title compound was prepared from methyl-phenyl-carbamic acid 4-iodo-phenyl ester and 5-chloro-2-thiopheneboronic acid. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane 1:9) (53%, pink crystals). 1H NMR (300MHz; CDCI3): 5 3.43 (br s, 3H), 6.87 /d, 1H), 7.00 (d, 1H), 7.13 (br d, 2H), 7.26-7.48 (m, 7H); HPLC-MS: mlz = 344.0 (M+1); Rt = 5.16 min. Example 527 (General procedure 20) Methyl-phenyl-carbamic acid 4,-benzylsuIfarnoyI-biphenyi-4-yl ester The title compound was prepared from methyl-phenyl-carbamic acid 4-iodo-phenyl ester and 4-benzyIsulfamoyIbenzeneboronic acid. The crude product was purified by preparative HPLC (Gilson) (35%, pink crystals). HPLC-MS : m!z = 473.0 (M+1); Rt = 4.80 min. ■ Example 528 Methyl-phenyl-carbamic acid 4-styryl-phenyl ester Styrene (1.2 mmol), N-methyldicyclohexyiamine (1.2 mmol), Pd2(dba)3 (0.03 mmol), Pd(P(f-Bu)3)2 (0.06 mmol) and methyl-phenyl-carbamic acid 4-iodo-phenyl ester (1.0 mmol) were added to a Schlenk tube under nitrogen. The Schlenk tube was evacuated and refilled with nitrogen five times. Then dioxane (2 mL) was added and the reaction mixture was stirred at 70 °C for 8 h. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) giving the title compound in 17% yield as colorless crystals. HPLOMS : mfz = 330.1 (M+1); Rt= 5.08 min. Example 529 Methyl-phenyl-carbamic acid 4-phenyIethynyl-phenyI ester Phenylacetylene (1.2 mmol), diisopropylarnine (1.2 mmol), Cul (0.03 mmol), Pd2(dba)3 (0.03 mmol), Pd(P(M3u)3>2 (0.06 mmol) and methyl-phenyl-carbamic acid 4-iodo-phenyl ester (1.0 mmol) were added to a Schlenk tube under nitrogen. The Schlenk tube was evacuated and refilled with nitrogen five times. Then dioxane (2 mL) was added and the reaction mixture was stirred at 70 °C for 8 h. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) giving the title compound in 41% yield as brown oil. HPLC-MS : mlz= 328.1 (M+1); Rt = 5.07 min.. Example 530 3-[4-(Methyl-phenyl-carbamoyloxy)-phenyri-acrylic acid methyl ester Methylacrylate (1.2 mmol), N-methyldicyclohexylamine (1.2 mmol), Pd2(dba)3 (0.03 mmol), Pd(P(f-Bu)3)2 (0.06 mmol) and methyl-phenyl-carbamic acid 4-iodo-phenyl ester (1.0 mmol) were added to a Schlenk tube under nitrogen.. The Schlenk tube was evacuated and refilled with nitrogen five times. Then dioxane (2 mL) was added and the reaction mixture was stirred at 70 °C for 8 h. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) giving the title compound in 70% yield as a yellow solid. HPLC-MS : m/z= 312.1 (M+1); Rt = 4.19 min. Example 531 (General procedure 8) Methyl-phenyl-carbamic acid 5-phenyIsuIfanyl-pyrazoI-1-yI ester The title compound was prepared from 1-hydroxy-5-phenyIsulfanylpyrazole and N-methyl-N-phenylcarbamoyl chloride. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (80%, oil). 1H NMR (300MHz; CDC!3): S 3.36 (br s, 3H), 6.47 (d, 1H) 7.16-7.32 (m, 10H), 7.40 (df 1H); HPLC-MS : mlz = 326.0 (M+1); Rt = 4.42 min. Example 532 (General procedure 21) Methyl-phenyl-carbamic acid 4-(toIuene-4-sulfonylamino)-phenyI ester The title compound was prepared in 8% yield as a clear oil using toluenesulfonyl chloride as the aryl sulfonyl chloride. HPLC-MS : mtz = 397.1 (M+1); R{ = 4.13 min Example 533 (General procedure 21) Methyl-phenyl-carbamic acid 4-(5-pyridin-2-yl-thiophene-2-sulfonylamino)-phenyl ester The title compound was prepared in 7% yield as an oil using 5-pyridin-2-yl-thiophene-2-sulfonyl chloride as the aryl sulfonyl chloride. HPLC-MS : m/z= 466.1 (M+1); Rt = 4.23 min. Example 534 (General procedure 21) Methyl-phenyl-carbamic acid 4-(1-methyHH-imidazole-4-sulfonylamino)-phenyl ester The title compound was prepared in 21% yield as crystals using 1-methyMH-imidazole-4-sulfonyl chloride as the aryl sulfonyl chloride. HPLC-MS :m/z= 387.1 (M+1); Rt= 3.14 min. Example 535 (General procedure 21) tfethyl-phenyl-carbamic acid 4-(2f5-dichlorothiophene-3-suIfonylamino)-phenyI ester The title compound was prepared in 2% yield as an oil using 2,5-dichloro-thiophene-3-sulfonyl chloride as the aryl sulfonyl chloride. rIPLC-MS : m/z = 458.6 (M+1); Rt = 4.38 min. Example 536 (General procedure 21) Methyl-phenyl-carbamic acid 4-(5-chloro-1,3-dimethyl-1 H-pyrazo!e-4-sulfonylamino)-phenyI ester The title compound was prepared in 3% yield as an oil using 5-chloro-1,3-dimethyl-1H-pyrazole-4-sulfonyl chloride as the aryl sulfonyl chloride. HPLC-MS : m/z = 435.1 (M+1); Rt = 3.74 min. Example 537 (General procedure 21) Methyl-phenyl-carbamic acid 4-(5-dimethylamlno-naphthalene-1-sulfonylamino)-phenyl ester The title compound was prepared in 14% yield as orange crystals using 5-dimethyIamino-naphthalene-1 -sulfonyl chloride as the aryl sulfonyl chloride. HPLC-MS : m/z = 476.0 (M+1); Rt = 4.48 min. Example 538 (General procedure 21) 2-[4-(Methyl-phenyl-carbamoyIoxy)-phenyisuIfamoyl]-benzoic acid methyl ester The title compound was prepared in 48% yield as a yellow oil using 2-chlorosulfonyl-benzoic acid methyl ester as the aryl sulfonyl chloride. HPLC-MS : m/z = 441.1 (M+1); R{ = 4.19 min. Example 539 (General procedure 21) Methyl-phenyl-carbamic acid 4-(3I4-difluoro-benzenesulfonylamino)-phenyl ester The title compound was prepared in 1% yield as a clear oil using 3,4-difluoro-benzenesulfonyl chloride as the aryl sulfonyl chloride. HPLC-MS : mlz = 419.1 (M+1); Rt = 4.23 mln. Example 540 (General procedure 22 and 1) Methyl-phenyl-carbamic acid 4-pyridin-2-ylmethyl-phenyI ester 4-Pyridin-2-yImethyI-pheno! was prepared following general procedure PVe3 using pyridine-2-carboxaldehyde. Subsequent carbamoylation using general procedure 1 (CH2CI2 was used as solvent) produced the crude product which was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (86%, oil). 1H NMR (400MHz; CDCI3): 8 3.40 (br s, 3H), 4.14 (s, 2H), 7.04-7.12 (m, 4H), 7.21-7.26 (m, 3H)f 7.32-7.40 (m, 4H), 7.55 (t, 1H), 8.52 (df 1H). Example 541 (General procedure 22 and 1) Methyl-phenyl-carbamic acid 4-pyridin-3-yimethyl-phenyl ester 4-Pyridin-3-ylmethyl-phenol was prepared following general procedure PVe3 using pyridine-3-carboxaldehyde. Subsequent carbamoylation using general procedure 1 (CH2CI2 was used as solvent) produced the crude product which was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (50%, oil). 1H NMR (400MHz; CDCI3): 5 3.42 (brs, 3H), 3.96 (s, 2H). 7.03-7.42 (m, 11H), 8.46 (d, 1H), 8.49 (dp 1H). Example 542 (General procedure 22 and 1) Methyl-phenyl-carbamic acid 4-(4-trifIuoromethyI-benzyI)-phenyl ester 4-(4-TrifIuoromethyl-benzyl)-phenol was prepared following general procedure PVe3 using 4-trifluoromethylbenzaldehyde. Subsequent carbamoylation using general procedure 1 (CH2CI2 was used as solvent) produced the crude product which was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (92%, oil). 1H NMR (400MHz; CDCI3): S 3.42 (br s, 3H)( 4.00 (s, 2H)f 7.06 (br s, 2H), 7.13 (d, 2H), 7.24-7.40 (m, 7H), 7.52 (d, 2H). Example 543 (General procedure 22 and 1) Methyl-phenyl-carbamic acid 4-thiophen-3-ylmethyl-phenyl ester 4-Thiophen-3-ylmethyl-phenol was prepared following general procedure PVe3 using thio- phene-3-carboxaldehyde. Subsequent carbamoylation using general procedure 1 (CH2CI2 was used as solvent) produced the crude product which was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (83%, oil). 1H NMR (400MHz; CDC!3): S 3.42 (bs, 3H), 3.95 (s, 2H), 6.86-7.39 (m, 12H). Example 544 (General procedure 22 and 1) Methyl-phenyl-carbamic acid 4-thiophen-2-ylmethyl-phenyl ester 4-Thiophen-2-ylmethyl-phenol phenol was prepared following general procedure PVe3 using thiophene-3-carboxaidehyde. Subsequent carbamoylation using genera! procedure 1 (CH2C!2 was used as solvent) produced the crude product which was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (83%, oil). 1H NMR (400MHz; CDC!3): S 3.40 (br s, 3H), 4.13 (s, 2H), 6.78 (dd, 1H), 6.90. (dd, 1H), 7.04 (brd, 2H), 7.13 (dd, 1H), 7.20-7.39 (m, 7H). HPLC-MS : m/z- 324.1 (M+1); Rt = 4.82 min. Example 545 4-Hydroxy-piperidine-1-carboxyIic acid 4-[2-(toIuene-4-suIfonyIamino)-ethyI]-pheny] ester N-Boc protected tyramin (10 mmol), triethylamine (10 mmol) and 3-[4-(tert-Butyl-dimethyl-silanyloxy)-piperidine-1-carbonyI]-1-methyI-3H-imidazoI-1-ium; iodide (10 mmol) in MeCN (25 mL) was stirred at room temperature for 16 hours. Acetonitrile was removed by evaporation and the crude product was purified by flash chromatography (Quad flash 40, EtOAc-heptane 1:2) providing 72% 4-tert-butyIsilanyloxy-piperidine-1-carboxyIic acid 4-(2-tert-butoxycarbony!amino-ethyI)-phenyl ester. This was deprotected by stirring with a 3.2 M solution of HCI in Et20 (50 mL) for 3 h at rt and subsequently washed with ether to give 91% of 4-(4-hydroxy-piperidine-1-carbonyloxy)-phenyI-ammonium; chloride as a solid. This compound was N-tosyiated as described for methyl-phenyl-carbamic acid 4-[2-(toluene-4-sulfonylamino)-ethy[]-phenyl ester to give the title compound in 26% yield as yellow crystals after purification by flash chromatography (Quad flash 12, ChfeCtrMeOH 95:5). HPLC-MS : mfc= 391.0 (M+1); Rt= 3.04 min. Example 546 4-Hydroxy-piperidine-1 -carboxylic acid 4-[2-(5-pyridin-2-yI-thiophene-2-sulfonylamino)-ethyI]-phenyi 4-(4-Hydroxy-piperidine-1-carbonyIoxy)-phenyl»ammonium; chloride (see above) was N- sulfonylated as described for methyl-phenyl-carbamic acid 4-[2-(5-pyridin-2-yl-thiophene-2-sutfonylamino)-ethyO-phenyl ester to give the title compound in 59% yield as an oil after purification by preparative HPLC (Gilson). HPLC-MS : m/z = 488.0 (M+1); Rt = 3.10 min. Example 547 4-Hydroxy-piperidine-1 -carboxylic acid 4-(5-pyridin-2-yl-thiophene-2-sulfonyiamino)-phenyl ester N-Boc protected 4-aminophenol (10 mmol), triethylamine (10 mmol) and 3-[4-(tert-ButyI-dimethyl-siIanyloxy)-piperidine-1-carbonyI]-1«methyl-3H-imida2ol-1-ium; iodide (10 mmol) in MeCN (25 mL) was stirred at room temperature for 16 hours. Acetonitrile was removed by evaporation and the crude product was purified by flash chromatography (Quad flash 40, EtOAc-heptane 1:2) providing 64% 4-tert-butyisilanyioxy-piperidine-1-carboxylic acid 4-tert-butoxycarbonylamino-phenyl ester. This was deprotected by stirring with a 3.2 M solution of HCI in Et20 (50 mL) for 3 h at rt and subsequently washed with ether to give 91 % of 4-(4-Hydroxy-piperidine-1-carbonyloxy)-phenyl-ammoniurn; chloride as a hygroscopic solid. This compound was N-sulfonylated as described for methyl-phenyl-carbamic acid 4-[2-(5-pyridin-2-yl-thiophene-2-sulfonylamino)-ethy!]-phenyI ester to give the title compound in 1% yield as crystals after purification by preparative HPLC (Gilson). HPLC-MS :/77/z= 482.8 (M+1); Rt = 1.01 min. Example 548 Methyl-phenyl-carbamic acid 4-[2-(4-amino-benzenesulfonylamino)-ethyI]-phenyl ester Methyl-phenyl-carbamic acid 4-[2-(4-nitro-benzenesulfonylamino)-ethy(]-phenyl ester, 5% palladium on carbon, and ethanol were stirred under hydrogen at 1 bar and rt for 16 h. Filtration and removal of ethanol produced the title compound in 94% yield as an oil. HPLC-MS: mlz = 426.1 (M+1); Rt= 3.61 min. Example 549 Methyl-phenyl-carbamic acid 4-{2-[(pyridine-3-carbonyl)-amino]-ethyI}-phenyl ester A solution of 3-pyridinecarboxylic acid (0.3 mmol), EDAC (0.36 mmol) and triethylamine (0.36 mmol) in CH2CI2 (10 mL) was added N-hydroxybenzoetriazofe and N-methyl-N-phenyl-carbamic acid 4-(2-amino-ethyl)phenyl ester as its TFA salt (0.3 mmol). The mixture was stir- stirred 16 h at rt and purified by preparative HPLC (Gilson) to give the title compound in 15% yield as an oil. HPLC-MS: m/z= 376.1 (M+1); Rt = 3.01 min. Example 550 Methyl-phenyl-carbamic acid 4-[2-(2-dimethylamino-acetyIamino)-ethyI]-phenyl ester A solution of N.N-dimethyiglycine, HCI (0.3 mmol), EDAC (0.36 mmol) and triethylamine (1.0 mmol) in CH2CI2 (10 mL) was added N-hydroxybenzoetriazole and N-methyl-N-phenyl-carbamic acid 4-(2-amino-ethyI)phenyl ester as its TFA salt (0.3 mmol). The mixture was stirred 16 h at rt and purified by preparative HPLC (Gilson) to give the title compound in 66% yield as an oil. HPLC-MS : mlz = 356.4 (M+1); Rt = 2.09 min. Example 551 (General procedure 23) Methyl-phenyl-carbamic acid 2-(toluene-4-sulfony!)-1,2,3,4-tetrahydro-isoquinolin-7-yl ester The title compound was prepared using methyl-phenyl-carbamic acid 4-[2-(toluene-4-suifonylamino)-ethyI]-phenyl ester as the sulfonamide. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane 2:3) (71%, yellow oii). HPLC-MS : m/z= 437.4 (M+1); Rt = 4.43 min. Example 552 Methyl-phenyl-carbamic acid 4-[4-(2-pyrroIidin-1-yl-ethoxy)-benzyI]-phenyI ester To a stirred solution of 1-[2-(4-bromo-phenoxy)-ethy!]-pyrrolidine (2.89 g, 10.7 mmol) in THF (30 mL) was added dropwise 1.6 M solution in hexanes n-BuLi (7 mL, 10.2 mmol) over a 5-min period at -78°C. The mixture was stirred at -78°C for 15 min before 4-trimethylsilyloxybenzaldehyde (2.08 g, 10.7 mmol) was added. The mixture was allowed to warm to rt during 20 min and quenched with water. Extraction with CH2CI2, drying (MgS04), filtration and evaporation provided the crude diarylmethanol which was dissolved in CH2Ci2 (30 mL) and stirred with triethylsilane (4 mL) and TFA (5 mL) for 16 h at rt. Evaporation gave 3.0 g (84%) 4-[4-(2-pyrrolidin-1-yl-ethoxy)-benzyl]-phenol. This was carbamoylated using general procedure. 1 (CH2CI2 was used as solvent) to give the title product after purification by preparative HPLC (Gilson) (35%, oil). HPLC-MS : m/z = 431.5 (M+1); Rt = 2.93 min. Example 553 (General procedure 24) 4-Hydroxy-piperidine-1-carboxylic acid 4-pyridin-2-ylmethyl-phenyl ester The title compound was prepared as its hydrochloride using 4-pyridin-2-yimethy!-phenol as the phenol. 1H NMR (300MHz; D20): S 1.50 (br s, 2H), 1.90 (df 2H), 3.04-3.27 (m, 2H), 3.78-4.08 (m, 3H), 4.41 (s, 2H), 7.07 (d, 2H), 7.30 (df 2H), 7.79-7.85 (m, 2H), 8.40 (dt, 1H), 8.55 (d, 1H). Example 554 (Genera! procedure 24) 4-Hydroxy-piperidine-1-carboxyIic acid 4-pyridin-3-ylmethyI-phenyl ester The title compound was prepared as its hydrochloride using 4-pyridin-3-yImethyl-phenol as the phenol. 1H NMR (300MHz; D20): 8 1.48 (br s, 2H), 1.90 (d, 2H), 3.03-3.26 (m, 2H), 3.80-4.05 (m, 3H), 4.18 (s, 2H), 7.03 (d, 2H), 7.25 (d, 2H), 7.40 (dd, 1H), 8.40 (d, 1H), 8.54-8.57 (m, 2H). Example 555 (General procedure 24) 4-Hydroxy-piperidine-1-carboxylic acid 4-(4-trifluoromethyI-benzyI)-phenyi ester The title compound was prepared using 4-(4-trifluoromethyl-benzyl)-phenol as the phenol. 1H NMR (300MHz; D20): 5 1.43-1.55 (m, 2H), 1.76-1.88 (m, 2H), 3.10-3.29 (m, 2H), 3.79-3.94 (m, 5H), 6.97 (d, 2H), 7.08 (d. 2H), 7.20 (d, 1H), 7.45 (d, 2H). Example 556 (General procedure 23) Methyl-phenyl-carbamic acid 2»[4-(2-pyrroIidin-1-yl-ethoxy)-benzenesulfonyl]-1,2,3,4- tetrahydro-isoquinolin-7-yI ester The title compound was prepared using methyl-phenyl-carbamic acid 4-{2-[4-(2-pyrrolidin-1-yI-ethoxy)-benzenesulfonylamino]-ethyI}-phenyl ester as the sulfonamide. The crude product was purified by preparative HPLC (Gilson) and isolated as its TFA salt (45%, foam). HPLC-MS : m/z= 536.2 (M+1); Rt = 3.10 min. Example 557 Methyl-phenyl-carbamic acid 4-{2-[(1-methyI-piperidine-4-carbonyl)-amino]-ethyI}-phenyl ester A solution of 1-methylpiperidine-4-carboxylic acid (0.3 mmol), EDAC (0.36 mmol) and triethy-lamine (1.0 mrnol) in CH2CI2 (10 mL) was added N-hydroxybenzoetriazole and N-methyl-N-phenyl-carbamic acid 4-(2-amino-ethyI)phenyl ester as its TFA salt (0.3 mmol). The mixture was stirred 16 h at rt and purified by preparative HPLC (Gilson) to give the title compound in 5% yield as an oil. HPLC-MS : m/z= 396.4 (M+1); Rt = 2.03 min. Example 558 (General procedure 23) Methyl-phenyl-carbamic acid 2-(3,4-difluoro-benzenesuIfonyl)-1,2,3,4-tetrahydro-isoquinoIin- 7-yI ester The title compound was prepared using methyl-phenyl-carbamic acid 4-[2-(3,4-difluoro-benzenesu!fonylamino)-ethyI]-phenyl ester as the sulfonamide. The crude product was purified by preparative HPLC (Gilson) (24%, oil). HPLC-MS : m/z= 481.0 (M+23); Rt= 4.73 min. Example 559 (General procedure 23) Methyl-phenyl-carbamic acid 1-methyl-2-(toluene-4-sulfony!)-1 ^^^-tetrahydro-isoquinoIin-T- yl ester The title compound was prepared using methyl-phenyl-carbamic acid 4-[2-(toluene-4-sulfonylamino)-ethyI]-phenyl ester as the sulfonamide and acetaldehyde in stead of formaldehyde. The crude product was purified by preparative HPLC (Gilson) (22%, brown oil). HPLC-MS : m/z = 451.5 (M+1); Rt = 4.43 min. Example 560 (General procedure 23) Methyl-phenyl-carbamic acid 2-[4-(4-methyl-piperazin-1-yl)-benzenesuIfonyl]-1,2,3,4- tetrahydro-isoquinolin The title compound was prepared using methyl-phenyl-carbamic acid 4-{2-[4-(4-methyl-piperazin-1-yl)-benzenesulfonylamino]-ethy(}-phenyi ester as the sulfonamide. The crude product was purified by preparative HPLC (Gilson) and isolated as its TFA salt (79%, crystals). HPLOMS : m/z= 521.5 (M+1); Rt= 2.65 min. Example 561 (General procedure 23) Methyl-phenyl-carbamic acid 1 -methyl-2-[4-(4-methyl-piperazin-1 -yl)-benzenesulfonyl]- 1,2,3,4-tetrahydro-isoquinoIin-7-yl ester The title compound was prepared using methyl-phenyl-carbamic acid 4-{2-[4-(4-methyl-piperazin-1-yI)-benzenesulfonyIamino]-ethyl}-phenyl ester as the sulfonamide and acetalde-hyde in stead of formaldehyde. The crude product was purified by preparative HPLC (Gilson) (12%, brown oil). HPLC-MS: mtz* 535.4 (M+1); Rt= 2.69 min. Example 562 3,3-Dimethyl-4-{2-[4-(methyl-pheny!-carbamoy^ A solution of 3,3-dimethylglutaric anhydride (0.3 mmol), diisopropylethylamine (0.30 mmol) and N-methyl-N-phenyl-carbamic acid 4-(2-amino-ethyI)phenyl ester as its TFA salt (0.3 mmol) in CH2CI2 (3 mL) was stirred 1 h at rt. The mixture was washed with water and brine, dried and evaporated to give the title compound in 95% yield as an oil. HPLC-MS : m/z = 413.2 (M+1); Rt = 3.20 min. Example 563 Methyl-phenyl-carbamic acid 4-{2-[4-(4-methyl-piperazin-1 -yl)-benzoylamino]-ethyI}-phenyl ester A solution of 4-(4-methylpiperazino)benzoic acid (0.3 mmol), EDAC (0.36 mmol) and triethyl-amine (1.0 mmol) in CH2CI2 (10 mL) was added N-hydroxybenzoetriazo!e and N-methyl-N-phenyl-carbamic acid 4-(2-amino-ethyI)phenyl ester as its TFA salt (0.3 mmol). The mixture was stirred 16 h at rt and purified by preparative HPLC (Gilson) to give the title compound in 54% yield as its crystalline hydrochloride after treatment with HCI in diethyl ether. HPLC-MS : mlz = 473.2 (M+1); Rt = 2.22 min. Example 564 Methyl-phenyl-carbamic acid 4-{2-[4-(4-methyI-piperazin-1 -ylmethy[)-benzoyiamino]-ethyl}-pheny! ester A solution of 4-(4-methylpiperazinyI)methyl benzoic acid (0.3 mmol), EDAC (0.36 mmol) and triethylamine (1.0 mmol) in CH2CI2 (10 mL) was added N-hydroxybenzoetriazole and N- methyl-N-phenyl-carbamic acid 4-(2-amino-ethyl)phenyI ester as its TFA salt (0.3 mmol). The mixture was stirred 16 h at rt and purified by preparative HPLC (Gilson) to give the title compound in 25% yield as its crystalline hydrochloride after treatment with HCI in diethyl ether.. HPLC-MS : mfz= 487.3 (M+1); Rt = 2.13 min. Example 565 Methyl-phenyl-carbamic acid 4-[2-(4,4-dimethyI-2,6-dioxo-piperidin-1-yI)-ethyl]-phenyI ester A solution of 3,3-dimethylglutaric anhydride (0.3 mmol), diisopropylethylamine (0.30 mmol) and N-methyl-N-phenyl-carbamic acid 4-(2-amino-ethyl)phenyI ester as its TFA salt (0.3 mmol) in CH2CI2 (3 mL) was stirred 1 h at rt. Thionylchloride (3 mmol) was added and the mixture was stirred for 2 h at rt. Addition of ethanol (5 mL) followed by evaporation to dryness gave a crude product which was purified by flash chromatography (Quad flash 12, EtOAc-heptane 1:1). This gave the title compound in 23% yield as crystals. Furthermore 3,3-dimethyI-4-{2-[4-(methyl-phenyl-carbamoyloxy)-pheny[]-ethylcarbamoyl}-butyricacid ethyl ester could be isolated in 27% yield as an oil (see characterization below) 1H NMR (400MHz; CDCI3): 5 1.04 (s, 6H), 2.47 (s, 4H), 2.79 (t, 2H), 3.42 (br s, 3H), 3.97 (t, 2H), 7.03 (br d, 2H), 7.21-7.28 (m, 3H), 7.33-7.41 (m, 4H). HPLC-MS : m/z = 395.2 (M+1); Rt = 4.23 min. Example 566 3,3-DimethyI-4-{2-[4-(methyl-phenyl-carbamoyIoxy)-phenyI]-ethylcarbamoyI}-butyricacid ethyl ester For experimental details, see preparation of methyl-phenyl-carbamic acid 4-[2-(4,4-dimethyl- 2,6-dioxo-piperidin-1 -yl)-ethyl]-phenyl ester. 1H NMR (400MHz; CDCl3): 8 1.05 (s, 6H), 1.24 (t, 3H), 2.19 (s, 2H), 2.22 (s, 2H), 2.80 (t, 2H), 3.42 (br s, 3H), 3.50 (q, 2H), 4.1 (q, 2H), 6.53 (t, 1H), 7.03 (br d, 2H), 7.18 (d, 2H), 7.26 (t,1H)( 7.33-7.41 (m,4H), HPLC-MS: m/z = 441.2 (M+1); Rt = 4.11 min. Example 567 Methyl-phenyl-carbamic acid 4-hydroxymethyl-phenyl ester To a solution of 4-hydroxymethylphenol (10 mmol) and 4-diazabicyclo[2.2.2]octane (DABCO) (10 mmol) in CH2CI2 (30 mL) was added N-methyl-N-phenylcarbamoyI chloride (10 mmol). The reaction mixture was stirred for 16 hours at rt, added CH2Cl2 (20. mL) and washed with 1M aqueous HCI and brine. The organic phase was dried (MgS04).and evaporated to give the crude product which was purified by FC (Quad flash 40 EtOAc-Heptane 1:1) to give 2-18 g (85%) of the title compound as an oil. 1H NMR (400MHz; CDCI3): S. 1.70 (br s, 1H), 3.40 (br s, 3H), 4.66 (s, 2H), 7.08 (br d, 2H), 7.25-7.42 (m, 7H); HPLC-MS : mlz = 258.1 (M+1); Rt = 2.99 min. Example 568 Methyl-phenyl-carbamic acid 4-(2-hydroxy-ethy[)-phenyl ester To a solution of 4-(2-Hydroxyethyl)phenol (10 mmol) and 4-diazabicyclo[2.2.2]octane (DABCO) (10 mmol) in CH2CI2 (30 mL) was added N-methy!-N-pheny)carbamoy! chloride (10 mmol). The reaction mixture was stirred for 16. hours at rt, added CH2Cl2 (20 mL), and washed with 1M aqueous HCI and brine. The organic phase was dried (MgS04) and evaporated to give the 2.69 g (99%) of the title compound as crystals. 1H NMR (400MHz; CDCI3): 8 1.52 (br s, 1H), 2.54 (t, 2H), 3.41 (br s, 3H), 3.81 (t, 2H), 7.04 (br d, 2H), 7.20 (d, 2H), 7.22-7.42 (m, 5H); HPLC-MS : m/z= 272.1 (M+1); Rt = 3.17 min. Example 569 (General procedure 1) Methyl-phenyl-carbamic acid 4-(4-dimethylamino-pyridin-2-ylmethyi)-phenyl ester A solution of 2-(dimethyIamino)ethanoI (32 mmol) in hexane (120 mL) was cooled to - 5°C and n-BuLi (64 mmol) was added. After 30 min 4-(dimethyIamine=pyridine (16 mmol) was added and the red-orange mixture was stirred for further 1 h. The solution was cooled to -78 °C and 4-(trimethylsilyIoxy)benzaldehyde (40 mmol) dissolved in hexane (80 mL) was added and the suspention was allowed to warm to rt over 20 min. The reaction mixture was quenched with water, and the aqueous phase was washed with CH2CI2, The aqueous phase was. evaporated to dryness, added Nal (96 mmol) and dissolved in MeCN (160 mL). Addition of trimethylsilylchloride (96 mmol) and stirring at rt for 16h. The purple reaction mixture was evaporated to dryness and treated with an aqueous solution of Na2S03 and pH was adjusted to 8. Extraction with CH2CI2 gave after evaporation 560 mg (15%) slightly impure 4-(4-dimethylaminO"pyridin-2-ylmethyl)phenol as yellow crystals. This was carbamoylated using general procedure 1 (CH2CI2 was used as solvent) to give the title, product as its hydrochloride after purification by preparative HPLC (Gilson) and treatment with HCI in Et20 (48%, ligt yellow crystals). HPLC-MS: mlz = 362.2 (M+1); Rt = 2.27 min. Example 570 (General procedure 25) Methyl-phenyl-carbamic acid 4-(4-imidazol-1-yl-phenoxymethy!)-phenyl ester The title compound was prepared in 53% yield as light yellow crystals using and 4-imidazol-1-yt-phenol. 1H NMR (400MHz; CDC)3): 8 3.42 (br s, 3H), 5.08 (s, 2H), 7.03 (d, 2H), 7.12-7.42 (m, 15H), 7.77 (s, 1H); HPLC-MS : mlz = 400.1 (M+1); Rt = 2.62 min. Example 571 (General procedure 25) Methyl-phenyl-carbamic acid 4-[4-(2-dimethylamino-ethyl)-phenoxymethy[]-phenyl ester The title compound was prepared in 52% yield as colorless crystals using methyl-phenyl-carbamic acid 4-hydroxymethyl-phenyl ester and 4-(2-dimethylaminoethyI)-phenol. 1H NMR (400MHz; CDCi3): 5 2.85 (s, 6H), 2.98-3.02 (m, 2H), 3.17-3.21 (mf 2H), 3.42 (br s, 3H), 5.02 (s, 2H), 6.90 (d, 2H), 7.12 (d, 2H), 7.25-7.43 (m, 7H); HPLC-MS : m/z = 405.2 (M+1); Rt = 2.91 min. Example 572 (General procedure 25) Methyl-phenyl-carbamic acid 4-(pyrazoI-1-yloxymethy!)-phenyl ester The title compound was prepared in 79% yield as an oil using and 1-hydroxypyrazoIe. 1H NMR (400MHz; CDCl3): 5 3.42 (br s, 3H), 5.26 (s, 2H), 6.03 (t, 1H), 6.95 (dd, 1H), 7.11 (br s, 2H), 7.25-7.42(m, 8H); HPLC-MS : m/z= 324.1 (M+1); Rt= 3.58 min. Example 573 (General procedure 25) Methyl-phenyl-carbamic acid 4-(imidazo!-1-yloxymethyI)-phenyl ester The. title compound was prepared as its TFAsalt in 87% yield as a solid using methyl-phenyl-carbamic acid 4-hydraxymethyl-phenyl ester and 1-hydroxyimidazole, hydrochloride. 1H NMR (400MHz; CDCI3): S 3.42 (br s, 3H)f 5.21 (s, 2H), 6.95 (s, 1H), 7.16-7.45 (m, 10H), 8.28 (br s, 1H); HPLC-MS :m/z= 324.1 (M+1); Rt = 1.92min. Example 574 (General procedure 25) Methyl-phenyl-carbamic acid 4-(2-oxo-2H-pyridin-1-ylmethy!)-phenyl ester The title compound was prepared in 29% yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyl)-phenyl ester and 2-hydroxypyridine. in addition 50% of the isomeric methyl-phenyl-carbamic acid 4-[2-(pyridin-2-yIoxy)-ethyO-phenyl ester was isolated, see characterization below. 1H NMR (400MHz; CDCI3): £.3.05 (t, 2H)f 3.41. (br s, 3H), 4.14 (s, 2H)f 6.08. (t, 1H)f 6.66 (d, 1H), 6.90 (dd, 1H), 7.02 (br s, 2H), 7.10 (d, 2H), 7.25-7.42 (m, 6H); HPLC-MS : mlz = 349.2 (M+1); Rt = 3.04 min. Example 575 (General procedure 25) Methyl-phenyl-carbamic acid 4-[2-(pyridin-2-yloxy)-ethyl]-phenyl ester The title compound was prepared in 50%. yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyl)-phenyl ester and 2-hydroxypyridine. In addition 29% of the isomeric methyl-phenyl-carbamic acid 4-(2-oxo-2H-pyridin-1-ylmethyi)-phenyl ester was isolated, see characterization above. 1H NMR (400MHz; CDCI3): 5 3.08 (t, 2H), 3.41 (br s, 3H), 4.49 (s, 2H), 6.73 (d, 1H), 6.88 (dd, 1H), 7.05 (br d, 2H), 7.22-7.42 (m, 7H), 7.61 (dt, 1H), 8.18 (dd, 1H); HPLC-MS : mlz = 349.2 (M+1); Rt = 3.97 min. Example 576 (General procedure 25) Methyl-phenyl-carbamic acid 4-[2-(4-imidazoM-yl-phenoxy)-ethyl]-phenyl ester The title compound was prepared as its TFA salt in 62% yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyl)-phenyl ester and 4-imidazol-1-yl-phenol. 1H NMR (400MHz; CDCI3): 5 3.11 (t, 2H)f 3.42 (br s, 3H), 4.22 (s, 2H)f 7.00-7.10 (m, 5H)f 7.25-7.42 (m, 9H), 7.52 (s, 1H)f 8.81 (s, 1H); HPLC-MS : mlz = 414.2 (M+1); Rt = 2.73 min. Example 577 (General procedure 25) Methyl-phenyl-carbamic acid 4-{2-[4-(2-dimethylamino-ethyl)-phenoxy]-ethyl}-phenyl ester The title compound was prepared as its TFA salt in 92% yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyl)-phenyl ester and 4-(2-dimethyIaminoethyl)-phenoL HPLC-MS : mlz = 419.2 (M+1); Rt = 2.77 min. Example 578 (General procedure 25) Methyl-phenyl-carbamic acid 4-[2-(pyrazoM-yloxy)-ethyl]-pheny! ester The title compound was prepared in 62% yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyl)-phenyl ester and 1-hydroxypyrazoIe. 1H NMR (400MHz; CDCl3): 8 3.02 (t( 2H)( 3.42 (br s, 3H), 4.50 (t, 2H), 6.16 (t, 1H), 7.05 (br d, 2H), 7.20-7.41 (m, 9H); HPLC-MS : mlz= 338.2 (M+1); Rt = 3.74 min. Example 579 (General procedure 25) Methyl-phenyl-carbamic acid 4-[2-(imidazoI-1-yioxy)-ethyl]-phenyI ester The title compound was prepared as its TFA salt in 79% yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyI)-phenyI ester and 1-hydroxyimidazoIe hydrochlorid. 1H NMR (400MHz; CDCI3): 8 3.06 (t, 2H), 3.42 (br s, 3H), 4.52 (t, 2H), 7.08-7.42 (m, 11H), 8.53 (s, 1H); HPLC-MS : m/z = 338.2 (M+1); Rt= 2.18 min. Example 580 (General procedure 1) Methyl-phenyl-carbamic acid 4-(5-methyI-pyridin-2-ylmethyI)-phenyI ester To a stirred solution of 2-bromo-5-methylpyridine (3.45 g, 20 mmol) in THF (10 ml_) was added dropwise 1.6 M solution in hexanes n-BuLi (12 mL, 19.2 mmol) over a 10-min period at -78°C. The mixture was stirred at -78°C for 2 min before 4-trimethylsilyloxybenzaldehyde (4.2 g, 21.6 mmol) dissolved in THF (10 mL) was added. The mixture was allowed to warm to • -40 °C and quenched with water. The pH of the aqueous phase was adjusted to 7 which causes precipitation of 4-[hydroxy-(5-methyI-pyridin-2-yI)~methyI]phenoL This was isolated by filtration to give 1.13 g (27%) of 4-[hydroxy-(5-methyl-pyridin-2-yl)-methyl]phenol as crystals. This intermediate was dissolved in CH2CI2 (15 mL) and stirred with triethylsiiane (4 mL) and TFA (5 mL) for 16. h at 50 °C. Evaporation gave 99% of 4-(5-methyl-pyridin-2-ylmethyl)phenol as a hygroscopic solid. This was carbamoylated using general procedure 1 (CH2Cl2 was used as solvent and N-phenyl-N-methyl carbamoyl chlorid) to give 99% of the title product as its crystalline hydrochloride after purification by flash chromatography (Quad flash 12, EtOAc-heptane) and treatment with HCI in Et20. 1H NMR (400MHz; CDCI3): 8 2.50 (s, 3H), 3.41 (br s, 3H), 4.57 (s, 2H), 7.10 (br s, 2H), 7.25-7.42 (m, 8H), 8.00 (dd, 1H), 8.46 (br s, 1H); HPLC-MS: mlz = 333.1 (M+1); Rt = 2.60 min. Example 581 (General procedure 24) 4-Hydroxy-piperidine-1-carboxylic acid 4-(5-methyl-pyridin-2-ylmethyl)-phenyI ester The title compound was prepared as its hydrochloride using of 4-(5-methyl-pyridin-2- flmethyI)phenol as the phenol. H NMR (300MHz;. CDCl3): S 1.57-1.67 (m, 3H), 1.95 (d, 2H), 2.51 (s, 3H), 3.21-3.40 (m, 2H), 3.90-4.05 (m, 3H), 4.58 (s, 2H), 7.11 (d, 2H), 7.38 (d, 2H), 7.45 (d, 1H), 8.02 (d, 1H), 3.48(brs, 1H). Example 582 (General procedure 25) Methyl-phenyl-carbamic acid 4-(4-oxo-4H-pyridin«1-ylmethyl)-phenyl ester The title compound was prepared in 33% yield as colorless crystals using methyl-phenyl-carbamic acid 4-hydroxymethyl-phenyl ester and 4-hydroxypyridine. 1H NMR (400MHz; CDCI3): S 3.43 (br s, 3H), 4.92 (sf 2H), 6.43 (d, 2H), 7.17 (br s, 4H), 7.22-7.42 (m, 9H); HPLC-MS : mlz = 335.0 (M+1); Rt = 2.55 min. Example 583 (General procedure 25) Methyl-phenyl-carbamic acid 4-[2-(pyridin-3-yloxy)-ethyi]-phenyl ester The title compound slightly contaminated with tributylphosphine oxide was prepared in 80% yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyI)-phenyl ester and 3- hydroxypyridine. 1H NMR (400MHz; CDCI3): 5 3.11 (t, 2H), 3.42 (br s, 3H), 4.23 (t, 2H), 7.07 (br d, 2H), 7.24- 7.41 (m, 9H)( 8.29 (br s, 1H), 8.40 (br s, 1H); HPLC-MS : mlz = 349.2 (M+1); Rt = 2.87 min. Example 584 (General procedure 25) Methyl-phenyl-carbamic acid 4-(2-oxo-2H-pyridin-1-ylmethyl)-phenyl ester The title compound was prepared in 66% yield as an oil using methyl-phenyl-carbamic acid 4-hydroxymethyl-phenyl ester and 2-hydroxypyridine. 1H NMR (400MHz; CDCI3): 5 3.42 (br sf 3H), 5.12 (s, 2H), 6.13 (t, 1H), 6.60 (d, 1H), 7.10 (br s, 2H), 7.22-7.41 (m, 9H); HPLC-MS : mlz = 335.2 (M+1); Rt = 2.97 min. Example 585 (General procedure 25) Methyl-phenyl-carbamic acid 4-(pyridin-3-yloxymethyl)-phenyl ester The title compound was prepared in 43% yield as an oil using methyl-phenyl-carbamic acid 4-hydroxymethyl-phenyl ester and 3-hydroxypyridine. 1H NMR (400MHz; CDCI3): S 3.44 (br s, 3H), 5.12 (s, 2H), 7.17 (br s, 2H), 7.27-7.46 (m, 9H), 8.29 (br s, 1H), 8.49 (br s, 1H); HPLC-MS : m/z = 335.0 (M+1); Rt = 2.74 min. Example 586 (General procedure 26) Methyl-phenyl-carbamic acid 4-[2-(2,5-dioxo-pyrroIidin-1-yI)-ethyI]-phenyl ester The title compound was prepared in 85% yield as crystals using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyI)-phenyI ester and succinimide. 1H NMR (400MHz; CDCl3): 5 2.65 (s, 4H), 2.86 (t, 2H), 3.41 (br s, 3H), 3.72 (t, 2H), 7.04 (br d, 2H), 7.19 (d, 2H), 7.26-7.42 (m, 5H); HPLC-MS : m/z = 353.2 (M+1); Rt = 3.17 min. Example 587 (General procedure 26) Methyl-phenyl-carbamic acid 4-[2-(1,3-dioxo-1,3-dihydro-pyrrolo[3,4-]pyridin-2-y[)-ethyI]- phenyl ester The title compound was prepared in 58% yield as crystals using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyI)-phenyl ester and 3,4-pyridinedicarboximide. 1H NMR (400MHz; CDCl3): 8 . 2.98 (tf 2H), 3.40 (br s, 3H), 3.93 (t, 2H), 7.05 (br d, 2H), 7.20-7.42 (m, 7H), 7.73 (dd, 1H), 9.06 (d, 1H), 9.12 (d, 1H); HPLC-MS : m/z = 402.1 (M+1); Rt = 3.56 min. Example 588 (General procedure 26) Methyl-phenyl-carbamic acid 4-(1-methyl-1H-imidazol-2-ylsulfanylmethyl)-phenyl ester. The title compound was prepared as its TFA salt in 22% yield as an oil using methyl-phenyl-carbamic acid 4-hydroxymethyl-phenyl ester and 2-mercapto-1-methyIimidazole. 1H NMR (400MHz; CDCI3): S 3.34 (s, 3H), 3.40 (br s, 3H), 4.30 (s, 2H), 6.98 (br s, 2H), 7.08-7.11 (m, 3H),7.27-7.42 (m, 5H), 7.48 (d, 1H); HPLC-MS : m/z = 354.1 (M+1); Rt = 2.12 min. Example 589 (General procedure 26) Methyl-phenyl-carbamic acid 4-tetrazoM-ylmethyl-phenyl ester The title compound was prepared in 6% yield as an oil using methyl-phenyl-carbamic acid 4-hydroxymethyl-phenyl ester and tetrazole. 1H NMR (400MHz; CDCI3): S 3.42 (br s, 3H), 5.57 (s, 2H), 7.17 (br s, 2H), 7.26-7.42 (m, 7H), 8.52 (s, 1H); HPLC-MS : m/z = 332.0 (M+23); Rt = 3.24 min. Example 590 (General procedure 26) Methyl-phenyl-carbamic acid 4-(2,5-dioxo-pyrroIidin-1-yImethyI)-phenyl ester The title compound was prepared in 57% yield as beige crystals using methyl-phenyl-carbamic acid 4-hydroxymethyl-phenyl ester and succinimide. 1H NMR (400MHz; CDCI3): S 2.68 (s, 4H), 3.41 (br s, 3H), 4.60. (s, 2H), 7.04 (br d, 2H), 7.23-7.41 (m, 7H); HPLC-MS : mlz = 339.1 (M+1); Rt= 3.40 min. Example 590 (General procedure 26) Methyl-phenyl-carbamic acid 4-[2-(2-thioxo-2H-pyridin-1-yl)-ethyl]-phenyl ester The title compound was prepared in 25% yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyI)-phenyl ester and 2-mercaptopyridine. HPLC-MS : mlz- 365.2 (M+1); Rt = 4.08 min. Example 591 (General procedure 26) Methyl-phenyl-carbamic acid 4-(1,3-dioxo-1,3-dihydro-pyrrolo[3,4)pyridin-2-ylmethyI)-phenyl ester The title compound was prepared in 21% yield as an oil using methyl-phenyl-carbamic acid 4-hydroxymethyl-phenyl ester and 3,4-pyridinedicarboximide. 1H NMR(400MHz; CDCI3); S 3.40 (brs. 3H)f 4.82 (s, 2H), 7.06 (d, 2H), 7.22-7.44 (m, 8H), 7.73 (d, 1H), 9.04 (df 1H), 9.12 (s, 1H); HPLC-MS : m/z= 388.0 (M+1); Rt = 3.80 min. Example 592 (General procedure 26) Methyl-phenyl-carbamic acid 4-[1,2,4]1xiazol-1-ylmethyl-phenyl ester The title compound was prepared as its TFA salt in 27% yield as an oil using methyl-phenyl-carbamic acid 4-hydroxymethyl-phenyl ester and 1,2,4-triazole. 1H NMR (400MHz; CDCI3): 5 3.42 (br s. 3H), 5.34 (s, 2H), 7.15 (br d, 2H), 7.26-7.43 (m, 7H), 8.10 (s. 1H), 8.38 (s, 1H); HPLC-MS : m/z= 309.1 (M+1); Rt = 2.74 min. Example 593 (General procedure 26) Methyl-phenyl-carbamic acid 4-(2-thioxo-2H-pyridin-1-ylmethyi)-phenyl ester The title compound was prepared in 14% yield as an oil using methyl-phenyl-carbamic acid 4-hydroxymethyl-phenyl ester and 2-mercaptopyridine. HPLC-MS: mlz = 351.1 (M+1); Rt = 3.95 min. Example 594 (General procedure 26) Methyl-phenyl-carbamic acid 4-[2-(1-methyl-1H«imida2oI-2-ylsulfanyI)-ethyi]-phenyI ester The title compound was prepared as its TFA salt in 37% yield as an oil using methyl-phenyi-carbarnic acid 4-(2-hydroxy-ethyI)-phenyI ester and 2-mercapto-1-methyIimidazole. NMR (400MHz; CDCl3): 8 3.01 (t, 2H), 3.40 (br s, 3H)f 3.47 (s, 1H), 3.64 (t, 2H), 6.92 (br d, 2H), 6.98 (s, 1H), 7.08 (d, 2H), 7.26-7.43 (m, 6H); HPLC-MS : mlz = 368.2 (M+1); Rt = 2.30 min. Example 595 (General procedure 26) Methyl-phenyl-carbamic acid 4-(2-tetrazol-1-yl-ethyl)-phenyl ester The title compound was prepared in 10% yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyl)-phenyI ester and tetrazole. NMR (400MHz; CDCI3): 8 3.19 (t, 2H), 3.40 (br s, 3H), 3.47 (s, 1H), 4.61 (t, 2H), 6.98-7.07 (m, 4H), 7.25-7.42 (m, 5H), 8.26 (s, 1H); i HPLC-MS : mlz = 324.1 (M+1); Rt = 3.36 min. Example 596 (General procedure 26) Methyl-phenyl-carbamic acid 4-[2-(pyrimidin-2-yloxy)-ethyI]-phenyI ester The title compound was prepared in 24% yield as light yellow crystals using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyl)-phenyl ester and 2-hydroxypyrimidine. NMR (400MHz; CDCI3): 8 3.11 (t, 2H), 3.42 (br s, 3H), 4.54 (tf 2H), 6.93 (t, 1H), 7.05 (d, 2H), 7.25-7.42 (m, 7H), 8.51 (d, 2H); HPLC-MS : mlz = 350.2 (M+1); Rt = 2.86 min. Example 597 (General procedure 26) Methyl-phenyl-carbamic acid 4-[2-(pyridin-4-ylsulfanyI)-ethyl]-phenyl ester The title compound was prepared as its TFA salt in 5% yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyl)-phenyl ester and 4-mercaptopyridine. NMR (400MHz; CDCI3): 8 3.07 (t, 2H), 3.36 (t, 2H), 3.44 (br s, 3H), 7.06 (br d, 2H), 7.20 (d( 2H), 7.25-7.43 (m, 7H)( 8.51 (d, 2H); HPLC-MS: mlz = 365.2 (M+1); Rt = 2.53 min. Example 598 (General procedure 12) 4-(3-Amino-phenyI)-piperidine-1-carboxylic acid 4-(5-trifluoromethyI-pyridin2-yIoxy)-phenyl ester, The title product was prepared from 4-(3-aminophenyI)piperidine (released form the correspondent hydrochloride by a standard procedure) and 4-(5-trifluoromethyl-pyridin-2-yIoxy)-phenyI chloroformate, preparative HPLC (method C) (reaction performed in a mixture of dichloro-methane and dimethylformamide, 5:3). 1.7 M HCI in ethyl acetate was added to the pooled fractions containing the title product, and the fractions was evaporated to dryness (7%, light yellow solid). HPLC-MS m/z = (M+1) 458.0, Rt: 3.09 min. Example 599 (Genera! procedure 26) Methyl-phenyl-carbamic acid 4-[2-(1-pyridin-3-yl-1H-imida2ol-2-ylsulfanyI)-ethy!]-phenyl ester The title compound was prepared as its TFA salt in 5% yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyI)-phenyl ester and 3-(2thio-1H-imidazoI-1-yl)pyridine. NMR (400MHz; CDCI3): 5 2.95 (t, 2H), 3.42 (br s, 2H), 3.56 (t, 3H), 6.98 (br d, 2H), 7.05 (d, 2H), 7.15 (d, 1H), 7.23-7.43 (m, 5H), 7.48 (d, 1H), 7.53 (dd, 1H), 7.70 (ddd, 1H), 8.65 (d, 1H), 8.77 (dd, 1H); HPLC-MS : mlz = 431.2 (M+1); Rt = 2.79 min. Example 600 (General procedure 26) Methyl-phenyl-carbamic acid 4-[2-(1f3-dioxo-1l3-dihydro-isoindol-2-yI)-ethyl]-phenyl ester The title compound was prepared in 39% yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyl)~phenyl ester and isoindole-1,3-dione. NMR (400MHz; CDCI3): 8 2.98 (t, 2H), 3.41 (br sf 2H), 3.89 (t, 3H), 7.04 (br d, 2H), 7.20-7.40 (m, 7H), 7.68-7.71 (m, 2H), 7.80-7.83 (m, 2H); HPLC-MS : mlz = 401.1 (M+1); Rt = 4.41 min. Example 601 4-Phenyl-piperidine-1-carboxylic acid 4-(5-methyl-pyridin-2-ylmethyI)-phenyl ester To a solution of 4-(5-methyl-pyridin-2-ylmethyl)phenol (0.8 mmol) prepared as described above and ethyldiisopropylamine (1.5 mmol) in CH2CI2 (5. mL) at -30 °C was added trichloro-methyl chloroformiate (1.0 mmol). The solution was stirred at -30 °C for 10 min and at reflux temperature, for 2 h. The solution was evaporated to dryness and redissolved in CH2CI2 (5 mL) and cooled to 0. °C before addition of 4-phenyIpiperidine (1.5 mmol). The solution was stirred at room temperature for 16 h evaporated, to give the crude product which was purified by FC (Quad flash 40 CH2CI2:Et20:Heptane:Et3N 1:1:2:0.25 ->1:1:1:0.25) to give the title compound in 28% yield as an oil. 1H NMR (400MHz; CDCI3): £1.70-1.80 (mf 2H), 1.91 (br d, 2H), 2.29 (s, 3H), 2.72 (tt, 1H)f 2.94 (br t, 1H), 3.08 (br.t, 1H), 4.10 (s, 2H), 4.42 (br s, 1H), 7.00 (d, 1H), 7.06 (d, 2H), 7.21-7.26 (m, 5H), 7.32 (d, 2H), 7.38 (dd, 1H), 8.37 (d, 1H); HPLC-MS :.m/z= 387.2 (M+1); Rt = 2.95 min. Example 602 4-(4-Methoxy-phenyl)-3l6-dihydro-2H-pyridine-1-carboxyIicacid 4-(5-methyl-pyridin-2-ylmethyl)-phenyl ester To a solution of 4-(5-methyl-pyridin-2-ylmethyl)phenol (0.8 mmol) prepared as described above and ethyldiisopropylarnine (1.5 mmol) in CH2CI2 (5 mL) at -30 °C was added trichloro-methyl chloroformiate (1.0 mmol). The solution was stirred at -30 °C for 10 min and at reflux temperature for 2 h. The solution was evaporated to dryness and redissolved in CH2Cl2 (5 mL) and cooled to 0 °C before addition of 4-(4-methoxyphenyI)-1l2,3,6-tetrahydro-pyridine (1.5 mmol). The solution was stirred at room temperature for 16 h evaporated to give the crude product which was purified by FC (Quad flash 40 CH2Cl2:Et20:Heptane:Et3N 1:1:2:0.25 ->1-.1:1:0.25) to give the title compound in 10% yield as colorless crystals. 1H NMR (400MHz; CDCI3): £2.30 (s, 3H), 2.60 (br s, 2H), 3.75-3.88 (m, 5H), 4.12 (s. 2H), 4.20 (br s, 1H), 4.30 (br s, 1H), 5.98 (br s, 1H), 6.88 (d, 2H), 7.00 (d, 1H), 7.07 (d, 2H), 7.24 (d, 2H), 7.34 (d, 2H), 7.39 (dd, 1H), 8.38 (d, 1H); HPLC-MS : mlz= 415.3. (M+1); Rt = 2.95 min. PHARMACOLOGICAL METHODS Compounds of formula I may be evaluated in vitro for their efficacy and potency to inhibit HSL, and such evaluation may be performed as described below. ASSAYS Hormone-sensitive lipase (HSL) Materials. The Hormone-sensitive lipase was provided by Dr. Cecilia Holm, from Lund University Sweden or produced and purified by Novo Nordisk (NN) using the reagents and protocols used by Dr. Holm. The substrates used are: 3H-Iabeled triolein (TO) from Amersharn, Buckinghamshire, U.K. cat No. TRA191; 5-20 Ci/mmol dissolved in toluene, triolein (Sigma, Cat. No. T-1740), fluorochrome-Iabeled triacyiglyceride (c/s-octadec-9-enoic acid 2-[12-(7-nitroben2o[1,2)5]oxadiazoI-4"yiamino)dodecanoyIoxy]-1-c/s-octadec-9-enoyloxymethyl-ethyl ester) prepared by Novo Nordisk (NN) by conventional methods, and 1,3-(di[3H]-stearin), 2-(PEG-Biotin)glyceroI prepared in collaboration with Amersharn Pharmacia Biotech, UK and described in WO 01/073442. Phosphatidyl choline (PC) and phosphatidyl inositol (Pi) are from Sigma (St Luis MO cat. Nos. P-3556 and P-5954 respectively). All other reagents are of commercial grade and obtained from various commercial sources. Methods. 3180.1: Assay for determination of inhibitor IC50 values. A lipid emulsion with 3H-TrioIein and phospholipid is used as substrate with a standard cencentration of highly purified HSL. BSA is added as product receptor. The substrate is. prepared as follows: 30 pi PC:PI (20 mg/ml solution of PC:PI 3:1 prepared in chloroform) + 128 pi cold TO + 15 pi 3H-TO are mixed and then evaporated under a gentle stream of N2 followed by 20-30 minutes in a Speedvac to ensure the absence of residual solvent. Compound and HSL are incubated for 30 min at 25 °C before addition of substrate. Reaction is stopped after 30 min at 25 °C by adding a mixture of methanol, chloroform and heptane at high pH. Formed product is separated from substrate by phase separation. Standard concentrations of compound are 100//M, 20//M, 4//M, 0.8//M, 0.16//M and 0.03^/M (sample concentrations). Results are given as IC50 values after 4PL fit of obtained activity data. 3180.2: Assay for determination of percent inhibition by compound at 10//M concentration. A lipid emulsion with 3H-Triolein and phospholipid is used as substrate with a standard cencentration of highly purified HSL. BSA is added as product receptor. The substrate is prepared as follows:. 30 pi PC:PI (20 mg/ml solution of PC:PI 3:1 prepared in chloroform) + 128 pi cold TO + 15 pi 3H-TO are mixed and then evaporated under a gentle stream of N2 followed by 20-30 minutes in a Speedvac to ensure the absence of residual solvent. Compound and HSL are incubated for 30 min at 25 °C before addition of substrate. Reaction is stopped after 30 min at 25 °C by adding a mixture of methanol, chloroform and heptane at high pH. Formed product is separated from substrate by phase separation. Results are given as percent activity relative to an un-inhibited sample (no compound). 3190.1: Assay for determination of percent inhibition of hormone sensitive lipase by compound at 10pM sample concentration. A lipid emulsion with fluorochrome-labeled triacylglyceride and phospholipid is used as substrate with a standard concentration of highly purified HSL (12pg/mL initial concentration cor-. responding to 600ng/mL final concentration), BSA is added as product receptor. The transfer of the fluorochrome from the lipid phase to the water (BSA) phase changes the fluorescent properties of the fluorochrome. The changes can be monitored on a fluorimeter with an excitation wavelength of 450nm and an emission wavelength of 545nm. Compound and HSL (20pL compound, 10pL enzyme and 70pL PED-BSA buffer) is pre-incubated for 30min at 25°C before addition of substrate (100yL). Amount of formed product is measured after 120min incubation at 37°C. Results are given as percent activity, relative to a non-inhibited sample (no compound). 3190.2: Assay for determination of IC5o value for the inhibition of hormone sensitive lipase by compound. Standard concentrations of compound are 100//M and 5-fold dilutions (initial concentration corresponding to 10//M final concentration and 5-fold). A lipid emulsion with fluorochrome-labeled triacylglyceride and phospholipid is used as substrate with a standard concentration of highly purified HSL (12pg/mL initial concentration corresponding to 600ng/mL final concentration). BSA is added as product receptor. The transfer of the fluorochrome from the lipid phase to the water (BSA) phase changes the fluorescent properties of the fluorochrome. The changes can be monitored on a fluorimeter with an excitation wavelength of 450nm and an emission wavelength of 545nm. Compound and HSL (20JJL compound, 10pL enzyme and 70pL PED-BSA buffer) is pre-incubated for 30min at 25°C before addition of substrate (100pL). Amount of formed product is measured after 120min Incubation at 37°C. Results are given as IC50 values after 4PL fit of obtained activity data. 2848,2: This high-volume screening assay uses para-nitrophenyl butyrate (p-NPB) as substrate for HSL.HSL cleaves p-NPB and the reaction is monitored as an increase in the concentration of para-nitropheno! (p-NP). p-NP can be monitored as an increase in UV-absorbance at 405 nm. The reaction is carried out at room-temp, for 20 min. The action is not stopped, but instead UV-abs is measured at a fixed time (20 min.) Due to autohydrolysis of the substrate the reaction is read at t = 0 min. too and t = 20 min. and the increase in Abs is calculated as the difference between the. two readings. When a compound that inhibits HSL is present, it results in a relative decrease in UV-absorbance. %Eff (%lnhibition) = (S-SOEff)/(SmaxEff-S0Eff) x 100 Where S = signal in UV-abs., SOEff = assaybuffer alone, SmaxEff = Assaybuffer with the lipase inhibitor. 2898.2: This method is an enzyme assay based upon SPA (scintillation proximity assay) particles. The substrate, 1,3-(di-[3H]-stearin), 2-(PEG-Biotin)-gIyceroI, is marked with 3H in both fatty acid moieties in the tri-glyceride. The third moiety of the tri-glyceride is a PEG linked Biotin. The substrate binds through Biotin to streptavidin in the SPA particles and the proximity between the radioactive tritium in the stearic acid moiety and the SPA particle results in emission of light from the SPA particles. The assay is an on-bead assay where HSL degrades the substrate, where after 3H-stearin acid is released from the bead. The amount of light emitted is proportional to the amount of substrate bound to the receptor. When a compound that inhibits the activity of HSL is present it results in a decrease in degradation of the substrate and thus an increase in the amount of light emitted and a concomitant increase in %Eff. %Eff (%lnhibitlon) = (S-SOEfQ/(SmaxEff~SOEfF) x 100 Where S = signal in dpm., SOEff = no inhibitor added, SmaxEff» with maximum concentration of inhibitor. CLAIMS 1. A compound of the general formula II wherein R1 is selected from Chalky!, C^-alkenyl and C^io-cycioalkyl, each of which is optionally substituted with one or more substituents independently selected from hydroxy, sul-fanyl, oxo, halogen, amino, cyano and nitro; and R2 is selected from C1-6alky!, C2-6-alkenyl, aryl, heteroaryl, C3-8heterocyclyl and C3.10-cycloalkyl, each of which is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-8-alkyl, c2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-8-alkyl, C2-8alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3.10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C1-6-alkyl, C2-6-alkenyl, aryl. heteroaryl, C3-8-heterocycIyl and C3-10-cycloalkyI, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-4-alkyl, C2-6-alkenyl, aryl, heteroaryl, C38-heterocyclyl and C3-1o-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C^-alkyl, C2_6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-1o-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Ci^-alkyl, C2.6-alkenyl, aryl, heteroaryl,. C3-8heterocyclyl and C3-1o-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C-alkyl, C2-alkenyl, aryl, heteroaryl, (Wheterocyclyl and C3. 10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C^-alkyl, C2^-alkenyl, aryl, heteroaryl, C«-heterocyclyl and C3-10-cycloalkyl. is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Ci-e-alkyI, CWalkenyl, perhalomethyl and perhalomethoxy, and wherein R2 is optionally covalently bound to R1 by an ether, thioether, C-C or C-N bond, to form a ring system with the N-atom to which R1 and R2 are bound; and R3 is selected from hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6alkenyl, aryl, heteroaryl, C3. e-heterocydyl and c3-c10cycloalkyi, each of which is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Chalky!, (^-alkenyl, aryl, heteroaryl, c1-c6B-heterocyclyl and c1-c6io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2.6-alkenyl, aryl, heteroaryl, CM-heterocyclyl and C3-io-cycloalkyi is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, d-e-alkyl, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Ci-e-alkyi, Qwralkenyl, aryl, heteroaryl, CWheterocyclyl and C3.10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3_1o-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Ci-e-alkyi, C2.6-alkenyl, aryl, heteroaryl, C3-s-heterocycIyl and c1-c6crcycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2-e-alkenyl, perhalomethyl and perhalomethoxy; and X is O or S; or a pharmaceutical^ acceptable salt thereof, or a pharmaceutical^ acceptable solvate thereof, or any tautomeric forms, stereoisomers, mixture of stereoisomers including a racemic mixture, or polymorphs. 2. A compound of the general formula III wherein R1a and R23 are independently selected from c1-c6-alkyl, C2.6-alkenyi, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyl, each of which is optionally substituted with one or .-more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C1-6-silkyt. C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyI and c1-c6^-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-6-alkyl, C2_8-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6io-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano and nitro, Ci-e-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-1o-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-8alkenyl, aryl, heteroaryl, C3_8-heterocyclyl and C3-10-cycioalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, perhalomethyl and perha-lomethoxy; and wherein R1a is optionally covalently bound to R2a by an ether, thioether, C-C or C-N bond; to form a ring system with the N-atom to which R1a and R23 are bound; and R48, R53, R6a and R7a are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3. 10-cycloalkyl, each of which is optionally substituted by one or more substituents selected from hydroxy, sulfanyl, sulfo, oxo, amino, cyano, nitro, c1-c6-alkyl, C2-6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c1-c6^-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-e-aIkenyl, aryl, heteroaryl, C3_8-heterocyclyl and c1-c6io-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, perhalomethyl and perhalomethoxy; and A1" is N or OR8a; A2* is N or C-R9a; A3a is N or C-R10a; A4a is N or C-R11a; and A5a is N or C-R12a; and wherein R8a, R93, R10a, R11a and R12a are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alky!, C2^-alkenyl, aryl, heteroaryl, C«-heterocyclyl and C3.io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, CWalkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Cs-io-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2-8-alkenyl, aryl, heteroaryl, C3-a-heterocyclyl and C3. 10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, (^-alkeny!, aryl, heteroaryl, c1-c6-heterocyclyl and C3-1o-cycloaIkyI is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2-6-alkenyI, aryl, heteroaryl, C3-e-heterocyclyl and Qj-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-e-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-1o-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, perha-lomethyl and perhalomethoxy. 3. The compound according to claim 2, wherein R23 is phenyl, optionally substituted by halo gen or methyl. 4. The compound according to any one of claims 2-3, wherein R1a is selected from methyl and ethyl, optionally substituted by one or more halogen. 5. The compound according to claim 2, wherein R1a and R23 are covalently bound so as. to form a ring system with the N-atom to which they are bound, wherein said ring system is a piperidine, piperazine, morpholine, or thiomorpholine. 6. The compound according to any one of claims 2-5, wherein R48, R5a, R6a and R7a are inde pendently selected from hydrogen, F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, - S(=0)2-NH2, -NH-S(=0)rOH, hydroxy, amino and perhalomethyl. 7. The compound according to any one of claims 2-6, wherein A1a, A23, A38, A43 and A5a are independently selected from N, CH, CF, C-CI and C-CF3. 8. A compound of the general formula IV wherein R1b and R2* are independently selected from c1-c6-alkyl, c1-c6alkoxy, c1-c6-aikenyl, aryl, heteroaryl, c1-c6-heterocyc)yl and C3-1o-cycloalkyl, each of which may optionally be substituted with one or more substituents selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-6alkyl, C1-6alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d^-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-8-alkyl, C2-8alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6^-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6e-alkyl, C-^-alkoxy, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3.io-cycioalkyl, perhalomethy! and perhalomethoxy; wherein R1b is optionally covalently bound to R2b by an ether, thioether, C-C or ON bond, to form a ring system with the N-atom to which R1b and R25 are bound; R56 and R6b are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, sulfo, c1-c6-alky!, C2^-alkenyl, aryl, heteroaryl, C3-e-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2.e-alkenyl, aryl, heteroaryl, C3*-heterocyclyI and c3-c10cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ct-6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyi, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c3-c10cydoalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, c1-c6e-alkyl, perhalomethyl and perhalomethoxy; R4* and R7* are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6io-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, aryl, heteroaryl, c1-c6-heterocycIyl and C3.10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloaIkyl, wherein each of hydroxy, sulfanyl, sulfo, c1-c6-alkyl, C2-s-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl is optionally substi- tuted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, d-e-alkyl, perhalomethyl and perhalomethoxy; and A1b is N or C-R8b; A2* is N or. C-R9b; A3b is N or OR10b; A4b is N or C-R11b; and A5b is N or C-R12b; and wherein R8b, R*, R10b, R11b and R12b are selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, sulfo, Chalky!, C2-6-alkenyl, aryl, heteroaryl, CWheterocyclyl and c3-c10 cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alky!, C2-6-alkenyl, aryl, heteroaryl, C«-heterocyclyl and c3-c10cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, Ci-e-alkyi, C2-e-alkenyl, aryl, heteroaryl, C3-8-heterocydyl and C3.io-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, Ci.6-alkyl, perhalomethyl and perhalomethoxy; wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R4b, R5b, RBb, R7b, R8b, R9b, R10b, R11b and R12b. 9. The compound according to claim 8, wherein R2b is phenyl, optionally substituted by halo gen. 10. The compound according to any one of claims 8-9, wherein R1b is selected from methyl and ethyl, optionally substituted by one or more halogen. 11. The compound according to claim 8, wherein R1b and R2b are covalently bound so as to form a ring system with the N-atom to which they, are bound, wherein the ring system is a piperidine, piperazine, morpholine, or thiomorpholine. 12. The compound according any one of claims 8-11, wherein R4b, R51*, R6b and R7b are independently selected from hydrogen, F, CI, Ci_6-alkyl, c1-c6-alkoxy, -C(0)NH2, -NHC(=0)-OH, -S^O^NH* -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 13. The. compound according to any one of claims 8-12, wherein A1b, A2b, A3b, A4b and A5b are independently selected from N, CH and CF. 14. A compound of the general formula V wherein R4c, R5c, R6c, R7c and R8c are independently selected from hydrogen, hydroxy, sul-fanyl, amino, halogen, cyano, suifo, c1-c6-alkyl, Ci-e-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, c1-c6-alkyl, d^-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Cs-io-cycloalky! may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-i0-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalky!, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alky!, c1-c6alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6^-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perha-lomethoxy, and R90, R10G, R11C, R12C and R13c are independently selected from hydrogen, sulfanyl, amino, halogen, cyano, nitro, sulfo, d-e-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-i0-cycloalkyl, wherein each of sulfanyl, amino, sulfo, C1_6-alkyl, c1-c6e-alkoxy, C2_6-aIkenyl, aryl, heteroaryl, c1-c6-heterocycIyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sutfo, c1-c6-alkyl, d-e-alkoxy, C2.e-alkenyl, aryl, heteroaryl, C«-heterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, Ci-e-alkoxy, C2-e-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6alkoxy, Cs-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-aIkenyl, aryl, heteroaryl, C3-s-heterocyclyI and c3-c10 cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ci_e-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and pertia-lomethoxy; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R40, R5°, R60, R7c and R8c; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9c, R10c, R11c, R12c and R13c; and. at least one of R40, R50, R6c, R7c, R8c, R9c, R10c, R11c, R12c and R13c are different from hydrogen. 15. The compound according to daim 14, wherein R9c, R10G, R11c, R12c and R13c are selected from H and F. 16. The compound according to any one of claims 14-15, wherein R4c, R50, R6c, R7c and R80 are independently selected from hydrogen, F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 17. The compound according to claim 14, where there are no covalent bonds between any of the substituents R9c, R10c, R11c, R12c and R13c. 18. The compound according to any one of claims 14-16, where there are no covalent bonds between any of the substituents R40, R5c, R6c, R7c and R8c. 19. The compound of the general formula wherein R46 and R5d are independently selected from hydrogen, hydroxy, sulfanyl, amino, C2. e-alkyl, c1-c6-alkoxy, C2-e-alkenyI, aryl, heteroaryl, C3^-heterocyclyl and Ca-io-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, c1-c6-alkyl, Ci-e-alkoxy, C2_e-alkenyl, aryl, heteroaryl, CM-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more sub-stituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6alkoxy, C2^-aIkenyl, aryl, heteroaryl, Cs-a-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, Ci-e-alkoxy, C2_e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ci-e-alkoxy, C2.6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, Ci-e-alkoxy, C2^-aIkenyl, aryl, heteroaryl, C3^-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, Cs^-heterocydyl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy: and R6d, R7df R**, R", R10d, R11d, R12d, R13d and R14d are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6alkoxy, C2^-alkenyl, aryl, heteroaryl, C3^-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3^-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, Q^e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-i0-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-e-aIkenyl, aryl, heteroaryl, C3^-heterocyclyl, and C3_10-cycioalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e- alkyl, d-e-alkoxy, C2.e-alkeny!, aryl, heteroaryl, c1-c6-e-heterocyclyl and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d^-alkyl, d-e-alkoxy, C2-6-alkenyl1 aryl, heteroaryl, c1-c6-heterocyclyl and d-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitre, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6e-alkenyl, aryl, heteroaryl, dm-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R*. R5d, R6d, R7d, R*1 and RM; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R10d, R11d, R12d, R13d and R14d. 20. The compound according to claim 19, wherein R4d and R5d are H. 21. The compound according to any one of claims 19-20, wherein R6d, R7d, RBd and RM are selected from the group consisting of hydrogen, F, CI, d-ralkyl, d-e-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2l -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 22. The compound according to any one of claims 19-21, wherein R10d, R11d, R12d, R13d and R14d are selected from the group consisting of hydrogen, F, CI, d-e-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 23. The. compound according to any one of claims 19-22, wherein there are no covalent bonds between any of the substituents R4*, R5d, R6d, R7d, RBd and R9d. 24. The compound according to any one of claims 19-23, wherein there are no covalent bonds between any of the substituents R10d, R11d, R12d, R13d and R14d. 25. A compound of the general formula wherein R4& is selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, C2-e-alkyl, c1-c6alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c68-heterocyciyl and c1-c6io-cycloalkyl, wherein each of c1-c6r-alky!, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl, wherein each of the. hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2_e-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and c3-c10 cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Ca-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, (Walkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10cycloalkyl, perha-lomethyl and perhalomethoxy; and R56 is selected from hydrogen, F, cyano, c1-c6-alkyl, d-e-alkoxy, C2^-alkenyt, aryl, heteroaryl, C3-e-heterocyclyl and C3-10-cycloalkyl, wherein each of c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, CWalkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and CiMo-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6alkyl, c1-c6alkoxy, C2_6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1^-alkyl, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyi, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, c1-c6-alkoxy, C2-6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, C3-icrcycloalkyl, perhalomethyl and perhalomethoxy; wherein R40 and R56 may be covalentiy bound to each other by a C-0 bond. 26. The compound according to claim 25, wherein R4e or R5e is selected from the group con sisting of wherein R6e, R7\ R8e, R9e and R10e are independently selected from hydrogen, hydroxy, sulfanyi, sulfo, halogen, amino, cyano, nitro, Chalky!, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyi, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyi, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-a-heterocyclyI and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyi, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyi, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6alkenyl. 27. The compound according to claim 25, wherein R4* or R56 is selected from the group con sisting of. wherein R6e, R7e, R8e, R9* and R10e are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkoxy, C2-6-aIkenyl, aryl, heteroaryl, C3-s-heterocyclyl and C3-io-cycloalkyi, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, CWalkoxy, CWalkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycIoalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Chalky!, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10 cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Cn-alkoxy and C2^-alkenyl. 28. The compound according to any one of claims 26-27, wherein at least one of the substituents R6e, R7e, R86, R9e and R10e are selected from the group consisting of F and perha-lomethyl. 29. The compound according to claim 25, wherein R4e and R56 are connected by a C-0 bond to form the compound wherein R11e is selected from hydrogen, hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2_e-alkenyl, aryl, heteroaryl, C3_8-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C1-C6B-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ct-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and Cs-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, ^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10 cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-e-alkenyl, aryl, heteroaryl, C3-8-heterocyclyI and C3-10-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and perhalomethoxy, and R12e is selected from hydrogen, F, CI, c1-c6-alkyl, d^-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 30. A compound of the general formula wherein R4f, R5f, R6f, R7f, R9* and R10f are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, Cswrheterocyclyl and C3-io-cyc!oalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Q^o-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2.6-alkenyi, aryl, heteroaryl, c1-c6s-heterocyclyl and C3-io-cycloaIkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Ci-e-alkyI, c1-c6-alkoxy, c1-c6e-alkenyl, aryl, heteroaryl, C3-B-heterocyclyi, and Qj-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocydyl, C3-10-cydoaikyl, perhalomethyl and perhalomethoxy: with the proviso that R* and R5f are not both methoxy; and R8f is selected from hydrogen, sulfo, d-e-alkyl, c1-c6alkoxy, C2.e-alkenyl( aryl, heteroaryl, CW heterocyclyt and c3-c10cycloalkyl, wherein each of sulfo, Chalky!, CWalkoxy, C2-6-alkenyl, aryl, heteroaryl, C«-heterocyclyl and C3_10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen,, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, (^-alkeny!, aryl, heteroaryl, C3-8-heterocyclyI, and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alky!, c1-c6-alkoxy, C2-6-alkenyI, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, perhalomethyl and perhalomethoxy, wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R4f, R5f, RBf, Rn and R*; and wherein there may optionally be a covalent bond between R9f and R10f. 31. The compound according to claim 30, wherein R9f and R10f are covalently bound so as to form a ring system with the C-atom to which they are bound. 32. The compound according to claim 31, wherein said ring system is a cycloalkyl, phenyl, heteroaryl, piperidine, piperazine, morpholine, orthiomorpholine. 33. The compound according to claim 30, wherein R4f and R8f are connected by a C-0 bond to form the compound wherein R11f is selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-10-heterocyclyl and C3-io-cycIoalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6alkenyl, aryl, het-eroaryl, c1-c6-heterocyclyl and C3_10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, ni-tro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, (^.eralkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyl, perhalomethyl and perhalomethoxy; and R17f is selected from hydrogen, F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2J -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl; and wherein there may optionally be a covalent bond between R9* and R10f. 34. The compound according to claim 30, wherein R8f is selected from the group consisting of wherein R12f, R13f, R14f, R15f and R16f are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, d-e-alkyl, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyc!yl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6 alkyl, c1-c6-alkoxy, CM-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, CWalkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Q^rheterocyclyl and CS-K,-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyI, perhalomethyl and perhalomethoxy. 35. The compound according to claim 30, wherein only R9f and R10f are covalently bound. 36. A compound of the general formula IX wherein R49, R59, R69, R7g, R*9, R", R100 and R119 are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, c1-c6-alky!, c1-c6-alkoxy, (^B-alkenyl, aryl, het-eroaryl, CM-heterocyclyl and c1-c6io-cycloalkyl, wherein each of c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C-^-alkyl, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-a-heterocyclyl, and Cs-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6aHcyl. Ci_6-alkoxy, C2-e-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, c1-c6s-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and perhalomethoxy: and R129 is selected from the group consisting of -C(=0)-, -C(=0)NH-, -CH2-, -CH2CH2-, -: CHR159-, -CH2CHR15g-, -CHR159-CH2-, -NH-, -NR15g~, -NHC(=0)-, -NR15g-C(=0)-, -O-, -S-, - S(=OK -s(=o)r; wherein R15g is selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, d-e-alkoxy,. C2^-alkenyl, aryl, heteroaryl, C3^-heterocyclyl and C3-io-cycloalkyI, wherein each of hydroxy, sulfanyl, sulfo, amino, Ci-e-alkyI, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2^-alkenyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be one or. more covalent bonds between any of the substituents selected from the group consisting of R49, R5g, R6g, R7fl and R159; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R89, R", R10sf R11fl. and R159; and R13g is selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, c1-c6alkyl, d. e-alkoxy, C2-e-aIkenyl, aryl, heteroaryl, Cw-heterocydyl and C3-io-cycloalkyl, wherein each of C1-6-aIkyl( c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6alkoxy, C2^-alkenyl, aryl, heteroaryl, Cs-e-heterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, G|_ e-alkyl, c1-c6-alkoxy, C2_e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycIoaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6ralkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, Ca^-heterocyclyl and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalky!, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-e-alkyI, c1-c6-alkoxy, C2_6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and perha-lomethoxy: and R14g is selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, C2_6-alkyI, d. 6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of C2_e-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and d-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, d-e-alkoxy, C2^-alkenyl, aryl, heteroaryl, d-s-heterocyclyl, and d-10-cycloalkyI, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, C1r6-alkoxy, d-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and d-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Cve-alkyl, C-i-e-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloaIkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, d-e-alkoxy, C2_6-aIkenyl, aryl, heteroaryl, dwrheterocyclyl and d-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-eralkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Csj-s-heterocyclyl, C2-NH2l -NH-S(=OVOH, hydroxy, amino and perhalornethyl. 44. The compound according to. any one of claims 42-43, wherein there are no covaient bonds between R4h, R5h, R6\ R7h, R8h and R9h. 45. The compound according to any one of claim 42-44, wherein there are no covaient bonds between R10h, R11h, R12h, R13\ R14h and R15h. 46. The compound according to any one of claims 42-45, wherein R15h is hydrogen. 47. The compound according to any one of claims 42-46, wherein R11h and R13h are selected from the group consisting of hydrogen, F, CI, C2-6-alkyl, methoxy, c1-c6-alkoxy, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalornethyl. 48. A compound of the general formula Rs is selected from hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, CWalkyl, c1-c6 alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloaIkyl, wherein each of Ci-e-alkyl, c1-c6-alkoxy, CWalkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3.io-cycloalkyl may. optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6B-alkyl, d-e-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6alkoxy, C2_6-alkenyl, aryl, heteroaryl, Qj-s-heterocyclyl, and Cs.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C-^-alkyl, c1-c6alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloaIkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, c1-c6-alkoxy, C2^-alkenyI, aryl, heteroaryl, (W heterocyclyl, and c1-c6^-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6 alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl, c3-c10cycloalkyl, perha-lomethyl and perhalomethoxy: and R6i, R71, R*, R9i, R101, R1* and R15i are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3.io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and Ca-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6e-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, Qj-s-heterocyclyU and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6ralkyl, Ci_6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3.8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci_e-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, perhalomethyl and perhalomethoxy: and R11i and R13i are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6alkyl, methoxy, C3-6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, wherein each of sulfanyl, sulfo, c1-c6-alkyl, CsMi-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-a-heterocyclyl and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Cj-e-alkyl, d-ralkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C*.10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, d-e-alkoxy, d-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and d-io-cycloalkyl may optionally be substituted with one. or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-e-alkyI, c1-c6-alkoxy, C2^»alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Ga-io-cycloalkyl, perhalomethyl and perhalomethoxy: and R12 is selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, d-e-alkyl, d^-alkoxy, C2-e-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and d-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-6-alkyl, d-ralkoxy, c1-c6-alkenyl, aryl, heteroaryl, d-s-heterocyclyl and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d^alkyl, c1-c6alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C&.10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyi, d-ralkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, Ci-e-alkyI, d-e-alkoxy, d-e-alkenyl, aryl, heteroaryl, C3_8-heterocyclyl and c1-c6Krcycloalkyl, perhalomethyl and perhalomethoxy. 49. The compound according to claim 48, wherein R6i, R71, R8' and R91 are selected from the group consisting of hydrogen, F, CI, d^-alkyl, d-ralkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)z-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 50. The compound according to any one of claims 48-49, wherein R101, R11i, R12i, R131 and R14i are selected from the group consisting of hydrogen, F, CI, Chalky!, d-ralkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2l -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 51. The compound according to any one of claims 48-50, wherein R1S is hydrogen. 52. The compound according to any. one of claims 48-50, wherein R10i, R11i, R12, R13i, R14i and R15i are selected from the group consisting of H, F and methyl. 53. A compound of the general formula wherein R4', R^', R6j, R71, R8j, R9j and R10j are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyi, c1-c6-alkoxy, C2_6-alkenyl, aryl, het-eroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ci-e-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloaIkyI, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, (Walkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6 alkyl, c1-c6alkoxy, C2-6-aIkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, CWalkenyl, aryl, heteroaryl, Qj-s-heterocyclyl, C3.10-cycloalkyl, perhalomethyl and perhalomethoxy: and wherein there may optionally be a covalent bond between the. substituents RBi and R73; and wherein there may optionally be a covalent bond between Rg and R8]; and R11Jand R1^ are independently selected from cyano, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6e-heterocyclyl and C3-io-cycloalkyl, wherein each of c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, CM-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-e-alkyl, c1-c6-alkoxy, C2_6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and Gs-io-cycloalkyl, perhalomethyl and perhalomethoxy; and with the proviso that R9j and R10j are both hydrogen, there may optionally be a covaient bond connecting R11iand R1^. 54. The compound according to claim 53, wherein R*j, Rs, R6j and R7* are selected from the group consisting of hydrogen, F, CI, d^-alkyl, C-^-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OHf hydroxy, amino and perhalomethyl. 55. The compound according to any one of claims 53-54, wherein at least one of the substituents R4*, R**, R6J and R73 are different from hydrogen. 56. The compound according to claim 53, wherein R8i is covalently bound to R^. 57. A compound of the general formula wherein R4* is selected from hydrogen, hydroxy, sulfanyl, sulfo; halogen, amino, cyano, nitro, c1-c6e-alkyl, Ci.6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci_6-alkyl, c1-c6-alkoxy, C2^-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalky!, C-^-alkoxy, C2^-alkenyi, aryl, heteroaryl, C3-8-heterocyclyl, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, d-e-alkoxy, C2.6-alkenyl, aryl, heteroaryl, CM-heterocyclyl and dt-10-cycloalkyl, perhalomethyl and perhalomethoxy: and Ra is selected from hydroxy, suffanyl, sulfo, halogen, amino, cyano, nitro, d-e-alkyl, d-e-alkoxy, C2^-alkenyI, aryl, heteroaryl, d-e-heterocyclyl and Cs-io-cydoalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, d-e-alkoxy, (Walkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-6-alkyl, d-e-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and Gs^o-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, d-e-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, d-e-alkoxy, C2^-alkenyl, aryl, heteroaryl, dwrheterocyclyl and C3-10-cycioalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, d-e-alkoxy, C2-6~ alkenyl, aryl, heteroaryl, d-e-heterocyclyl, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, d-e-alkoxy, C2.6-alkenyl, aryl, heteroaryl, C3_8-heterocyclyl and c3-c10cycloalkyl, perhalomethyl and perhalomethoxy: with the proviso that when R4k is hydrogen, then R5* is not C(=0)N(Me)2; and R6k, R7kf R8k, R9k, R10k, R11k, R13k and R14k are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, d-e-alkyl, d-e-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3_8-heterocyclyI and C3.io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, d-e-alkoxy, C2_e-alkenyl, aryl, heteroaryl, C3-e-heterocycIyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, d-e-alkoxy, d-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and d-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, d-e-alkoxy, d-e-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-io-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, d-e-alkoxy, d-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, perhalomethyl and perhalomethoxy: and R12k is selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, cyano, nitro, d-e-alkyl, d-e-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, d-e-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Ci-e-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C&r heterocyclyl and C3-io-cycloalkyl may optionally be. substituted with one or more substituents independently selected from hydroxy, sulfanyl, halogen, amino, cyano, n'rtro, sulfo, c1-c6alkyl, Ci_6-alkoxy, c1-c6e-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and c1-c6io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C1.6-alkoxy, C2-e-alkenyl, aryl, heteroaryl, C3. 8-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci_6-alkyl, c1-c6alkoxy, C2-e-alkenylr aryl, heteroaryl, C3-8-heterocydyl and c3-c10cycloalkyl, perhalomethyl and perhalomethoxy. and wherein there may optionally be a covalent bond between any of the substituents selected from the group consisting of R4k, R5k, R7* and R8k; and wherein there may optionally be a covalent bond between R5k and any one of the substituents R7* and R8k; and wherein there may optionally be one or more covalent bonds between R10k, R11k, R12\ R13k and R1458. The compound according to claim 57, wherein the substituents R4k and R5k are connected by a covalent bond. 59. The compound according to any one of claims 57-58, wherein the substituents R5* and R8k are connected by a covalent bond. 60. The compound according to any one of claims 57-59, wherein the substituents R10k and R11k are connected by a covalent bond. 61. The compound according to any one of claims 57-60, wherein the substituents R12k and R13k are connected by a covalent bond. 62. The compound according to any one of claims 57-61, wherein R6k, R7k, R8k and R9k are selected from the group consisting of hydrogen, F, CI, hydroxy, amino, methyl, methoxy, eth-oxy and perhalomethyl. 63.. The compound according to any one of claims 57-59, wherein R10k, R11k, R12\ R13k and R14k are selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, C-^-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH»S(=0)rOH( hydroxy, amino and perhalomethyi. 64. A compound of the general formula wherein R1 is c1-c6-alkyl, c1-c6-alkenyl or c1-c6io-cycloalkyl, each of which is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano and nitro; and R2 is c1-c6alkyl, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, or C3-io-cycloalkyl, each of which is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, c1-c6alkyl, c1-c6alkenyl, aryl, heteroaryl, 0*. s-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, amino, c1-c6-aikyl, Q2-6-alkenyl, aryl, heteroaryl,. C3_8-heterocyclyl and C3-io-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo,. halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3.10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, C3.8-heterocyclyl and C3-io-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, perhalomethyi and perhalomethoxy; with the proviso that when R1 and R2 are identical they are not methyl or benzyl; and R2 is optionally covalently bound to R1 by an ether, thioether or C-C bond, to form a ring system with the N-atom to which R1 and R2 are bound; and Ra, R61, R81, R9V R101 and R111 are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, d-e-alkyl, Ci_6-alkoxy, C2^alkenyl, aryl, heteroaryl, C3-8- heterocydyl and C3_10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, (1^.6-aIkoxy, c1-c6eralkenyl, aryl, heteroaryl, c1-c6rheterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alky!, c1-c6-alkoxy, C2.6-aIkenyl, aryl, heteroaryl, C3-e-heterocyclyl, and C3-io-cycloaIkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6 e-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C-^-alkoxy, C2^alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and CjMo-cycloalkyl, perhalomethyl and perhalomethoxy. and R41 and R71 are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, methoxy, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, wherein each of sulfanyl, sulfo, amino, c1-c6-alkyl, C3-e-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Ca-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3*-heterocyclyl, and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, c1-c6-alkoxy, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloaIkyl, perhalomethyl and perhalomethoxy: and wherein there may optionally be one or more covalent bonds between any of the substituents. selected from the group consisting of R41, Ra, R61, R71, R81, R91, R101 and R111. 65. The compound according to claim 64, wherein R1 and R2 are covalently bound so as to form a ring system with the N-atom to which they are bound. 66. The compound according to claim 65, wherein said ring system is a piperidine, piperazine, morpholine, or thiomorpholine. 67. The compound according to claim 64, wherein there are no covalent bonds between R1 and R2. 68. The compound according to any one of claims 64-67, wherein there are no covalent bonds between Ra and any of the substituents selected from the group consisiting of R91, R101, R11'. 69. The compound according to any one of claims 64-68, wherein there are no covalent bonds between R8! and any of the substituents selected from the group consisting of R4', R51, R61 and R71. 70. The compound according to any one of claims 64-69, wherein there are no covalent bonds between any of the substituents R41, R51, R61, R71, R8!, R91, R10' and R111. 71. The compound according to any one of claims 64-70, wherein R41, Ra, R61 and R71 are selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, Ci-e-alkoxy, -C(=0)NH2( -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 72. A compound of the general formula wherein R4m is selected from hydrogen, sulfo, c1-c6-alky!, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloaIkyl, wherein each of sulfo, C1^-alkyl, c1-c6-alkenyl, aryl, het-eroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, ni-tro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, (Walkenyl, aryl, heteroaryl, CWheterocyclyl, and c3-c10 cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalky!, c1-c6-alkoxy, c1-c6- alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6alkoxy, C2-6-aIkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6e-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and c3-c10cycloaikyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2^alkenyl, aryl, heteroaryl, CWheterocyclyl and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Cn^-alkyl, CWalkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy,, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-e-alkyI, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and perha-lomethoxy: and R5m, R6m, R7m, R8m, R9m, R10m, R11m, R12m, R13m, R14m, R15mand R16m are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, Ci_6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1_6-alkyl, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3.nrcycIoalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ci-e-alkoxy, C2^-aIkenyl, aryl, heteroaryl, c1-c6s-heterocyclyl, and C3-io-cycIoalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyi, and C3_io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-e-alkyI, c1-c6-alkoxy, (Walkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3.10-cycloalkyl, perhalomethyl and perhalomethoxy: and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R4m, R5n\ R6m, R7m and R8m; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9m, R10m, R1lm, R12m, R13m, R14m, R15m and R16m. 73. The compound according to claim 72, wherein there are no covalent bonds between any of the substituents selected from the group consisting of R5m, R6m, R7m and RBm. 74. The compound according to any one of claims 72-73, wherein there are no covalent bonds between any of the substituents R9"1, R10m, R11m, R12m and R13m. 75. The compound according to any one of claims 72-73, wherein there are no covalent bonds between any of the substituents R14m, R15m and R16m. 76. The compound according to any one of claims 72-75, wherein R4m is covalently bound to R6m.. 77. The compound according to any one of claims 72-75, wherein R5m, R6m, R7m, R8m, R9m, R10m, R11m, R12m, R13m and R14m are selected from the group consisting of hydrogen, F, CI, Ci-B-alkyl, d-e-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyi. 78. The compound according to any one of claims 72-77, wherein R14m, R15m and R18m are selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyi. 79.. A compound of the general formula wherein R4" is selected from hydrogen, sulfo, C2_e-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3.10-cycloalkyl, wherein each of sulfo, C2_6-alkyI, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyc!yl and Qj-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, Ci-e-alkyI, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyi, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alky!, d-e-alkoxy, C2_e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, d-e-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3. to-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, d-e-alkoxy, C2^-afkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6alky^ c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-hetero-cyclyl, c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, Ci-e-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and Cs-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyI, perhalomethyl and perhalomethoxy; and Z is selected from S, S(=0) and S(=0)2; and R5n, R6n, R7n, R8n, R9n, R10n, R11n, R12n, R13n and R14n are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C-^-alkyl, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heteroc1-c6clyl and CjMo-cycIoalkyI, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-aikoxy, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-^cloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ci_e-alkoxy, CWalkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^»alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6 alkyl, c1-c6alkoxy, c1-c6e-alkenyl, aryl, heteroaryl, C3_s-heterocyclyl and c3-c10cycloalkyl, perhalomethyl and perhalomethoxy: and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R4n, R5", R6n, R7n and R8n,; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R10n, R11n, R12n and R14n; and at least one of the substituents R5n, R6n, R7n, R8n, R9n, R10n, R11n, R12n, R13n and R14n are different from hydrogen. 80. The compound according to claim 79, wherein there are no covalent bonds between any of the substituents R5n, R6n, R7n and R8n. 81. The compound according to any one of daims 79-80, wherein there are no covalent bonds between any of the substituents R10n, R11n, R12n. 82. The compound according to any one of claims 79-81, wherein R14nis not covalently bound to any other substituent selected from the group consisting of R4n, R5n, R6n, R7nf R8nr plOn D"l1n p!2n 83. The compound according to any one of claims 79-82, wherein R4n is covalently bound to R6n. 84. The compound according to any one of claims 79-82, wherein R5n, R6n, R7n and R8n are independently selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 85. The compound according to any one of claims 79-84, wherein R14n is selected from the group, consisting of hydrogen, F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=O)-0H, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 86. A compound of the general formula wherein R20 is selected from sulfo, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocycly! and c1-c6no-cycloalkyl, each of which may optionally be substituted with one or more substitu- ents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, suffo, CLs-alkyl, c1-c6-alkoxy, C2,6-aIkeny[, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyI> wherein each of the hydroxy, sulfanyl, amino, suffo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-aIkenyII aryl, heteroaryl, C3-6-heterocyclyI, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, C3. 10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyciyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ci-e-alkoxy, c1-c6-alkenyi, aryl, heteroaryl, c1-c6r heterocyclyl, c3-c10cydoalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6alkoxy, C2^alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C-i-e-alkoxy, C2„6-alkenyI, aryl, heteroaryl, Q^s-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy; with the proviso that R20 is not methyl; and R40, R5°, R60 and R70 are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyi, c1-c6ralkoxy, C2^alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, Cve-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, CWheterocycIyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-to-cycloaIkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d. e-alkyl, c1-c6-alkoxy, C2_e-alkenyl, aryl, heteroaryl, C3-B-heterocyclyl, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, perhalomethyl and perhalomethoxy: and A10 is N or C-R80; A20 is N or OR90; A30 is N or C-R100; A40 is N or C-R110;. and A50 is N or C- R120; and wherein R80, R90, R100, R110 and R12° are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and Qwo-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl and c1-c6io-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d^-alkyl, C2-6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, Cs-a-heterocyciyf and c3-c10cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-e-alkyl, c1-c6alkenyl, aryl, heteroaryl, Q^rheterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6alkyl, C2„6-aIkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cydoalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, per-halomethyl and perhalomethoxy; with the proviso that when A1°, A20, A30, A40 and A50 are all CH, and R40, R50, R60 and R70 are all hydrogen, then R2° is not phenyl; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R40, R50, R60, R7°, R8°, R9°, R100, R110 and R120 87. The compound according to claim 86, wherein there are no covalent bonds between any of the substituents R40, R50, R60 and R70. 88. The compound according to any one of claims 86-87, wherein there are no covalent bonds between any of the substituents A10, A20, A30, A40 and A50. 89. The compound according to any one of claims 86-88, wherein R^is selected from the group consisting of cycloalkyl, phenyl, piperidine, piperazine, morpholine, thiomorpholine and heteroaryl. 90. The compound according to any one of claims 86-89, wherein R40, R5°, Reo and R70 are independently, selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, c1-c6alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)rNH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 91. A compound of the general formula wherein R4p is selected from hydrogen, sulfo, C2_6-alkyl, C2-6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of sulfo, C2.$-aIkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl rnay optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, Cn^-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6rheterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3_s-heterocyclyl, C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalky!, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyI, and Cs-io-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, (Walkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and Cs-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C-^-alkoxy, C2^-alkenyI, aryl, heteroaryl, c1-c6s-heterocyclyl, C3-io-cydoalkyl, perhalomethyl and perhalomethoxy: and R5p, R6p, R7p and R^ are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, F, amino, cyano, c1-c6-alkyl, c1-c6-alkoxy, C2-e-alkenyl, aryl, heteroaryl, C3-8-heterocyc!yl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6^-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-a-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, (Walkenyl, aryl, heteroaryl, C3^-heterocyclyl, and Cs-to-cycioalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C«- alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloafkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo( halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl,. c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, Cs-to-cycloalkyf, perhalomethyl and perhalomethoxy; and R9p, R10p, R11p, R12p, R13p, R14p, R15pand R16p are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, d-e-alkyl, c1-c6-alkoxy, c1-c6e-alkeny!, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cydoalkyI, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, Ci-e-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C3^-heterocyc!yl and Cs-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-e-alkyI, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6alkoxy, C2-e-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, d-e-alkoxy, C2-e-alkenyl, aryl, heteroaryl, Cw-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy: and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R5p, R8p and R7p; and wherein there may optionally be a covalent bond between R4p and R5p so as to form a chromen ring system; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R* R10p, R11p, R12p, R13p, R14p, R15pand R16p; and E is selected from the group consisting of -0-, -S-, -S(=0)-, -S(=0)2-, -NR17p- and -CR17pR18p-; and wherein R17p and R18p are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6alkoxy, c1-c6-alkenyl, aryl, heteroaryl, CM-heterocyclyl and c1-c6crcycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, Ct-e-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen,, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ci-e-alkoxy, Cu-alkenyl, aryl, heteroaryl, C3-8-heterocyclyI, and c1-c6trcycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d. 6-alkyl, c1-c6-alkoxy, d-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyciyl, and C3-io-cycIoalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2^-aikenyl, aryl, heteroaryl, C3-s-heterocyclyl, C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, d-e-alkoxy, c1-c6alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cydoalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, C3-e-heterocyclyl, c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Ci_e-alkyl, c1-c6-alkoxy, d-e-alkenyl, aryl, heteroaryl, Q^-heterocyclyl, and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6 alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy. 92. The compound according to claim 91, wherein E is selected from the group consisting of -O- and -CR17pR18p-. 93. The compound according to claim 91, wherein R4p and R5p are connected by a covalent bond so as to. form said chromen ring system. 94. The compound according to claim 93, wherein R4p and R5p are. connected by a covalent bond so as to form the chromen ring system i wherein R19p is selected from the group consisting of hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6s- heterocyclyl and C3-i0-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, Cve-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocydyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-e-alkyI, Ci-e-alkoxy, C2^alkenyl, aryl, heteroaryl, C3-rheterocyclyI, C3-io-cycloalkyI, perhalomethyl and perhalomethpxy. 95. The compound according to any one of claims 91-92, wherein R4p is selected from the group consisting of wherein R20*, R21p, R2^, R239 and R24p are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocydyl and c3-c10cydoalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyI, aryl, heteroaryl, C3-s-heterocyc!yl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6alkyl, c1-c6-alkoxy, C2-6-alkenyl, perhalomethyl and perhalomethoxy. 96. The compound according to any one of claims 91-92, wherein there are no covalent bonds between any of the substituents R4p, R5p, R6pt R7p and R8p. 97. The compound according to any one of claims 91-96, wherein there are no covalent bonds between any of the substituents R9p, R10p, R11p, R12p, R13p, R14p, R15pand R16p. 98. The compound according to any one of claims 91-96, wherein R10p and R11p are connected by a covalent bond. 99. The compound according to claim 91-97, wherein R9p, R10p, R11p, R12p, R13p, R14p, R15pand R16p are independently selected from hydrogen, F, CI, C-i.e-alkyl, d-e-alkoxy, -C(=0)IMH2, -NHC(=0)-OH) -S(=0)2-NH2| -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 100. The compound according to any one of claims 91, 92,95-99, wherein R5p, R6p, R7p and RBp are independently selected from hydrogen, F, CI, c1-c6-aikyl, c1-c6-alkoxy, -C(=0)NH2, -NHc1-c6OJ-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 101. A compound of the general formula wherein R4q, R6q, R7q, R9q, R10q, R11q, R12q, R13q, R14q, R15q, R16q, R17q,and R18q are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, Chalky!, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Ca-io-cycloalkyl may optionally be substituted with one or more sub-st'rtuents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, d-e-alkoxy, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, CW-alkenyl, aryl, heteroaryl, C3-B-heterocyclyl, C3.i0-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and C3_10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, C3*-heterocyclyl, C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d^-alkyl, c1-c6-alkoxy, CWalkenyl, aryl, heteroaryl, C3^-heterocycIyl, and C3-io-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C«-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy: and R5* and R8* are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, F, Br, amino, cyano, nitro, c1-c6-alkyl, d-e-alkoxy, CWalkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10 cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alky!, c1-c6-alkoxy, C2_6-alkenylr aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, suifo, c1-c6-alkyl, c1-c6-alkoxy, CWalkenyl, aryl, heteroaryl,'C3_8-heterocyclyl, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-B-heterocyclyl, C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.e-a!kenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perha-lomethoxy: and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of Ft4*, R5q, R6q, R7q and R8* and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9q, R10q, R11q, R12q, R13q, R14q, R15q, R16q, R17q and R18q. 102. The compound according to claim 101, wherein R^ and R6q are connected by a covalent bond. 103. The compound according to claim 101, wherein R^ is selected from the group consisting of substituted heteroaryl and substituted C3-s-heterocyclyl. 104. The compound according to any one. of claims 101 and 103, wherein R4q is selected from the group consisting of wherein R19q, R20q, R™\ R22* and R23" are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, het-eroaryl, c1-c6-heterocyclyl and c1-c6io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6alkyl, G^-alkoxy, c1-c6-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10 cycloalkyl may optionally be substituted with one or more substituents independently, selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloaIkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Chalky!, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, Cve-alkyl, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Ci_6-alkylf c1-c6e-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3_8-heterocyclyl and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, CM-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy. 105. The compound according to any one of claims 101 and 103-104, wherein there are no covalent bonds between any of the substituents R4^ R5q, R6q, R7q and RBq. 106. The compound according to any one of claims 101-105, wherein there are no covalent bonds between any of the substituents R9q, R10q, R11q, R12q, R13q, R14q, R15q' R16q, R17q and R18q. 107. The compound according to any one of claims 101-105, wherein R10p and R11p are connected by a covalent bond. 108. The compound according to any one of claims 101-105, wherein R11p and R13p are con nected by a covalent bond. 109. The compound according to any one of claims 101-106, wherein R9q, R10q, R11q, R12q, R13qf R14q( R15q, R16q, R17q and R18q are independently selected from hydrogen, F, CI, c1-c6 alkyl. c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=OyOH, hydroxy, amino and perhalomethyl. 110. The compound according to any one of claims 101-106 and 109, wherein R9q, R10q, R11q, R12qf R14q, R15q, R16qt R17q and R18q are all hydrogen or F. 111. The compound according to any one of claims 101 and 103-110, wherein R^, R6qf R7q and R8q are independently, selected from hydrogen, F, CI, c1-c6-alkyl, d-e-alkoxy, -C(=0)NH2> -NHC(=0)-OH, «S(=0)2-NH2, -NH-S(=0)rOH, hydroxy, amino and perhalomethyl. 112. A compound of the genera! formula wherein R^ is selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, d^-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3.io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C-j-6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10 cycloalkyl, wherein each of the hydroxy, sulfanyl, sulfo, Ci-e-alkyI, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C3-a-heterocyclyl, C3-to-cycloalkyl, perhalomethyl and perhalomethoxy: provided that R4ris not methyl or phenyl; and R* R6r, R7r, R8r, R9r, R10r, R11r, R12r, R13r, R14r, R15r, R16r, R17p and R18r are independently selected from hydrogen, hydroxy, sulfanyl, sulfa, F, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, whereia each of hydroxy, sulfanyl, sulfo, amino, c1-c6alkyl, d^-alkoxy, c1-c6e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Cs-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ci-e-. alkoxy, C2^-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-i0-cycloalkyl, perha-lomethyl and perhalomethoxy: and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R5r, R6r, R7r and R8r; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9r, R10r, R11r, R12r, R13r, R14r, R15r, R16r, R17r and R18r. 113. The compound according to claim 112, wherein R* and R5r are connected by a covalent bond. 114. The compound according to claim 112, wherein R4r is selected from the group consist ing of substituted heteroaryl and substituted c1-c6s-heterocyclyl. 115. The compound according to any one of claims 112 and 114, wherein R4r is selected from the group consisting of wherein R19r, R20r, R21r, R2* and R23' are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, d-e-alkoxy, C2^-alkenyl, aryl, heteroaryl, d-e-heterocyclyl and c3-c10cycioalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1BC-alkyl, d-e-alkoxy, d-e-a'kenyl, aryl, heteroaryl, c1-c6-heterocydyl and d-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, d-r-alkyl,. d-6-aIkoxy, C2-e-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and d-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-s-alkyl, c1-c6-alkoxy, d-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and CMO-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, d-s-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, d-a-heterocyclyl and c1-c6io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, G^-alkoxy, d^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and d-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, Qt-6-aIkyl, d-e-alkoxy, C2^-alkenyl, aryl, heteroaryl, d-8-heterocyclyl, c3-c10cycloalkyl, perha-lomethyl and perhalomethoxy. 116. The compound according to any one of claims 112-115, wherein there are no covalent bonds between any of the substituents R5r, R6r, R7r and R8r. 117. The compound according to any one of claims 112-116, wherein there are no covalent bonds between any of the substituents R* R10rf R11r, R12r, R13r, R14r, R15r and R16r. 118. The. compound according to any one of claims 112-116, wherein R10r and R11r are connected by a covalent bond. 119. The compound according to claim 116, wherein R11r and R13r are connected by a covalent bond. 120. The compound according to any one of claims 112-116, wherein R9r, R10r, R1lr, R12r, R13r, R14r, R15r, R16r, R17r and Rn8r are independently selected from hydrogen, F, CI, d-e-alkyl, d-e-alkoxy, -C(=0)NH2l -NHC(=0)-OH, -S(=0)rNH2, -NH-S(=O)r0H, hydroxy, amino and perhalomethyl. 121. The compound according to any one of claims 112-117 and 120, wherein R9r, R10r, R11r, R12r, R14r, R15r, R16r, R17r and R18r are all hydrogen or F. 122. The compound according to any one of claims 112 and 114-121, wherein R5r, RBr, R7r and R8r are independently selected from hydrogen, F, CI, Chalky!, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0);rOH, hydroxy, amino and pertnalomethyl. 123. A compound of the general formula wherein A1s is N or C-R17s; A25 is N or C-R18s; A3s is N or C-R19s; A4s is N or C-R20s; and A5s is N or C-R21s; and wherein R17s, R18s, R19s, R20s and R21s are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3_s-heterocycIyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10 cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2^-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyi is. optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, c1-c6e-alkyl, C2^-alkenyl, aryl, heteroaryl, CWheterocyclyl and Cs-io-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkenyU aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C-^-alkyl, C2^alkenyl, aryl, heteroaryl, Oj-s-heterocyclyl and c1-c6io-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, Cs-io-cycloalkyl, perhalomethyl and perhalomethoxy; and R5s, R68, R7s and R8s are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, F, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cw-heterocyclyl and Cs-io-c1-c6cloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.e-alkenyl, aryl, heteroaryl, c1-c6r heterocyclyl, and C3-io-cycioalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, Ci-e-alkoxy, c1-c6alkenyl, aryl, heteroaryl, c1-c6s-heterocyclyl, and Cs-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^alkenyl, aryl, heteroaryl, c1-c6e-heterocyclyl, CiMcrcycloalkyl, perhalomethyl and perhalomethoxy: and R9S, R10s, R11s, R12s, R13s, R14s, R15s and R16s are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, F, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3_a-heterocyclyl and C3-io-cycIoalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Chalky!, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, c1-c6-alkoxy, C2.e-alkenyl, aryl, heteroaryl, c1-c6s-heterocyclyl, and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, Ci-e-alkoxy, C2_e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c1-c6^-cycloalkyl, perhalomethyl and perhalomethoxy: and E is selected from the group consisting of -0-, -S-, -S(=0)-, -S(=0)2-, -NR225- and -CR^R235-; and wherein R225 and R23s are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alky!, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, d-e-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, CWalkoxy, (Walkenyl, aryl, heteroaryl, c1-c6B-heterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfany!, amino, sulfo, d. e-alkyl, c1-c6-alkoxy, (W-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-i0-cycloaIkyl may optionally be substituted with one. or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-e-alkyl, c1-c6-alkoxy, c1-c6alkenyl, aryl, heteroaryl, c1-c6rheterocyclyl, C3-io-cycIoaIkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R58, R68, R7s and R8s; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9s, R10s, Rl1s, R12s, R13s, R14s, R15s, R16s, R18s. R19s, R208, R21s, R226 and R235. 124. The compound according to claim 123, wherein E is selected from the group consisting of.-O-and-CR^R235-. 125. The compound according to any one of claims 123-124, wherein there are no covalent bonds between any of the substituents R5s, R6s, R7s and RBs. 126. The compound according to any one of claims 123-125, wherein R5s, R6s, R7s and R8s are independently selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, Ci_e-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)rOH, hydroxy, amino and perhalomethyl. 127. The compound according to any one of claims 123-126, wherein there is a covalent bond between R10s and R11s. 128. The compound according to any one of claims 123-127, wherein there is a covalent bond between R13s and R228. 129. The compound according to any one of claims 123-126, wherein R9s, R10s, R11s, R128, R13s, R14s, R15s and R16s are all hydrogen or R 130. A compound of. the general formula wherein E is selected from the group consisting of -0-, -S-, -S(=0)-, -S(=0>2-, -NR18t- and -CR18tR19t-; and R41, R5t, Rm, R7t, R*, R91, R10t, R1tt, R12t, R131, R14t, R15t, R16t, R17t, R18t and R19t are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, nitro, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl and C3-io-cycIoalkyi, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyciyl and C3_i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, d-e-alkyl, c1-c6e-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl, and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, c1-c6-alkyl, d-e-alkoxy, C2-6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C3-B-heterocydyl, and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, c1-c6-alkyl, C-j-e-alkoxy, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl, and C3-i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, Ci-e-alkyl, c1-c6-alkoxy, (Walkenyl, aryl, heteroaryl, C3-8-heterocyc!yl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy; with the proviso that R4t and R5t are not both methyl; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9t, R10t, R11t, Riat R13t, R14t, R15t, R16t, R17t,R18t and R19t. 131. The compound according to claim 130, wherein E is selected from the group consisting of -0-, -S-, -S(=OH -S(=0)r and -CR18lR19t-. 132. The compound according to any one of claims 130-131, wherein R18t is hydrogen or F. 133. The compound according to any one of claims 130-132, wherein R10t, R12t, R4t and R61 are all hydrogen. 134. The compound according to any one of claims 130-132, wherein R6t, R7t, R8t and R91 are independently selected from the group consisting of hydrogen, F, CI, C-i-e-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 135. The compound according to any one of claims 130-134, wherein there is a covalent bond between R11t and R131. 136. The compound according to any one of claims 130-135, wherein there is a covalent bond between R13t and R19t. 137. The compound according to any. one of claims. 130-134, wherein R10\ R11t, R12t, R13t, R14t, R15t, R16t and R17t are all hydrogen or F. < 138. A compound of the general formula wherein R4u, R5u, R6U, R7u, R8u, R90, R10u, Rl1u, R12u( R13u, R14u and R15u are independently selected, from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkoxy, CWalkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c1-c6crcycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-8-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c1-c6Krcydoalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, (^-alkenyl, aryl, het-eroaryl, C3-8-heterocyclyI, and c1-c6io-c1-c6cloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, ni-tro, sulfo, d^-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-e~heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C-^-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycioalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, c1-c6Krcycloalkyl, perhalomethyl and perhalomethoxy: with the proviso that R4", R5u and R6u are not all hydrogen; and E is selected from the group consisting of -0-, -S-, -S(=0>, -S(=0)2-, -NR16u- and _CR16UR17US wherein R16u and R17u are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, Chalky!, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6e-alkoxy, C2_6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3_i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-e-alkenyI, aryl, heteroaryl, CM-heterocyclyl, and C3_10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d. 6-alkyl, C-i-e-alkoxy, c1-c6alkenyl, aryl, heteroaryl, c1-c6heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci.6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Ca-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, Ci-6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-e-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R4u( R5u and R6u; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R8u, R9u, R10u and R11u; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R12u, R13u, R14u, R15u, R16u and R17u. 139. The compound according to claim 138, wherein E is selected from the group consisting of -0-, -S-, -S(=Oh -S(=0)2- and -CR16uR17140. The compound according to any one of claims 138-139, wherein R17u is hydrogen or F. 141. The compound according to any one of claims 138-140, wherein there are no covalent bonds between any of the substituents R8U, R90, R10u and R11u. 142. The compound according to any one of claims 138-141, wherein R8u, R9u, R10u and R11u are independently selected from the group consisting of hydrogen, F, CI, d-e-alkyl, Ci-e" alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0}2-NH2, -NH-S(=0)2-OH, hydroxy, amino and per-halomethyl. 143. The compound according to any one of claims 138-142, wherein there is a covalent bond between R12u and R13u. 144. The compound according to claim 138-142, wherein R12u, R13u, R14u and R15u are all selected from the group consisting of hydrogen, F, methyl and c1-c6-alkyl. 145. A compound of the general formula wherein R4v, R5*, R6v, R7\ R8v, R9*, R10v, R11v, R12v, R13v, R14v, R15v, R16v, R17v and R18v are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C-i-e-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, Ci.B-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-s-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10 cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alky!, c1-c6e-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6e-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocydyl and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2_6-alkenyIf aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6e-alkyl, c1-c6-aikoxy, C2^-alkenyl, aryl, heteroaryl, CM-heterocycIyl, c3-c10cycloalkyl, perhalomethyl and perhalomethoxy; with the proviso that none of the substituents R4v, R5v and R6v are benzothiazolyl or benzooxazolyl; and E is selected from the group consisting of -0-, -S-, -S(=0)-, -S(=0)2-, -NR19v- and. -CR^R**-; and wherein R19v and R20v are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alky!, (Walkenyl, aryl, heteroaryl, CM-heterocyclyl and C3. io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^-alkenyI, aryl, heteroaryl, Cs-s-heterocyclyl, and c3-c10 cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-B-heterocycfyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci_6-alkyl, C2_6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy, and wherein there may optionally be a covalent bond between the substituents R7v and R8v or between the substituents R9* and R10v; and wherein there may optionally be a covalent bond between R6v and a substituent selected from R8v and R9*; and wherein there may be a covalent bond between any of the substituents selected from the group consisting of R4v, R5v and RSv; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R"v, R12v, R13v, R14v, R15v, R16v, R17v, R18v, R19v and R20v. 146. The compound according to claim 145, wherein E is selected from the group consisting of -0-, -S-, -S(=Oh -S(=0)2- and -CR19vR20v-. 147. The compound according to claim 145, wherein R20v is hydrogen or F. 148. The compound according to any one of claims 145-147, wherein there are no covalent bonds between any of the substituents R4vf R5v and R6*. 149. The compound according to any one of claims 145-148, wherein there are no covalent bonds between any of the substituents R7v, R8v, R9* and R10v. 150. The compound according to any one of claims 145-149, wherein there are no covalent bonds between a substituent selected from the group consisting of R4v, R5v and R6v and a substituent selected from the group consisting of R7v, R8v, R9v and R10v. 151. The compound according to claim 145-150, wherein R7v, R8v, R9v and R10v are independently selected from the group consisting of hydrogen, F, CI, Chalky!, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)rNH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 152. The compound according to claim 145-151, wherein there is a covalent bond between R12v and R13v. 153. The compound according to any one of claims 145-151, wherein R11v, R12v, R13v, R14v, R15v, R16v, R17v and R18v are all hydrogen or F. 154. A compound of the general formula wherein R4w is selected from hydrogen, hydroxy, amino, suifo, c1-c6alkyl, C2_e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, amino, sulfo, Chalky!, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyc!yl and C$.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, (^-alkenyl, aryl, heteroaryl, c1-c6-heterocydyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Ci_e-alkyl, c1-c6alkoxy, C2-6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and Quo-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, d-e-alkyl, c1-c6-alkoxy, C2^-alkenylf aryl, heteroaryl, C3.B-heterocyclyl and Cs-io-cydoalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Ci. e-alkyl, Ci_6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyciyl, and Cs-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfa, C1-6aikyl, C-^e-aikoxy, C2^-aIkenyi, aryl, heteroaryl, c1-c6-heterocydyl, Cs-io-cycloalkyl, perhalomethyl and perhalomethoxy: with the proviso that R4* is not methyl, morpholine or a 2-chromen derivative; and Z is selected from S, S(=0) and S(=0)2; and R*\ R**, R7", R*\ R*", R10w, R11w, R12*, Rn3w, R14w, R15w and R16w are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nltro, Ci-r-aJkyl, G>.6-aikoxy, C2-ralkenyl, aryl, heteroaryl, Cs^-heterocyclyl and Cs-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Chalky!, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, CM-heterocyclyl and c3-c10cycloalkyi may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and CM0-cycloalkyI, wherein each of the hydroxy, sulfanyl, amino, sutfo, c1-c6-alkyl, C-^-alkoxy, C2^alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and C3-io~cycloaikyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ci-e-alkoxy, C2.«ralkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and CMo-cycloalkyl, perhalomethyl and perhalomethoxy: and E is selected from the group consisting of -O-, -S-, -S(=0)-, -S(=0)2-, -NR17w- and. -CR17wRl8ws and wherein R17wand R18w are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyciyl and c1-c6io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2^-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Ca-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6alkyi, c1-c6-alkoxy, c1-c6B-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyi, and C3.10-cycloaikyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Cv e-alkyl, c1-c6-alkoxy, C2-ralkenyl, aryl, heteroaryl, Cs^-heterocyciyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2-6-alkenyt, aryl, heteroaryl, c1-c6-heterocyciyi, c3-c10cycloalkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be one or more covalent bonds between any. of the substituents selected from the group consisting of R4w, R5", R6w, R7w and R8w; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9w, R10w, R11w, R12w, R13w, R14w, R15w, R16w, R17w and R1Sw. 155. The compound according to claim 154, wherein the only substituents which are cova-lently bound are R4* and R5*. 156. The compound according to any one of claims 154-155, wherein there are no covalent bonds between any of the substituents R* R6w, R7w and R8". 157. The compound according to any one of claims 154-156, wherein there are no covalent bonds between any of the substituents R9w, R10w, R11w, R12w, R13w, R14wt R15w and R16w. 158. The compound according to any one of claims 154-157, wherein E is selected from the group consisting of -0-, -S-, -S(=0)-, -S(=0)2- and -CR17wR18w~. 159. The compound according to any one of claims 154-158, wherein R18w is hydrogen or F. 160. The compound according to any one of claims 154 and 156-159, wherein R5*, R6W, R7w and R8* are independently selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy; amino and perhalomethyL 161. The compound according to any one of claims 154,156 and 158-160, wherein there is a covalent bond between R10w and R11w. 162. The compound according to claim 154,156 and 158-161, wherein there is a covalent bond between R13w and R17w. 163. The compound according to any one of claims 154-160, wherein R9*, R10w, R11w, R12w, R13w, R14w, R15w and R16w are all hydrogen or F. 164. A compound of the general formula wherein R4x is selected from imino, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyciyl and C3-io-cycloalkyl, wherein each of imino, c1-c6-alkyl, C2^-aIkenyl, arylf heteroaryl, c1-c6-heterocydyl and C3_io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyII aryl, heteroaryl, Cs_ 8-heterocyclyl, and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^alkenyl, aryl, heteroaryl, Qwrheterocyclyl, c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, d-e-aikoxy, C2^-alkenyl, aryl, heteroaryl, Ca-s-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, CWalkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6e-heterocyclyl, Qj-io-cycloalkyl, wherein each of the hydroxy, sulfanyl,. amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyi may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, c1-c6alkyl, Ci-e-alkoxy, C2^-alkenyl, pertialomethyl and perhalomethoxy; and R5x, R6x, R7x, R8x, R9x, R10x, R11x, R12x and R13x are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-aJkyl. c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-i0-cycloalkyI, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl and Cwo-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl, wherein each of the hy- droxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-aikenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2-6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, c1-c6io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6alkyl, c1-c6-alkoxy, C2-B-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6s-heterocyclyl, C3.10-cycloalkyl, perhalomethyl and perhalomethoxy; and E is selected from the group consisting of -0-, -S-, -S(=0)-, -S(=0)r. -NR14x- and -CR15xR16x-; wherein R14x is selected from hydrogen, sulfo, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3.to-cycloalkyl, wherein each of sulfo, c1-c6-alky!, C2-e-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.eralkenyl, aryl, heteroaryl, c1-c6-heterocycIyl, and Cs-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, Cn-e-alkyl, Ci-e-alkoxy, C2_6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, C3-KrcycloaIkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, d^-alkoxy, C2-6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2_6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c1-c610-cycloalkyl, perhalomethyl and perhalomethoxy; and R15x and R16x are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, C-i-e-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6Krcycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, Cs-s-heterocyciyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-i heterocyclyl, and c1-c6io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6 alkyl, C-j-e-alkaxy, c1-c6s-alkenyl, aryl, heteroaryl, C3-s-heterocyclyI, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, d^-alkoxy, C2^-aIkenyl, aryl, heteroaryl, CW-heterocyclyl, C3-10-cycloaIkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be a covalent bond between the substituents R4x and R5x; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R6x, R7x, R^ and R9x; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R10x, R11x, R12x, R13x, R14x, R15x and R16x. 165.. The compound according to claim 164, wherein R6x, R7x, R8x and R^ are independently selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2»NH2, -NH-S(=0);rOH( hydroxy, amino and perhalomethyl. 166. The compound according to any one of claims 164-165, wherein R10x, R11x, R12x and R13x are independently selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and per-halomethyl. 167. The compound according to any one of claims 164 and 166, wherein there is a covalent bond between the substituents R6x and R7x. 168. The compound according to any one of claims 164-165, wherein there is a covalent bond between the substituents Rnox and Rm. 169. The compound according to any one of claims 164-165 and 167, wherein there is a covalent bond between R10x and a substituent selected from R14x and R15x. 170. A compound of the general formula wherein R4y and R11y are independently selected from imino, CWalkyl, C2-6-aIkenyl, aryl, heteroaryl, CM-heterocyclyl and c1-c6urcycloalkyl, wherein each of imino, c1-c6-alkyl, C2^-aIkenyIf aryl, heteroaryl, Cs-s-heterocyclyl and dj-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, c1-c6-alkyl, Ci-e-alkoxy, C2^-alkenylI aryl, heteroaryl, C3-8-heterocyclyl, and c3-c10 cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c1-c6io-cycloalkyl may optionally, be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, d_e-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3. 10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-i0-cycIoalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c1-c6 10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and QMo-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, C-^-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, perhalomethyl and perhalomethoxy; and R5y, R6y, R7y, R8y, R9y and R10y are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, C-^-alkoxy, C2-6-alkenyl, aryl, heteroaryl, CM-heterocyclyl and C3-io-cydoalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6e-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen,'amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-icrcycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C,. e-alkyl, c1-c6-alkoxy, c1-c6-s-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyi, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, c1-c6-alkoxy, C2.e-alkenyl, aryl, heteroaryi, CW-heterocyclyl, c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Ci-e-alkyI, c1-c6alkoxy, c1-c6-alkenyl, aryl, heteroaryi, c1-c6s-heterocyclyl, and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyI1 aryl, heteroaryi, c1-c6-heterocyclyl, C3-i0-cycloalkylf wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyi, aryl, heteroaryi, CWheterocyclyl, and c3-c10cycloalk^ may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryi, c1-c6-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be a covalent bond between the substituents R4y and R5y; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R6y R7y, R8y and R9*; and wherein there may optionally be a covalent bond between the substituents R10y and R11y. 171. The compound according to claim 170, wherein R6y, R7y, R8y and R9* are independently selected from the group consisting of hydrogen, F, CI, C-^-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 172. The compound according to any one of claims 170-171, wherein there are no covalent bonds between any of the substituents R6y, R7y, RBy and R9y. 173. The compound according to any one of claims 170-172, wherein there is a covalent bond between the substituents R4y and R5y. 174. The compound according to any one of claims 170-173, wherein there is a covalent bond between the substituents R10y and R11y 175. A compound of the general formula '8z R wherein R4z, R82, R92, R102, R112, R12z, R132, R142, R152, R162 and R17z are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, d-e-alkyl, c1-c6-alkoxy, C2^-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ct-e-alkoxy, C2_e-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and C3_io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alky!, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.i0-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-e-heterocycIyl, and Ca-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and perhalomethoxy; and R52 is a carbon bound substituent selected from c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, CM-heterocyclyl and C3-io-cycloalkyl, each of which may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl, and CiMo-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-i0-cycloalkyi may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, Ci-6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cwrheterocyclyl, Cs-no-cycloalkyl, perhalomethyl and perhalomethoxy; and R62 and R7z are independently selected from hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, Ci-e-alkyl, c1-c6-alkoxy, C2-6-alkeny!, aryl, heteroaryl, c1-c6-heterocycIyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2-e-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-iQ-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C-^alkoxy, C2.6-aIkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloa!kyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6 alkyl, c1-c6-alkoxy, C2.e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl, and c3-c10 cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sutfo, c1-c6-alkyl, c1-c6e-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and perhalomethoxy; and E is selected from the group consisting of -0-, -S-, -S(=0)-, -S(=0)2-, -NR18z- and -CR19^202-; wherein R1Bz is selected from hydrogen, sulfo, c1-c6-alkyl, C2_6-alkenyI, aryl, heteroaryl, C3-8-heterocyclyl and Cs-io-cycloalkyl, wherein each of sulfo, c1-c6-alkyl, C2-e-alkenyl, aryl, heteroaryl, C3_8-heterocyclyl and C3-io-cydoalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, C-^-alkyl, c1-c6-alkoxy, C2^-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycioaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C-wrheterocyclyl, Ca-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, Q^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and perhalomethoxy; and R19z and R2te are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, Chalky!, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2-e-alkenyl, aryl, heteroaryl, C$s-heterocyclyl, and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6 alkyl, c1-c6alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c1-c6io-cycloalkyi, perhalomethyl and perhalomethoxy; and wherein there may optionally be a covalent bond between the substituents R4z and R52; and wherein there may optionally be a covalent bond between any of the substituents R7z, Rte, and R9*; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R10z, Rm, R12z, R13z, R14z, R15z, R16z, R17z, R18z, R19z, and R20*. 176. The compound according to claim 175, wherein there is a covalent bond between the substituents R4z and R5z. 177. The compound according to any one of claims 175-176, wherein R6z, R7z, R8z and R92 are independently selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2f -NHC(=0)-OH, -S(=0)2-NH2| -NH"S(=0)rOH, hydroxy, amino and perhalomethyl. 178. The compound according to any one of claims 175-177, wherein there is a covalent bond between R13z and a substituent selected from R18z and R19z. 179. A compound of the general formula wherein R433 is selected from hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyi, C2^-alkenyl, aryl, heteroaryl, Qwrheterocyclyl and C3_1crcycloalkyl, each of which may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2_6-alkenyl» aryl, heteroaryl, C3_8-heterocyclyl, and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycioaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2_e-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, CsMo-cycloalkyl, wherein each of the. hydroxy, sulfanyl, amino, sulfo, c1-c6-alky!, c1-c6-alkoxy, c1-c6alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perha-lomethoxy; and R5aa, R633, R7aa, R8aa, R933, R10aa, R11aa, R12aa and R13aa are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkoxy, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyciyl and c1-c6io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2_6-alkenyI, aryl, heteroaryl, C-^-heterocyclyl and C3-io-cydoalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C1-6-alkoxy, C2.$-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, and Cs-io-cycloalkyl, wherein each of the hydroxy, suifanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, ^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.no-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c1-c6trcycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-aIkenyIr aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl* c1-c6-alkoxy, C2-6-aIkenyl, aryl, heteroaryl, C3-e-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be a covalent bond between the substituents R5aa and R6aa or between the substituent R7aa and R8aa; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9aa, R10aa, R11aa and R12aa; and E is selected from the group consisting of -0-, -S-, -S(=0)- and -S(=0)2-. 180. The compound according to claim 179, wherein there is a covalent bond between the substituents R9aa and R10aa. 181. The compound according to any one of claims 179-180, wherein R5aa, R6aa, R7aa and R8aa are independently selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, d.e-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)z-OH, hydroxy, amino and perhalomethyl. 182. The compound according to any one of claims 179-181, wherein at least one of the substituents R5aa, R688, R7aa and R8aa are different from hydrogen. 183. A compound of the general formula wherein R4^ is selected from sulfanyl, sulfo, amino, c1-c6-alkyl, C2-s-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and Gs-io-cycioalkyl, each of which may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2_e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cydoalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C1^-aIkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, CWalkenyl, aryl, heteroaryl, C3-B-heterocycfyl, C3-«rcydoaIkyI, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C-j-e-alkoxy, C2^-alkenyI, aryl, heteroaryl, c1-c6-heterocyctyl, and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyi, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy; and E is selected from the group consisting of -NR13ab- and -CR14abR15ab-; and R5ab, R6ab, R7ab, R8ab, R9ab, R10ab, R11af\ R12ab, R13ab, R14ab and R15ab are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, d-e-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C«-heterocyclyl and C3-io"Cydoalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cydoalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6a-heterocyclyl, and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-oycloalkyI, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-io-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ci-e-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be a covalent bond between the substituents R5ab and R6ab or between the substituent R7aband R8ab; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9ab, R10ab, R11ab, R12ab, R13ab, R14ab and R15ab. 184. The compound according to claim 183, wherein there is a covalent bond between the substituents R9ab and R10ab. 185. The compound according to any one of claims 183-184, wherein there is a covalent bond between R10ab and a substituent selected from R13ab and R14ab. 186. The compound according to any one of claims 183-185, wherein R5ab, R6ab, R7ab and Rteb are independently selected from the group consisting of hydrogen, F, CI, c1-c6»alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=OK>H. -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and per-haiomethyl. 187. The compound according to any one of claims 183-186, wherein at least one of the substituents R5ab, R6ab, R7ab and RBab are different from hydrogen. 188.. The compound according to any one of claims 183-187, wherein at least one of the substituents R^, R10ab, R11ab,.R12ab, R13ab, Ruab and R15ab are different from hydrogen. 189. A compound of the general formula wherein R4ac is a carbon bound substituent selected from c1-c6-alkyl, c1-c6-alkenyl, arylr het-eroaryl, c1-c6-heterocydyl and Cs-nrcycloalkyl, each of which may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and Ca-nrcycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Ct-e-alkyl, c1-c6-alkoxy, C2„6-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alky!, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, (^-heterocyclyl, c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalky!, c1-c6alkoxy, C2^-alkenyl, aryl, heteroaryl, Cs-s-heterocydyl, and c1-c610-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perha-lomethoxy; and R5ac, R680, R7ac, R830, R9ac, R10ac and R11ac are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, Ci-e-alkoxy, (Walkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Chalky!, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-e-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2_e-alkenyl, aryl, heteroaryl, C3_g-heterocyclyl, c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C1fc6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.10-cycloalkyi may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano,. nitro, sulfo, Ci-e-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy; with the proviso that A3ac is not C-C(OH)(CF3)2; and R12ac and R13ac are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2-6-alkoxy, C2_6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyi and C3.io-cycloalkyl, wherein each of sulfanyl, sulfo, amino, c1-c6-alkyl, C2-e-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyctyl and C3-i0-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c1-c6io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6alkyl, C-^-alkoxy, C2-6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alky!, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cydoaIkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c1-c6io-cycloalkyl may optionally be substituted with one. or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c1-c6io-cycloalkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be a covalent bond between R4ac and a substituent selected from the group consisting of R5ac and R6aa; with the proviso that A1ac, A230, A3ac, A4ac and A5ac are not ail CH; and wherein there may optionally be a covalent bond between any of the substituents R6ac, R7ac and R830; and wherein there may optionally be one or more covalent bonds between any of the substituents in A1ac, A230, A380, A430 and A5ac. 190. The compound according to claim 189, wherein there is a covalent bond between the substituents R430 and R6ac. 191. The compound according to any one of claims 189-190, wherein there is a covalent bond between A3ac and A4ac. 192. The compound according to any one of claims 189-191, wherein there is a covalent bond between A330 and A230. 193. The compound according to any one of claims 189 and 191-192, wherein R530, R6ac, R7ac and RSac are independently selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)rNH2l -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 194. The compound according to any one of claims 189-193, wherein at least one of the sub- stituents A1aG, A280, A330, A430 and A5ac are different from CH. 195. A compound of the general formula wherein R43* is selected from hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2^alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, each of which may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6 alkyl, C-i-e-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl, and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ci_6-aIkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, CWalkyl, c1-c6-alkoxy, CWalkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c1-c6io-cycloalkyl, perhalomethyl and perha-lomethoxy; and R5ad, R5ad, R7ad, R8ad and R9ad are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkoxy, C2^-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-1CrcycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alky!, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and Cs-Kj-cycloallcyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Cv 6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-icrcycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkylv c1-c6alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d.6-alkyl, c1-c6-alkoxy, (Walkenyl, aryl, heteroaryl, c1-c6-heterocycIyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alky!, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl* Qj-s-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and perha-lomethoxy; and R10ad are selected from imino, c1-c6-alky!, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c1-c6io-cycloalkyl, each of which may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, Ci-e-alkoxy, C2-6«alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2_e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-to-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ct-e-alkoxy, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10 cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, CWalkoxy, C2^-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyI, aryl, heteroaryl, C3-8-heterocyclyl, C3-i0-cycloalkyl, perhalomethyl and perhalomethoxy; and wherein there'may optionally be a covalent bond between R4** and a substituent selected from R6ad and R7ad; and wherein there may optionally be a covalent bond between the substituents R9ad and R10ad so as to form a 5-membered ring system. 196. The compound according to claim 195, wherein the substituents R0* and R10ad are co- valently bound so as to form a 5-membered ring system. 197. The compound according to claim 196, wherein said 5-membered ring system com prises at least one nitrogen atom in the ring. 198. The compound according to claim 196, wherein said 5-membered ring system contains 5 carbons in the ring. 199. The compound according to any one of claims 195-198, wherein there is a covalent bond between the substituents R4*1 and R7ad. 200. The compound according to any one of claims 195-198, wherein R5ad, R65"1, R7ad and R8ad are independently selected from the group consisting of hydrogen, F, CI, Ci-6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(-0)-OH, -S(=0)2-NH2l -NH-S(=0)2-OH, hydroxy; amino and per-halomethyl. 201. A compound of the general formula wherein E is selected from the group consisting of -0-, -S-, -S(=0)-f -S(=0)2-, -NR16ae- and - CR17aeR1Bae_; and p4ae p5ae p6ae o7ae pBae p9ae n10ae p11ae p12ae p13ae p14ae p15ae p16ae p1"7ae aprl Rl&as arft independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, Ci-e-alkyi, c1-c6-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl and Cs-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, suifo, c1-c6-alkyl, CM-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, suifo, c1-c6-alkyl, C2-6-aIkenyl, aryl, heteroaryl, c1-c6e-heterocycfyl, and Cs-icr cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, suifo, c1-c6-alky!, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocydyl, c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, suifo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, suifo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and CjMD-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, suifo, Ci-e-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, suifo, c1-c6-alky!, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be a covalent bond between any of the substituents selected from R4ae, R5ae, R6afi and R7ae; with the proviso that when R536 and R636 are covaiently bound they do not form a isoquinolin-3-yl or a substituted isoquinolin-3-yl together with the pyridine which they are both bound to; and . wherein there may optionally be a covalent bond between any of the substituents selected from R8a9 P936 p1°a® p11ae p12ae p13ae p14ae n15ae p!6ae p17ae a-j p18ae 202. The compound according to claim 201, wherein there is a covalent bond between R6aB and R7ae. 203. The compound according to claim 201, wherein there is a covalent bond between R5ae and R6ae. 204. The compound according to any one of claims 201-203, wherein at least one of R8ae, pfl* R10ae( pHa^ R12» R13ae R14ae an(j R15ae js se|ected from F> C|, c1-c6-alkyl, d.6-alkOXy, - C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 205. A compound of the general formula wherein R4af, R5*, R6af, R7af( R8af, R9af, R10af, R11af, R12af, R13af, R14af and R15af are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2. e-alkenyl, aryl, heteroaryl, C3-8-heterocyclyI and Cs-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, CWalkyl, c1-c6-aikenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, Ctj-s-heterocyclyl, CiMo-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyi, c1-c6-alkenyl, aryl, heteroaryl, CM-heterocyclyl and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6 alkyl, C2^-alkenyI, aryl, heteroaryl, c1-c6-heterocydyl, and C3-io-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2_6-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, c1-c6io-cycloalkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be a covalent bond between R6af and any of the substituents selected from R5af and R7af; and wherein there may optionally be a covalent bond between the substituents R9af and R10af; and R16af is selected from hydrogen, hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkenyl, C3-8-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2.6-alkenyl, c1-c6-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, Ca-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and Cs-10-cycioalkyl, wherein each of the hydroxy, sulfanyl*. amino, sulfo, c1-c6-alkyl, C2^»alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, QMo-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl9 C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl, and c3-c10cycloalkyl may optionally be substituted with one. or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3_10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalky!, Cae-alkenyl, aryl, heteroaryl, (W heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Cn-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and per-halomethoxy; with the proviso that R16af is not methyl; and wherein there may optionally be a covalent bond between the substituents R12af and R16af. 206. The compound according to claim 205, wherein there is a covalent bond between the substituents R" and R6af. 207. The compound according to any one of claims 205-206, wherein there is a covalent bond between the substituents R9af and R10af. 208. The compound according to any one of claims 205-207, wherein at least one of R8af, R9af, R10af, Rl1af, R12af, R13af, R14af and R15af is selected from F, CI, c1-c6alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2l -NH-S(=0)rOH, hydroxy, amino and perhalomethyl. 209. A compound of the general formula wherein E is selected from the. group consisting of -0-, -S-, -S(=0)-, -S(=0)z- and - CR16agR17ag-; and R4ag, R539, R639, R10ag, R1139, R12ag, R13ag, R16a9 and R17ag are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Ca-io-cycloalkyi, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2^alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cydoalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and CiMo-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C<\s-alkyl, C2-e-alkenyl, aryl, heteroaryl, Cs-a-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-icrcycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Ca.10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C-^-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6rheterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and perhalomethoxy; with the proviso that R439 is not -CH2-N(CH3)2; and wherein there may optionally be a covalent bond between the substituents R5ag and R6a9; and R739 is selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, cyano, nitro, Ci-s-alkyi, CW alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sul- fanyl, sulfo, c1-c6-alkyl, C2-6-alkenyl, arylt heteroaryl, c1-c6-nexerocyuyi optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and Cs-^-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalky!. C2-e-alkenyIl aryl, heteroaryl, C3-8-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and Cs-io-cyoloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3.10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-alkenyl( aryl, heteroaryl, C3-8-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, c3-c10cycloalkyi, perhalomethyl and perhalomethoxy; R8*9, R9as, R14a9 and R15a9 are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2_6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3. 10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6io-cycloaikyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyi, C2.e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d^-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocydyl, Cs-io-cycloalkyi, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-alkenyf, aryl, heteroaryl, C3-s-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, C2_6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-i0-cycloa!kyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6- alkyl, C2-6-alkenyl, heteroaryl, C3-8-heterocyclyl, C3-io-cycloalky[, perhalomethyl and perha-lomethoxy; and wherein there may optionally be a covalent bond between the substituents R9as and R10as; and wherein there may optionally be a covalent bond between the substituents R12a9 and R16a9. 210. The compound according to claim 209, wherein there is a covalent bond between the substituents R5ag and R639. 211. The compound according to any one of claims 209-210, wherein there is a covalent bond between the substituents R9a9 and R10a9. 212. The compound according to any one of claims 209-211, wherein at least one of RBa9, R9a9j plOag^ ^^ R12a9j Ria* R14ag an(j R15ag afe se)ected from F> C[i Q^-alkyl, C-^-alkOXy, - C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)rOH, hydroxy, amino and perhalomethyl. 213. A compound of the general formula wherein R4^, R5ah, R6ah, R7ah, R8ah and R9ah are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-to-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^-aikenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalky!, C2„6- alkenyl, aryl, heteroaryl, C3_6-heterocycIyl, and c1-c610-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10 cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6alkyl, CWalkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10 cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6alkyl, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2_e-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, Cs-io-cycloalkyl, perhalomethyl and perhalomethoxy; with the proviso that R53*1 and R6ah are not both CF3; and wherein there may optionally be a covalent bond between any of the substituents selected from R4*, R5ah, R6ah and R7ah; and wherein there may optionally be a covalent bond between the substituents R8ah and R9ah; with the proviso that when R8ah and R9ah together with the carbon to which they are bound forms phenyl then R5ahf R6ah, R7ah and R8ah are not all hydrogen. 214. The compound according to claim 213, wherein there is a covalent bond between R8ah and R9ah. 215.. The compound according to any one of claims 213-214, wherein there is a covalent bond between R6ah and R7ah. 216 . The compound according to any one of claims 213-215, wherein there is a covalent bond between R5ah and R6a217. The compound according to any one of claims 223-226, wherein at least one of R5ah, R6ah, R7ah and R8ah are selected from F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 218. A compound of the general formula R4ai, R**\ R6ai( R7ai, R8ai and R9ai are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2_6-alkenyl, aryl, heteroaryl, C3-e-heterocyclyl and C3-i0-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-e-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3.10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6s-heterocyciyl, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, CM-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c1-c6io-cycloalkyl, wherein each of the. hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and ^o-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, C2.e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and per-halomethoxy, with the proviso that R4ai is not CHrN(Me)2; and wherein there may optionally be a covalent bond between any of the substituents selected from R4ai, R5ai, R6ai and R7ai; and wherein there may optionally be a covalent bond between the substituents RBai and R9ai; with the proviso that R8*1 and R931 together with the carbon to which they are bound do not form 4-methoxy-phenyl, 4-chloro-phenyl or.4-nitro-phenyl. 219. The compound according to claim 218, wherein there is a covalent bond between R8aj and R93'. 220. The compound according to any one of claims 218-219, wherein there is a covalent bond between R631 and R7ai. 221. The compound according to any one of claims 218-220, wherein there is a covalent bond between R5al and R6a'. 222.: The compound according to any one of claims 218-221, wherein at least one of R5ai, R6aif R7ai and R831 are selected from F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 223. A compound of the general formula wherein R4aj, R5aif R6ai and R7aj are independently selected from amino, cyano, nitro, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of amino, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^-aIkenylf aryl, heteroaryl, C3-s-heterocyclyl, and Qj-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6 alkyl, C2-6-alkenyl, aryl, heteroaryl, Qj-B-heterocyclyl, and Cs.io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, Qwrheterocyclyl, Cs-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and CsMcrcycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Gt-6-alkyI, C2^-alkenyl, aryl, heteroaryl, Qj-B-heterocyclyl, CsMo-cycloalkyl, perhalomethyl and perhaiomethoxy; and wherein there may optionally be a covalent bond between the substituents R4* and R5ai; and wherein there may optionally be a covalent bond between the substituents R6- and R7aj. 224. The compound according to claim 223, wherein there is a covalent bond between R6aj and R7aj. 225. The compound according to claim 224, wherein R6aj, R7aj and said covalent bond are selected so as to form a ring system selected from an optionally substituted piperedine, piperazine, morpholine and thiomorpholine. 226. The compound according to claim 225, wherein said ring system is selected from piperedine, piperazine, morpholine and thiomorpholine 227. The compound according to any one of claims 223-226, wherein there, is a covalent bond between R4aj and R5aj, 228. A compound of the general formula wherein R4*, R5ak, R8* and R7ak are independently selected from amino, cyano, nitro, c1-c6-alkyl, C2.e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Ca-i0-cycloalkyl, wherein each of amino, c1-c6-alkyl, C2^-aikenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyi may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and c1-c6io-cycioalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, Cs^-heterocyclyl, and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-e-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloaIkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyi, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloa1kyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6alkyl, C2^-alkenyi, aryl, heteroaryl, C3-8-heterocyclyl and C3.10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and Cs.i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^-aikenylf aryl, heteroaryl, C3^-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy; with the proviso that none of R4akand R5ak are -C(=0)-0-isopropyl; and wherein there may optionally be a covalent bond between the substituents R43* and R5ak; with the proviso that R43*, R531* and the nitrogen to which they are bound do not form a substituted tetrazolyl moiety; and wherein there, may optionally be a covalent bond between the substituents Reak and R7ak; 229. The compound according to claim 228, wherein there is a covalent bond between R6ak and R7ak. 230. The compound according to claim 229, wherein R6a\ R7ak and said covalent bond are selected so as to form a ring system selected from an optionally substituted piperedine, piperazine, morpholine and thiomorpholine. 231. The compound according to claim 230, wherein said ring system is selected from piperedine, piperazine, morpholine and thiomorpholine 232. The compound according to any one of claims 228-231, wherein there is a covalent bond between R43* and R**. 233. A compound of the general formula wherein R481 and R5aI are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2_6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyctyl and C3-io-cycloaIkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2.a-alkenyl, aryl, heteroaryl, C3-B-heterocyclyl, and Cs-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Ct^-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3_10-cycloalkyi may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^-aIkenyl, aryl, heteroaryl, C3.s-heterocyclyI, C&.1Crcycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alky!, C2.e-alkenyl, aryl, heteroaryl, C3-B-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, c1-c6-alkenyl, aryl, heteroaryl, Cs^-heterocyclyl and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, C2-6-aIkenyl, aryl, c3-c10cycloalkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be a covalent bond between R43' and R5aI; with the proviso that R43* and R5al together with the nitrogen to which they are bound do not form 2,5-pyrrolidinedione or an annealed ring system comprising 3 or more rings; and wherein E is selected from the group consisting of -0-, -S-, -S(=0)-, «S(=0)2- and -NR14aI-, -CR15a,R16aIs and Rea R7* Reaf R9d Rioa R«* Ri* R«^ R14* RiM and RiBa» are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-e-heterocyclyl and C3.10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Quo-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6alkyl, c1-c6-alkenyl; aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloaIkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, C2^-alkenyl, aryl, heteroaryl, C3_s-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, CWalkyl, C2_6-aIkenyl, aryl, heteroaryl, C3-5-heterocyclyl, C3-io-cycloaIkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-«ncycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6rheterocyclyl and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalky!, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alky!, c1-c6-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.1(rcycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, Qj-io-cyctaalkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be a covalent bond between the substituents R7al and Rtol; and wherein there may optionally be a covalent bond between the substituents R10al and a sub-stituent selected from R14ai and R15aL 234. The compound according to claim 233, wherein there is a covalent bond between the substituents R431 and R5ai. 235. The compound according to any one of claims 233-234, wherein there is a covalent bond between the substituents R7al and R8al. 236. The compound according to any one of claims 233-235, wherein there is a covalent bond between R10al and a substituent selected from R14aI or R15al. 237. The compound according to any one of claims 233-235, wherein E is -NR14a'-. 238. The compound according to claim 237, wherein R14aI is selected from F, CI, d-e-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)rOH, hydroxy, amino and perftalomethyl. 239. The compound according to any one of claims 233-235, wherein E is -CR15alR16a1-. 240. The compound according to claim 239, wherein R16al is selected from F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 241. The compound according to any one of claims 239-240, wherein R15al is hydrogen. 242. The compound according to any one of claims 233-241, wherein at least one of R6al, R7a\ R8al, R9al, R10al, R11aIf R12al and R13aI are selected from F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH,-S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 243. A compound of the general formula wherein E is selected from the group consisting of-0-, -S-, -S(=0)-, -S(=0)2- and -NR14am-, -CR15amR16am~; and wherein A1am is N or C-R17am; A23"1 is N or C-R18am; A331" is N or C-R19am; A43"1 is N or OR20""1; and p6am p7am p8am pQam p10am p11am p12am p13am pt4am p15am p16am p17am p18am p19am «nf4 R20am are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C1_6-alkyl, C2^-alkenyl, aryi, heteroaryl, C3-8-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6nrcydoalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2^-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, C2.B-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloaIkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocycIyI, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and c1-c610-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, het-: eroaryl, c1-c6-heterocyclyl and C3-io-cycIoalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl,. C2_6-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6e-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and perhalomethoxy; with the proviso that R17am and R203™ are not both hydroxy; and wherein there may optionally be a covalent bond between R18am and a substituent selected from R17am and R19am; and wherein there may optionally be a covalent bond between the substituents R10am and a substituent selected from R14am and R15am; and wherein there may optionally be a covalent bond between the substituents R7am and R8am. 244. The compound according to claim 243, wherein there is a covalent bond between R1Bam and a substituents selected from R17am and R19am. 245. The compound according to any one of claims 243-244, wherein there is a covalent bond between R10am and a substituent selected from R14am or R15am. 246. The compound according to claim 243, and , wherein E is -NR14am-. 247. The compound according to claim 246, wherein R14am is selected from F, CI, c1-c6-alkyl, c1-c6e-alkoxy, -C(=0)NH2, -NHC(=0)-OH? -S(=0)2-NH2| -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 248. The compound according to claim 243, wherein E is -CR15amR16am-. 249. The compound according to claim 248, wherein R16am is selected from F, CI, d-e-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 250. The compound according to any one of claims 248-249, wherein R15am is hydrogen. 251. The compoud according to claim 248, wherein there is a covalent bond between R15am and R16am. 252. The compound according to any one of claims 243-251, wherein at least one of R6am, pTam^ R6am( R9am( plOarr^ pllar^ R12am and R13am gre se|ected from Fj Q|f c1-c6-alkyl, c1-c6-alkOXy, -C(=0)NH2f -NHC(=O)-0H, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 253. A compound of the general formula wherein E is selected from the group consisting of -0-, -S-, S(rO)~, -S(=0)r and -NR17an-, -CR18anR19an-; and p4an p5an p6an p7an p8an p9an p10an p11an p12an pl3an nUan p15an p16an p17an p18an anf4 R19an are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, Ci-e-alkyI, Cz^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, Ca-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, C2-e-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and Cs-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6alkyl, C2_e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2-e-alkenyl, aryl, heteroaryl, Ca-s-heterocyclyl, C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl,. amino, sulfo, Ct-e-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Ci_6-alkyl, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and Q^o-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocydyl and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and c3-c10cycioalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Cve-alkyl, (Walkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy; with the proviso that R43" is not methyl or phenyl; and i wherein there may optionally be a covalent bond between RiaBn and a substituent seiectea from R17an and R1&an; and wherein there may optionally be a covalent bond between the substituents R7an and RBan. 254. The compound according to claim 253, wherein R48" is a substituted heteroaryl. 255. The compound according to claim 254, wherein said substituted heteroaryl is a substituted pyridine. 256. The compound according to any one of claims 253-255, wherein there is a covalent bond between the substituents R7an and R830. 257. The compound according to any one of claims 253-256, wherein there is a covalent bond between R13an and a substituents selected from R17an and R1Ban. 258. The compound according to any one of claims 253-256, wherein E is -NR17an-. 259. The compound according to any one of claims 253-256, wherein E is -CRlBanR19an-. 260. The compound according to claim 259, wherein R19an is selected from F, CI, c1-c6-alkyl, c1-c6alkoxy, -C(=0)NH2) -NHC(=0)-OH, -S(=0)2-NH2, -NH^S(=0)rOH, hydroxy, amino and perhalomethyl. 261. The compound according to any one of claims 259-260, wherein R18an is hydrogen. 262. The compound according to any one of claims 253-261, wherein at least one of R5an, R6an, R7an, R8an, R9an, R10an, R11an, R12an, R13an, R14an, R15an and R16an are selected from F, CI, c1-c6-alkyl, Ci-e-aikoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=OVNH2l -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 263. A compound of the general formula wherein R4ao is selected from hydrogen, hydroxy, sulfo, halogen, amino, cyano, nitro, d-e-alkyl, d-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and d-io-cycloalkyl, wherein each of hydroxy, sulfo, amino, d-e-alkyl, d.«-alkenyl, aryl, heteroaryl, d-e-heterocyclyl and d-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, d-e-alkyl, d-e-alkenyl,. aryl, heteroaryl, d-s-heterocyclyl and d-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl* d-e-alkenyl, aryl, heteroaryl, d-e-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, d-e-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and d-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, d-e-alkenyl, aryl, heteroaryl, d-e-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, d-e-alkyl, d-s-alkenyl, aryl, heteroaryl, d-s-heterocyclyl and d-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, d-e-alkenyl, aryl, heteroaryl, d-s-heterocyclyl and d_10-cycloalkyl roay optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, d-e-alkyl, d-e-alkenyl, aryl, heteroaryl, d-e-heterocyclyl and d. to-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-s-alkyl. d-6-alkenyi, aryl, heteroaryl, c1-c6-heterocyclyl and C3.i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, d-e-alkyl, d^-alkenyl, perhalomethyl and perhalomethoxy; and wherein R5ao, RBao, R7a0, R8ao, R9ao, R10ao, R11ao and R12ao are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, d-e-alkyl, d-e-alkenyl, aryl, heteroaryl, d^-heterocyclyl, and d-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, d-s-alkenyl, aryl, heteroaryl, d^rheterocyclyl and d-to-cycloalkyl rnay optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, d-e-alkyl, d-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and d-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-s-alkyl, C2-6-a!kenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6alkyl, C2.6-aIkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyI, wherein each of hydroxy, sulfanyl, sulfo, amino, CWalkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocydyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2_6-alkenyI, aryl, heteroaryl, C3-8-heterocyclyl and C3-icrcycloaIkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-8-beterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, d-e-alkyl, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl and C3-icrcycloalkyI, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloaikyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2-6-a!kenyl, perhalomethyl and perhalomethoxy; with the proviso that any one of R6ao and R8ao is not methyl; and with the further proviso that R430, R530, R6ao, R7ao and R890 are not all hydrogen; and wherein there may optionally be a covalent bond beween R430 and R6a0; and wherein there may optionally be a covalent bond between R7ao and R8ao; and wherein there may optionally be. a covalent bond between R9ao and R10ao. 264. The compound according to claim 263, wherein R5a0, R6ao, R7ao and R8ao are independently selected from hydrogen and fluor. 265. The compound according to any one of claims 263-264, wherein R9ao, R10ao, R11a0 and R12ao are independently selected from hydrogen and fluor. 266. A compound of the general formula wherein R1ap and R23*5 are independently selected from Cnj-alkyl, C2^-aIkenyI, aryl, heteroaryl, CWheterocyclyl, and C3-io-cycloalkyl, herein each of Chalky!, C2_6-aIkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c1-c6io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6alkyl, C2^alkenyl, aryl, heteroaryl, C3.B-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, nitro, c1-c6-alkyl, C2„ralkenyl, aryl, heteroaryl, C3-8-heterocyc!yl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, CW-heterocycIyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2.6-alkenyi, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, perhalomethyl and perhalomethoxy; with the proviso that if R1ap and R28* are identical then they are not methyl or ethyl; and wherein there may optionally be a covalent bond between the substituents R1ap and R23*3; and wherein R5ap, R6ap and R7ap are independently selected from hydrogen and F; and wherein R4^ is selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, d^-alky!, C2^alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl, and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Chalky!, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, Q^-heterocyclyl and C3. 10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2_e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyi, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alky!, C2^-alkenyl, aryl, heteroaryl, C3^-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, Cs-e-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, d-e-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6icrcycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6~alkenyl, aryl, heteroaryl, Qj-a-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, Ca-e-alkenyl, perhalomethyl and perhalomethoxy; with the proviso that R4^ is not methyl. 267. The compound according to claim 266, wherein R1ap and R2ap are not identical. 268. A compound of the general formula wherein R1aq and R2** are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-oycloaIkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alky!, C2.5-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, C3-e-heterocyclyl and C3-io-cycloaIkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C«-alkyl, (Walkenyi, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Ci_6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6s-heterocyclyl and C3. io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Ci-e-alkyI, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3_io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, d-e-alkyl, c1-c6alkenyl, perha-lomethyl and perhalomethoxy; with the proviso that R1aq and R23" are not both methyl; and wherein there may optionally be a covalent bond between R1aq and R2^; and wherein R4aq, R5aq, R6aq, R7aq, R8aq, R9aq, R10aq and R11ao are indenpendently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6alkyl, c1-c6-alkenyl, aryl, heteroaryl, Q^rheterocyclyl, and Cs-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocydyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Ct-e-alkyI, C2.6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkenyi, aryl, heteroaryl, Cwrheterocyclyl and C3. 10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C-^-alkyl, C2^-alkenyl, aryl, heteroaryl, C3-6-heterocyc!yl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c3-c10cycioalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6alkyl. C2-e-alkenyl, aryl, heteroaryl, c1-c6r heterocyclyl and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2.6-alkenyl, aryl, heteroaryl, C3_g-heterocycIyl and C3-«rcycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3. 10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2-6-aIkenyl, perhalomethyl and perhalomethoxy; and 1 wherein there may optionally be a covalent bond between R4*1. and R5aq; and wherein R3aq is selected from the group consisting of-C(=0)-, -C(=0)NH-, -CH2-, -CH2CH2-, -CHF-, «CH2CHF-, -CHFCHr, -NH-, -S(=0)2-NH-, -NH-S(=0)r, -NHC(=0)-, -0-, -S-, -S(=0> . -S(=0)2-; and wherein there may optionally be a covalent bond between two substituents selected from R**, R9aq, R10aq and R11a0. 269. The compound according to claim 268, wherein there is one covalent bond between the substituents R1aq and R2^. 1 270. The compound according to any one of claims 268-269, wherein R4^, R5aq, R6aq and R7aq are independently selected from hydrogen and fluor. 271. The compound according to any one of claims 268-270, wherein R3^ is selected from -0-, -S-, -CHr, -CH2CHr, -NH-, -NH-C(=0)-, -C(=0)-NH-( -S(=0)2-NH- and -NH~S(=0)2-. 272. A compound of the general formula wherein A1ar is N or C-R10ar; and A2* is N or C-R11ar; and A3ar is N or C-R12ar; and wherein R1ar, R23', R3ar, R48', R5ar, R6ar, R7ar, R8ar, R93', R10ar, R11ar and R12ar are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2. e-alkenyl, aryl, heteroaryl, c1-c68-heterocyclyl, and C3-io-cycloaIkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alky!, c1-c6-alkenyl, aryl, heteroaryl, C3_8-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, (^-alkenyl, aryl, heteroaryl, C3^-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Cn^-alkyl, Ca^-alkenyl, aryl, heteroaryl, c1-c6rheterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyt, C2-e-alkenyl, aryl, heteroaryl, C3_8-heterocyclyl and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Chalky!, (Walkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3. 10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2^-aIkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6io-cycloalkyl may optionally be substituted with one or more, substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alky!, CWalkenyl, perhalomethyl and perhalomethoxy; with the proviso that if R1ar and R231" are identical then they are not methyl or ethyl; and wherein there may optionally be a covalent bond between R1ar and R23*". 273. The compound according to claim 272, wherein R9ar is S(=0)2-R13ar or C(=0)-R13ar; and wherein R13ar is selected from hydroxy, sulfanyl, sulfo, amino, Chalky!, C2-6-aIkenylf aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Ci-e-alkyI, C2^-a!kenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Ci-e-alkyI, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, Qj-s-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-aikyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl* sulfo, amino, c1-c6-alkyl, C2-e-alkenyl, aryl, heteroaryl, C3-a-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Ci-e-alkyI, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl and c1-c6trcycioaikyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloaIkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2.6-alkenyl, perhalomethyl and perhalomethoxy 274. The compound according to any one of claims 272-273, wherein R1ar and R291" are not identical. 275. The compound according to any one of claims 272-274, wherein there is a covalent bond between the substituents R1ar and R231". 276. A compound of the general formula wherein R1as, R285, R383, R4as, R5as, R6as, R7as, R8as and R938 are independetly selected from hydrogen and fluon and wherein R10as is selected from aryl and heteroaryl, which is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cydoalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Chalky!, Cs-e-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl and CsMo-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2^-aIkenyl, aryl, heteroaryl, C3^heterocyclyl and C3-1Crcycloalkyl may optionally be substituted with one. or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-aikyl, c1-c6-alkenyi, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Qs-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C1^-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6rheterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6»alkenyl, aryl, heteroaryl, c1-c6rheterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Chalky!, C2-e-aIkenyl, perhalomethyl and perhalomethoxy; and wherein R12as is selected from hydrogen, hydroxy, sulfanyl, sulfo, amino, cyano, c1-c6-alkyl, C2. e-alkenylr aryl, heteroaryl, c1-c6heterocyclyl, and C3_10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyi, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10 cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Ci-e-alkyi, C2^-alkenyl, aryl, heteroaryl, CM-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alky!, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxof halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and C3-i0-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Ci-e-alkyI, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and CsMo-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alky!, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^alkenyl, aryl, heteroaryl, C3-8-heterocyciyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-e-heterocyclyl and CsMo-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkenyl, perhalomethyl and perhalomethoxy; and wherein R13as, R14as, R15as and R16as are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, C3-a-heterocyclyl and c1-c6 10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6alkyl, C2^-alkenyl, aryl, heteroaryl, C3_e-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, d-e-alkyl, C2^-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and Cs-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, C2_6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Chalky!. C2.6-alkenyl, aryl, heteroaryl, Cs-8-heterocyclyl and C3-io-cycloaIkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-aikenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C$. 1crcycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Ci-e-alkyI, C2^-alkenyl, aryl, heteroaryl, C3_s-heterocyclyl and C3-io-cycioaIkyl, wherein each of hydroxy, sulfanyl, ilfo, amino, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl ay optionally be substituted with one or more substituents independently selected from hy-oxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, perha-methyl and perhalomethoxy; with the proviso that Rt2as, R13as, R14as, R15as and R16as are not I hydrogen; and herein there may optionally be a covalent bond between the substituents R13as and R14as. 77. The compound according to claim 276, wherein R13as, R14as, R15as and R16as are inde- endently selected from hydrogen and fluor. 78. A compound of the general formula wherein R5*, R6at, R7at R8al, R9at, R10at R11at, R12a\ R13at R14at, R15at, R16at, R17al and R18al are independently selected from hydrogen and fluor, and wherein R4at is selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, Ci_6-alkyl, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d^-alkyl, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, Q^e-alkeny!, aryl, heteroaryl, c1-c6-heterocyclyl and Cs-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2^-alkenyt, aryl, heteroaryl, c1-c6-heterocyclyl and C3-i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, het- eroaryl, C-^-heterocydyl and Gs-io-cycloalkyi, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alky!, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may op* tionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfb, oxo, halogen, amino, cyano, nitro, d-e-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6a-heterocyclyl and C3-to-cycloalkyl( wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nrtro, c1-c6-alkyl, C2-6-alkenyl, perhalomethyl and perhalomethoxy; and wherein R19at is selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, C% e-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and CMo-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Quo-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Ci-6-alkyl, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10 cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2_6-alkenyl, aryl, heteroaryl, C«-heterocyclyl and C3.io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloaikyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2^-alkenyI, aryl, heteroaryl, C3-B-heterocyclyl and C3-10-cycloaIkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, fluor, iodine, amino, cyano, nitro, c1-c6-alkyl, C2-e-aIkenyl, aryl, heteroaryl, C3-8-heterocycly! and C3-io-cycloalkyl; with the proviso that R19at is not methoxy. 279. The compound according to claim 278, wherein R5a\ R6*, R7at R8al, R9at, R10at R11at, R12at, R13at R14* R1S* R1M R17at and R18at ape aj( hydrogen. 280. The compound according to any one of claims 278-279, wherein R4at is an optionally substituted aryl or heteroaryl. 281. The compound according to any one of claims 1-280, wherein said compound com prises only one F. 282. The compound according to any one of claims 1-280, wherein said compound com prises two F and preferably three F. 283. The compound according to any one of claims 1-280, wherein said compound com prises a CF3 moiety. 284. The compound according to any one of claims 1-283, wherein said compound comprises a hydrophilic substituent selected from the group consisting of hydroxy, amino, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NHS(=0)2-OH, -NHC(=0)-R1am, -NHS(=0)2-R1an\ -N(R1am)C(=0)-R2am, -N(R1am)S(=0)2-R2aml wherein R1am and R2"" are independently selected from Chalky!. 285. The compound according to any one of claims 1-283, wherein said compound comprises a moiety selected from the group consisting of £ 2H), 2.63 (t, 2H), 2.12 (qu, 2H). Example 176 (General procedure 1) Methyl-phenyl-carbamic acid benzo[d]isoxazoI-3-yl ester The title product was prepared from benzo[d]isoxazol-3-ol and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC. (53%, colorless oil). HPLC-MS: mtz= 291.1 (M+23); Rt: 4.05 min. 1H NMR (CDCIs): 7.60-7.75 (m, 1H), 7.49-7.60 (m, 2H), 7.38-7.48 (m, 4H)i 7.28-7.36 (m, 2H), 3.46 (sf 3H). Example 177 (General procedure 1) Methyl-phenyl-carbamic acid pyridin-2-yI ester The title product was prepared from 2-hydroxypyridine and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC. (57%, colorless oil). HPLC-MS: m/z= 229.1 (M+23); Rt: 2.80 min. 1H NMR (CDCI3): 8.38 (d, 1H), 7.75 (t, 1H), 7.35-7.45 (m, 4H), 7.22-7.34 (m, 1H), 7.14-7.21 (t, 1H), 6.99-7.15 (bs, 1H), 3.44 (s, 3H). Example 178 (General procedure 1) Methyl-phenyl-carbamic acid 1-(methyl-phenyl-carbamoyl)-1H-benzimidazol-2-yl ester The title product was prepared from 2-hydroxybenzimidazole and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC. (14%, white crystals). HPLC-MS: m/z= 401.2 (M+1); Rt: 3.88 min, purity: 83%. 1H NMR (CDCI3): 7.32 (dd, 2H), 7.24-7.28 (m, 2H), 7.21-7.24 (m, 2H), 7.29 (t, 1H), 7.12-7.19 (mf 5H), 7.09-7.15 m, 2H), 3.28 (s, 6H). Example 179 (General procedure 1) Methyl-phenyl-carbamic acid 4-[(pyridine-3-carbonyI)-amino]-phenyl ester The title product was prepared from N-(4-Hydroxy-phenyl)-nicotinamide and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC. (1%, light yellow crystals). HPLC-MS: m/z= 348.1 (M+1); R<: 2.96 min. Example 180 (General procedure 11) 4-Py!ToIidin-1-yl-piperidine«1-carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester The title product was prepared from 4«(5-trifluoromethy!-pyridin}-2-yloxy)-phenoI and 4-(1-pyrrolidinyI)piperidine. The crude product was used without further purification (68%, white solid). HPLC-MS: rnlz = 436.2 (M+1); Rt: 2.98 min. 1H NMR (DMSO-d6): 10.90 (bs, 1H), 8.57 (s, 1H), 8.24 (dd, 1H), 7.15-7.30 (m, 5H), 4.00- 4.40 (m, 2H), 3.45-3.60 (m, 2H), 2.75-3.25 (m, 4H), 2.05-2.25 (d, 2H), 1.80-2.05 (m, 5H), 1.60-1.80 (m,2H). Example 181 (General procedure 12) Methyl-o-tolyl-carbamic acid 4-(trifluoromethyI-pyridin-2-yioxy)-phenyI ester The title product was prepared from 4-(5-trifluoromethyI-pyridin)»2-yloxy)-phenoI and N-methyl-o-toluidine. The crude product was subjected to preparative HPLC (51%, colorless oil). HPLC-MS: mlz = 403.2 (M+1); Rt: 4.89 min. 1H NMR (CDCI3): 8.40 (s, 1H), 7.87 (dd, 1H), 7.05-7.18 (m, 4H), 6.96 (d, 1H), 3.30 (s, 3H), 2.36 (s, 3H). Example 182 (General procedure 12) Methyl-pyridin-2-yl-carbamic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester The title product was prepared from 4-(5-trifluoromethyl-pyridin)-2-yloxy)-phenol and 2-(methylamino)pyridine. The crude product was subjected to preparative HPLC (55%, white solid). HPLC-MS: rnlz =390.1 (M+1); Rt: 4.31 min. Example 183 (General procedure 12) Methyl-m-tolyl-carbamic add 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester The title product was prepared from 4-(5«trifluoromethyl-pyridin)-2-yloxy)-phenol and N-methyl-m-toluidine. The crude product was subjected to preparative HPLC (51%, colorless oil). HPLC-MS: rnlz = 403.2 (M+1); Rt: 4.98 min. 1H NMR (CDCI3): 8.42 (s, 1H), 7.88 (dd, 1H), 7.28 (d, 1H), 7.05-7.25 (m, 7H), 6.97 (d, 1H), 3.41 (sf 3H), 2.38 (s, 3H). Example 184 (General procedure 12) (3-ChIoro-phenyI)-methyI-carbamic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester The title product was prepared from 4-(5-trifluoromethyl-pyridin)-2-yioxy)-phenoI and 3-chloro-N-methyianiline. The crude product was subjected to preparative HPLC (54%, colorless oil). HPLC-MS: mlz = 423.1 (M+1); R{: 5.07 min. 1H NMR (CDCI3): 8.42 (m, 1H), 7.88 (dd, 1H), 7.39 (m( 1H), 7.33 (t, 1H), 7.22-7.30 (m, 2H), 7.10-7.7.22 (m, 4H), 6.99 (d, 1H), 3.43 (s, 3H). Example 185 (General procedure 12) Methyl-p-tolyi-carbamic acid 4-(5-trifluoromethyl -pyridin-2-yloxy)-phenyl ester The title product was prepared from 4-(5-trifluoromethyl-pyridin)-2-yloxy)-phenoI and N-methyl-p-toluidine. The crude product was subjected to preparative HPLC (54%, white solid). HPLC-MS: m/z= 403.2 (M+1); Rt: 4.99 min. 1H NMR (CDCI3): 8.42 (s, 1H), 7.87 (dd, 1H), 7.05-7.30 (m, 8H), 6.98 (d, 1H), 3.40 (s, 3H)f 2.36 (s, 3H). Example 186 (General procedure 14) Methyl-phenyl-carbamic acid 4-(3-pyridin-3-yl-acryloyl)-phenyl ester The title product was prepared from 1-(4-hydroxy-phenyI)-3-pyridin-3-yl-prop-2-en-1-one and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC (56%, off-white solid). HPLC-MS: mlz = 359.0 (M+1); Rt: 3.27 min. 1H NMR (CDCI3): 8.87 (d, 1H), 8.65 (dd, 1H), 8.03 (d, 2H), 7.97 (dt, 1H), 7.79 (d, 1H), 7.57 (d, 1H), 7.33-7.47 (m, 5H), 7.27-7.33 (m, 3H), 3.44 (s, 3H), 3.49 (t, 1H), 1.21 (t, 1H). Example 187 (General procedure 14) Methyl-phenyl-carbamic add 4-[3-(3I4!5-trimethoxy-phenyl)-acryloyl]-phenyl ester The title product was prepared from 1-(4-hydroxyphenyl)-3-(3,4,5-trimethoxyphenyI)prop-2-en-1-one and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC (82%, yellow solid). HPLC-MS: mlz = 448.2 (M+1); Rt: 4.61 min. 1H NMR (CDCU): 8.01 (d, 2H), 7.70 (d, 1H), 7.33-7.47 (m, 4H), 7.28-7.33 (m, 2H), 6.86 (s, IH), 3.92 (s, 6H), 3.90 (s, 3H), 3.45 (s, 3H). Example 188 (General procedure 14) Methyl-phenyl-carbamic acid 4-diethylcarbamoyl-2-methoxy-phenyl ester The title product was prepared from N,N-diethyI-4-hydroxy-3-methoxy-benzamide and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC (58%, colorless oil). HPLC-MS: mlz= 357.1 (M+1); Rt: 3.64 min. 1H NMR (CDCI3): 7.34-7.44 (m, 4H), 7.21-7.28 (m, 1H), 7.03-7.09 (d, 1H), 6.99 (d, 1H), 6.90 (dd, 1H)f 3.87 (s, 3H), 3.15-3.65 (bs, 4H), 3.43 (s, 3H), 1.05-1.35 (m, 6H). Example 189 (General procedure 14) Methyl-phenyl-carbamic acid 3-phenylcarbamoyi-phenyl ester The title product was prepared from 3-hydroxy-N-phenyl-benzamide and N-methyl-N- phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC (54%, white solid). HPLC-MS: m/z= 347.2 (M+1); Rt: 4.01 min. 1H NMR (CDCl3): 7.76 (s, 1H), 7.68 (d, 1H), 7.58-7.65 (m, 3H), 7.27-7.51 (m, 8H), 7.15 (t, 1H),3.44(s,3H). Example 190 (General procedure 14) Methyl-phenyl-carbamic acid quinolin-7-yl ester The title product was prepared from 7-hydroxyquinoline and N-methyi-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC (28%, white solid). HPLC-MS: m/z= 279.1 (M+1); R*: 2.55 min. 1H NMR (CDCI3): 8.93 (dd, 1H), 8.18 (d, 1H), 7.83-7.86 (m, 1H), 7,82 (d, 1H), 7.35-7.50 (m, 6H), 7.27-7.32 (m, 1H)r 3.47 (s, 1H). Example 191 (General procedure 14) Methyl-phenyl-carbamic acid 4-(4-methyl-piperazine-1-carbonyl)-phenyl ester The title product was prepared from 1-(4-hydroxybenzoyl)-4-methyl-piperazine and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC (22%, colorless oil). HPLC-MS: m/z = 354.1 (M+1); Rt: 2.07 min. 1H NMR (CDCI3): 7.37-7.49 (m, 4H), 7.28-7.37 (m, 3H), 7.16-7.25 (m, 2H), 4.60-4.00 (bs( 2H), 3.43 (s, 3H), 3.35-3.90 (bs, 4H), 2.82 (s, 3H) 2.55-2.90 (bs, 2H). Example 192 (General procedure 14) Methyl-phenyi-carbamic acid 3-acetylamino-phenyI ester The title product was prepared from 3-acetamidophenol and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC (66%, white solid). HPLC-MS: m/z= 285.1 (M+1); Rt: 3.09 min. 1H NMR (CDC!3): 7.40-7.49 (m, 1H), 7.31-7.40 (m, 5H), 7.25-7.30 (m, 1H), 7.22 (d, 1H), 7.14 (d, 1H)f 6-84 (bd, 1H), 3.42 (s, 3H), 2.10 (s, 3H). Example 193 (General procedure 14) Methyl-phenyi-carbamic acid 4-benzoyI-phenyI ester The title product was prepared from (4-hydroxy-phenyI)-phenyI-methanone and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC (36%, colorless oil). HPLC-MS: m/z = 332.2 (M+1); Rt: 4.42 min. 1H NMR (CDCI3): 7.75-7.85 (m, 4H), 7.58 (tt, 1H), 7.33-7.52 (m, 6H), 7.27-7.32 (m, 1H), 7.18-7.25 (m, 2H), 3.44 (s, 3H). Example 194 (General procedure 14) Methyl-phenyi-carbamic acid biphenyl-3-yl ester The title product was prepared from 3-phenyiphenol and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC (52%, colorless oil). HPLC-MS: mtz = 304.2 (M+1); Rt: 4.75 min. 1H NMR (CDCI3): 7.52-7.67 (m, 2H), 7.22-7.52 (m, 11H), 7.03-7.22 (m, 1H), 3.45 (s, 3H). Example 195 (General procedure 14) Methyl-phenyi-carbamic add 1H-indol-4-yl ester The title product was prepared from 4-hydroxyindole and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC (48%T off-white solid). HPLC-MS; m/z = 267.1 (M+1); Rt: 3.57 min. 1H NMR (CDC!3): 8.20 (els, 1H), 7.36-7.50 (m, 4H), 7.17-7.35 (m, 2H), 7.08-7.17 (m, 2H), 6.94 (d, 1H), 6.44 (s, 1H), 3.48 (s, 3H). Example 196 (General procedure 14) Methyl-phenyl-carbamic acid 5,6,7,8-tetrahydro-naphthalen-1-yI ester The title product was prepared from 5,6,7,8-tetrahydro-1-naphthol and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC (42%, colorless oil). HPLC-MS: m/z= 282.1 (M+1); Rt: 4.77 min. 1H NMR (CDCI3): 7.33-7.45 (m, 4H), 7.22-7.32 (m, 1H), 7.02-7.13 (t, 1H), 6.82-7.96 (m, 2H), 3.42 (s, 3H), 2.70-2.82 (m, 2H), 2.50-2.65 (m, 2H), 1.62-1.83 (m, 4H). Example 197 (General procedure 14) Methyl-phenyl-carbamic acid 5-oxo-5,6,7,8-tetrahydro-naphthalen-1-y] ester The title product was prepared from 5,6J,8-tetrahydro-1-naphthoI and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC (60%, colorless oil). HPLC-MS: m/z= 296.1 (M+1); Rt: 3.81 min. 1H NMR (CDCI3): 7.91 (dd, 1H), 7.21-7.50 (m, 7H), 3.44 (s, 3H), 2.60-2.93 (bs, 2H), 2.62 (t, 2H), 2.02-2.20 (m, 2H). Example 198 (General procedure 14) Methyl-phenyl-carbamic acid 1,3-dioxo-1,3-dihydro-isobenzofuran-4-yi ester The title product was prepared from 4-hydroxy-isobenzofuran-1,3-dione and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC (50%, white solid). HPLC-MS: ro/z= 298.1 (M+1); Rt: 2.58 min, purity: 85%. 1H NMR (CDCI3): 7.90 (d, 1H), 7.48-7.62 (m, 2H), 7.28-7.45 (m, 5H), 3.38 (s, 3H). Example 199 (General procedure 1) Methyl-phenyl-carbamic acid 4-(5-chloro-pyridin-2-yloxy)-phenyl ester The title product was prepared from 4-(5-chloro-pyridin-2-yloxy)-phenol and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to column chromatography (ethyl acetate/heptane (1:5) (85%, white solid). HPLC-MS: mJz= 355.1 (M+1); R*: 4.56 min. 1H NMR (CDCI3): 8.10 (df 1H), 7.62 (dd, 1H), 7.31-7.44 (m, 4H), 7.25-7.30 (m, 1H), 7.05-7.20 (m, 4H), 6.84 (d, 1H), 3.43 (s, 3H). Example 200 (General procedure. 14) (3-Fluoro-pheny()-methyl-carbamic acid 4-(5-tnTIuoromethyl-pyridin-2-yIoxy)-phenyl ester The title product was prepared from 4-(5"TrifIuoromethyI-pyridin-2-yloxy)-phenoI and 3-fluoro-N-methylaniline. The crude product was subjected to preparative HPLC (31%, white solid). HPLC-MS: m/z = 407.0 (M+1); Rt: 4.93 min. 1H NMR (CDC!3): 8.42 (s, 1H), 7.88 (dd, 1H), 7.36 (q, 1H), 7.07-7.24 (m, 6H), 7.00 (d, 1H), 7.92-7.05 (rn, 1H), 3.44 (s, 3H). Example 201 (General procedure 11) 4-Benzy!-piperazine-1-carboxylic acid 4-(5-chloro~pyridin-2-yIoxy)-phenyI ester The title product was prepared from 4-(5-chIoro-pyridin-2-yIoxy)-phenol and 1-benzylpiperazine. The title product precipitated from the reaction mixture and was collected by filtration (88%, off-white solid). HPLC-MS: rnlz = 424.1 (M+1); Rt: 2.91 min. 1H NMR (CDCI3): 13.86 (bs, 1H)f 8.11 (d, 1H)f 7.60-7.70 (m, 3H), 7.45-7.55 (m, 3H), 7.05-7.20 (m, 4H), 6.98 (d? 1H), 4.26-4.40 (m, 2H, 4.15-4.25 (m, 2H), 3.38-3.53 (m, 2H)f 3.60-4.15 (m, 2H), 2.72-2.92 (m, 2H). Example 202 (General procedure 11) 4-Pyridin-3-ylmethyl-piperazine-1-carboxylic acid 4-(5-chloro-pyridin-2-yIoxy)-phenyI ester The title product was prepared from 4~(5-chloro-pyridin-2-yloxy)-phenoI and (3-pyridylmethyl)piperazine. The title product precipitated from the reaction mixture and was collected by filtration and recrystallized from ethanol (35%, off-white solid). HPLC-MS: mfz = 425.2 (M+1); Rt: 2.39 min. 1H NMR (CDCI3): 13.00-14.50 (bs, 1H), 8.72 (d, 2H)( 8.50 (bs, 1H), 8.11 (d, 1H), 7.64 (dd, 1H), 7.56 (bs, 1H), 7.06-7.14 (m, 4H)f 6.88 (df 1H), 3.6-4.4 (m, 6H), 2.70-3.50 (m, 4H). Example 203 (General procedure 14) 4-Hydroxymethyl-piperidine-1-carboxylic acid 4-(5-chloro-pyridin-2-yloxy)-pheny( ester The title product was prepared from 4-(5-chloro-pyridin-2-ylaxy)-phenoI and 4-hydroxymethyl-piperidine..The crude product was subjected to column chromatography (ethylacetate/heptane, 1:1) (75%, colorless oil). HPLC-MS: mlz- 363.1 (M+1); Rt: 3.58 min. 1H. NMR (CDCIs): 8.12 (d, 1H), 7.64 (dd, 1H), 7.05-7.24 (m, 4H), 6.85 (d, 1H), 4.33 (ds, 2H), 3.56 (t, 2H), 2.75-3.10 (m, 2H), 1.69-1.95 (m, 3H)f 1.56 (s, 1H), 1.19-1.45 (m, 2H). Example 204 (General procedure 1) Methyl-phenyl-carbamic acid 4-morpholin-4-yl-phenyl ester The title product was prepared from and 4-morpholin-4-yI-phenol and N-methyl-N-phenylcarbamoyl chloride. The crude product was extracted with dichloromethane from citric acid (5%). The combined organic phases were evaporated and the product crystallized from ethanol (22%, crystals). HPLC-MS: m/z= 313.2 (M+1); Rt: 3.75 min. 1H NMR (DMSO-d6): 7.35-7.50 (m, 4H), 7.22-7.32 (m, 1H), 7.00 (d, 2H), 6.92 (d, 2H), 3.72 (t, 4H), 3.32 (s, 3H), 3.05 (t, 4H). Example 205 (General procedure 1) 1,4-Dioxa-8-aza-spiro[4.5]decane-8-carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)- phenyl ester The title product was prepared from 4-(5-trifluoromethyl-pyridin)-2-yloxy)-phenol and 4-piperidone ethylene ketal. The crude product was extracted with dichloromethane from citric acid (5%). The. combined organic phases were evaporated and the product crystallized from ethanol (61 %, crystals). HPLC-MS: mlz = 425.2 (M+1); Rt: 4.45 min. Example 206 (General procedure 14) The title product was prepared from 2-(4-hydroxy-phenyl)-indan-1,3-dione and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC (1%, oil). HPLC-MS: mlz* 372.1 (M+1); Rt: 4.80 min. Example 207 (General procedure 14) Methyl-phenyl-carbamic acid 4-(5,6-dichloro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-phenyI ester The title product was prepared from 5,6-dichloro-2-(4-hydroxy-phenyI)-isoindole-1,3-dione and N-methyl-N-phenylcarbamoyI chloride. The crude product was subjected to preparative HPLC (2%,). HPLC-MS: m/z = 441.1 (M+1); Rt: 5.00 min. Example 208 (General procedure 14) Methyl-phenyl-carbamic acid 4-(2-phenoxy~acetylamino)~phenyI ester The title product was prepared from N-(4-hydroxy-phenyI)-2-phenoxy-acetamide and N-methyl-N-phenylcarbarnoyl chloride. The crude product was purified by preparative HPLC (54%, oil). HPLC-MS: m/z= 277.2 (M+1); Rt: 4.19 min. Example 209 (Genera! procedure 14) Methyl-phenyl-carbamic acid 4-[2-(4-chloro-phenyI)-ethyI]-phenyl ester The title product was prepared from 4-(4-chlorophenethyI)-phenoI and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC (57%, white crystals). HPLC-MS: m/z= 366.1 (M+1); Rt: 5.58 min. 1H NMR (CDCI3): 7.31-7.45 (m, 4H)( 7.17-7.30 (m, 3H)f 6.96-7.12 (m, 6H), 3.41 (s, 3H), 2.85 (s, 4H). Example 210 (General procedure 14) Methyl-phenyl-carbamic acid 4-[(pyridine-2-carbonyl)-amino]-phenyl ester The title product was prepared from pyridine-2-carboxylic acid (4-hydroxy-phenyl)-amide and N-methyl-N-phenylcarbamoyI chloride. The crude product was subjected to preparative HPLC (41%,)- HPLC-MS: m/z= 348.1 (M+1); Rt: 4.00 min. 1H NMR (CDCI3): 7.32-7.47 (m, 4H), 7.24-7.31 (m, 3H), 7.10-7.23 (m, 4H), 7.79 (d, 2H), 3.41 (m, 6H). Example 211 (General procedure 14) Methyl-phenyl-carbamic acid 4-[methyI-(thiophene-2-carbonyl)-amino]-phenyl ester The title product was prepared from thiophene-2-carboxylic acid (4-hydroxy-phenyI)-methyl-amide and N-methyl-N-phenylcarbamoyI chloride. The crude product was subjected to preparative HPLC (16%, oil). HPLC-MS: mlz = 367.2 (M+1); Rt: 3.97 min. Example 212 (General procedure 14) Methyl-phenyl-carbamic acid 4-butyrylamino-phenyl ester The title product was prepared from4'-hydroxybutyraniIide and N-methyl-N-phenylcarbarnoyl chloride. The crude product was subjected to preparative HPLC (60%, white solid). HPLC-MS: mlz = 313.2 (M+1); R*: 3.58 min. Example 213 (General procedure 14) Methyl-phenyl-carbamic acid 4-(4,6-dimethyI-pyrimidin-2-yIsulfanyl)-phenyl ester The title product was prepared from 4-(4,6-dimethyIpyrimidin-2-ylsuIfanyI)-phenoI and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC (59%, white solid). HPLC-MS: m/z = 366.1 (M+1); Rt: 4.50 min. 1H NMR (CDCI3): 7.59 (d, 2H), 7.32-7.45 (m, 4H), 7.23-7.31 (m, 1H), 7.16 (d, 2H), 6.68 (s, 1H), 3.43 (s,1H), 2.32. Example 214 (General procedure 14) Methyl-phenyl-carbamic acid 4-methanesulfonyl-phenyl ester The title product was prepared from 4-methyIsulfonylphenol and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC (50%, white solid). HPLC-MS: mlz = 306.1 (M+1); Rt: 3.22 min. Example 215 (General procedure 14) Methyl-phenyl-carbamic acid 4-[2-(3-oxo-1,2,3,4-tetrahydro-quinoxalin-2-yl)-acetylamino]- phenyl ester The title product was prepared from N-(4-hydroxyphenyl)-2-(3-oxo-1,2,3,4-tetrahydro-2-quinoxalinyf)acetamide and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC (20%, yellow solid). HPLC-MS: m/z= 431.2 (M+1); Rt: 3.55. min. Example 216 (General procedure 14) Methyl-phenyl-carbamic acid 4-phenylacetyl-phenyl ester The title product was prepared from benzyl 4-hydroxyphenyi ketone and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC (68%, light yellow oil). HPLC-MS: mtz = 431.2 (M+1); Rt: 3.55 min. Example 217 (General procedure 12) 4-Benzoyl-piperidine-1-carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester The title product was prepared from 4-(5-trifluoromethyl-pyridin)-2-yloxy)-phenoI and 4-benzoylpiperidine (29%, white solid). HPLC-MS: m/z= 471.3 (M+1); Rt: 5.12 min. Example 218 (General procedure 11) [1,4]BipiperidinyI-1'-carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI ester The title product was prepared from 4-(5-trifluoromethyl-pyridin)-2-yIoxy)-phenoI and 4-piperidinopiperidine. The crude product was filtered from the reaction mixture and washed with diethyl ether to give the title product (50%, off-white solid).. HPLC-MS: mlz = 450.1 (M+1); Rt: 3.12 min. Example 219 (General procedure 12) 4-(2-Oxo-2,3-dihydro-benzimidazol-1 -yl)-piperidine-1 -carboxylic acid 4-(5-trif luoromethyl- pyridin-2-y!oxy)-phenyl ester The title product was prepared from 4-(5-Trifluoromethyl-pyridin-2-yloxy)-phenol and 1-piperidin-4-yl-1,3-dihydro-benzoimidazof-2-one (44%, oil). HPLC-MS: m/z = 499.1 (M+1); Rt: 4.35 min. 1H NMR (CDCI3): 10.15 (s, 1H), 8.44 (s, 1H), 7.90 (dd, 1H), 7.23 (t, 1H), 7.13-7.20 (m, 4H), 7.06-7.13 (m. 2H), 7.02 (d, 1H), 4.40-4.70 (m, 3H), 2.95-3.30 (m, 2H), 2.40-2.63 (m, 2H), 1.86 (d,2H). Example 220 (General procedure 12) 3-Diethylcarbamoyl-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester The title product was prepared from 4-(5-Trifluoromethyl-pyridin-2-yloxy)-phenol and N,N-diethylnipecotamide (56%, oil). HPLC-MS: /77/z = 466.1 (M+1); R*: 4.51 min. Example 221 (Genera! procedure 12) 4-CarbamoyI-piperidine-1-carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI ester The title product was prepared from 4-(5-TrlfluoromethyI-pyridin«2-yloxy)-phenol and piperidine-4-carboxylic acid amide. The crude product was subjected to preparative HPLC (47%, white solid). HPLC-MS: m/z= 410.2 (M+1); Rt: 3.45 min. Example 222 (Genera! procedure 12) 3-CarbamoyI-piperidine-1-carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI ester The title product was prepared from 4-(5-TrifIuoromethyl-pyridin-2-yloxy)-phenoI and nipeco-tamide. The crude product was purified by preparative HPLC (60%, white solid). HPLC-MS: m/z= 410.2 (M+1); Rt: 3.45 min. Example 223 (General procedure 14) Methyl-phenyl-carbamic acid 4-{[4-(methyl-phenyl-carbamoyloxy)-2-oxo-1,2-dihydro- quinoline-3-carbonyI]-amino}-phenyi ester The title product was prepared from 4-hydroxy-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid (4-hydroxyphenyI)-amide and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative HPLC (6.6%, oil). HPLC-MS: m/z= 563.2 (M+1); Rt: 4.46 min. 1H NMR (CDC!3): 8.38 (d, 1H), 7.75 (t, 1H), 7.35-7.45 (m, 4H), 7.22-7.34 (m, 1H), 7.14-7.21 (t, 1H)f 6.99-7.15 (bs, 1H), 3.44 (s, 3H). Example 224 (General procedure 14) Methyl-phenyl-carbamic acid 4-[(4-hydroxy-2-oxo-1,2-dihydro-quinoline-3-carbonyl)-amino]- phenyl ester The title product was prepared from 4-hydroxy-2-oxo-1,2-dihydro-quinoIine-3-carboxylic acid (4-hydroxy-phenyI)-amide and N-methyl-N-phenylcarbamoyl chloride (5%,). HPLC-MS: mlz-430.1 (M+1); Rt: 4.80 min, purity: 70%. Example 225 (General procedure 14) Methyl-phenyl-carbamic acid 4-(4-hydroxy-benzyI)-phenyl ester The title compound was prepared from 4,4'-dihydroxydiphenylmethane and N-methyl-N-phenylcarbamoyl chloride. The crude product was subjected to preparative. HPLC (21 %, white crystals which turn red after standing). HPLC-MS: m/z = 324.2 (M+1); Rt: 4.21 min. Example 226. (General procedure 13) Methyl-phenyl-carbamic acid 4-(4-trifluoromethyl-benzylcarbamoyI)-phenyl ester The title product was prepared from 4-(methyI-phenyl-carbamoyloxy)-benzoic acid 2,5-dioxo-pyrrolidin-1-yl ester and 4-trifluoromethyl-benzylamine (94%, white crystals). HPLC-MS: mfz = 429.2 (M+1); R{: 4.35 min. Example 227 (General procedure 13) Methyl-phenyl-carbamic acid 4-(butyl-methyI-carbamoyI)-phenyI ester The title product was prepared from 4-(methyl-phenyl-carbamoyloxy)-benzoic acid 2,5-dioxo-pyrroIidin-1-yI ester and /7-butyI-methyl-amine. The crude product was subjected to preparative HPLC (20%, oil). HPLC-MS: mlz= 341.2 (M+1); Rt: 3.96 min. Example 228 (General procedure 13) Methyl-phenyl-carbamic acid 4-(methyl-phenethyl-carbamoyl)-phenyl ester The title product was prepared from 4-(methyl-phenyl-carbamoyloxy)-benzoic acid 2,5-dioxo-pyrroIidin-1-yl ester and methyl-phenethyl-amine. The crude product was subjected to preparative HPLC (29.%, oil). HPLC-MS: m/z=389.2 (M+1); Rt: 4.15 min. Example 229 (General procedure 13) Methyl-phenyl-carbamic acid 4-[(pyridin-2-ylmethyl)-carbamoyl]-phenyI ester The title product was prepared from 4-(methyl-phenyl-carbamoyloxy)-benzoic acid 2,5-dioxo-pyrrolidin-1-yl ester and 2-aminomethyIpyridine. The crude product was used without further purification (57%, oil). HPLC-MS: m!z= 362.2 (M+1); R,: 2.43 min. 1H NMR (MeOH-cU): 8.50 (d, 1H), 7.92 (d, 2H), 7.83 (dt, 1H), 7.38-7.50 (m, 5H), 7.26-7.37 (m, 2H), 7.15-7.26 (m, 2H), 4.69 (s, 2H), 3.41 (s, 3H). Example 230 (General procedure 13) Methyl-phenyl-carbamic acid 4-(2"pyridin-2-yl-ethylcarbamoyI)-phenyI ester The title product was prepared from 4-(methyl-phenyI-carbamoyloxy)-benzoic acid 2,5-dioxo-pyrroIidin-1-yl ester and 2-aminoethylpyridine. The crude product was used without further purification (26%, oil). HPLC-MS: m/z = 376.2 (M+1); Rt: 2.25 min. 1H NMR (MeOH-d4): 8.51 (d, 1H), 7.87 (dt, 1H), 7.78 (d, 2H), 7.33-7.50 m, 6H)t 7.25-7.33 (m, 1H), 7.18 (d, 2H), 3.74 (t, 2H), 3.41 (bs, 3H), 3.13 (t. 2H). Example 231 (General procedure 13) Methyl-phenyl-carbamic acid 4-(2-phenylamino-ethylcarbamoy!)-phenyI ester The title product was prepared from 4-(methy!-phenyi-carbamoy!oxy)-benzoic acid 2,5-dioxo-pyrrolidine 1-yI ester and N-phenylethylenediamine. The crude product was used without further purification (80%, off-white foam). HPLC-MS: m/z = 390.2 (M+1); Rt: 3.51 min. 1H NMR (MeOH-d4): 7.82 (d, 2H), 7.36-7.48 (m, 4H), 7.22-7.34 (m, 1H), 7.15-7.22 (d, 2H), 7.10. (t, 2H), 6.69 (d, 2H), 6.62 (t, 1H), 3.72 (t, 2H), 3.57 (t, 2H), 3.40 (s, 3H), 3.20 (s, 1H). Example 232 (General procedure 13) Methyl-phenyl-carbamic acid 4-{3-methyl-butyIcarbamoyl)-phenyl ester The title product was prepared from 4-(methyl-phenyl-carbamoyloxy)-benzoic acid 2,5-dioxo-pyrrolidin-1-yl ester and /so-amylamine. The crude product was used without further purification (95%, oil). HPLC-MS: m/z = 341.2 (M+1); Rt: 3.99 min. 1H NMR (MeOH-d4): 7,82 (d, 2H), 7.36-7.50 (m, 4H), 7.26-7.35 (m, 1H)( 7.15-7.24 (d. 2H), 3.34-3.46 (mr 5H), 1.67 (sept, 1H), 1.50 (q, 2H), 0.96 (d, 6H). Example 233 (General procedure 13) Methyl-phenyl-carbamic acid 4-(3,3~dimethyI-butylcarbamoyI)-phenyl ester The title product was prepared from 4-(methyl-phenyl-carbamoyloxy)-benzoic add 2,5-dioxo-pyrrolidin-1-yl ester and 3,3-dimethylbutylamine. The crude product was used without further purification(88%, oil). HPLC-MS: m/z= 355.1 (M+1); Rt: 3.10 min. 1H NMR (MeOH-d4): 7.82 (d, 2H), 7.36-7.50 (m, 4H), 7.25-7.35 (m, 1H), 7.15-7.25 (d, 2H), 3.33-3.47 (m, 5H), 1.49-1.57 (m, 2H), 0.97 (s, 9H). Example 234 (General procedure 13) Methyl-phenyl-carbamic acid 4-[(tetrahydro-furan-2-ylmethyl)-carbamoy!]-phenyl ester The title product was prepared from 4-(methyI-phenyl-carbamoyloxy)-benzoic acid 2,5-dioxo-pyrrolidin-1-yl ester and C-(tetrahydro-furan-2-yI)methyIamine. The crude product wasused without further purification (86%, oil). HPLC-MS: m/z = (M+1);Rt: min. 1H NMR (MeOH-d*): 7.84 (d, 2H), 7.35-7.50 (mf 4H), 7.25-7.35 (m, 1H), 7.12-7.25 (d, 2H), 4.10 (qui, 1H)f 3.87 (q, 1H), 3.68-3.82 (m, 1H), 3.41 (s, 3H), 3.35-3.54 (m, 2H), 1.82-2.10 (m, 3H), 1.58-1.72 (m,1H). Example 235 (General procedure 13) Methyl-phenyl-carbamic acid 4-cyclohexylcarbamoyI-phenyl ester The title product was prepared from 4-(methyl-phenyi-carbarnoyloxy)-benzoic acid 2,5-dioxo-pyrroIidin-1-yl ester and cyclohexylamine. The crude product was used without further purification (79%, off-white crystals). HPLC-MS: m/z= 353.2 (M+1); Rt: 3.98 min. 1H NMR (MeOH-d4): 8.18 (df 1H), 7.85 (d, 2H), 7.36-7.52 (m, 4H), 7.25-7.33 (m, 1H), 7.20 (d, 2H), 3.74 (m, 1H), 1.77-1.88 (m, 2H), 1.65-1.77 (m, 2H), 1.60 (d, 1H), 1.24-1.40 (m, 4H), 1-07-1.23 (m, 1H). Example 236 (General procedure 13) Methyl-phenyl-carbamic acid 4-cyclopropylcarbamoyl-phenyl ester The title product was prepared from 4-(methyl-phenyl-carbamoyloxy)-benzoic acid 2,5-dioxo-pyrrolidin-1-yl ester and cyclopropylamine. The crude product was used without further purification (97%, oil). HPLC-MS: m/z= 311.2 (M+1); Rt: 3.21 min. 1H NMR (MeOH-d4): 7.81 (d, 2H), 7.36-7.50 (m, 4H), 7.25-7.36 (m, 1H), 7:18 (d, 2H), 3.40 (bs, 3H), 2.78-2.87 (m, 1H), 0.75-0.85 (m, 2H)f 0.57-0.65 (m, 2H). Example 237 (General procedure 13) Methyl-phenyl-carbamic acid 4-(cyc!ohexylmethyI-carbamoyl)-phenyl ester The title product was prepared from 4-(methyl-phenyl-carbamoyloxy)-benzoic acid 2,5-dioxo-pyrrolidin-1-yl ester and C-cyclohexyl-methylamine. The crude product was used without further purification (84%, oil). HPLC-MS: m/z= 367.3 (M+1); Rt:4.28 min. 1H NMR (MeOH-d4):7.81 (d, 2H)f 7.36-7.49 (m, 4H), 7.25-7.32 (m, 1H), 7.19 (d, 2H), 3.40 (bs, 3H), 3.20 (d, 2H), 1.55-1.82 (m, 5H), 1.13-1.35 (m, 4H), 0.90-1.10 (m, 2H). Example 238 Methyl-phenyl-carbamic acid 5-nitro-pyridin-2-yl ester A solution of 2-hydroxy-5-nitropyridine (1.40 g, 10.0 mmol), 1-methyI-3-(methyl-phenyl-carbamoyI)-3H-imidazol-1-ium iodide (3.43 g, 10.0 mmol) and triethylamine (0.42 ml, 10.0 mmol) in acetonitrile (25 ml) was heated at 50 °C for 5 h. The solvent was evaporated in vacuo and the residue was purified by flash column chromatography (Si02, ethyl acetate:-heptane (25:75)) followed by crystallisation from ethyl acetate:heptane yielding the title compound (1.13 g, 41% yield) as a white solid. 1H NMR (300MHz, CDCl3): 53.44 (br.s, 3H), 7.17 (br.d, 1H), 7.27-7.45 (mf 5H), 8.49 (br.d, 1H), 9.19 (br.s, 1H); HPLC-MS (Method A): mlz = 296 (M+Na); Rt = 3.45 min. Example 239 Methyl-phenyl-carbamic acid pyrimidin-2-yl ester A solution of 2-hydroxypyrimidine hydrochloride (0.40 g, 3.00 mmol), 1-methyl-3-(methyl-phenyl-carbamoyl)-3H-imidazol-1-ium iodide (1.03 g, 3.00 mmol) and triethylamine (0.83 ml, 6.00 mmol) in acetonitrile (15 ml) was stirred at room temperature overnight. The solvent was evaporated in vacuo and the residue was purified by flash column chromatography (Si02l ethyl acetate) followed by crystallisation from ethyl acetaterheptane yielding the title compound (0.08 gf 12% yield) as a white solid. 1H NMR (300MHz, CDCI3): 53.43 (br.s, 3H), 7.14-7.31 (m, 2H), 7.39 (m, 4H), 8.68 (d, 2H); HPLC-MS (Method A): mlz = 252 (M+Na); Rt = 2.32 min. Example 240 Methyl-phenyl-carbamic acid 7-chloro-quinolin-4-yl ester A solution of 7-chloro-4-hydroxyquinoline (0.54 g, 3.00 mmol), 1-methyI-3-(methyl-phenyI-carbamoyl)-3H-imidazol-1-ium iodide (1.03 g, 3.00 mmol) and triethylamine (0.42 ml, 3.00 mmol) in acetonitrile (15 ml) was stirred at room temperature for. 18 hours. The solvent was evaporated in vacuo and the. residue was purified by flash column chromatography (Si02, ethyl acetate:heptane (40:60)) yielding the title compound (0.87 g, 93% yield) as a colourless oil which solidified upon standing. 1H NMR (300MHz, CDCI3): £3.47 (br.s, 3H), 7.28-7.58 (m, 8H), 8.05 (br.s, 1H), 8.85 methyI)-2-pyrimidoi (0.49 g, 3.00 mmol), 4-morpholinecarbonyl chloride (0.45 g, 3.00 mmol) and 1,4-diazabicyclo[2.2.2]octane (0.51 g, 3.00 mmol) in N,N-dimethylformamide (15 ml) was stirred at room temperature for 2 hours. Water was added and the solution was extracted twice with dichloromethane. The combined organic layers were dried over sodium sulphate, filtered and evaporated in vacuo. The residue was purified by flash column chromatography (Si02, ethyl acetate:heptane (30:70 -» 50:50)) yielding the title compound (0.66 g, 80% yield) as a white solid. 1H NMR (300MHz, CDCl3): £3.57-3.81 (m, 8H), 7.57 (d, 1H), 8.97 (d, 1H).; HPLC-MS (Method A): mfz^ 300. (M+Na); Rt = 2.36 min. Example 252 Methyl-phenyl-carbamic acid 3-nitn>pyridin-2-yI ester A solution of 2-hydroxy-3-nitropyridine (0.42 g, 3.00 mmol), 1-methyl-3-(methyl-phenyl-caitamoyf)-3H-imidazol-1-ium iodide (1.03 g, 3.00 mmol) and triethylamine (0.42 ml, 3.00 mmol) in acetonitrile (15 m!) was stirred at room temperature for 3 days. The solvent was evaporated in vacuo and the residue was purified by flash column chromatography (Si02, ethyl acetate;heptane (40:60)) yielding the title compound (0.41 g, 50% yield) as a yellow solid. 1H NMR (300MHz, CDCI3): £3.41 + 3.58 (2 x br.s, 3H), 7.30 (m, 1H), 7.42 (m, 5H), 8.45 (br.d, 1H), 8.49 (br.s, 1H); HPLC-MS (Method A): mlz = 296 (M+Na); Rt = 3.22 min. Example 253 Methyl-phenyl-carbamic acid 5-chloro-pyridin-2-yI ester A solution of 5-chloro-2-pyridol (0.39 g, 3.00 mmol), 1-methyl-3-(methyl-phenyl-carbamoyl)-3H-imidazol-1-ium iodide (1.03 g, 3.00 mmol) and triethylamine (0.42 ml, 3.00 mmol) in acetonitrile (15 ml) was stirred at room temperature for 3 days. The solvent was evaporated in vacuo and the residue was purified by flash column chromatography (Si02, ethyl ace-tate:heptane (30:70)) yielding the title compound (0.78 g, 99% yield) as a white solid. 1H NMR (300MHz, CDCl3): 53.44 (br.s, 3H), 7.00 (br.s, 1H), 7.27 (m, 1H), 7.39 (m, 4H), 7.69 (d, 1H), 8.30 (d, 1H); HPLC-MS (Method A): mlz = 285 (M+Na); Rt = 3.47 min. Example 254 Methyl-phenyl-carbamic acid 5-(2-nitro-phenyl)-pyrimidin-2-yl ester A solution of 5-(2-nitrophenyl)-pyrimidin-2-ol (0.35 g, 1.61 mmol), 1-methyl-3-(methyl-phenyl-carbamoyI)-3tf-imidazol-1-ium iodide (0.55 g, 1.61 mmol). and triethylamine (0.22 ml, 1.61 mmol) in acetonitrile (15 ml) was heated at 50 °C for 18 hours. The solvent was evaporated in vacuo and the residue was purified by flash column chromatography (Si02, ethyl ace-tateiheptane (50:50)) yielding the title compound (0.18 g, 32% yield) as a yellow oil. 1H NMR (300MHz, CDCI3): £3.47 (br.s, 3H), 7.29 (m, 1H), 7.40 (m, 5H), 7.63 (dt, 1H), 7.72 (dt, 1H), 8.10 (d, 1H), 8.61 (br.s, 2H); HPLC-MS (Method A): mlz = 351 (M+H), 373 (M+Na), 723 (2M+Na).; Rt = 3.65 min. Example 255 Methyl-phenyi-carbamic acid 5-trifluoromethyI-pyridin-2-yl ester A solution of 2-hydroxy-5-(trifluoromethyI)pyridine (0.49 g, 3.00 mmol), 1-methyI-3-(methyl-phenyl-carbamoyI)-3H-imidazol-1-ium iodide (1.03 g, 3.00 mmol) and triethylamine (0.42 ml, 3.00 mmol) in acetonitrile (15 ml) was stirred at room temperature for 18 hours. The solvent was evaporated in vacuo and the residue was purified by flash column chromatography (Si02) ethyl acetate:heptane (15:85)) yielding the title compound (0.59 g, 66% yield) as a white solid. 1H NMR (300MHz, CDCI3): £3.43 (br.s, 3H), 7.23 (br.s, 1H), 7.28 (m, 1H)r 7.37 (m, 4H), 7.94 (br.d, 1H), 8.62 (br.s, 1H); HPLC-MS (Method A): m/z= 319 (M+Na); Rt = 3.85 min. Example 256 Methyl-phenyi-carbamic acid 3-chloro-5-trifluoromethyl-pyridin-2-yI ester A solution of 3-chloro-5-(trifluoromethyI)"2-pyridinol (0.59 g, 3.00 mmol), 1-methyI-3-(methyl-phenyl-carbamoyI)-3H-imidazol-1-ium iodide (1.03 g, 3.00 mmol) and triethylamine (0.42 ml, 3.00 mmol) in acetonitrile (15 ml) was stirred at room temperature for 18 hours. The solvent was evaporated in vacuo and the residue was purified by flash column chromatography (Si02, ethyl acetate:heptane (15:85)) yielding the title compound (146 mg, 15% yield) as a white solid. 1H NMR (300MHz, CDCI3): £3.43 (br.s, 3H), 7.30 (m, 1H), 7.40 (d, 4H), 8.00 (br.s, 1H), 8.52 (br.s, 1H).; HPLC-MS (Method A): mfz = 353 (M+Na); Rt = 4.29. min. Example 257 Methyl-phenyi-carbamic acid 5-nitro-3-trifluoromethyl-pyridin-2-yl ester A solution of 2-hydroxy-5-nitro-3-(trifluoromethyl)pyridine (0,36 g, 1.73 mmol), N-methyl-N-phenylcarbamoyl chloride (0.44 g, 2.59 mmol) and 1,4-diazabicyclo[2.2.2]octane (0.29 g, 2.59 mmol) in tetrahydrofuran (15 ml), was stirred at room temperature for 18 hours. The solvent was evaporated in vacuo and the. residue was purified by flash column chromatography (Si02, ethyl acetate:heptane (15:85)) yielding the title compound (0.55 g, 92% yield) as an orange solid.. 1H NMR (300MHz, CDCI3): (53.46 (br.s, 3H), 7.23-7.46 (m, 5H), 8.70 (br.s, 1H), 9.37 (br.s, 1H); HPLC-MS (Method A): mlz = 364 (M+H); Rt = 4.08 min. Example 258 (3-Chloro-phenyI)-methyl-carbamic acid 4-trifluoromethyl-pyrimidin-2-yl ester At 0 °C diphosgene (0.99 g, 5.00 mmol) was added to a stirred solution of 4-trifluoromethyI-2-hydroxypyrimidine (1.64 g, 10.0 mmol) in tetrahydrofuran (25 ml). The cooling bath was removed and stirring was continued at room temperature for 1 hour. (3-ChIorophenyI)-methylamine (0,35 g, 2.50 mmot) was added to one-fourth of the solution. After stirring overnight at room temperature the solvent was evaporated In vacuo and the residue was purified by flash column chromatography (Si02( ethyl acetate:heptane (20:80)) followed by preparative HPLC, yielding the title compound (332 mg, 40%) as a colourless oil. 1H NMR (300MHz, CDCI3): S3.45 (br.s, 3H), 7.23-7.44 (m, 4H), 7.56 (d, 1H), 8.94 (d, 1H); HPLC-MS (Method A): m/z= 354 (M+H); Rt = 4.03 min. Example 259 Methyl-m-tolyl-carbamic acid 4-trifluoromethyl-pyrimidin-2-yl ester At 0 °C diphosgene (0.99 g, 5.00 mmol) was added to a stirred solution of 4-trifluoromethyI-2-hydroxypyrimidine (1.64 g, 10.0 mmol) in tetrahydrofuran (25 ml). The cooling bath was removed and stirring was continued at room temperature for 1 hour. Methykn-tolyl-amine (0,30 g, 2.50 mmol) was added to one-fourth of the solution. After stirring overnight at room temperature the solvent was evaporated in vacuo and the residue was purified by flash column chromatography (Si02, ethyl acetate:heptane (20:80)) followed by preparative HPLC, yielding the title compound (51 mg, 7%) as a colourless oil. 1H NMR (300MHz, CDCi3): 52.37 (s, 3H). 3.42 (br.s, 3H), 7.07-7.31 (m, 4H)f 7.52 (br.s, 1H), 8.92 (br.s, 1H); HPLC-MS (Method A): mlz = 334 (M+Na); Rt = 3.92 min. Example 260 Morpholine-4-carboxylic acid 4-trifluoromethyl-pyrimidin-2-yl ester A solution of 4-trifluoromethyl-2-hydroxypyrimidine (0.49 g, 3.00 mmol), 4-morpholinecarbonyl chloride (0.45 g, 3.00 mmol) and 1,4-diazabicyclo[2.2.2]octane (0.34 g, 3.00 mmol) in dimethylformamide (15 ml) was stirred at room temperature for 1 hour. Water and brine were added and the solution was extracted twice with dichloromethane. The combined organic layers were dried over sodium sulphate, filtered and evaporated in vacuo. The residue was purified by flash column chromatography (Si02, ethyl acetate:heptane (30:70 -* 50:50)) yielding the title compound (0.66 g, 80% yield) as. a white solid. 'H NMR (300MHz, CDCI3): 53.45 (br.s, 3H), 7.23-7.44 (m, 4H), 7.56 (d, 1H), 8.94 (d, 1H); HPLC-MS (Method A): mlz = 354 (M+H); Rt =. 4.03 min. Example 261 Methyl-phenyl-carbamic acid 4,5-dichloro-pyridazin-3-yl ester A solution of 4,5-dichloro-3-hydroxypyridazine (0.49 g, 3.00 mmol), Af-methyl-W-phenylcarbamoyl chloride (0.51 g, 3.00 mmol) and triethylamine (0.42 ml, 3.00 mmol) in tet-rahydrofuran (15 ml) was stirred at room temperature for 3 days. The solvent was evaporated in vacuo and the residue was purified by flash column chromatography (Si02j ethyl acetate:heptane (20:80)) yielding the title compound (0.12 g, 14% yield) as a white solid. 1H NMR (300MHz, CDCI3): 53.50 (s, 3H), 7.18-7.32 (m. 5H), 7.63 (s, 1H); HPLC-MS (Method A): mlz = 320 (M+Na); Rt = 2.91 min. Example 262 Methyl-phenyl-carbamic acid 5-benzoylamino-pyridin-2-yI ester A solution of N-(6-hydroxy-pyridin-3-yl)-benzamide (0.64 g, 3.00 mmol), A/-methyl-/V-phenylcarbamoyl chloride (0.51 g, 3.00 mmol) and 1,4-diazabicyclo[2.2.2]octane (0.34 g, 3.00 mmol) in dimethylformamide (15 ml) was stirred at room temperature for 1 hour. Water was added and the precipitates were collected by suction. The solids were dissolved in di-chloromethane and the solution was dried over sodium sulphate, filtered and evaporated in vacuo. The residue was dissolved in ethyl acetate and filtered over a short pad of silica. Evaporation of the solvent in vacuo yielded the title compound (0.70 g, 68% yield) as a thick oil. 1H NMR (300MHz, CDCI3): £3.40 (br.s, 3H), 6.90 (br.s, 1H), 7.26 (m, 1H), 7.31-7.44 (m, 6H), 7.50 (m, 1H), 7.88 (d, 2H), 8.08 (dd, 1H)( 8.37 (d, 1H)f 8.79 (br.s, 1H); HPLC-MS (Method A): mlz = 348 (M+H); Rt = 3.49 min. Example 263 Methyl-phenyl-carbamic acid 5-(cyclohexanecarbonyI-amino)-pyridin-2-yl ester A solution of cyclohexanecarboxylic acid (6-hydroxy-pyridin-3-yI)-amide (0.66 g, 3.00 mmol), N-methyl-A/-phenylcarbamoyl chloride (0.51 g, 3.00 mmol) and 1,4-diazabicycio[2.2.2]octane (0.34 g, 3.00 mmol) in dimethylformamide (20 ml) was stirred at room temperature for 18 hours. Water was added and the precipitates were collected by suction. The solids were dissolved in dichloromethane and the solution was dried over sodium sulphate, filtered and evaporated in vacuo. The residue was crystallised from ethyl acetate:heptane yielding the title compound (0.75 g, 71% yield) as a slightly coloured solid. 1H NMR (300MHz, CDCI3): 51.18-1.33 (m, 3H), 1.42-1.59 (m, 2H), 1.60 (m, 1H), 1.77-1.94 (m, 4H), 2.20 (m, 1H), 3.45 (br.s, 3H), 6.91 (br.s, 1H), 7.28 (m, 1H), 7.39 (m, 4H), 7.94 (br.s, 1H)( 8.00 (dd, 1H), 8.20 (d, 1H); HPLC-MS (Method A): mlz = 354 (M+H); Rt = 3.74 rnin. Example 264 Methyl-phenyl-carbamic acid 4,4-dimethyI-2,6-dioxo-3,4,5)6-tetrahydro-2H-[1 ^bipyridinyl-e1-yl ester A solution of e'-hydroxy-4,4-dimethyl-4,5-dihydro-SH-tl^lbipyridinyl-^e-dione (0.70 g, 3.00 mmol), /V-methyl-N-phenylcarbamoyl chloride (0.51 g, 3.00 mmo!) and 1,4-diazabi-cyclo[2.2.2]octane (0.34 g, 3.00 mmol) in dimethylformamide (20 ml) was stirred at room temperature for 18 hours. Water was added and the precipitates were collected by suction and subsequently dried in a vacuum oven yielding the title compound (0,75 g, 71% yield) as a white solid. 1H NMR (300MHz, CDCI3): oxylic acid 4-(54rifluoromethyl-pyridin-2-yioxy)phenyl ester The hydrochloride of the title compound was prepared from 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyl chloroformate and 1-(2-thienyIethy[)piperazine, white crystals, yield 62 %; m.p. 236 - 237 °C; 1H NMR (DMSO-cf6): 511.51 (br s, 1H), 8.61 - 8.54 (br m, 1H), 7.48 -7.17 (m, 6H), 7.06 - 6.89 (m, 2H), 4.4 - 3.9 (br, 2H), 3.9 - 2.6 (br m, 15.5 H ~ 12H + water); HPLC-MS: m/z = 478 (M+H); IR (KBr): v 1714 (C=0) cm-1. Example 279 (General procedure 15) 4-(1-PhenyIethyI)piperazine-1-carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yIoxy)phenyl ester The crude hydrochloride of the title compound was prepared from 4-(5-trifluoromethyi-pyridin-2-yIoxy)-phenyl chloroformate and l~(1-phenylethyl)piperazine. Trituration with water, filtering and drying of the residue gave white crystals, yield 31 %; m.p. 242 °C; 1H NMR (DMSO-ofe): S11.56 (br s, 1H), 8.61 - 8.52 (br m, 1H), 8.30. - 8.19 (dd-like m, 1H), 7.77 - 7.31 (br. m, 5H), 7.31 - 7.13 (m, 5H), 4.60 - 3.27 (br m, 6H + water), 3.27 - 2.57 (br, 3H), 1.73 (br d, 3H); IR (KBr): v 1712 (C=0) cm"1. Example 280 (General procedure 15) 4-Octylpiperazine-1-carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)phenyl ester The crude hydrochloride of the title compound was prepared from4-(5-trifluoromethyl-pyiidin-2-yloxy)-phenyl chloroformate and 1-(1-phenylethyl)piperazine. Trituration with water, filtering and drying of the residue gave white crystals, yield 31 %; m.p. 244-245 °C; 1H NMR (DMSO-cfe): 511-16 (br s, 1H), 8.61 - 8.57 (br m, 1H), 8.30 - 8.20 (dd-like mT 1H)f 7.32 - 7.18 (m, 5H), 4.39 - 3.96 (br, 2H), 3,77 - 3.38 (br, 4H), 3.25 - 2.88 (br, 4H), 1.84 -1.58 (br, 2H), 1.42 - 1.12 (br s, 10H), 0.87 (br t, 3H); IR (KBr): v 1731,1713 (C=0) cm"1. Example 281 (General procedure 15) 4-(3-Dimethylamino-propyl)-piperazine-1 -carboxylic acid 4«(5"trifluoromethyl-pyridin-2-yloxy)- phenyl ester The crude hydrochloride of the title compound was prepared from 4-(5-trifluorornethyl-pyridin-2-yloxy)-phenyI chloroformate and 1-(3-dimethylaminopropyl)piperazine. A suspension of the product in ether was stirred with an excess of HCI in ether and the precipitate was washed with ether and dried to give the dihydrochloride of the title compound as white crystals, m.p. 292 - 293 °C; 'H NMR (DMSO-cf6): S11.35 (br s, 1H), 10.46. (br s, 1H), 8.61 - 8.52 (br m, 1H), 8.31 - 8.17 (m, 1H), 7.35 - 7.16 (m, 5H), 4.45 - 4.00 (br, 2H), 3.80 - 3.45 (br, 4H), 3.30 - 3.01 (br, 6H), 2.78 (br s, 6H), 2.31 - 2.07 (br, 2H); lR (KBr): v 1731, 1713 (C=0) cm-1. Example 282 (General procedure 15) 4-Pyrimidin-2-yI-piperazine-1 -carboxylic acid 4-(5-trifluoromethyI-pyridin-2-yioxy)-phenyI ester The hydrochloride of the title compound was prepared from 4-(5-trifiuoromethyI-pyridin-2-yloxy)-phenyl chloroformate and 1-(pyrimidin-2-yI)piperazine. The crude product was dried in vacuo at 50 °C for 80 min and extracted with ether. The ether phase was evaporated and the residue was purified by flash chromatography on silica eluted with ethyl acetate - heptane 1:1 to give the title compound as white needles. Yield 14 %; m.p. 120-121 °C; 1H NMR (DMSO-af6): £8.61 - 8.56 (br, 1H), 8.41 (d, J = 4.8 Hz, 2H)f 8.29 - 8.20 (dd-like, 1H), 7.31 - 7.20 (m, 5H), 6,69 (Hike m, J - 4.8 Hz, 1H), 3.94 - 3.78 (br s, 4H), 3.78 - 3.45 (br d, 4H); HPLC-MS: m/z = 446 (M+H); lR (KBr): v 1719 (C=0) cm"1. Example 283 (General procedure 15) 4-CycIopropylmethyl-piperazine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI ester The hydrochloride of the title compound was prepared from 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyl chloroformate and 1-cyclopropyIpiperazine, yield 62 %. Recrystallisation from 0.2 M HCI gave white, crystals, m.p. 238 - 239 °C; 1H NMR (DMSO-cfe): 611.51 (br s, 1H), 8.61 - 8.55 (m, 1H), 8.30 - 8.20 ( m, dd, 1H), 7.32 - 7.19 (m, d+s, 5H), 4.44 - 4.00 (br, 2H), 3.80 - 3.40 (br m, 4H), 3.29 - 2.93 (br m, 4H), 1.28 - 1.05 (br m, 1H), 0.75 - 0.58 (m, 2H), 0.50 - 0.35 (m, 2H).IR (KBr): v 1730, 1713 (C=0) cm"1. Example 284 (General procedure 15) 4-Methyl-1,4-diazepane-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yIoxy)phenyl ester The hydrochloride of the title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate and 1-methylhomopiperazine; white crystals, m.p. 210 - 211 °C; 1H NMR (DMSO-d6): 511.27 (br s, 1H), 8.61 - 8,54 (m, 1H), 8.30 - 8.20 (dd-Iike m, 1H). 7.34 - 7.18 (m, 5H), 4.13 - 3.08 (br, 11H, 8H + water), 2.80 (br s, 3H), 2.47 -1.98 (br m, 2H); IR (KBr): v 1723, 1711 (C=0) cm"1. Example 285. (General procedure 15) 4-Phenethyl-piperazine-1-carboxylic acid 4-(5-trifluorornethyI-pyridin-2-yloxy)-phenyI ester The hydrochloride of the title compound was prepared from 4-(5-trifluoromethy!-pyridin-2-y!oxy)-phenyI chloroformate and 1-phenethylpiperazine, yield 54 %. Recrystallisation from 99% EtOH gave white crystals, m.p. 245 - 247 °C; 1H NMR (DMSOcf6): 8 11.72 (br, 1H), 8.63 - 8.53 (br, 1H), 8.31 - 8.19 (dd-Iike m, 1H), 7.44 - 7.16 (m, 10H), 4.44 - 4.01 (br, 2H), 3.83.-3.45 (br, 4H), 3.45 - 2.95 (br, ~8H, 6H + water); IR (KBr): v 1713 (C=0) cm-1. Example 286 (General procedure 15) 4-Pyridin-2-ylmethyl-piperazine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI ester The hydrochloride of the title compound was prepared from 4-(5-trifiuoromethyl-pyridin-2-yloxy)-phenyl chloroformate and 1-pyridin-2-yImethyl-piperazine. White crystals, yield 64 %; m.p. 189 - 190 °C; 1H NMR (DMSO-d6): 58.72 - 8.63 (m, 1H), 8.60 - 8.55 (br, 1H), 8.29 -8.20 (dd-Iike, 1H), 8.02 - 7.90 (m( 1H). 7.80 - 7.65 (m, 1H)r 7.56 - 7.45 (m. 1H)f 7.31- 7.22 (m, 5H), 4.52 (br. s, 2H), 4.06 - 3.68 (br s, 4H), 3.68 - 2.93 (br, 4H + NH + water); HPLC-MS: m/z = 459 (M+H); IR (KBr): v 1717 (C=0) cm"1. Example 287 (General procedure 15) 4-Pyridin-3-y)methyl-piperazine-1 -carboxylic acid 4-(5-trif luoromethyl-pyridin-2-yloxy)-phenyl ester The hydrochloride of the title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate and 1-pyridin-3-ylmethyl-piperazine. Trituration with water, filtering and drying of the residue gave white crystals. 1H NMR (DMSO-cfe): £8.78 - 8.51 (m, 3H), 8.30 - 8.18 (dd-Iike, 1H), 8.12 - 8.00 (br d, 1H), 7.57 -7.46 (m, 1H), 7.32 - 7.17 (m, 5H), 4.65 - 4.11 (br, 2H), 4.11 - 2.78 (br m, 6H + water); HPLC-MS: m/z = 459 (M+H); IR (KBr): v 1723 (00) cm"1. Example 288 (General procedure 15) 4-(3-Phenylpropyl)piperazine-1 -carboxylic acid 4-(54rifluoromethyl-pyridin«2-yloxy)-phenyI ester The hydrochloride, of the title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate and 1-(3-phenylpropyl)piperazine, yield 68 %. m.p. 235 - 238 °C; 1H NMR(DMSO-d6): 5 11.51 (br, 1H), 8.61 -8.55.(br, 1H), 8.29 - 8.20 (dd-like m, 1H)f 7.38 - 7.16 (m, 10H), 4.38 - 3.96 (br, 2H), 3.83 - 3.40 (br, 4H), 3.30 - 2.91 (br, 4H), 2.75 - 2.57 (Hike m, 2H), 2.20 -1.94 (m, 2H); IR (KBr): v 1715 (C=0) cm"1. Example 289 (General procedure 15) 4-(4-PhenylbutyI)piperazine-1-carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI ester The hydrochloride of the title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate and 1-(4-phenyIbutyI)piperazine, yield 71 %. m.p. 232 - 234 °C; 1H NMR (DMSO-cf6): tf 11.32 (br s, 1H), 8.61 - 8.55 (br, 1H), 8.29- 8.20. (dd-like m, 1H), 7.36 - 7.13 (m, 10H), 4.4Q - 3-97 (br, 2H), 3.81 - 3.39 (br m, 4H), 3.26 - 2.91 (br, 4H), 2.71 - 2.55 (t-like m, 2H)f 1.88 -1.51 (br m, 4H); IR (KBr): v 1728,1713 (C=0) cm"1. Example 290 (General procedure 15) 4-Benzyl-1,4-diazepane-1-carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester The hydrochloride of the title, compound was prepared from 4-(5-trifluoromethyl«pyridin-2-yloxy)-phenyl chloroformate and 1-benzyIhomopiperazine, crude yield 70 %. 0.20 g Of the crude product was heated with 3 ml of water, cooled at 0 °C, the precipitate filtered off and dried; m.p. 231 - 233 °C; 1H NMR (DMSO-of6): 811.38 (br s, 1H), 8.62 - 8.55 (br, 1 H)r 8.30 -8.20 (dd-like m, 1H), 7.76 - 7.60 (br, 2H), 7.52- 7.41 (br m, 3H), 7.32 - 7.19 (m. 5H), 4.38 (br s, 2H), 4.18 - 3.01 (br m, 8H + water), 2.6 - Z0 (brf 2H + DMSO); IR (KBr): v 1726,1710 (C=0) cm"1. Example 291 (General procedure 15) 4-(3,4-DichlorophenyI)piperazine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)phenyI ester The hydrochloride of the title compound was prepared from 4-(5-trifluoromethy!-pyridin-2-yloxy)-phenyl chloroformate and 1-(3,4-dichlorophenyl)piperazine. The crude product was partitioned between dichlorormethane and 2 M aqueous sodium carbonate. The organic layer was washed with water, dried and evaporated. The residue was triturated with ethyl acetate - heptane (1:4) and the precipitate was collected by filtration and dried to give the title compound as white crystals. Yield 28 %; m.p. 115 -116 °C; 1H NMR (DMSO-cf6): 8 8.61 -8.55 (br, 1H), 8.30 - 8.20 (dd-like, 1H), 7.48 - 7.40 (d-Iike,1H), 7.31 - 7.16 (m, 6H), 7.04 - 6.94 (dd-like, 1H), 3.83 - 3.47 (br m, 4H), 3.36 - 3.24 (br s, 4H + water); HPLC-MS: m/z = 512 (M+H); IR (KBr): v 1724,1706 cm"1. Example 292 (General procedure 15) 4-(4-Fluorophenyt)piperazine-1 -carboxylic acid 4-(5-trifluoromethyI-pyridin-2-yloxy)phenyl ester The hydrochloride of the title compound was prepared from 4-(5~trifluoromethyI-pyridin-2-yloxy)-phenyl chloroformate and 1-(4-fluoropheny()piperazine. White crystals, yield 20 %; m.p. 131-132 °C; 1H NMR (DMSO-cf6): 8 8.61 - 8.53 (br, 1H), 8.30 - 8.19 (dd-like, 1H), 7.33 -7.17 (m, 5H), 7.17 - 6.95 (m, 4H), 3.85 - 3.47 (br d, 4H), 3.25 - 3.07 (br m, 4H); HPLC-MS: m/z = 462 (M+H); IR (KBr): v 1739,1714 cm'1. Example 293 (General procedure 15) 4-(2-ChlorophenyI)piperazine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)phenyl ester The the hydrochloride of title compound was prepared from 4-(5-trifluoromethyi-pyridin-2-yloxy)-phenyl chloroformate and 1-(2-chlorophenyl)piperazine. Drying in vacuo at 50 °C for 3Yz h gave the title compound; 1H NMR (DMSO-of6): £8.61 - 8.55 (br, 1H), 8.29 - 8.20 (dd-like, 1H), 7.53-7.41 (m, 1H), 7.39 - 7.17 (m, 7H), 7.14 - 7.03 (m, 1H), 4.58 (br s, NH + water), 3.85 - 3.55 (br m, 4H), 3.12 - 2.99 (br m, 4H); HPLOMS: m/z = 478 (M+H); IR (KBr): v 1733(C=0)cm- Example 294 (General procedure 15) (2-Dimethylamino-ethyl)methyicarbamic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester The hydrochloride of the title compound was prepared from 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyl chloroformate and N,N,N'-trimethyIethylenediamine; m.p. 139 -140 °C; 1H NMR (MeOH-de): 8 8.45 - 8.38 (br, 1H), 8.15 - 8.05 (dd-!ike m, 1H), 7.31 - 7.11 (m, 5H), 3.84 - 3.73 (br m, 2H), 3.54 - 3.38 (br m, 3H), 3.19 (br s, 2H)f 2.99 (br s, 6H); traces of impurities at 3.9 (br) and 3.1 (br); lR (KBr): v 2695, 1705 cm 1 (C=0) cm"1. Example 295 (General procedure 15) 4-Methylpiperazine-1~carboxyIic acid 4-chIorophenyl ester The hydrochloride of the title compound was prepared from 4-chlorophenyI chloroformate and 1-methy!piperazinef yield 81 %. White crystals, m.p. 237 - 240 DC; 1H NMR (DMSO-of6): 4»4-dimethyl-piperidine-2,6-dione (0.60 g, 2.55 mmol), N-methyl-N-phenylcarbamoyI chloride (0.48 g, 2.81 mmol) and 1,4-diazabicyclo-[2,2,2]octane (0.31 g, 2.81 mmol) in dichloromethane (25 mL) was stirred at room temperature for 15 minutes. The solvent was evaporated in vacuo and the residue was purified by flash column chromatography (Si02l ethyl acetate:heptane 50:50), yielding the title compound as a white solid. 1H NMR (300MHz, CDCI3): 8 = 1.22 (s, 6H), 2.65 (s, 4H), 3.44 (br.s, 3H), 7.28-7.48 (m, 5H), 8.68 (br.s, 2H); HPLC-MS (Method A): m/z = 369 (M+H)+; Rt = 3.45 min. Example 369 Methyl-phenyl-carbamic acid 5-bromo-pyrimidin-2-yI ester A mixture of 4-bromo-2-hydroxypyrimidine (0.96. g, 5.49 mmol), N-methyl-N-phenylcarbamoyl chloride (1.02 g, 6.04 mmol) and 1 ,4-diazabicyclo[2,2,2]octane (0.68. g, 6.04 mmol) in dry tet-rahydrofuran (15mL) was stirred at room temperature for 1 hour. Dichloromethane was added and the solution was extracted twice with water. The organic layer was dried over sodium sulphate, filtered and evaporated in vacuo yielding the title compound (170 g, 100% yield) as a white solid. 1H NMR (300MHz, CDCI3): 8 = 3.43 (br.s, 3H), 7.27 (m, 1H), 7.38 (m, 4H), 8.68 (br.s, 2H); HPLC-MS (Method A): m/z = 330 and 332 (M+H)+; Rt = 3.33 min. Example 370 Methyl-phenyl-carbamic acid 5-[(6-chloro-pyridine-3-carbonyI)-amino]-pyridin-2-yl ester A mixture of 4-chIoro-N-(6-hydroxy-pyridin-3-y!)-nicotinamide (0.56 g, 2.25 mmol), N-methyl-N-phenylcarbamoyl chloride (0.51 g, 3.00. mmol) and 1,4-diazabicyclo[2,2,2]octane (0.67 g, 6.00 mmol) in dry tetrahydrofuran (15mL) was stirred at room temperature for 1 hour. Dichloromethane was added and the solution was extracted twice with water. The organic layer was dried over sodium sulphate, filtered and evaporated in vacuo. The residue was purified by flash column chromatography (Si02, ethyl acetate;heptane 70:30) followed by crystallised from ethyl acetate:heptane, yielding the title compound (44 mg, 5% yield) HPLC-MS (Method A): m/z = 383 (M+H)+; Rt = 3.40 min. Example 371 Methyl-phenyl-carbamic acid 5-(2,2-dimethyl-propylcarbamoyl)-pyridin-2-yl ester A solution of N-(2,2-dimethyl-propyI)-6-hydroxy-nicotinamide (0.50 g, 2.40 mmol), N-methyl-N-phenylcarbamoyl chloride (0.41 g, 2.40 mmol) and 1,4-diazabicyclo[2,2,2]octane (0.27 g, 2.40 mmol) in tetrahydrofuran (15 mL) was stirred at room temperature for 3 hours. The solvent was evaporated in vacuo and the residue was purified by flash column chromatography (first column: Si02, dichloromethane:ethyl acetate 95:5, second column: Si02) ethyl acetate), yielding the title compound (0.43 g, 52% yield). 1H NMR (300MHz, CDCI3): 5 = 0.97 (s, 9H), 3.26 (d, 2H), 3.44 (br.s, 3H), 6.26 (br.s, 1H), 7.08 (br.s, 1H), 7.29 (m, 1H), 7.39 (m, 4H), 8.13 (br.d, 1H), 8.70 (br.s, 1H); HPLC-MS (Method A): m/z = 383 (M+H)+; Rt = 3.40 min. Example 372 [Methyl-phenyl-carbamic add 6-(3,4-clichloro-phenoxy)-pyridazin-3-yl ester A solution of 6-(3,4t4-thiomorpholine-4-carboxylic acid 4-(5-trifIuoromethyI-pyridin-2-yIoxy)-phenyl ester The title compound was prepared from 4-(5-trifluoromethyI-pyridin-2-yIoxy)-phenyI chloroformate and thiomorpholine 1-oxide and purified by flash chromatography (ethyl acetate), yield 37%. White crystals, m.p. 156 -157 °C; 1H NMR (CDCI3) .£8.47 - 8.40 (s-like, 1H), 7.94 -7.87 (dd-Iike, 1H), 7.24 - 7.13 (m, 4H), 7.06 - 6.99 (d-like), 4.31 - 3.91 (m, 4H), 2.97 - 2.87 -2.75 (m, 2H + 2H); IR (KBr): v 1710 (C=0) cm'1. Example 441 (General procedure 18) 4-(2,4-Dimethoxypheny[)-piperazine-1 -carboxyiic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)- phenyl ester The title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate and 1-(2,4-dimethoxyphenyl)-piperazine. Purified by flash chromatography (ethyl acetate - heptane 1:4), yield 69%. White crystals, m.p. 98-99 °C; HPLC-MS: m/z = 504 (M+1) at Rt = 4.0 min.; IR (KBr): v 1733,1712 (C=0) cm'1. Example 442 (General procedure 15) 5-Benzyl-2,5-diazabicycIo[2.2. 1 ]heptane-2-carboxylic acid 4-(5-trifluoromethylpyridin-2- yloxy)-phenyI ester The hydrochloride of the title compound was prepared from 4-(5-trifluoromethyI-pyridtn-2-yIoxy)-phenyl chloroformate and 2-benzyl-2,5-diazabicyclo[2.2.1]heptane. The crude product was converted to the free base and further purified by flash chromatography (ethyl acetate -heptane 1:4), yield 16 %. White crystals, m.p. 114-115 °C; HPLC-MS: m/z: 470 (M+1) at Rt = 2.6 min.; IR (KBr): v 1718 (C=0) cm'1. Example 443 (General procedure 10) 4-Aminomethyl-piperidine-1-carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester The title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate and 4-aminomethylpiperidine. The crude product was purified by preparative HPLC (Method C) (32%, off-white crystals). HPLC-MS m/z = 396.1 (M+1), Rt: 2.65 min. purity: 86%. Example 444 (General procedure 10) 4-Pyrimidin-2-yl-piperazine-1-carboxylic acid 4-(5-chloro-pyridin-2-yloxy)-phenyl ester The' title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate and 1-(2-pyrimidinyI)-piperazine, two equivalent of diisopropylethyiamine was added. The crude product was obtained by filtration of the reaction mixture. The crude product was washed with diethyl ether and subjected to column chromatography, ethyl acetate/heptane (1:3) (18%, white crystals). HPLC-MS m/z = 412.1 (M+1), Rt: 4.12 min. Example 445 (General procedure 12) 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 4-(4,4-dirnethyl-2,6-dioxo-piperidin-1 -yl)- phenyl ester The title compound was prepared from 4-(4,4-dimethyl-2,6"dioxo-piperidin-1-yI)-phenyI chloroformate and 1-cyclopropylmethyI-piperazine, preparative HPLC (Method C) (45%, off-white crystals). HPLC-MS m/z = 400.3 (M+1), Rt 1.83 min. Example 446 (General procedure 12) 4-(4-Methoxy-benzyI)-piperazine-1 -carboxylic acid 4-(4,4-dimethyI-2,6-dioxo-piperidin-1-yI)- phenyl ester The title compound was prepared from 4-(4I4-dimethyI-2,6-dioxo-piperidin-1*yI)-phenyI chloroformate and 1-(4-methoxybenzy!)-piperazine, preparative HPLC (Method C) (54%, white crystals). HPLC-MS m/z = 466.3 (M+1), Rt: 2.26 min. Example 447 (General procedure 12) 4-Pyridin-3-ylmethyI-piperazine-1-carboxyIic acid 4-(4,4-dimethyl-2J6-dioxo-piperidin-1 -yl)- phenyl ester The title compound was prepared from 4-(4,4-dimethyI-2,6-dioxo-piperidin-1-y!)-phenyl chloroformate and 1-pyridin-3-ylmethyl-piperazine, hydrochloride, preparative HPLC (Method C) (75%, colourless oil). HPLC-MS m/z = 437.2 (M+1), Rt: 1.70 min. Example 448 (General procedure 12) 4-(4-Methoxy-benzyI)-piperazine-1-carboxyIic acid 4-(2-cyclohexyI-acetylamino)-phenyl ester The title compound was prepared from 4-(2-cyclohexyl-acetyIamino)-phenyI chloroformate and 1-(4-methoxybenzyl)-piperazine, preparative HPLC (Method C) (49%, white crystals). HPLC-MS m/z = 466.3 (M+1), Rt: 2.85 min. Example 449 (General procedure 12) 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 4-(2-cycIohexyl-acetylamino)-phenyl ester The title compound was prepared from 4-(2-cyclohexyl-acetylamino)-phenyI chloroformate and 1-cyclopropylmethyl-piperazine, preparative HPLC (methode C (60%, off-white crystals). HPLC-MS m/z = 400.3 (M+1), Rt: 2.42 min. Example 450 (General procedure 12) 4-Pyrid»n-3-ylmethyl-piperazine-1-carboxylic acid 4-(2-cyclohexyl-acetylamino)-phenyl ester The title compound was prepared from 4-(2-cyclohexyl-acetyiamino)-phenyl chioroformate and 1-pyridin-3-ylmethyl-piperazine, hydrochloride, preparative HPLC (method© C) (64%, white crystals). HPLC-MS m/z = 437.4 (M+1), Rfc 2.38 min. Example 451 (General procedure 14) Methyl-phenyl-carbamic acid 4-(2-cyclohexyl-ethyIsulfamoyI)-phenyl ester The title compound was prepared from N-(2-cyclohexyI-ethyI)-4-hydroxy-benzenesulfonarnide and N-methyl-N-phenyl carbamoylchloride, preparative HPLC (Method C) (14%, light yellow oil). HPLC-MS m/z = 417.3 (M+1), Rt: 4.89 min. Example 452 (General procedure 14) Methyl-phenyl-carbamic acid 4-(3-methyI-butylsulfamoyl)-phenyI ester The title compound was prepared from 4-hydroxy-N-(3-methyl-butyl)-benzenesulfonamide and N-methyl-N-phenyl carbamoylchloride, preparative HPLC (Method C) (11%, light yellow oil). HPLC-MS m/z = 377.2 (M+1), Rt: 4.32 min. Example 453 (General procedure 12) (6-Methoxy-pyridin-2-yl)-methyl-carbamicacid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester The crude product was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI chioroformate and and 2-methoxy-6-methylaminopyridine. The reaction mixture was evaporated to dryness, dissolved in dichloromethane (100 ml) and extracted with a aqueous phosphate buffer, pH 7. The aqueous phase was extracted with dichloromethane (100 ml x 2) and the combined organic phases were dryed and evaporated to dryness. The product was subjected to flash chromatography, ethyl acetate/heptane (1:7) to give the titlew product (86%, white crystals). HPLC-MS m/z = 420.4 (M+1), Rt 5.23 min. Example 454 (General procedure 12) 4-Benamidazol-1-yI-piperidine-1-carboxyfc ester The crude product was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chlorofor- mate and l-piperidine-4-yl-IH-benzimidazoIe, 5 equivalent of diisopropylamine was added, preparative HPLC (method C) (23%, colourless crystals). HPLC-MS m/z = 483.3 (M+1), Rt: 3.14. min. Example 455 (General procedure 12) 4-Hydroxymethyl-piperidine-1-carboxylic acid 4-(2-cyclohexyI-acetylamino)-phenyI ester The title compound was prepared from 4-(2-cyclohexyl-acetylamino)-phenyI chloroformate and 4-hydroxymethyI-piperidine, praeparative HPLC (Method C) (37%, off-white crystals). HPLC-MS m/z = 375.2 (M+1), Rt: 3.41 min. Example 456 (General procedure 12) 4-(4-Amino-phenyI)-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-y!oxy)-pheny] ester The title compound was prepared from 4-(5-trifluoromethyI-pyridin-2-yIoxy)-phenyl chloroformate and 4-(4-aminophenyl)piperidine, hydrochloride, praeparative HPLC (Method C) (30%, light yellow crystals). HPLC-MS m/z = 458.2 (M+1), Rt: 3.42 min. Example 457 (General procedure 12) 4-(Methy!-pyridin-3-ylmethyl-amino)-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin- 2-yIoxy)-phenyl ester The title compound was prepared from 4-(5-trifIuoromethyl-pyridin-2-yIoxy)-phenyl chloroformate and methyl-piperidin-4-yI-pyridin-3-ylmethyl-amine, hydrochloride, praeparative HPLC. (Method C) (31%, orange oil). HPLC-MS m/z = 487.1 (M+1), Rt: 2.64 min. Example 458 (Genera! procedure 12) 4-(2-Oxo-pyrrolidin-1 -yl)-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)- phenyl ester The title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate and 1-piperidin-4-yI-pyrrolidine-2-one, hydrochloride, praeparative HPLC (Method C) (55%, semi-crystaline oil). HPLC-MS m/z = 450.1 (M+1), Rt: 3.81 min. Example 459 (General procedure 12) 4-(MethyI-phenethyl-amino)-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yIoxy)- phenyl ester The title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI chlorofor-mate and methyI-phenethyl-piperidin-4-yI-amine, hydrochloride, prasparative HPLC (Method C) (37%, colourless oil). HPLC-MS m/z = 500.1 (M+1), Rt: 3.26 min. Example 460 4-[(Benzyl-ethyI-amino)-methyl]-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester Benzyl-ethyl-piperidin-4-yImethyI-amine (1.42 mmol) was dissolved in dichloromethane. 4-(5-Trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate (1.42 mmol, 0.451 g) (prepared from the corresponding phenol by conventional methods) was added at room temperature. The reaction mixture was stirred overnight and evaporated to dryness. The crude product was subjected to column chromatography, ethyl acetate/heptane (1:3) -+ Triethylamine/ethyl acetate 1:9). The fractions containing the title product, was evaporated to dryness and HCI (g) in ethyl acetate was added and stirred for 16 hours. The solution was evaporated to dryness and dryed in vacoum for 16 h. to give the title product. (58%, light yellow crystals). HPLC-MS m/z = 514.1 (M+1), Rt: 3.27 min. Example 461 (General procedure 12) 4-[Methyl-phenethyI-amino)-methy!]-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yIoxy)-phenyI ester The title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate and methyl-phenethyl-piperidin-4-ylmethyl-amine, hydrochloride, 5 equivalent of diiso-propylamine was added, praeparative HPLC (Method C) (46%, colourless crystals). HPLC-MS m/z = 514.1 (M+1), Rt: 3.31 min. Example 462 (General procedure 12) 4-[(CyclohexyI-methyl-amino)-methyl]«piperidine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester The title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chlorofor-mate and cyclohexyI-methyl-piperidine-4-ylmethyI-amine, hydrochloride, 5 equivalent of diisopropylamine was added, prasparative HPLC (Method C). (43%, white crystals). HPLC-MS m/z = 492.3 (M+1), Rt 3.22 min. Example 463 (General procedure 12) 4-[(Ethyl-pyridin-4-ylmethyl-amino)-methyI]-piperidine-1 -carboxylic acid 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyi ester The title compound was prepared from 4-(5-trifIuoromethyl-pyridin-2-yloxy)-pheny! chlorofor-mate and ethyI-piperidin-4-ylmethyI-pyridin-4-ylmethyl-amine, hydrochloride, 5 equivalent of diisopropylamine was added, prasparative HPLC (Method C) (25%, off-white crystals). HPLC-MS m/z = 515.2 (M+1), Rt: 2.77 min. Example 464 (General procedure 12) 4-[(Benzyl-methyl-amino)-methyI]-piperidine-1 -carboxylic acid 4-(5-trifluoromethyI-pyridin-2- yloxy)-phenyl ester The title compound was prepared from 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyl chlorofor-mate and benzyl-methyl-piperidin-4-ylmethyl-amine, hydrochloride, 5 equivalent of diisopropylamine was added, praaparative HPLC (Method C) (56%, colourless crystals). HPLC-MS m/z = 500.2 (M+1), Rt: 3.18 min. Example 465 (General procedure 12) 4-[(Methyl-pyrldin-3-ylmethyl-amino)-methyI]-piperidine-1 -carboxylic acid 4~(5-trifluoromethyI-pyridin-2-yloxy)-phenyl ester The title compound was prepared from 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyl chlorofor-mate and methyl-piperidine-4-ylmethyl-pyridine«4-ylmethyl-amine, hydrochloride, 5 equivalent of diisopropylamine was added, praeparative HPLC (Method C) (36%, colourless crystals). HPLC-MS m/z = 501.1 (M+1), Rt: 2.74 min. Example 466 (General procedure 12) 4-(1,3-Dihydro-isoindol-2-ylmethyl)-piperidine-1-carboxylic acid 4-(5-trifluoromethyI-pyridin-2- yloxy)-phenyl ester The title compound was prepared from 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyl chlorofor-mate and 2-piperidin-4-yImethyl-2f3-dihydro-1H-isoindole, hydrochloride, 5 equivalent of diisopropylamine was added, prseparative HPLC (Method C) (63%, colourless crystals). HPLC-MS m/z = 498.1 (M+1),. Rt: 3.07 min. Example 467 4-BenzotriazoM -yl-piperidine-1 -carboxylic acid 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyl ester The title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yIoxy)-phenyI chlorofor-mate and 1-piperidin-4-yMH-benzotriazolef hydrochloride, 5 equivalent of diisopropylamine was added, preparative HPLC (Method C) (7%, colourless crystals). HPLC-MS m/z = 506.2 (M+1), Rt 4.56 min. Example 468 (General procedure 12) 4-[(CyclopropylmethyI-amino)-methyI]-piperidine-1-carboxylicacid 4-(5-trifluoromthyI-pyridin-2-yIoxy)-phenyI ester CyclopropylmethyI-piperidine-4-ylmethyi-amine (0.65 mmol, 110 mg) was dissolve in di-chloromethane. 4-(5-trifIuoromethyI-pyridin-2-yloxy)-phenyl chloroformate (0.65 mmol, 0.208 g) (prepared from the corresponding phenol by conventional methods) was added at - 15 °C for 15 min and stired at room temperature overnight and evaporated to dryness. The crude product was purified by preparative HPLC (Method C) (16%, colourless crystals). HPLC-MS m/z = 450.1 (M+1), Rt: 2.98 min. Example 469 (General procedure 12) 4-[Methyl-(2-pyridin-2-yl-ethyl)-amino]»piperidine-1 -carboxyfic add 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyl ester The title product was prepared from methyl-piperidin-4-yl-(2-pyridin-2-yl-ethyl)"amine and 4-(5-trifluoromethyl-pyridin"2-y}oxy)-phenyl chloroformate, 5 equivalent of diisopropylamine was added, preparative HPLC (method C) (48%, colourless oil). HPLC-MS m/z = 501.1 (M+1), Rt: 2.77 min. Example 470 (General procedure 12) 4-(CyclohexyI-methyI-amino)-piperidine-1 -carboxylic acid 4-(5-trifluoromethyI-pyridin«2- y!oxy)-phenyl ester The title product was prepared from cyclohexyI-methyl-piperidin-4-yl-amine, dihydrochloride and 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI chloroformate, 2 equivalent of diisopro-pylamine; dimethylformamide/ tetrahydrofuran (2:1). The reaction mixture was evaporated to dryness and the crude product extracted with ethyl acetate from an aqueous HCI solution saturated with sodium chloride, pH 1-2. The title product was crystallized from ethyl acetate during evaporation of the solvent, filtered and dryed in vacoum (45%, white crystals). HPLC-MS m/z = 478.2 (M+1), Rt: 3.10 min. Example 471 (General procedure 12) 4-(IsopropyI-methyI-amino)-piperidine-1 -carboxylic acid 4-(5-trifIuoromethyl-pyridin-2-yIoxy)- phenyl ester The title product was prepared from isopropyl-methyl-piperidin-4-yi-amine, dihydrochloride and 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate; dimethylformamide as solvent, preparative HPLC (method C) (77%, light yellow oil). HPLC-MS m/z = 438.3 (M+1), Rt: 2.77 min. Example 472 (General procedure 12) (4-Methoxy-phenyl)-methyl-carbamic acid 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyI ester The title product was prepared from N-methyl-p-anisidine and 4-(5-trifluoromethyl-pyrldin-2-yloxy)-phenyl chloroformate, preparative HPLC (method C) (61%, off-white crystals). HPLC-MS m/z = 419.2 (M+1), Rt: 4,67 min. Example 473 (General procedure 12) (2-Methoxy-phenyl)-methyl-carbamic add 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester The title product was prepared from 2-methoxy-N-methylamine and 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate, preparative HPLC (method C) (63%, colourless oil). HPLC-MS m/z = 419.2 (M+1), Rt 4.75 min. Example 474 (General procedure 12) (2-Cart3amoyl-chIoro-phenyI)-methyI-carbamic phenyl ester. The title product was prepared from 5-chloro-2-(methyIamino)-benzamide and 4-(5- trifluoromethyI-pyridin-2~yloxy)-phenyI chloroformate, preparative HPLC (method C) (31%, light yellow oil). HPLC-MS m/z = 466.1 (M+1), Rt: 3.99 min. Example 475 (General procedure 12) (2-CarbamoyI-phenyI)-methyI-carbamic acid 4«(5-trifluoromethyI-pyridin-2-yloxy)-phenyI ester The title product was prepared from 2-(methylamino)benzamide and 4-(5-trifIuoromethyI-pyridin-2-yloxy)-phenyI chloroformate, preparative HPLC (method C) (57%, light yellow oil). HPLC-MS m/z = 454.2 (M+Na), Rt: 3.66 min. Example 476 (General procedure 12) (2-Chloro-phenyI)-methyl-carbamic acid 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyl ester The title product was prepared from 2-chlor-N-methylani!ine and 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate, preparative HPLC (method C) (48%, light yellow oil). HPLC-MS m/z = 423.1 (M+1), Rt: 4.98 min. Example 477 (General procedure 12) (2,4-Difluoro-phenyl)-methy!-carbamic acid 4-(5-trifIuoromethyI-pyridin-2»yloxy)-phenyl ester The title product was prepared from 2,4-difluouro-N-methyIaniIine and 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate, preparative HPLC (method C) (37%, white crystals). HPLC-MS m/z = 425.1 (M+1), Rt: 4.90 min. Example 478 (General procedure 12) Methyl-(2-trifluoromethoxy-phenyI)-carbamic acid 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyl ester The title product was prepared from N-methyl-2-(trifluoromethoxy)-aniline and 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate, preparative HPLC (method C) (49%, colourless oil). HPLC-MS m/z = 473.2 (M+1), Rt 5.18 min. Example 479 (General procedure 13) Methyl-phenyl-carbamic acid 4-(1,1,3,3-tetramethyI-butylcarbamoyI)-phenyI ester The title product was prepared from tert-octylamine and 4-(methyI-pheny!-carbamoyIoxy)-benzoic acid 2,5-dioxo-pyrroiidin-1-yl ester, preparative HPLC. (method C) (26%, white crystals). HPLC-MS m/z = 383.5. (M+1), Rt: 4.67 min. Example 480 (General procedure 13) Methyl-phenyl-carbamic acid 4-[(2-dimethyIamino-ethyI)-methyl-carbamoyl]-phenyl ester The title product was prepared from N.NX-trimethylethylendiamine and 4-(methyl-phenyl-carbamoyloxy)-benzoic acid 2,5-dioxo-pyrroIidin-1-yl ester, preparative HPLC (method C) (2%, colourless oil!). HPLC-MS m/z = 356.2 (M+1)f Rt: 2.17 min. Example 481 (General procedure 13) Methyl-phenyl-carbamic acid 4-(cyclopropyImethyI-carbamoyI)-phenyI ester The title product was prepared from cyclopropylmethylamine and 4-(methy!-phenyl-carbamoyloxy)-benzoic acid 2,5-dioxo-pyrroIidin-1-yl ester. The crude product was used without further purification (100%, semi-crystal oil). HPLC-MS m/z = 325.1 (M+1), Rt: 3.40 min. Example 482 (General procedure 13) Methyl-phenyl-carbamic acid 4-(methyl-pyridin-3-ylmethyl-carbamoyl)-phenyI ester The title product was prepared from methyl-pyridin-3-ylmethyI-amine and 4-(methyl-phenyI-carbamoyloxy)-benzoic acid 2,5-dioxo-pyrroIidin-1-yI ester. The crude product was subjected to preparative HPLC (method C) (48%, clear colourless oil). HPLC-MS m/z = 376.2 (M+1), Rt: 2.37 min. Example 483 (General procedure 13) Methyl-phenyl-carbamic acid 4-[(1H-benzimidazoI-2-ylmethyl)-carbamoyl]-phenyI ester The title product was prepared from 0(1 H-benzimidazol-2-yI)-methyIamine and 4-(methyI- phenyl-carbamoyloxy)-benzoic acid 2,5-dioxo-pyrroiidin-1-yl ester. The crude product was subjected to preparative HPLC (method C) (8%, off-white crystals). HPLC-MS m/z = 401.1 (M+1), Rt: 2.56 min. Example 484 (General procedure 13) Methyl-phenyl-carbamic acid 4-[2-(4-chloro-pheny!)-ethylcarbamoyl3-phenyI ester The title product was prepared from 2-(4-chIoro-phenyI)-ethyIamine and 4-(methyl-phenyI-carbamoyloxy)-benzoic acid 2,5-dioxo-pyrrolidin-1-yl ester. The crude product was subjected to preparative HPLC (method C) (39%, off-white crystals). HPLC-MS m/z = 409.2 (M+1), Rt: 4.27 min. Example 485 4-Cyclopropy)methyI-piperazine-1 -carboxylic acid 4-(3,3-dimethyl-butylcarbamoyI)-phenyl ester The title product was prepared from 1-cycIopropyImethyIpiperazine (0.35 mmol) dissolved in dichloromethane (5 ml). 4-(3,3-dimethyl-butyIcarbamoyi)-phenyl chloroformate (0.35 mmol) was added at room temperature. The reaction mixture was stirred for 16 h and evaporated to . -dryness and subjected to preparative HPLC (metod C) (5%, white crystals). HPLC-MS m/z = 388.2 (M+1), Rt: 2.43 min. Example 486 4-Hydroxymethy!-piperidine-1-carboxylic acid 4-(3,3-dimethyl-butylcarbamoyI)-phenyI ester ester The title product was prepared from 4-hydroxymethyIpiperidtne (0,35 mmol) was dissolved in dichloromethane (5 ml). Diisopropylethylamine (0.35 mmol was added together with 4-(3,3-dimethyl-butylcarbamoyl)-phenyl chloroformate (0.35 mmol) at room temperature. The reaction mixture was stirred for 16 h and evaporated to dryness and subjected to preparative HPLC (metod C). (25%, white crystals). HPLC-MS m/z = 363.3 (M+1), Rt 3.27 min. Example 487 4-Pyridin-3-ylmethyl-piperazine-1-carboxylic acid 4-(3,3-dimethyl-butylcarbamoyl)-phenyl ester The title product was prepared from 1-pyridin-3-yImethyl-piperazine was dissolved in di-chloromethane (5 ml). 4-(3,3-DimethyI-butylcarbamoyl)-phenyl chloroformate (0.35 mmol) was added at room temperature. The reaction mixture was stirred for 16 h and evaporated to dryness and subjected to preparative HPLC (metod C) (88%, light yellow oil).. HPLC-MS m/z = 425.4 (M+1),Rt 2.33 min. Example 488 4-(4-Methoxy-benzyI)-piperazine-1-carboxyiicacid 4»(313-dimethyI-butyIcarbamoyI)-pheny! ester The title product was. prepared from 1-(4-methoxy-benzyI)-piperazine (0.35 mmol) was dissolved in dichloromethane (5 ml). 4-(3,3-Dimethyl-butylcarbamoyl)-phenyl chloroformate (0.35 mmo!) was added at room temperature. The reaction mixture was stirred for 16 h and evaporated to dryness and subjected to preparative HPLC (metod C). (54%, colourless semi-crystaline oil). HPLC-MS m/z = 454.3 (M+1), Rt: 2.78 min. Example 489 4-(2-Pyridin-2-yl-acetyI)-piperazine-lK^rbo^ ester a) Piperazine-I^dicarboxylicacid tert-butyl ester 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester (General procedure 18) The title compound was prepared from 4-(5-trifluoromethyl-pyridin-2-yIoxy)-phenyl chloroformate and 1-tert-butoxycarbonyl-piperazin, yield 59% (recrystallized from EtOAc - heptane 1:1). White crystals, m.p. 165 -166 °C; 1H NMR (CDCI3) D 8.45 - 8.42 (m, 1H), 7.92 - 7.87 (m, dd-like, 1H), 7.21 - 7.12 (AB-system, 4H), 7.03 - 6.98 (m, d-iike, 1H), 3.72 - 3.45 (br mf 8H), 1.49 (s, 9H); 13C-NMR (CDCI3) Q (ref. CDCI3 77.00 ppm):165,71,154.56,153.51,150.21,148.34, 145.43 (q, J= 4.4 Hz), 136.701 (q, J = 3 Hz), 123.65 (q, J= 271.5 Hz), 122.86,122.24,121.62 (q, J = 33 Hz), 11.20, 80.32,44.38,43.78,44.6 - 42.3 (br), 28.36 ppm; IR (KBr) p 1722 (CO), 1691(C=0)cnrb) Piperazin&-1-carboxylic acid 4-(5-trifluoromethyl-pyridirh2-yloxy)-phenyl ester hydrochloride Piperazine-1,4-dicarboxyIic acid tert-butyl ester 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester (0.12 g, 0.26 mmol) was stirred at 100 °Cfor 10 min in a mixture of ethanol (3 ml) and concentrated hydrochloric acid (1 ml). The solvent was removed in vacuum. The residue was stirred with toluene (10 ml) and evaporated, then stirred with ethanol and evaporated to dryness to give white crystals (0.10 g). Recrystallization from absolute ethanol gave the title compound. White crystals, 0.068 g (65%); m.p. 279 - 282 °C (decomp.); 1H-NMR (DMSO) q 9.62 (br, 2H, NH2+), 8.61 - 8.55 (m, 1H), 8.29 - 8.21 (m, dd-Iike, 1H), 7.30 - 7.20 (m, 5H), 3.86 and 3.70 (br s, 4H), 3.19 (br s, 4H); 13C-NMR (DMSO) □ (ref DMSO 39.50 ppm): 165.51,152.71,149.98,148.04, 145.20 (J = 4.4 Hz), 137.62 (J = 3.7 Hz), 123.87 (J = 271.5 Hz), 123.11,123.39, 120.39 (J = 32.2Hz), 111.80,42.15 and a broad signal partly overlapping with the DMSO signal. IR (KBr) □ 1731,1709(0=0) cm"1. c) 4-(2-Pyridin-2-yl-acetyI)-piperazine-1-carboxytic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-pheny! ester Triethylamine (0.026 ml) was added to a stirred solution of (pyridin-2-yI)acetic acid hydrochloride (0.033 g, 0.19 mmol) in DMF (2.5 ml) at 0 DC. 1-Hydroxy-benzotriazole containing 8% of water (0.034 g) and then 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.044 g) was added and the mixture was stirred for 50 min. Piperazine-1-carboxyIic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI ester hydrochloride (0.070 g) in a mixture of DMF (1 ml) and triethylamine (0.032 ml) was added and stirring was continued over night at room temperature. The solvent was removed in vacuum and the residue was partitioned between dichloro-methane (10 ml) and water (10 ml). The organic phase was washed with water (10 ml), dried over sodium sulfate, filtered and evaporated. The residue was triturated with ether-petroleumsether 1:1 and the (2 + 1 ml). The residue was dried to give the title compound. White solid, m.p. 143 -146 °C; HPLC-MS m/z: IR (KBr) D 1732 (C=0), 1643 (C=0). Example 490 (General procedure 15) 4-(2-Pyridin-4-yl-ethyl)-piperazine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester The hydrochloride of the title compound was prepared from 4-(5-trifluoromethyI-pyridin-2-yloxy)-phenyl chloroformate and 1-(4-pyridin-2-yI-ethyI)-piperazine. White crystals, m.p. 268 - 271 °C (decomp); IR (KBr) □ 2680, 2579, 2456 (N+-H), 1731,1713 (C=0) cm-1; HPLC-MS m/z: 473 (M+H) Rt = 2.3 min. Example 491 Methyl-phenyl-carbamic acid 5-amino-pyridin-2-yI ester A solution of methyl-phenyl-carbamic acid 5-nitro-pyridin-2-yl ester (10.41 g, 38.1 mmol) in tet-rahydrofuran (100 mL) was hydrogenated in a Parr apparatus with wet 5% palladium on carbon and 20 psi hydrogen pressure. After 2 hours the solution was filtered over a short pad of Celite, washed thoroughly with ethyl acetate and evaporated in vacuo, yielding title compound (9.51 g, 103% yield) as a thick oil, which solidified upon standing. 1H NMR (300MHz, CDCl3): 5 = 3.40 (br.s, 3H), 3.70 (br.s, 2H), 6.80 (br.d, 1H), 6.97 (dd, 1H), 7.22 (m, 1H), 7.36 (m, 4H), 7.72 (d, 1H); HPLC-MS (Method A): m/z = 244 (M+H)+; Rt = 2.28 min. Example 492 Methyl-phenyl-carbamic acid 5-benzenesu]fonylamino-pyridin-2-yl ester. Benzenesuiphonyl chloride (0.18 g, 1.00 mmol), dissolved in a small amount of dichloro-methane, was added dropwise to a stirred solution of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (0.24 g, 1.00 mmol) and triethylamine (0.10 g, 1.00 mmol) in dichloromethane (10 mL). After stirring for 4 hours the solution was extracted with water and evaporated in vacuo. The residue was purified by flash column chromatography (Si02l ethyl acetate:heptane 40:60 followed by 50:50) yielding the title compound (108 mg, 23% yield) as a white solid. 1H NMR (300MHzr CDCI3): 5 = 3.46 (br.s, 3H), 6.82 (br.s, 1H), 7.24-7.52 (m, 9H), 7.63 (m, 3H), 7.84 (br.s, 1H); HPLC-MS (Method A): m/z = 384 (M+H)+; Rt = 3.26 min. Example 493 3,3-DimethyI^[6-(methykphenyk^^ A solution of methyl-phenyl-carbamic acid 5-amino-pyriditv2-yl ester (243 mg, 1.00 mmol) and 3,3-dimethylglutaric anhydride (142 mg, 1.00 mmol) in dichloromethane (10 mL) was stirred at room temperature for 48 hours. Evaporation of the solvent yielded the title compound as a thick oil. HPLC-MS (Method A): m/z = 386 (M+H)+; R( = 2.76 min. Example 494 Piperidine-1-carboxylic acid 4J4-dimethyI-2)6-dioxo-3,4,5,6-tetrahydro-2H-[1 ^bipyridinyl-e-yl 1-PiperidinecarbonyI chloride (63 microL, 0.50 mrnol) was added to a solution of B'-hydroxy^,^ dimethyl^.S^lihydrc^SH-tl^^ipyridinyl-^e-dione (117 mg, 0.50 mmol) and DABCO (56 mg, 0.50 mmol) in dimethylformamide (10 mL). After stirring for 1 hour at room temperature water was added and the solution was extracted twice with dichloromethane. The combined organic layers were dried over sodium sulphate, filtered and evaporated in vacuo. The residue was crystallised from ethyl acetate:heptane yielding the title compound (0.12 g, 69% yield) as a white solid. 1H NMR (300MHz, CDCI3): 5 = 1.21 (s, 6H), 1.64 (s( 6H), 2.69 (s, 4H), 3.53 (m, 2H), 3.63 (m, 2H), 7.22 (df 1H), 7.49 (dd, 1H), 8.09 (d, 1H); HPLC-MS (Method A): m/z = 346 (M+H)+; Rt = 3.12 min. Example 495 2,2-Dimethyl-N-[6-(methy!-phenyl-carbamoyloxy)-pyridin-3-yI]-succinamicacid A solution of methyl-phenyl-carbamic acid 5-amino-pyridin-2-yl ester (0.49 g, 2.00 mmol) and 2,2-dimethylsuccinic anhydride (0.26 g, 2.00 mmol) in dichloromethane (10 mL) was stirred at room temperature overnight Evaporation of the solvent in vacuo yielded the title compound. HPLC-MS (Method A): m/z = 372 (M+H)+; Rt = 2.84 min. Example 496 Methyl-phenyl-carbamic add 5-(3l3-dimethyl-2l5-dioxo-pyrroIidin-1-y()-pyridin-2-y[ ester A mixture of thionyl chloride (0.726 mL, 10.00 mmol) and 2,2-dimethyI-N-[6-(methyl-phenyl-carbamoyloxy)-pyridin"3-yI]-succinamic acid (0.74 g, 2.00 mmol) in dichloromethane (25 mL) was stirred at room temperature for 18 hours. The solvent and excess thionyl chloride were evaporated in vacuo. The crude product was redissolved in dichloromethane (25 mL) and pyridine (316 mg, 4.00 mmol) was added. The solution was extracted with water, dried over sodium sulphate, filtered and evaporated in vacuo. The residue was purified by flash column chromatography (SiO* ethyl acetaterheptane 50:50), yielding the title compound (490 mg, 69% yield) as a white solid. 1H NMR (300MHz, CDCI3): S = 1.43 (s, 6H), 2.74 (sf 2H), 3.45 (br.s, 3H), 7.14 (br.s, 1H), 7.26 (m, 1 H)f 7.38 (m, 4H), 7.76 (br.d, 1H), 8.39. (s, 1H); HPLC-MS (Method A): m/z = 354 (M+H)+; Rt = 3.35 min. Example 497 Methyl-phenyl-carbamic acid 5-[3,3-dimethyI-5-(4-methyI-piperazin-1 -yI)-5-oxo-pentanoy!amino]-pyridin-2-yI ester Thionyl chloride (56 microL, 0.78 mmol) was added to a stirred solution of 3,3-dimethyl-4-[6-(methyl-phenyi-rarbamoyloxy)-pyridin-3-ylcarbamoy!]-butyric acid (0.15 g, 0.39 mmol) in di-chloromethane (5 mL) and 2 drops of dimethylformamide. After stirring for 10 minutes N-methylpiperazine (1. mL) was added and stirring was continued for 2 hours. The solvent was evaporated in vacuo. The residue was redissolved in dichloromethane and extracted with water, dried over sodium sulphate, filtered and evaporated in vacuo. The crude product was purified by filtration over a short column (Si02, ethyl acetate followed by acetone) yielding the title compound (93 mg, 51% yield) as a thick oil. 1H NMR (300MHz, CDCI3): 5 = 1.11 (s, 6H), 2.32 (s, 3H), 2.43 (m, 8H), 3.42 (br.s, 3H), 3.61 (m, 2H), 3.74 (m, 2H), 7.00 (br.s, 1H), 7.38 (dt 4H), 8.21 (dd, 1H), 8.47 (d, 1H)f 10.90 (s, 1H); HPLC-MS (Method A): mfe = 468 (M+H)+; Rt = 2.20 min. Example 498 Methyl-phenyl-carbamic acid 5-[3,3-dime^ ester Thionylchloride (237 microL, 3.27 mmol) was added to a stirred solution of 3,3-dimethy!-4«[6-(methyl-phenyl-carbamoyIoxy)-pyridin-3-ylcarbamoyl]-butyric acid (0,63 g, 1.63 mmol) in dichloromethane (10 mL). After stirring for 10 minutes the solution was divided into 4 equal portions of acid chloride. To one portion was added 2-aminopyridine (0.5 mL) and after stirring for 2 hours at room temperature the crude product was purified by flash column chromatography (SiOa, ethyl acetate followed by ethyl acetate:acetone 90:10), yielding the title compound (105 mg, 56% yield). 1H NMR (300MHz, CDCl3): 8 = 1.09 (s, 6H)f 2.36 (s, 2H), 2,38 (s, 2H), 3.44. (br.s, 3H), 6.95 (br.s, 1H), 7.26 (m, 2H), 7.38 (m, 4H), 8.05 (dd, 1H), 8.10 (dt, 1H), 8.30 (m, 2H), 8.67 (d, 1H); HPLC-MS (Method A): mfe = 462 (M+H)+; Rt = 2.52 min. Example 499 Methyl-phenyi-rarbamic add 5-@^ yl ester Thionylchloride (237 microL, 3.27. mmol) was added to a stirred solution of 3,3-dimethyl-4-[5- (methyl-phenyi-rarbamoyloxy)-pyridin-3-ylcaft^ acid (0.63 g, 1.63 mmol) in di- chloromethane (10 mL). After stirring for 10 minutes the. solution was divided into 4 equal portions of acid chloride. To one portion was added morpholine (0.5 mL) and after stirring for 2 hours at room temperature the crude product was purified by flash column chromatography (Si02), yielding the title compound (117 mg, 63% yield). 1H NMR (300MHz, CDCI3): 5= 1.11 (s, 6H), 2.44 (s, 4H), 3.42 (br.s, 3H), 3.59 (m, 2H), 3.70 (m, 6H), 7.00 (br.s, 1H), 7.24 (m, 1H), 7.38 (d, 4H), 8.21 (dd, 1H), 8.45 (d, 1H), 10.76 (s, 1H); HPLC-MS (Method A): m/z = 455 (M+H)+; Rt = 2.87 min. Example 500 Methyl-phenyl-carbamic acid 5-[4«(2-dimethyIamino-ethyIcarbamoyl)-3)3-dimethy!-butyrylamino]-pyridin-2-yl ester Thionylchloride (237 microL, 3.27 mmol) was added to a stirred solution of 3r3-dimethyl-4-[6-(methyl-phenyl-carbamoyloxy)-pyridin-3-ylcarbamoyI]-butyric acid (0.63 g, 1.63 mmol) in di-chloromethane (10 mL). After stirring for 10 minutes the solution was divided into 4 equal portions of acid chloride. To one portion was added N.N-dimethylethylenediamine (0.5 mL) and after stirring for 2 hours at room temperature the crude product was purified by flash column chromatography (Si02), yielding the title compound (74 mg, 39% yield). 1H NMR (300MHz, CDCI3): 5 = 1.10 (s, 6H), 2.22 (s, 2H), 2.27 (s, 6H), 2.44 (m, 4H), 3.37 (m, 2H), 3.43 (br.s, 3H), 6.60 (br.t, 1H), 7.00 (br.s, 1H), 7.25 (m, 1H), 7.38 (d, 4H), 8.21 (dd, 1H), 8.46 (d, 1H), 10.70 (s, 1H); HPLC-MS (Method A): m/z = 456 (M+H)+; Rt = 1.93 min. Example 501 (General procedure 12) 4-[Methyl-(2-pyridin-4-yI-ethyl)-amino]-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI ester The title product was prepared from methyI-piperidine-4-yl-(2-pyridin-4-yl-ethyl)-amine and 4-(5-trifluoramethyl-pyridin-2-yloxy)-phenyl chloroformate, 3 equivalent of diisopropylamine was added, preparative HPLC (method C) (15%, colourless oil). HPLC-MS m/z = 501.4 (M+1), Rt 2.04 min. Example 502 (General procedure 12) 4-(Cyclopropyl«pyridin-4-ylmethyl-amino)-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl- pyridin-2-yloxy)-phenyl ester The title product was prepared from cyclopropyl-piperidine«4-yl-pyridin-4-ylmethyl-amine and 4-(5-trifIuoromethyI-pyridin-2-yIoxy)-phenyI chloroformate, 3 equivalent of diisopropylamine was added, solvent: dimethylformamide. The crude reaction mixture was evaporated without addition of acetic acid, preparative HPLC (method C) (19%, yellow oil). HPLC-MS m/z = (M+1), Rt:2.82min. Example 503 (General procedure 12) 4-[Cyclopropyl-(2-fluoro-benzyl)-amino]-piperidine-1-carboxyIicacid 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl ester The title product was prepared from cyclopropyl-(2-fluoro-benzy[)-piperidin-4-yI-amine and 4-(5-trifIuoromethyI-pyridin-2-yloxy)-phenyl chloroformate, 3 equivalent of diisopropylamine was added, solvent; dimethylformamide. The crude reaction mixture was evaporated without addition of acetic acid, preparative HPLC (method C) (60%, colourless oil). HPLC-MS m/z = (M+1), Rt:3.02min. Example 504 (General procedure 12) 4-(Cyclopropyl-pyridin-3-ylmethyl«amino)-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yIoxy)-phenyI ester The title product was prepared from cyclopropyl-piperidin-4-yl-pyridin-3-ylmethyl-amine and 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI chloroformate, 3 equivalent of diisopropylamine was. added, solvent: dimethylformamide. The crude reaction mixture was evaporated without addition of acetic acid, preparative HPLC (method C) (26%, light brown solid). HPLC-MS m/z = (M+1) 513.3, Rt: 2.64 min. Example 505 (General procedure 12) 4-(Cyclopropylmethyl-pyridin-3-ylmethyl-amino)-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl"pyridin-2-yloxy)-phenyl ester The title product was prepared from cyclopropylmetiiyl-piperidin-4-yl-pyridin-3-ylmethyl-amine and 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate, 3 equivalent of diisopropylamine was added, solvent dimethylformamide. The crude reaction mixture was evaporated without addition of acetic acid, preparative HPLC (method C) (47%, off-white solid. HPLC-MS m/z = (M+1) 513.3, Rt: 2.70 min. Example 506 (General procedure 12) 4-(C^clopropylmethyl-pyridin-3-y!methy!-amino)-piperidine-1 -carboxylic acid 4-(5-trif!uoromethyl~pyridin-2-yloxy)-phenyl ester The title product was prepared from cyclopropyImethyI-piperidin-4-yl-pyridin-4-ylmethy!-amine and 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyI chloroformate, 3 equivalent of diiso-propylamine was added, solvent: dimethylformamide. The crude reaction mixture was evaporated without addition of acetic acid, preparative HPLC (method C) (22%, off-white solid. HPLC-MS m/z = (M+1) 513.3, Rt: 2.70 min. Example 507 (General procedure 12) 4-(4-Hydroxy-piperidin-1-ylmethyI)-piperidine-1-carboxyIicacid4-(5-trifiuoromethyl-pyridin«2-yloxy)-phenyl ester The title product was prepared from 1-piperidin-4-yimethyl-piperidine-4-ol (released form the correspondent hydrochloride by a standard procedure) and 4-(5-trifluoromethyI-pyridin-2-ybxy)-phenyl chloroformate, preparative HPLC (method C) (reaction performed in a mixture of dichloromethane and dimethylformamide). 1.7 M HCI in ethyl acetate was added to the pooled fractions containing the title product, and the fractions was evaporated to dryness (92%, white solid. HPLC-MS m/z = (M+1) 480.4, Rt: 2.38 min. Example 508 (General procedure 11) 4-{3-[1 -(2-Hydroxy-ethyi)-piperidin-4-yi]-propyI}-piperidine-1 -carboxylic acid 4-(5- trifluoromethyl-pyridin-2-yioxy)-phenyl ester The title product was prepared from 2-[4-(3-piperidin-4-yl-propy!)-piperidin-1-yr|-ethanol and 4-(5-trifluoromethyl-pyridin-2-yloxy)-phenyl chloroformate. The reaction mixture was evaporated, diethyl ether (30 ml) was added and the title product isolated by filtration, washed with diethyl ether and ried to give (67%, white solid. HPLC-MS m/z = (M+1) 536.2, Rt: 3.39 min. Example 509 (General procedure 12) 4-(2-PyrroIidin-1 -yl-ethyl}-piperidine-1 -carboxylic acid 4-(5-trifluoromethyl-pyridin-2-yloxy)- phenyl ester The title product was prepared from 2-[4-(3-piperidin-4-yI-propyI)-piperidin-1-yI3-ethanoI and 4-(5-trifluoromethyI-pyrJdin-2-yloxy)-phenyl chloroformate, preparative HPLC (method C). 1.7 M HCI in ethyl acetate was added to the pooled fractions containing the title product, and the fractions was evaporated to dryness (65%, white solid). HPLC-MS m/z = (M+1) 464.1, Rt: 2.99 min. Example 510 (General procedure 16) Methyl-o-tolyl-carbamic acid 4-iodo-pyrazol-1-yl ester The title compound was prepared from 1-hydroxy-4-iodopyrazole and methy!-o-tolylamine. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (40%, oil). HPLC-MS : mfz = 380.1 (M+23); Rt = 4.05 min. Example 511 (General procedure 16) Methyl-m-tolyl-carbamic acid 4-iodo-pyrazoM-yI ester The title compound was prepared from 1-hydroxy-4-iodopyrazole and methyl-m-tolylamine. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (44%, oil). HPLC-MS : mfz = 380.1 (M+23); Rt = 4.13 min. Example 512 (General procedure 16) Methyl-p-tolyl-carbamic acid 4-iodo-pyrazol-l-yI ester The title compound was prepared from 1-hydroxy-4-iodopyrazole and methyl-p-tolylamine. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (55%, oil). HPLC-MS : mfz = 380.1 (M+23); Rt = 4.13 min. Example 513 (General procedure 16) (3-Chloro-phenyI)-methyl-carbamic acid 4-iodo-pyrazoI-1-yl ester The title compound was prepared from 1-hydroxy-4-iodopyrazole and 3-chlorophenyl-methylamine. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (54%, oil). HPLC-MS : mlz = 399.9 (M+23); R* = 4.28 min. Example 514 (General procedure 16) (3-Fluoro-phenyI)-methyl-carbamic acid 4-iodo-pyrazoM-yl ester The title compound was prepared from 1-hydroxy»4-iodopyrazoIe and 3-fIuorophenyl-methylamine. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (51%, oil). HPLC-MS : mlz = 384.0 (M+23); Rt = 4.00 min. Example 515 (General procedure 16) 4-(3-TrifluoromethyI-pyridin-2-yl)-piperazine-1-carboxyIic acid 4-iodo-pyrazol-1-yI ester The title compound was prepared from 1-hydroxy-4-iodopyrazoie and 1-(3-trifluoromethylpyridin-2-yI)piperazine. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (13%, oil). HPLC-MS : mlz = 468.1 (M+1); Rt = 4.38 min. Example 516 (General procedure 16) 2f6-Dimethyl-morpholine-4-carboxylic acid 4-iodo-pyrazoI-1~yI ester The title compound was prepared from 1-hydroxy-4~iodopyrazoIe and 2,6-dimethyImorphoIin. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (11%, oil). HPLOMS: mlz = 374.0 (M+23); Rt = 3.24 min. Example 517 (General procedure 16) Thiomorpholine-4-carboxylic acid 4-iodo-pyrazoM-yI ester The title compound was prepared from 1-hydroxy-4-iodopyrazole and thiomorpholin. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (27%, oil). HPLC-MS: m!z= 340.0 (M+1); Rt = 3.22 min. Example 518 (General procedure 16) 3r5-DimethyI-morpholine-4-carboxyIic acid 4-iodo-pyrazol-1-yi ester The title compound was prepared from 1-hydroxy-4~iodopyrazole and 3,5-dimethylmorphoiin. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (15%, oil). HPLC-MS : m/z= 352.0 (M+1); Rt = 3.17 min. Example 519 (General procedure 16) Piperidine-1-carboxy!ic acid 4-iodo-pyrazoI-1-yl ester The title compound was prepared from 1-hydroxy-4-iodopyrazoIe and piperidine. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (46%, oil). HPLC-MS : mlz = 322.0 (M+1); Rt = 3.38 min. Example 520 (Genera! procedure 16) Methy!-o-tolyl-carbamic acid 2-chloro-imidazo!-1-yI ester The title compound was prepared from 1-hydroxy-2-chloroimidazole, hydrochloride and methyl-o-tolyiamine. The crude product was purified by preparative HPLC (Gilson) (4%, red oil). HPLC-MS : mlz = 266.0 (M); Rt = 3.28 min. Example 521 (General procedure 16) (3-Fluoro-phenyl)-methyl-carbamic acid 2-chloro-imidazoM-yl ester The title compound was prepared from 1-hydroxy-2-chloroimidazole, hydrochloride and 3-fluorophenyl-methylamine. The crude product was purified by preparative HPLC (Gilson) (2%, oil). HPLC-MS : mlz = 270.1 (M); Rt = 3.08 min. Example 522 Methyl-phenyl-carbamic acid 4-iodo-phenyl ester To a solution of 4-iodophenol (30 mmol) in CH2CI2 (100 mL) was added N-methyl-N-phenylcarbamoyi chloride (27 mmol) and diisopropylethylamine (60 mmol) at room temperature.. The reaction mixture was stirred for 16 hours at rt, added CH2CI2 (20 mL) and washed with aqueous citric acid (5%), aqueous Na2C03 and brine. The organic phase was dried (MgS04) and evaporated to give the crude product which was purified by FC (Quad flash 40 EtOAc-Heptane) to give 6.55 g (69%) of the. title compound as light brown crystals. 1H NMR (300MHz; CDCI3): 8 3.38 (brs, 3H), 6.88 (d, 2H), 7.22-7,46 (m, 5H), 7.62 (d, 2H); HPLC-MS : mlz = 354.0 (M+1); Rt = 4.54. min. Example 523 (General procedure 20) Methyl-phenyl-carbamic acid 4,-trifluoromethyl-biphenyl-4-yI ester The title compound was prepared from methyl-phenyl-carbamic acid 4-iodo-phenyl ester and 4-trifluoromethylphenyIboronic acid. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane 1:9) (42%, light brown crystals). HPLC-MS : mlz = 372.1 (M+1); Rt = 5.19 min. Example 524 (General procedure 20) Methyl-phenyl-carbamic acid 4,-trifluoromethoxy-biphenyI-4-yi ester The title compound was prepared from methyl-phenyl-carbamic acid 4-iodo-phenyl ester and 4-trifIuoromethoxyphenylboronic acid. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane 1:9) (17%, brown oil). HPLC-MS : m/z= 388.1 (M+1); Rt= 5.27 min. Example 525 (General procedure 20) Methyl-phenyl-carbamic acid 4-pyridin-3-yl-phenyl ester The title compound was prepared from methyl-phenyl-carbamic acid 4-iodo-phenyl ester and pyridine-3-boronic acid. The crude product was purified by preparative HPLC (Gilson) (5%, brown oil). 1H NMR (300MHz; CDCI3): 8 3.46 (br s, 3H), 7.29-7.46 (m, 7H), 7.61 (d, 2H), 7.88 (dd, 1H), 8.41 (d, 1H), 8.78 (d, 1H); HPLC-MS : mlz = 305.1 (M+1); Rt = 2.99 min. Example 526 (General procedure 20) Methyl-phenyl-carbamic acid 4-(5-chloro-thiophen-2-yI)-phenyl ester The title compound was prepared from methyl-phenyl-carbamic acid 4-iodo-phenyl ester and 5-chloro-2-thiopheneboronic acid. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane 1:9) (53%, pink crystals). 1H NMR (300MHz; CDCI3): 5 3.43 (br s, 3H), 6.87 /d, 1H), 7.00 (d, 1H), 7.13 (br d, 2H), 7.26-7.48 (m, 7H); HPLC-MS: mlz = 344.0 (M+1); Rt = 5.16 min. Example 527 (General procedure 20) Methyl-phenyl-carbamic acid 4,-benzylsuIfarnoyI-biphenyi-4-yl ester The title compound was prepared from methyl-phenyl-carbamic acid 4-iodo-phenyl ester and 4-benzyIsulfamoyIbenzeneboronic acid. The crude product was purified by preparative HPLC (Gilson) (35%, pink crystals). HPLC-MS : m!z = 473.0 (M+1); Rt = 4.80 min. ■ Example 528 Methyl-phenyl-carbamic acid 4-styryl-phenyl ester Styrene (1.2 mmol), N-methyldicyclohexyiamine (1.2 mmol), Pd2(dba)3 (0.03 mmol), Pd(P(f-Bu)3)2 (0.06 mmol) and methyl-phenyl-carbamic acid 4-iodo-phenyl ester (1.0 mmol) were added to a Schlenk tube under nitrogen. The Schlenk tube was evacuated and refilled with nitrogen five times. Then dioxane (2 mL) was added and the reaction mixture was stirred at 70 °C for 8 h. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) giving the title compound in 17% yield as colorless crystals. HPLOMS : mfz = 330.1 (M+1); Rt= 5.08 min. Example 529 Methyl-phenyl-carbamic acid 4-phenyIethynyl-phenyI ester Phenylacetylene (1.2 mmol), diisopropylarnine (1.2 mmol), Cul (0.03 mmol), Pd2(dba)3 (0.03 mmol), Pd(P(M3u)3>2 (0.06 mmol) and methyl-phenyl-carbamic acid 4-iodo-phenyl ester (1.0 mmol) were added to a Schlenk tube under nitrogen. The Schlenk tube was evacuated and refilled with nitrogen five times. Then dioxane (2 mL) was added and the reaction mixture was stirred at 70 °C for 8 h. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) giving the title compound in 41% yield as brown oil. HPLC-MS : mlz= 328.1 (M+1); Rt = 5.07 min.. Example 530 3-[4-(Methyl-phenyl-carbamoyloxy)-phenyri-acrylic acid methyl ester Methylacrylate (1.2 mmol), N-methyldicyclohexylamine (1.2 mmol), Pd2(dba)3 (0.03 mmol), Pd(P(f-Bu)3)2 (0.06 mmol) and methyl-phenyl-carbamic acid 4-iodo-phenyl ester (1.0 mmol) were added to a Schlenk tube under nitrogen.. The Schlenk tube was evacuated and refilled with nitrogen five times. Then dioxane (2 mL) was added and the reaction mixture was stirred at 70 °C for 8 h. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) giving the title compound in 70% yield as a yellow solid. HPLC-MS : m/z= 312.1 (M+1); Rt = 4.19 min. Example 531 (General procedure 8) Methyl-phenyl-carbamic acid 5-phenyIsuIfanyl-pyrazoI-1-yI ester The title compound was prepared from 1-hydroxy-5-phenyIsulfanylpyrazole and N-methyl-N-phenylcarbamoyl chloride. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (80%, oil). 1H NMR (300MHz; CDC!3): S 3.36 (br s, 3H), 6.47 (d, 1H) 7.16-7.32 (m, 10H), 7.40 (df 1H); HPLC-MS : mlz = 326.0 (M+1); Rt = 4.42 min. Example 532 (General procedure 21) Methyl-phenyl-carbamic acid 4-(toIuene-4-sulfonylamino)-phenyI ester The title compound was prepared in 8% yield as a clear oil using toluenesulfonyl chloride as the aryl sulfonyl chloride. HPLC-MS : mtz = 397.1 (M+1); R{ = 4.13 min Example 533 (General procedure 21) Methyl-phenyl-carbamic acid 4-(5-pyridin-2-yl-thiophene-2-sulfonylamino)-phenyl ester The title compound was prepared in 7% yield as an oil using 5-pyridin-2-yl-thiophene-2-sulfonyl chloride as the aryl sulfonyl chloride. HPLC-MS : m/z= 466.1 (M+1); Rt = 4.23 min. Example 534 (General procedure 21) Methyl-phenyl-carbamic acid 4-(1-methyHH-imidazole-4-sulfonylamino)-phenyl ester The title compound was prepared in 21% yield as crystals using 1-methyMH-imidazole-4-sulfonyl chloride as the aryl sulfonyl chloride. HPLC-MS :m/z= 387.1 (M+1); Rt= 3.14 min. Example 535 (General procedure 21) tfethyl-phenyl-carbamic acid 4-(2f5-dichlorothiophene-3-suIfonylamino)-phenyI ester The title compound was prepared in 2% yield as an oil using 2,5-dichloro-thiophene-3-sulfonyl chloride as the aryl sulfonyl chloride. rIPLC-MS : m/z = 458.6 (M+1); Rt = 4.38 min. Example 536 (General procedure 21) Methyl-phenyl-carbamic acid 4-(5-chloro-1,3-dimethyl-1 H-pyrazo!e-4-sulfonylamino)-phenyI ester The title compound was prepared in 3% yield as an oil using 5-chloro-1,3-dimethyl-1H-pyrazole-4-sulfonyl chloride as the aryl sulfonyl chloride. HPLC-MS : m/z = 435.1 (M+1); Rt = 3.74 min. Example 537 (General procedure 21) Methyl-phenyl-carbamic acid 4-(5-dimethylamlno-naphthalene-1-sulfonylamino)-phenyl ester The title compound was prepared in 14% yield as orange crystals using 5-dimethyIamino-naphthalene-1 -sulfonyl chloride as the aryl sulfonyl chloride. HPLC-MS : m/z = 476.0 (M+1); Rt = 4.48 min. Example 538 (General procedure 21) 2-[4-(Methyl-phenyl-carbamoyIoxy)-phenyisuIfamoyl]-benzoic acid methyl ester The title compound was prepared in 48% yield as a yellow oil using 2-chlorosulfonyl-benzoic acid methyl ester as the aryl sulfonyl chloride. HPLC-MS : m/z = 441.1 (M+1); R{ = 4.19 min. Example 539 (General procedure 21) Methyl-phenyl-carbamic acid 4-(3I4-difluoro-benzenesulfonylamino)-phenyl ester The title compound was prepared in 1% yield as a clear oil using 3,4-difluoro-benzenesulfonyl chloride as the aryl sulfonyl chloride. HPLC-MS : mlz = 419.1 (M+1); Rt = 4.23 mln. Example 540 (General procedure 22 and 1) Methyl-phenyl-carbamic acid 4-pyridin-2-ylmethyl-phenyI ester 4-Pyridin-2-yImethyI-pheno! was prepared following general procedure PVe3 using pyridine-2-carboxaldehyde. Subsequent carbamoylation using general procedure 1 (CH2CI2 was used as solvent) produced the crude product which was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (86%, oil). 1H NMR (400MHz; CDCI3): 8 3.40 (br s, 3H), 4.14 (s, 2H), 7.04-7.12 (m, 4H), 7.21-7.26 (m, 3H)f 7.32-7.40 (m, 4H), 7.55 (t, 1H), 8.52 (df 1H). Example 541 (General procedure 22 and 1) Methyl-phenyl-carbamic acid 4-pyridin-3-yimethyl-phenyl ester 4-Pyridin-3-ylmethyl-phenol was prepared following general procedure PVe3 using pyridine-3-carboxaldehyde. Subsequent carbamoylation using general procedure 1 (CH2CI2 was used as solvent) produced the crude product which was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (50%, oil). 1H NMR (400MHz; CDCI3): 5 3.42 (brs, 3H), 3.96 (s, 2H). 7.03-7.42 (m, 11H), 8.46 (d, 1H), 8.49 (dp 1H). Example 542 (General procedure 22 and 1) Methyl-phenyl-carbamic acid 4-(4-trifIuoromethyI-benzyI)-phenyl ester 4-(4-TrifIuoromethyl-benzyl)-phenol was prepared following general procedure PVe3 using 4-trifluoromethylbenzaldehyde. Subsequent carbamoylation using general procedure 1 (CH2CI2 was used as solvent) produced the crude product which was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (92%, oil). 1H NMR (400MHz; CDCI3): S 3.42 (br s, 3H)( 4.00 (s, 2H)f 7.06 (br s, 2H), 7.13 (d, 2H), 7.24-7.40 (m, 7H), 7.52 (d, 2H). Example 543 (General procedure 22 and 1) Methyl-phenyl-carbamic acid 4-thiophen-3-ylmethyl-phenyl ester 4-Thiophen-3-ylmethyl-phenol was prepared following general procedure PVe3 using thio- phene-3-carboxaldehyde. Subsequent carbamoylation using general procedure 1 (CH2CI2 was used as solvent) produced the crude product which was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (83%, oil). 1H NMR (400MHz; CDC!3): S 3.42 (bs, 3H), 3.95 (s, 2H), 6.86-7.39 (m, 12H). Example 544 (General procedure 22 and 1) Methyl-phenyl-carbamic acid 4-thiophen-2-ylmethyl-phenyl ester 4-Thiophen-2-ylmethyl-phenol phenol was prepared following general procedure PVe3 using thiophene-3-carboxaidehyde. Subsequent carbamoylation using genera! procedure 1 (CH2C!2 was used as solvent) produced the crude product which was purified by flash chromatography (Quad flash 12, EtOAc-heptane) (83%, oil). 1H NMR (400MHz; CDC!3): S 3.40 (br s, 3H), 4.13 (s, 2H), 6.78 (dd, 1H), 6.90. (dd, 1H), 7.04 (brd, 2H), 7.13 (dd, 1H), 7.20-7.39 (m, 7H). HPLC-MS : m/z- 324.1 (M+1); Rt = 4.82 min. Example 545 4-Hydroxy-piperidine-1-carboxyIic acid 4-[2-(toIuene-4-suIfonyIamino)-ethyI]-pheny] ester N-Boc protected tyramin (10 mmol), triethylamine (10 mmol) and 3-[4-(tert-Butyl-dimethyl-silanyloxy)-piperidine-1-carbonyI]-1-methyI-3H-imidazoI-1-ium; iodide (10 mmol) in MeCN (25 mL) was stirred at room temperature for 16 hours. Acetonitrile was removed by evaporation and the crude product was purified by flash chromatography (Quad flash 40, EtOAc-heptane 1:2) providing 72% 4-tert-butyIsilanyloxy-piperidine-1-carboxyIic acid 4-(2-tert-butoxycarbony!amino-ethyI)-phenyl ester. This was deprotected by stirring with a 3.2 M solution of HCI in Et20 (50 mL) for 3 h at rt and subsequently washed with ether to give 91% of 4-(4-hydroxy-piperidine-1-carbonyloxy)-phenyI-ammonium; chloride as a solid. This compound was N-tosyiated as described for methyl-phenyl-carbamic acid 4-[2-(toluene-4-sulfonylamino)-ethy[]-phenyl ester to give the title compound in 26% yield as yellow crystals after purification by flash chromatography (Quad flash 12, ChfeCtrMeOH 95:5). HPLC-MS : mfc= 391.0 (M+1); Rt= 3.04 min. Example 546 4-Hydroxy-piperidine-1 -carboxylic acid 4-[2-(5-pyridin-2-yI-thiophene-2-sulfonylamino)-ethyI]-phenyi 4-(4-Hydroxy-piperidine-1-carbonyIoxy)-phenyl»ammonium; chloride (see above) was N- sulfonylated as described for methyl-phenyl-carbamic acid 4-[2-(5-pyridin-2-yl-thiophene-2-sutfonylamino)-ethyO-phenyl ester to give the title compound in 59% yield as an oil after purification by preparative HPLC (Gilson). HPLC-MS : m/z = 488.0 (M+1); Rt = 3.10 min. Example 547 4-Hydroxy-piperidine-1 -carboxylic acid 4-(5-pyridin-2-yl-thiophene-2-sulfonyiamino)-phenyl ester N-Boc protected 4-aminophenol (10 mmol), triethylamine (10 mmol) and 3-[4-(tert-ButyI-dimethyl-siIanyloxy)-piperidine-1-carbonyI]-1«methyl-3H-imida2ol-1-ium; iodide (10 mmol) in MeCN (25 mL) was stirred at room temperature for 16 hours. Acetonitrile was removed by evaporation and the crude product was purified by flash chromatography (Quad flash 40, EtOAc-heptane 1:2) providing 64% 4-tert-butyisilanyioxy-piperidine-1-carboxylic acid 4-tert-butoxycarbonylamino-phenyl ester. This was deprotected by stirring with a 3.2 M solution of HCI in Et20 (50 mL) for 3 h at rt and subsequently washed with ether to give 91 % of 4-(4-Hydroxy-piperidine-1-carbonyloxy)-phenyl-ammoniurn; chloride as a hygroscopic solid. This compound was N-sulfonylated as described for methyl-phenyl-carbamic acid 4-[2-(5-pyridin-2-yl-thiophene-2-sulfonylamino)-ethy!]-phenyI ester to give the title compound in 1% yield as crystals after purification by preparative HPLC (Gilson). HPLC-MS :/77/z= 482.8 (M+1); Rt = 1.01 min. Example 548 Methyl-phenyl-carbamic acid 4-[2-(4-amino-benzenesulfonylamino)-ethyI]-phenyl ester Methyl-phenyl-carbamic acid 4-[2-(4-nitro-benzenesulfonylamino)-ethy(]-phenyl ester, 5% palladium on carbon, and ethanol were stirred under hydrogen at 1 bar and rt for 16 h. Filtration and removal of ethanol produced the title compound in 94% yield as an oil. HPLC-MS: mlz = 426.1 (M+1); Rt= 3.61 min. Example 549 Methyl-phenyl-carbamic acid 4-{2-[(pyridine-3-carbonyl)-amino]-ethyI}-phenyl ester A solution of 3-pyridinecarboxylic acid (0.3 mmol), EDAC (0.36 mmol) and triethylamine (0.36 mmol) in CH2CI2 (10 mL) was added N-hydroxybenzoetriazofe and N-methyl-N-phenyl-carbamic acid 4-(2-amino-ethyl)phenyl ester as its TFA salt (0.3 mmol). The mixture was stir- stirred 16 h at rt and purified by preparative HPLC (Gilson) to give the title compound in 15% yield as an oil. HPLC-MS: m/z= 376.1 (M+1); Rt = 3.01 min. Example 550 Methyl-phenyl-carbamic acid 4-[2-(2-dimethylamino-acetyIamino)-ethyI]-phenyl ester A solution of N.N-dimethyiglycine, HCI (0.3 mmol), EDAC (0.36 mmol) and triethylamine (1.0 mmol) in CH2CI2 (10 mL) was added N-hydroxybenzoetriazole and N-methyl-N-phenyl-carbamic acid 4-(2-amino-ethyI)phenyl ester as its TFA salt (0.3 mmol). The mixture was stirred 16 h at rt and purified by preparative HPLC (Gilson) to give the title compound in 66% yield as an oil. HPLC-MS : mlz = 356.4 (M+1); Rt = 2.09 min. Example 551 (General procedure 23) Methyl-phenyl-carbamic acid 2-(toluene-4-sulfony!)-1,2,3,4-tetrahydro-isoquinolin-7-yl ester The title compound was prepared using methyl-phenyl-carbamic acid 4-[2-(toluene-4-suifonylamino)-ethyI]-phenyl ester as the sulfonamide. The crude product was purified by flash chromatography (Quad flash 12, EtOAc-heptane 2:3) (71%, yellow oii). HPLC-MS : m/z= 437.4 (M+1); Rt = 4.43 min. Example 552 Methyl-phenyl-carbamic acid 4-[4-(2-pyrroIidin-1-yl-ethoxy)-benzyI]-phenyI ester To a stirred solution of 1-[2-(4-bromo-phenoxy)-ethy!]-pyrrolidine (2.89 g, 10.7 mmol) in THF (30 mL) was added dropwise 1.6 M solution in hexanes n-BuLi (7 mL, 10.2 mmol) over a 5-min period at -78°C. The mixture was stirred at -78°C for 15 min before 4-trimethylsilyloxybenzaldehyde (2.08 g, 10.7 mmol) was added. The mixture was allowed to warm to rt during 20 min and quenched with water. Extraction with CH2CI2, drying (MgS04), filtration and evaporation provided the crude diarylmethanol which was dissolved in CH2Ci2 (30 mL) and stirred with triethylsilane (4 mL) and TFA (5 mL) for 16 h at rt. Evaporation gave 3.0 g (84%) 4-[4-(2-pyrrolidin-1-yl-ethoxy)-benzyl]-phenol. This was carbamoylated using general procedure. 1 (CH2CI2 was used as solvent) to give the title product after purification by preparative HPLC (Gilson) (35%, oil). HPLC-MS : m/z = 431.5 (M+1); Rt = 2.93 min. Example 553 (General procedure 24) 4-Hydroxy-piperidine-1-carboxylic acid 4-pyridin-2-ylmethyl-phenyl ester The title compound was prepared as its hydrochloride using 4-pyridin-2-yimethy!-phenol as the phenol. 1H NMR (300MHz; D20): S 1.50 (br s, 2H), 1.90 (df 2H), 3.04-3.27 (m, 2H), 3.78-4.08 (m, 3H), 4.41 (s, 2H), 7.07 (d, 2H), 7.30 (df 2H), 7.79-7.85 (m, 2H), 8.40 (dt, 1H), 8.55 (d, 1H). Example 554 (Genera! procedure 24) 4-Hydroxy-piperidine-1-carboxyIic acid 4-pyridin-3-ylmethyI-phenyl ester The title compound was prepared as its hydrochloride using 4-pyridin-3-yImethyl-phenol as the phenol. 1H NMR (300MHz; D20): 8 1.48 (br s, 2H), 1.90 (d, 2H), 3.03-3.26 (m, 2H), 3.80-4.05 (m, 3H), 4.18 (s, 2H), 7.03 (d, 2H), 7.25 (d, 2H), 7.40 (dd, 1H), 8.40 (d, 1H), 8.54-8.57 (m, 2H). Example 555 (General procedure 24) 4-Hydroxy-piperidine-1-carboxylic acid 4-(4-trifluoromethyI-benzyI)-phenyi ester The title compound was prepared using 4-(4-trifluoromethyl-benzyl)-phenol as the phenol. 1H NMR (300MHz; D20): 5 1.43-1.55 (m, 2H), 1.76-1.88 (m, 2H), 3.10-3.29 (m, 2H), 3.79-3.94 (m, 5H), 6.97 (d, 2H), 7.08 (d. 2H), 7.20 (d, 1H), 7.45 (d, 2H). Example 556 (General procedure 23) Methyl-phenyl-carbamic acid 2»[4-(2-pyrroIidin-1-yl-ethoxy)-benzenesulfonyl]-1,2,3,4- tetrahydro-isoquinolin-7-yI ester The title compound was prepared using methyl-phenyl-carbamic acid 4-{2-[4-(2-pyrrolidin-1-yI-ethoxy)-benzenesulfonylamino]-ethyI}-phenyl ester as the sulfonamide. The crude product was purified by preparative HPLC (Gilson) and isolated as its TFA salt (45%, foam). HPLC-MS : m/z= 536.2 (M+1); Rt = 3.10 min. Example 557 Methyl-phenyl-carbamic acid 4-{2-[(1-methyI-piperidine-4-carbonyl)-amino]-ethyI}-phenyl ester A solution of 1-methylpiperidine-4-carboxylic acid (0.3 mmol), EDAC (0.36 mmol) and triethy-lamine (1.0 mrnol) in CH2CI2 (10 mL) was added N-hydroxybenzoetriazole and N-methyl-N-phenyl-carbamic acid 4-(2-amino-ethyI)phenyl ester as its TFA salt (0.3 mmol). The mixture was stirred 16 h at rt and purified by preparative HPLC (Gilson) to give the title compound in 5% yield as an oil. HPLC-MS : m/z= 396.4 (M+1); Rt = 2.03 min. Example 558 (General procedure 23) Methyl-phenyl-carbamic acid 2-(3,4-difluoro-benzenesuIfonyl)-1,2,3,4-tetrahydro-isoquinoIin- 7-yI ester The title compound was prepared using methyl-phenyl-carbamic acid 4-[2-(3,4-difluoro-benzenesu!fonylamino)-ethyI]-phenyl ester as the sulfonamide. The crude product was purified by preparative HPLC (Gilson) (24%, oil). HPLC-MS : m/z= 481.0 (M+23); Rt= 4.73 min. Example 559 (General procedure 23) Methyl-phenyl-carbamic acid 1-methyl-2-(toluene-4-sulfony!)-1 ^^^-tetrahydro-isoquinoIin-T- yl ester The title compound was prepared using methyl-phenyl-carbamic acid 4-[2-(toluene-4-sulfonylamino)-ethyI]-phenyl ester as the sulfonamide and acetaldehyde in stead of formaldehyde. The crude product was purified by preparative HPLC (Gilson) (22%, brown oil). HPLC-MS : m/z = 451.5 (M+1); Rt = 4.43 min. Example 560 (General procedure 23) Methyl-phenyl-carbamic acid 2-[4-(4-methyl-piperazin-1-yl)-benzenesuIfonyl]-1,2,3,4- tetrahydro-isoquinolin The title compound was prepared using methyl-phenyl-carbamic acid 4-{2-[4-(4-methyl-piperazin-1-yl)-benzenesulfonylamino]-ethy(}-phenyi ester as the sulfonamide. The crude product was purified by preparative HPLC (Gilson) and isolated as its TFA salt (79%, crystals). HPLOMS : m/z= 521.5 (M+1); Rt= 2.65 min. Example 561 (General procedure 23) Methyl-phenyl-carbamic acid 1 -methyl-2-[4-(4-methyl-piperazin-1 -yl)-benzenesulfonyl]- 1,2,3,4-tetrahydro-isoquinoIin-7-yl ester The title compound was prepared using methyl-phenyl-carbamic acid 4-{2-[4-(4-methyl-piperazin-1-yI)-benzenesulfonyIamino]-ethyl}-phenyl ester as the sulfonamide and acetalde-hyde in stead of formaldehyde. The crude product was purified by preparative HPLC (Gilson) (12%, brown oil). HPLC-MS: mtz* 535.4 (M+1); Rt= 2.69 min. Example 562 3,3-Dimethyl-4-{2-[4-(methyl-pheny!-carbamoy^ A solution of 3,3-dimethylglutaric anhydride (0.3 mmol), diisopropylethylamine (0.30 mmol) and N-methyl-N-phenyl-carbamic acid 4-(2-amino-ethyI)phenyl ester as its TFA salt (0.3 mmol) in CH2CI2 (3 mL) was stirred 1 h at rt. The mixture was washed with water and brine, dried and evaporated to give the title compound in 95% yield as an oil. HPLC-MS : m/z = 413.2 (M+1); Rt = 3.20 min. Example 563 Methyl-phenyl-carbamic acid 4-{2-[4-(4-methyl-piperazin-1 -yl)-benzoylamino]-ethyI}-phenyl ester A solution of 4-(4-methylpiperazino)benzoic acid (0.3 mmol), EDAC (0.36 mmol) and triethyl-amine (1.0 mmol) in CH2CI2 (10 mL) was added N-hydroxybenzoetriazo!e and N-methyl-N-phenyl-carbamic acid 4-(2-amino-ethyI)phenyl ester as its TFA salt (0.3 mmol). The mixture was stirred 16 h at rt and purified by preparative HPLC (Gilson) to give the title compound in 54% yield as its crystalline hydrochloride after treatment with HCI in diethyl ether. HPLC-MS : mlz = 473.2 (M+1); Rt = 2.22 min. Example 564 Methyl-phenyl-carbamic acid 4-{2-[4-(4-methyI-piperazin-1 -ylmethy[)-benzoyiamino]-ethyl}-pheny! ester A solution of 4-(4-methylpiperazinyI)methyl benzoic acid (0.3 mmol), EDAC (0.36 mmol) and triethylamine (1.0 mmol) in CH2CI2 (10 mL) was added N-hydroxybenzoetriazole and N- methyl-N-phenyl-carbamic acid 4-(2-amino-ethyl)phenyI ester as its TFA salt (0.3 mmol). The mixture was stirred 16 h at rt and purified by preparative HPLC (Gilson) to give the title compound in 25% yield as its crystalline hydrochloride after treatment with HCI in diethyl ether.. HPLC-MS : mfz= 487.3 (M+1); Rt = 2.13 min. Example 565 Methyl-phenyl-carbamic acid 4-[2-(4,4-dimethyI-2,6-dioxo-piperidin-1-yI)-ethyl]-phenyI ester A solution of 3,3-dimethylglutaric anhydride (0.3 mmol), diisopropylethylamine (0.30 mmol) and N-methyl-N-phenyl-carbamic acid 4-(2-amino-ethyl)phenyI ester as its TFA salt (0.3 mmol) in CH2CI2 (3 mL) was stirred 1 h at rt. Thionylchloride (3 mmol) was added and the mixture was stirred for 2 h at rt. Addition of ethanol (5 mL) followed by evaporation to dryness gave a crude product which was purified by flash chromatography (Quad flash 12, EtOAc-heptane 1:1). This gave the title compound in 23% yield as crystals. Furthermore 3,3-dimethyI-4-{2-[4-(methyl-phenyl-carbamoyloxy)-pheny[]-ethylcarbamoyl}-butyricacid ethyl ester could be isolated in 27% yield as an oil (see characterization below) 1H NMR (400MHz; CDCI3): 5 1.04 (s, 6H), 2.47 (s, 4H), 2.79 (t, 2H), 3.42 (br s, 3H), 3.97 (t, 2H), 7.03 (br d, 2H), 7.21-7.28 (m, 3H), 7.33-7.41 (m, 4H). HPLC-MS : m/z = 395.2 (M+1); Rt = 4.23 min. Example 566 3,3-DimethyI-4-{2-[4-(methyl-phenyl-carbamoyIoxy)-phenyI]-ethylcarbamoyI}-butyricacid ethyl ester For experimental details, see preparation of methyl-phenyl-carbamic acid 4-[2-(4,4-dimethyl- 2,6-dioxo-piperidin-1 -yl)-ethyl]-phenyl ester. 1H NMR (400MHz; CDCl3): 8 1.05 (s, 6H), 1.24 (t, 3H), 2.19 (s, 2H), 2.22 (s, 2H), 2.80 (t, 2H), 3.42 (br s, 3H), 3.50 (q, 2H), 4.1 (q, 2H), 6.53 (t, 1H), 7.03 (br d, 2H), 7.18 (d, 2H), 7.26 (t,1H)( 7.33-7.41 (m,4H), HPLC-MS: m/z = 441.2 (M+1); Rt = 4.11 min. Example 567 Methyl-phenyl-carbamic acid 4-hydroxymethyl-phenyl ester To a solution of 4-hydroxymethylphenol (10 mmol) and 4-diazabicyclo[2.2.2]octane (DABCO) (10 mmol) in CH2CI2 (30 mL) was added N-methyl-N-phenylcarbamoyI chloride (10 mmol). The reaction mixture was stirred for 16 hours at rt, added CH2Cl2 (20. mL) and washed with 1M aqueous HCI and brine. The organic phase was dried (MgS04).and evaporated to give the crude product which was purified by FC (Quad flash 40 EtOAc-Heptane 1:1) to give 2-18 g (85%) of the title compound as an oil. 1H NMR (400MHz; CDCI3): S. 1.70 (br s, 1H), 3.40 (br s, 3H), 4.66 (s, 2H), 7.08 (br d, 2H), 7.25-7.42 (m, 7H); HPLC-MS : mlz = 258.1 (M+1); Rt = 2.99 min. Example 568 Methyl-phenyl-carbamic acid 4-(2-hydroxy-ethy[)-phenyl ester To a solution of 4-(2-Hydroxyethyl)phenol (10 mmol) and 4-diazabicyclo[2.2.2]octane (DABCO) (10 mmol) in CH2CI2 (30 mL) was added N-methy!-N-pheny)carbamoy! chloride (10 mmol). The reaction mixture was stirred for 16. hours at rt, added CH2Cl2 (20 mL), and washed with 1M aqueous HCI and brine. The organic phase was dried (MgS04) and evaporated to give the 2.69 g (99%) of the title compound as crystals. 1H NMR (400MHz; CDCI3): 8 1.52 (br s, 1H), 2.54 (t, 2H), 3.41 (br s, 3H), 3.81 (t, 2H), 7.04 (br d, 2H), 7.20 (d, 2H), 7.22-7.42 (m, 5H); HPLC-MS : m/z= 272.1 (M+1); Rt = 3.17 min. Example 569 (General procedure 1) Methyl-phenyl-carbamic acid 4-(4-dimethylamino-pyridin-2-ylmethyi)-phenyl ester A solution of 2-(dimethyIamino)ethanoI (32 mmol) in hexane (120 mL) was cooled to - 5°C and n-BuLi (64 mmol) was added. After 30 min 4-(dimethyIamine=pyridine (16 mmol) was added and the red-orange mixture was stirred for further 1 h. The solution was cooled to -78 °C and 4-(trimethylsilyIoxy)benzaldehyde (40 mmol) dissolved in hexane (80 mL) was added and the suspention was allowed to warm to rt over 20 min. The reaction mixture was quenched with water, and the aqueous phase was washed with CH2CI2, The aqueous phase was. evaporated to dryness, added Nal (96 mmol) and dissolved in MeCN (160 mL). Addition of trimethylsilylchloride (96 mmol) and stirring at rt for 16h. The purple reaction mixture was evaporated to dryness and treated with an aqueous solution of Na2S03 and pH was adjusted to 8. Extraction with CH2CI2 gave after evaporation 560 mg (15%) slightly impure 4-(4-dimethylaminO"pyridin-2-ylmethyl)phenol as yellow crystals. This was carbamoylated using general procedure 1 (CH2CI2 was used as solvent) to give the title, product as its hydrochloride after purification by preparative HPLC (Gilson) and treatment with HCI in Et20 (48%, ligt yellow crystals). HPLC-MS: mlz = 362.2 (M+1); Rt = 2.27 min. Example 570 (General procedure 25) Methyl-phenyl-carbamic acid 4-(4-imidazol-1-yl-phenoxymethy!)-phenyl ester The title compound was prepared in 53% yield as light yellow crystals using and 4-imidazol-1-yt-phenol. 1H NMR (400MHz; CDC)3): 8 3.42 (br s, 3H), 5.08 (s, 2H), 7.03 (d, 2H), 7.12-7.42 (m, 15H), 7.77 (s, 1H); HPLC-MS : mlz = 400.1 (M+1); Rt = 2.62 min. Example 571 (General procedure 25) Methyl-phenyl-carbamic acid 4-[4-(2-dimethylamino-ethyl)-phenoxymethy[]-phenyl ester The title compound was prepared in 52% yield as colorless crystals using methyl-phenyl-carbamic acid 4-hydroxymethyl-phenyl ester and 4-(2-dimethylaminoethyI)-phenol. 1H NMR (400MHz; CDCi3): 5 2.85 (s, 6H), 2.98-3.02 (m, 2H), 3.17-3.21 (mf 2H), 3.42 (br s, 3H), 5.02 (s, 2H), 6.90 (d, 2H), 7.12 (d, 2H), 7.25-7.43 (m, 7H); HPLC-MS : m/z = 405.2 (M+1); Rt = 2.91 min. Example 572 (General procedure 25) Methyl-phenyl-carbamic acid 4-(pyrazoI-1-yloxymethy!)-phenyl ester The title compound was prepared in 79% yield as an oil using and 1-hydroxypyrazoIe. 1H NMR (400MHz; CDCl3): 5 3.42 (br s, 3H), 5.26 (s, 2H), 6.03 (t, 1H), 6.95 (dd, 1H), 7.11 (br s, 2H), 7.25-7.42(m, 8H); HPLC-MS : m/z= 324.1 (M+1); Rt= 3.58 min. Example 573 (General procedure 25) Methyl-phenyl-carbamic acid 4-(imidazo!-1-yloxymethyI)-phenyl ester The. title compound was prepared as its TFAsalt in 87% yield as a solid using methyl-phenyl-carbamic acid 4-hydraxymethyl-phenyl ester and 1-hydroxyimidazole, hydrochloride. 1H NMR (400MHz; CDCI3): S 3.42 (br s, 3H)f 5.21 (s, 2H), 6.95 (s, 1H), 7.16-7.45 (m, 10H), 8.28 (br s, 1H); HPLC-MS :m/z= 324.1 (M+1); Rt = 1.92min. Example 574 (General procedure 25) Methyl-phenyl-carbamic acid 4-(2-oxo-2H-pyridin-1-ylmethy!)-phenyl ester The title compound was prepared in 29% yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyl)-phenyl ester and 2-hydroxypyridine. in addition 50% of the isomeric methyl-phenyl-carbamic acid 4-[2-(pyridin-2-yIoxy)-ethyO-phenyl ester was isolated, see characterization below. 1H NMR (400MHz; CDCI3): £.3.05 (t, 2H)f 3.41. (br s, 3H), 4.14 (s, 2H)f 6.08. (t, 1H)f 6.66 (d, 1H), 6.90 (dd, 1H), 7.02 (br s, 2H), 7.10 (d, 2H), 7.25-7.42 (m, 6H); HPLC-MS : mlz = 349.2 (M+1); Rt = 3.04 min. Example 575 (General procedure 25) Methyl-phenyl-carbamic acid 4-[2-(pyridin-2-yloxy)-ethyl]-phenyl ester The title compound was prepared in 50%. yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyl)-phenyl ester and 2-hydroxypyridine. In addition 29% of the isomeric methyl-phenyl-carbamic acid 4-(2-oxo-2H-pyridin-1-ylmethyi)-phenyl ester was isolated, see characterization above. 1H NMR (400MHz; CDCI3): 5 3.08 (t, 2H), 3.41 (br s, 3H), 4.49 (s, 2H), 6.73 (d, 1H), 6.88 (dd, 1H), 7.05 (br d, 2H), 7.22-7.42 (m, 7H), 7.61 (dt, 1H), 8.18 (dd, 1H); HPLC-MS : mlz = 349.2 (M+1); Rt = 3.97 min. Example 576 (General procedure 25) Methyl-phenyl-carbamic acid 4-[2-(4-imidazoM-yl-phenoxy)-ethyl]-phenyl ester The title compound was prepared as its TFA salt in 62% yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyl)-phenyl ester and 4-imidazol-1-yl-phenol. 1H NMR (400MHz; CDCI3): 5 3.11 (t, 2H)f 3.42 (br s, 3H), 4.22 (s, 2H)f 7.00-7.10 (m, 5H)f 7.25-7.42 (m, 9H), 7.52 (s, 1H)f 8.81 (s, 1H); HPLC-MS : mlz = 414.2 (M+1); Rt = 2.73 min. Example 577 (General procedure 25) Methyl-phenyl-carbamic acid 4-{2-[4-(2-dimethylamino-ethyl)-phenoxy]-ethyl}-phenyl ester The title compound was prepared as its TFA salt in 92% yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyl)-phenyl ester and 4-(2-dimethyIaminoethyl)-phenoL HPLC-MS : mlz = 419.2 (M+1); Rt = 2.77 min. Example 578 (General procedure 25) Methyl-phenyl-carbamic acid 4-[2-(pyrazoM-yloxy)-ethyl]-pheny! ester The title compound was prepared in 62% yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyl)-phenyl ester and 1-hydroxypyrazoIe. 1H NMR (400MHz; CDCl3): 8 3.02 (t( 2H)( 3.42 (br s, 3H), 4.50 (t, 2H), 6.16 (t, 1H), 7.05 (br d, 2H), 7.20-7.41 (m, 9H); HPLC-MS : mlz= 338.2 (M+1); Rt = 3.74 min. Example 579 (General procedure 25) Methyl-phenyl-carbamic acid 4-[2-(imidazoI-1-yioxy)-ethyl]-phenyI ester The title compound was prepared as its TFA salt in 79% yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyI)-phenyI ester and 1-hydroxyimidazoIe hydrochlorid. 1H NMR (400MHz; CDCI3): 8 3.06 (t, 2H), 3.42 (br s, 3H), 4.52 (t, 2H), 7.08-7.42 (m, 11H), 8.53 (s, 1H); HPLC-MS : m/z = 338.2 (M+1); Rt= 2.18 min. Example 580 (General procedure 1) Methyl-phenyl-carbamic acid 4-(5-methyI-pyridin-2-ylmethyI)-phenyI ester To a stirred solution of 2-bromo-5-methylpyridine (3.45 g, 20 mmol) in THF (10 ml_) was added dropwise 1.6 M solution in hexanes n-BuLi (12 mL, 19.2 mmol) over a 10-min period at -78°C. The mixture was stirred at -78°C for 2 min before 4-trimethylsilyloxybenzaldehyde (4.2 g, 21.6 mmol) dissolved in THF (10 mL) was added. The mixture was allowed to warm to • -40 °C and quenched with water. The pH of the aqueous phase was adjusted to 7 which causes precipitation of 4-[hydroxy-(5-methyI-pyridin-2-yI)~methyI]phenoL This was isolated by filtration to give 1.13 g (27%) of 4-[hydroxy-(5-methyl-pyridin-2-yl)-methyl]phenol as crystals. This intermediate was dissolved in CH2CI2 (15 mL) and stirred with triethylsiiane (4 mL) and TFA (5 mL) for 16. h at 50 °C. Evaporation gave 99% of 4-(5-methyl-pyridin-2-ylmethyl)phenol as a hygroscopic solid. This was carbamoylated using general procedure 1 (CH2Cl2 was used as solvent and N-phenyl-N-methyl carbamoyl chlorid) to give 99% of the title product as its crystalline hydrochloride after purification by flash chromatography (Quad flash 12, EtOAc-heptane) and treatment with HCI in Et20. 1H NMR (400MHz; CDCI3): 8 2.50 (s, 3H), 3.41 (br s, 3H), 4.57 (s, 2H), 7.10 (br s, 2H), 7.25-7.42 (m, 8H), 8.00 (dd, 1H), 8.46 (br s, 1H); HPLC-MS: mlz = 333.1 (M+1); Rt = 2.60 min. Example 581 (General procedure 24) 4-Hydroxy-piperidine-1-carboxylic acid 4-(5-methyl-pyridin-2-ylmethyl)-phenyI ester The title compound was prepared as its hydrochloride using of 4-(5-methyl-pyridin-2- flmethyI)phenol as the phenol. H NMR (300MHz;. CDCl3): S 1.57-1.67 (m, 3H), 1.95 (d, 2H), 2.51 (s, 3H), 3.21-3.40 (m, 2H), 3.90-4.05 (m, 3H), 4.58 (s, 2H), 7.11 (d, 2H), 7.38 (d, 2H), 7.45 (d, 1H), 8.02 (d, 1H), 3.48(brs, 1H). Example 582 (General procedure 25) Methyl-phenyl-carbamic acid 4-(4-oxo-4H-pyridin«1-ylmethyl)-phenyl ester The title compound was prepared in 33% yield as colorless crystals using methyl-phenyl-carbamic acid 4-hydroxymethyl-phenyl ester and 4-hydroxypyridine. 1H NMR (400MHz; CDCI3): S 3.43 (br s, 3H), 4.92 (sf 2H), 6.43 (d, 2H), 7.17 (br s, 4H), 7.22-7.42 (m, 9H); HPLC-MS : mlz = 335.0 (M+1); Rt = 2.55 min. Example 583 (General procedure 25) Methyl-phenyl-carbamic acid 4-[2-(pyridin-3-yloxy)-ethyi]-phenyl ester The title compound slightly contaminated with tributylphosphine oxide was prepared in 80% yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyI)-phenyl ester and 3- hydroxypyridine. 1H NMR (400MHz; CDCI3): 5 3.11 (t, 2H), 3.42 (br s, 3H), 4.23 (t, 2H), 7.07 (br d, 2H), 7.24- 7.41 (m, 9H)( 8.29 (br s, 1H), 8.40 (br s, 1H); HPLC-MS : mlz = 349.2 (M+1); Rt = 2.87 min. Example 584 (General procedure 25) Methyl-phenyl-carbamic acid 4-(2-oxo-2H-pyridin-1-ylmethyl)-phenyl ester The title compound was prepared in 66% yield as an oil using methyl-phenyl-carbamic acid 4-hydroxymethyl-phenyl ester and 2-hydroxypyridine. 1H NMR (400MHz; CDCI3): 5 3.42 (br sf 3H), 5.12 (s, 2H), 6.13 (t, 1H), 6.60 (d, 1H), 7.10 (br s, 2H), 7.22-7.41 (m, 9H); HPLC-MS : mlz = 335.2 (M+1); Rt = 2.97 min. Example 585 (General procedure 25) Methyl-phenyl-carbamic acid 4-(pyridin-3-yloxymethyl)-phenyl ester The title compound was prepared in 43% yield as an oil using methyl-phenyl-carbamic acid 4-hydroxymethyl-phenyl ester and 3-hydroxypyridine. 1H NMR (400MHz; CDCI3): S 3.44 (br s, 3H), 5.12 (s, 2H), 7.17 (br s, 2H), 7.27-7.46 (m, 9H), 8.29 (br s, 1H), 8.49 (br s, 1H); HPLC-MS : m/z = 335.0 (M+1); Rt = 2.74 min. Example 586 (General procedure 26) Methyl-phenyl-carbamic acid 4-[2-(2,5-dioxo-pyrroIidin-1-yI)-ethyI]-phenyl ester The title compound was prepared in 85% yield as crystals using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyI)-phenyI ester and succinimide. 1H NMR (400MHz; CDCl3): 5 2.65 (s, 4H), 2.86 (t, 2H), 3.41 (br s, 3H), 3.72 (t, 2H), 7.04 (br d, 2H), 7.19 (d, 2H), 7.26-7.42 (m, 5H); HPLC-MS : m/z = 353.2 (M+1); Rt = 3.17 min. Example 587 (General procedure 26) Methyl-phenyl-carbamic acid 4-[2-(1,3-dioxo-1,3-dihydro-pyrrolo[3,4-]pyridin-2-y[)-ethyI]- phenyl ester The title compound was prepared in 58% yield as crystals using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyI)-phenyl ester and 3,4-pyridinedicarboximide. 1H NMR (400MHz; CDCl3): 8 . 2.98 (tf 2H), 3.40 (br s, 3H), 3.93 (t, 2H), 7.05 (br d, 2H), 7.20-7.42 (m, 7H), 7.73 (dd, 1H), 9.06 (d, 1H), 9.12 (d, 1H); HPLC-MS : m/z = 402.1 (M+1); Rt = 3.56 min. Example 588 (General procedure 26) Methyl-phenyl-carbamic acid 4-(1-methyl-1H-imidazol-2-ylsulfanylmethyl)-phenyl ester. The title compound was prepared as its TFA salt in 22% yield as an oil using methyl-phenyl-carbamic acid 4-hydroxymethyl-phenyl ester and 2-mercapto-1-methyIimidazole. 1H NMR (400MHz; CDCI3): S 3.34 (s, 3H), 3.40 (br s, 3H), 4.30 (s, 2H), 6.98 (br s, 2H), 7.08-7.11 (m, 3H),7.27-7.42 (m, 5H), 7.48 (d, 1H); HPLC-MS : m/z = 354.1 (M+1); Rt = 2.12 min. Example 589 (General procedure 26) Methyl-phenyl-carbamic acid 4-tetrazoM-ylmethyl-phenyl ester The title compound was prepared in 6% yield as an oil using methyl-phenyl-carbamic acid 4-hydroxymethyl-phenyl ester and tetrazole. 1H NMR (400MHz; CDCI3): S 3.42 (br s, 3H), 5.57 (s, 2H), 7.17 (br s, 2H), 7.26-7.42 (m, 7H), 8.52 (s, 1H); HPLC-MS : m/z = 332.0 (M+23); Rt = 3.24 min. Example 590 (General procedure 26) Methyl-phenyl-carbamic acid 4-(2,5-dioxo-pyrroIidin-1-yImethyI)-phenyl ester The title compound was prepared in 57% yield as beige crystals using methyl-phenyl-carbamic acid 4-hydroxymethyl-phenyl ester and succinimide. 1H NMR (400MHz; CDCI3): S 2.68 (s, 4H), 3.41 (br s, 3H), 4.60. (s, 2H), 7.04 (br d, 2H), 7.23-7.41 (m, 7H); HPLC-MS : mlz = 339.1 (M+1); Rt= 3.40 min. Example 590 (General procedure 26) Methyl-phenyl-carbamic acid 4-[2-(2-thioxo-2H-pyridin-1-yl)-ethyl]-phenyl ester The title compound was prepared in 25% yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyI)-phenyl ester and 2-mercaptopyridine. HPLC-MS : mlz- 365.2 (M+1); Rt = 4.08 min. Example 591 (General procedure 26) Methyl-phenyl-carbamic acid 4-(1,3-dioxo-1,3-dihydro-pyrrolo[3,4)pyridin-2-ylmethyI)-phenyl ester The title compound was prepared in 21% yield as an oil using methyl-phenyl-carbamic acid 4-hydroxymethyl-phenyl ester and 3,4-pyridinedicarboximide. 1H NMR(400MHz; CDCI3); S 3.40 (brs. 3H)f 4.82 (s, 2H), 7.06 (d, 2H), 7.22-7.44 (m, 8H), 7.73 (d, 1H), 9.04 (df 1H), 9.12 (s, 1H); HPLC-MS : m/z= 388.0 (M+1); Rt = 3.80 min. Example 592 (General procedure 26) Methyl-phenyl-carbamic acid 4-[1,2,4]1xiazol-1-ylmethyl-phenyl ester The title compound was prepared as its TFA salt in 27% yield as an oil using methyl-phenyl-carbamic acid 4-hydroxymethyl-phenyl ester and 1,2,4-triazole. 1H NMR (400MHz; CDCI3): 5 3.42 (br s. 3H), 5.34 (s, 2H), 7.15 (br d, 2H), 7.26-7.43 (m, 7H), 8.10 (s. 1H), 8.38 (s, 1H); HPLC-MS : m/z= 309.1 (M+1); Rt = 2.74 min. Example 593 (General procedure 26) Methyl-phenyl-carbamic acid 4-(2-thioxo-2H-pyridin-1-ylmethyi)-phenyl ester The title compound was prepared in 14% yield as an oil using methyl-phenyl-carbamic acid 4-hydroxymethyl-phenyl ester and 2-mercaptopyridine. HPLC-MS: mlz = 351.1 (M+1); Rt = 3.95 min. Example 594 (General procedure 26) Methyl-phenyl-carbamic acid 4-[2-(1-methyl-1H«imida2oI-2-ylsulfanyI)-ethyi]-phenyI ester The title compound was prepared as its TFA salt in 37% yield as an oil using methyl-phenyi-carbarnic acid 4-(2-hydroxy-ethyI)-phenyI ester and 2-mercapto-1-methyIimidazole. NMR (400MHz; CDCl3): 8 3.01 (t, 2H), 3.40 (br s, 3H)f 3.47 (s, 1H), 3.64 (t, 2H), 6.92 (br d, 2H), 6.98 (s, 1H), 7.08 (d, 2H), 7.26-7.43 (m, 6H); HPLC-MS : mlz = 368.2 (M+1); Rt = 2.30 min. Example 595 (General procedure 26) Methyl-phenyl-carbamic acid 4-(2-tetrazol-1-yl-ethyl)-phenyl ester The title compound was prepared in 10% yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyl)-phenyI ester and tetrazole. NMR (400MHz; CDCI3): 8 3.19 (t, 2H), 3.40 (br s, 3H), 3.47 (s, 1H), 4.61 (t, 2H), 6.98-7.07 (m, 4H), 7.25-7.42 (m, 5H), 8.26 (s, 1H); i HPLC-MS : mlz = 324.1 (M+1); Rt = 3.36 min. Example 596 (General procedure 26) Methyl-phenyl-carbamic acid 4-[2-(pyrimidin-2-yloxy)-ethyI]-phenyI ester The title compound was prepared in 24% yield as light yellow crystals using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyl)-phenyl ester and 2-hydroxypyrimidine. NMR (400MHz; CDCI3): 8 3.11 (t, 2H), 3.42 (br s, 3H), 4.54 (tf 2H), 6.93 (t, 1H), 7.05 (d, 2H), 7.25-7.42 (m, 7H), 8.51 (d, 2H); HPLC-MS : mlz = 350.2 (M+1); Rt = 2.86 min. Example 597 (General procedure 26) Methyl-phenyl-carbamic acid 4-[2-(pyridin-4-ylsulfanyI)-ethyl]-phenyl ester The title compound was prepared as its TFA salt in 5% yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyl)-phenyl ester and 4-mercaptopyridine. NMR (400MHz; CDCI3): 8 3.07 (t, 2H), 3.36 (t, 2H), 3.44 (br s, 3H), 7.06 (br d, 2H), 7.20 (d( 2H), 7.25-7.43 (m, 7H)( 8.51 (d, 2H); HPLC-MS: mlz = 365.2 (M+1); Rt = 2.53 min. Example 598 (General procedure 12) 4-(3-Amino-phenyI)-piperidine-1-carboxylic acid 4-(5-trifluoromethyI-pyridin2-yIoxy)-phenyl ester, The title product was prepared from 4-(3-aminophenyI)piperidine (released form the correspondent hydrochloride by a standard procedure) and 4-(5-trifluoromethyl-pyridin-2-yIoxy)-phenyI chloroformate, preparative HPLC (method C) (reaction performed in a mixture of dichloro-methane and dimethylformamide, 5:3). 1.7 M HCI in ethyl acetate was added to the pooled fractions containing the title product, and the fractions was evaporated to dryness (7%, light yellow solid). HPLC-MS m/z = (M+1) 458.0, Rt: 3.09 min. Example 599 (Genera! procedure 26) Methyl-phenyl-carbamic acid 4-[2-(1-pyridin-3-yl-1H-imida2ol-2-ylsulfanyI)-ethy!]-phenyl ester The title compound was prepared as its TFA salt in 5% yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyI)-phenyl ester and 3-(2thio-1H-imidazoI-1-yl)pyridine. NMR (400MHz; CDCI3): 5 2.95 (t, 2H), 3.42 (br s, 2H), 3.56 (t, 3H), 6.98 (br d, 2H), 7.05 (d, 2H), 7.15 (d, 1H), 7.23-7.43 (m, 5H), 7.48 (d, 1H), 7.53 (dd, 1H), 7.70 (ddd, 1H), 8.65 (d, 1H), 8.77 (dd, 1H); HPLC-MS : mlz = 431.2 (M+1); Rt = 2.79 min. Example 600 (General procedure 26) Methyl-phenyl-carbamic acid 4-[2-(1f3-dioxo-1l3-dihydro-isoindol-2-yI)-ethyl]-phenyl ester The title compound was prepared in 39% yield as an oil using methyl-phenyl-carbamic acid 4-(2-hydroxy-ethyl)~phenyl ester and isoindole-1,3-dione. NMR (400MHz; CDCI3): 8 2.98 (t, 2H), 3.41 (br sf 2H), 3.89 (t, 3H), 7.04 (br d, 2H), 7.20-7.40 (m, 7H), 7.68-7.71 (m, 2H), 7.80-7.83 (m, 2H); HPLC-MS : mlz = 401.1 (M+1); Rt = 4.41 min. Example 601 4-Phenyl-piperidine-1-carboxylic acid 4-(5-methyl-pyridin-2-ylmethyI)-phenyl ester To a solution of 4-(5-methyl-pyridin-2-ylmethyl)phenol (0.8 mmol) prepared as described above and ethyldiisopropylamine (1.5 mmol) in CH2CI2 (5. mL) at -30 °C was added trichloro-methyl chloroformiate (1.0 mmol). The solution was stirred at -30 °C for 10 min and at reflux temperature, for 2 h. The solution was evaporated to dryness and redissolved in CH2CI2 (5 mL) and cooled to 0. °C before addition of 4-phenyIpiperidine (1.5 mmol). The solution was stirred at room temperature for 16 h evaporated, to give the crude product which was purified by FC (Quad flash 40 CH2CI2:Et20:Heptane:Et3N 1:1:2:0.25 ->1:1:1:0.25) to give the title compound in 28% yield as an oil. 1H NMR (400MHz; CDCI3): £1.70-1.80 (mf 2H), 1.91 (br d, 2H), 2.29 (s, 3H), 2.72 (tt, 1H)f 2.94 (br t, 1H), 3.08 (br.t, 1H), 4.10 (s, 2H), 4.42 (br s, 1H), 7.00 (d, 1H), 7.06 (d, 2H), 7.21-7.26 (m, 5H), 7.32 (d, 2H), 7.38 (dd, 1H), 8.37 (d, 1H); HPLC-MS :.m/z= 387.2 (M+1); Rt = 2.95 min. Example 602 4-(4-Methoxy-phenyl)-3l6-dihydro-2H-pyridine-1-carboxyIicacid 4-(5-methyl-pyridin-2-ylmethyl)-phenyl ester To a solution of 4-(5-methyl-pyridin-2-ylmethyl)phenol (0.8 mmol) prepared as described above and ethyldiisopropylarnine (1.5 mmol) in CH2CI2 (5 mL) at -30 °C was added trichloro-methyl chloroformiate (1.0 mmol). The solution was stirred at -30 °C for 10 min and at reflux temperature for 2 h. The solution was evaporated to dryness and redissolved in CH2Cl2 (5 mL) and cooled to 0 °C before addition of 4-(4-methoxyphenyI)-1l2,3,6-tetrahydro-pyridine (1.5 mmol). The solution was stirred at room temperature for 16 h evaporated to give the crude product which was purified by FC (Quad flash 40 CH2Cl2:Et20:Heptane:Et3N 1:1:2:0.25 ->1-.1:1:0.25) to give the title compound in 10% yield as colorless crystals. 1H NMR (400MHz; CDCI3): £2.30 (s, 3H), 2.60 (br s, 2H), 3.75-3.88 (m, 5H), 4.12 (s. 2H), 4.20 (br s, 1H), 4.30 (br s, 1H), 5.98 (br s, 1H), 6.88 (d, 2H), 7.00 (d, 1H), 7.07 (d, 2H), 7.24 (d, 2H), 7.34 (d, 2H), 7.39 (dd, 1H), 8.38 (d, 1H); HPLC-MS : mlz= 415.3. (M+1); Rt = 2.95 min. PHARMACOLOGICAL METHODS Compounds of formula I may be evaluated in vitro for their efficacy and potency to inhibit HSL, and such evaluation may be performed as described below. ASSAYS Hormone-sensitive lipase (HSL) Materials. The Hormone-sensitive lipase was provided by Dr. Cecilia Holm, from Lund University Sweden or produced and purified by Novo Nordisk (NN) using the reagents and protocols used by Dr. Holm. The substrates used are: 3H-Iabeled triolein (TO) from Amersharn, Buckinghamshire, U.K. cat No. TRA191; 5-20 Ci/mmol dissolved in toluene, triolein (Sigma, Cat. No. T-1740), fluorochrome-Iabeled triacyiglyceride (c/s-octadec-9-enoic acid 2-[12-(7-nitroben2o[1,2)5]oxadiazoI-4"yiamino)dodecanoyIoxy]-1-c/s-octadec-9-enoyloxymethyl-ethyl ester) prepared by Novo Nordisk (NN) by conventional methods, and 1,3-(di[3H]-stearin), 2-(PEG-Biotin)glyceroI prepared in collaboration with Amersharn Pharmacia Biotech, UK and described in WO 01/073442. Phosphatidyl choline (PC) and phosphatidyl inositol (Pi) are from Sigma (St Luis MO cat. Nos. P-3556 and P-5954 respectively). All other reagents are of commercial grade and obtained from various commercial sources. Methods. 3180.1: Assay for determination of inhibitor IC50 values. A lipid emulsion with 3H-TrioIein and phospholipid is used as substrate with a standard cencentration of highly purified HSL. BSA is added as product receptor. The substrate is. prepared as follows: 30 pi PC:PI (20 mg/ml solution of PC:PI 3:1 prepared in chloroform) + 128 pi cold TO + 15 pi 3H-TO are mixed and then evaporated under a gentle stream of N2 followed by 20-30 minutes in a Speedvac to ensure the absence of residual solvent. Compound and HSL are incubated for 30 min at 25 °C before addition of substrate. Reaction is stopped after 30 min at 25 °C by adding a mixture of methanol, chloroform and heptane at high pH. Formed product is separated from substrate by phase separation. Standard concentrations of compound are 100//M, 20//M, 4//M, 0.8//M, 0.16//M and 0.03^/M (sample concentrations). Results are given as IC50 values after 4PL fit of obtained activity data. 3180.2: Assay for determination of percent inhibition by compound at 10//M concentration. A lipid emulsion with 3H-Triolein and phospholipid is used as substrate with a standard cencentration of highly purified HSL. BSA is added as product receptor. The substrate is prepared as follows:. 30 pi PC:PI (20 mg/ml solution of PC:PI 3:1 prepared in chloroform) + 128 pi cold TO + 15 pi 3H-TO are mixed and then evaporated under a gentle stream of N2 followed by 20-30 minutes in a Speedvac to ensure the absence of residual solvent. Compound and HSL are incubated for 30 min at 25 °C before addition of substrate. Reaction is stopped after 30 min at 25 °C by adding a mixture of methanol, chloroform and heptane at high pH. Formed product is separated from substrate by phase separation. Results are given as percent activity relative to an un-inhibited sample (no compound). 3190.1: Assay for determination of percent inhibition of hormone sensitive lipase by compound at 10pM sample concentration. A lipid emulsion with fluorochrome-labeled triacylglyceride and phospholipid is used as substrate with a standard concentration of highly purified HSL (12pg/mL initial concentration cor-. responding to 600ng/mL final concentration), BSA is added as product receptor. The transfer of the fluorochrome from the lipid phase to the water (BSA) phase changes the fluorescent properties of the fluorochrome. The changes can be monitored on a fluorimeter with an excitation wavelength of 450nm and an emission wavelength of 545nm. Compound and HSL (20pL compound, 10pL enzyme and 70pL PED-BSA buffer) is pre-incubated for 30min at 25°C before addition of substrate (100yL). Amount of formed product is measured after 120min incubation at 37°C. Results are given as percent activity, relative to a non-inhibited sample (no compound). 3190.2: Assay for determination of IC5o value for the inhibition of hormone sensitive lipase by compound. Standard concentrations of compound are 100//M and 5-fold dilutions (initial concentration corresponding to 10//M final concentration and 5-fold). A lipid emulsion with fluorochrome-labeled triacylglyceride and phospholipid is used as substrate with a standard concentration of highly purified HSL (12pg/mL initial concentration corresponding to 600ng/mL final concentration). BSA is added as product receptor. The transfer of the fluorochrome from the lipid phase to the water (BSA) phase changes the fluorescent properties of the fluorochrome. The changes can be monitored on a fluorimeter with an excitation wavelength of 450nm and an emission wavelength of 545nm. Compound and HSL (20JJL compound, 10pL enzyme and 70pL PED-BSA buffer) is pre-incubated for 30min at 25°C before addition of substrate (100pL). Amount of formed product is measured after 120min Incubation at 37°C. Results are given as IC50 values after 4PL fit of obtained activity data. 2848,2: This high-volume screening assay uses para-nitrophenyl butyrate (p-NPB) as substrate for HSL.HSL cleaves p-NPB and the reaction is monitored as an increase in the concentration of para-nitropheno! (p-NP). p-NP can be monitored as an increase in UV-absorbance at 405 nm. The reaction is carried out at room-temp, for 20 min. The action is not stopped, but instead UV-abs is measured at a fixed time (20 min.) Due to autohydrolysis of the substrate the reaction is read at t = 0 min. too and t = 20 min. and the increase in Abs is calculated as the difference between the. two readings. When a compound that inhibits HSL is present, it results in a relative decrease in UV-absorbance. %Eff (%lnhibition) = (S-SOEff)/(SmaxEff-S0Eff) x 100 Where S = signal in UV-abs., SOEff = assaybuffer alone, SmaxEff = Assaybuffer with the lipase inhibitor. 2898.2: This method is an enzyme assay based upon SPA (scintillation proximity assay) particles. The substrate, 1,3-(di-[3H]-stearin), 2-(PEG-Biotin)-gIyceroI, is marked with 3H in both fatty acid moieties in the tri-glyceride. The third moiety of the tri-glyceride is a PEG linked Biotin. The substrate binds through Biotin to streptavidin in the SPA particles and the proximity between the radioactive tritium in the stearic acid moiety and the SPA particle results in emission of light from the SPA particles. The assay is an on-bead assay where HSL degrades the substrate, where after 3H-stearin acid is released from the bead. The amount of light emitted is proportional to the amount of substrate bound to the receptor. When a compound that inhibits the activity of HSL is present it results in a decrease in degradation of the substrate and thus an increase in the amount of light emitted and a concomitant increase in %Eff. %Eff (%lnhibitlon) = (S-SOEfQ/(SmaxEff~SOEfF) x 100 Where S = signal in dpm., SOEff = no inhibitor added, SmaxEff» with maximum concentration of inhibitor. CLAIMS 1. A compound of the general formula II wherein R1 is selected from Chalky!, C^-alkenyl and C^io-cycioalkyl, each of which is optionally substituted with one or more substituents independently selected from hydroxy, sul-fanyl, oxo, halogen, amino, cyano and nitro; and R2 is selected from C1-6alky!, C2-6-alkenyl, aryl, heteroaryl, C3-8heterocyclyl and C3.10-cycloalkyl, each of which is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-8-alkyl, c2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-8-alkyl, C2-8alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3.10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C1-6-alkyl, C2-6-alkenyl, aryl. heteroaryl, C3-8-heterocycIyl and C3-10-cycloalkyI, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-4-alkyl, C2-6-alkenyl, aryl, heteroaryl, C38-heterocyclyl and C3-1o-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C^-alkyl, C2_6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-1o-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Ci^-alkyl, C2.6-alkenyl, aryl, heteroaryl,. C3-8heterocyclyl and C3-1o-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C-alkyl, C2-alkenyl, aryl, heteroaryl, (Wheterocyclyl and C3. 10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C^-alkyl, C2^-alkenyl, aryl, heteroaryl, C«-heterocyclyl and C3-10-cycloalkyl. is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Ci-e-alkyI, CWalkenyl, perhalomethyl and perhalomethoxy, and wherein R2 is optionally covalently bound to R1 by an ether, thioether, C-C or C-N bond, to form a ring system with the N-atom to which R1 and R2 are bound; and R3 is selected from hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6alkenyl, aryl, heteroaryl, C3. e-heterocydyl and c3-c10cycloalkyi, each of which is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Chalky!, (^-alkenyl, aryl, heteroaryl, c1-c6B-heterocyclyl and c1-c6io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2.6-alkenyl, aryl, heteroaryl, CM-heterocyclyl and C3-io-cycloalkyi is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, d-e-alkyl, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Ci-e-alkyi, Qwralkenyl, aryl, heteroaryl, CWheterocyclyl and C3.10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3_1o-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Ci-e-alkyi, C2.6-alkenyl, aryl, heteroaryl, C3-s-heterocycIyl and c1-c6crcycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2-e-alkenyl, perhalomethyl and perhalomethoxy; and X is O or S; or a pharmaceutical^ acceptable salt thereof, or a pharmaceutical^ acceptable solvate thereof, or any tautomeric forms, stereoisomers, mixture of stereoisomers including a racemic mixture, or polymorphs. 2. A compound of the general formula III wherein R1a and R23 are independently selected from c1-c6-alkyl, C2.6-alkenyi, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyl, each of which is optionally substituted with one or .-more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C1-6-silkyt. C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyI and c1-c6^-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-6-alkyl, C2_8-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6io-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano and nitro, Ci-e-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-1o-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-8alkenyl, aryl, heteroaryl, C3_8-heterocyclyl and C3-10-cycioalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, perhalomethyl and perha-lomethoxy; and wherein R1a is optionally covalently bound to R2a by an ether, thioether, C-C or C-N bond; to form a ring system with the N-atom to which R1a and R23 are bound; and R48, R53, R6a and R7a are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3. 10-cycloalkyl, each of which is optionally substituted by one or more substituents selected from hydroxy, sulfanyl, sulfo, oxo, amino, cyano, nitro, c1-c6-alkyl, C2-6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c1-c6^-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-e-aIkenyl, aryl, heteroaryl, C3_8-heterocyclyl and c1-c6io-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, perhalomethyl and perhalomethoxy; and A1" is N or OR8a; A2* is N or C-R9a; A3a is N or C-R10a; A4a is N or C-R11a; and A5a is N or C-R12a; and wherein R8a, R93, R10a, R11a and R12a are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alky!, C2^-alkenyl, aryl, heteroaryl, C«-heterocyclyl and C3.io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, CWalkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Cs-io-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2-8-alkenyl, aryl, heteroaryl, C3-a-heterocyclyl and C3. 10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, (^-alkeny!, aryl, heteroaryl, c1-c6-heterocyclyl and C3-1o-cycloaIkyI is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2-6-alkenyI, aryl, heteroaryl, C3-e-heterocyclyl and Qj-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-e-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-1o-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, perha-lomethyl and perhalomethoxy. 3. The compound according to claim 2, wherein R23 is phenyl, optionally substituted by halo gen or methyl. 4. The compound according to any one of claims 2-3, wherein R1a is selected from methyl and ethyl, optionally substituted by one or more halogen. 5. The compound according to claim 2, wherein R1a and R23 are covalently bound so as. to form a ring system with the N-atom to which they are bound, wherein said ring system is a piperidine, piperazine, morpholine, or thiomorpholine. 6. The compound according to any one of claims 2-5, wherein R48, R5a, R6a and R7a are inde pendently selected from hydrogen, F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, - S(=0)2-NH2, -NH-S(=0)rOH, hydroxy, amino and perhalomethyl. 7. The compound according to any one of claims 2-6, wherein A1a, A23, A38, A43 and A5a are independently selected from N, CH, CF, C-CI and C-CF3. 8. A compound of the general formula IV wherein R1b and R2* are independently selected from c1-c6-alkyl, c1-c6alkoxy, c1-c6-aikenyl, aryl, heteroaryl, c1-c6-heterocyc)yl and C3-1o-cycloalkyl, each of which may optionally be substituted with one or more substituents selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-6alkyl, C1-6alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d^-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C1-8-alkyl, C2-8alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6^-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6e-alkyl, C-^-alkoxy, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3.io-cycioalkyl, perhalomethy! and perhalomethoxy; wherein R1b is optionally covalently bound to R2b by an ether, thioether, C-C or ON bond, to form a ring system with the N-atom to which R1b and R25 are bound; R56 and R6b are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, sulfo, c1-c6-alky!, C2^-alkenyl, aryl, heteroaryl, C3-e-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2.e-alkenyl, aryl, heteroaryl, C3*-heterocyclyI and c3-c10cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ct-6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyi, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c3-c10cydoalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, c1-c6e-alkyl, perhalomethyl and perhalomethoxy; R4* and R7* are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6io-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, aryl, heteroaryl, c1-c6-heterocycIyl and C3.10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloaIkyl, wherein each of hydroxy, sulfanyl, sulfo, c1-c6-alkyl, C2-s-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl is optionally substi- tuted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, d-e-alkyl, perhalomethyl and perhalomethoxy; and A1b is N or C-R8b; A2* is N or. C-R9b; A3b is N or OR10b; A4b is N or C-R11b; and A5b is N or C-R12b; and wherein R8b, R*, R10b, R11b and R12b are selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, sulfo, Chalky!, C2-6-alkenyl, aryl, heteroaryl, CWheterocyclyl and c3-c10 cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alky!, C2-6-alkenyl, aryl, heteroaryl, C«-heterocyclyl and c3-c10cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, Ci-e-alkyi, C2-e-alkenyl, aryl, heteroaryl, C3-8-heterocydyl and C3.io-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, Ci.6-alkyl, perhalomethyl and perhalomethoxy; wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R4b, R5b, RBb, R7b, R8b, R9b, R10b, R11b and R12b. 9. The compound according to claim 8, wherein R2b is phenyl, optionally substituted by halo gen. 10. The compound according to any one of claims 8-9, wherein R1b is selected from methyl and ethyl, optionally substituted by one or more halogen. 11. The compound according to claim 8, wherein R1b and R2b are covalently bound so as to form a ring system with the N-atom to which they, are bound, wherein the ring system is a piperidine, piperazine, morpholine, or thiomorpholine. 12. The compound according any one of claims 8-11, wherein R4b, R51*, R6b and R7b are independently selected from hydrogen, F, CI, Ci_6-alkyl, c1-c6-alkoxy, -C(0)NH2, -NHC(=0)-OH, -S^O^NH* -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 13. The. compound according to any one of claims 8-12, wherein A1b, A2b, A3b, A4b and A5b are independently selected from N, CH and CF. 14. A compound of the general formula V wherein R4c, R5c, R6c, R7c and R8c are independently selected from hydrogen, hydroxy, sul-fanyl, amino, halogen, cyano, suifo, c1-c6-alkyl, Ci-e-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, c1-c6-alkyl, d^-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Cs-io-cycloalky! may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-i0-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalky!, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alky!, c1-c6alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6^-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perha-lomethoxy, and R90, R10G, R11C, R12C and R13c are independently selected from hydrogen, sulfanyl, amino, halogen, cyano, nitro, sulfo, d-e-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-i0-cycloalkyl, wherein each of sulfanyl, amino, sulfo, C1_6-alkyl, c1-c6e-alkoxy, C2_6-aIkenyl, aryl, heteroaryl, c1-c6-heterocycIyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sutfo, c1-c6-alkyl, d-e-alkoxy, C2.e-alkenyl, aryl, heteroaryl, C«-heterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, Ci-e-alkoxy, C2-e-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6alkoxy, Cs-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-aIkenyl, aryl, heteroaryl, C3-s-heterocyclyI and c3-c10 cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ci_e-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and pertia-lomethoxy; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R40, R5°, R60, R7c and R8c; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9c, R10c, R11c, R12c and R13c; and. at least one of R40, R50, R6c, R7c, R8c, R9c, R10c, R11c, R12c and R13c are different from hydrogen. 15. The compound according to daim 14, wherein R9c, R10G, R11c, R12c and R13c are selected from H and F. 16. The compound according to any one of claims 14-15, wherein R4c, R50, R6c, R7c and R80 are independently selected from hydrogen, F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 17. The compound according to claim 14, where there are no covalent bonds between any of the substituents R9c, R10c, R11c, R12c and R13c. 18. The compound according to any one of claims 14-16, where there are no covalent bonds between any of the substituents R40, R5c, R6c, R7c and R8c. 19. The compound of the general formula wherein R46 and R5d are independently selected from hydrogen, hydroxy, sulfanyl, amino, C2. e-alkyl, c1-c6-alkoxy, C2-e-alkenyI, aryl, heteroaryl, C3^-heterocyclyl and Ca-io-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, c1-c6-alkyl, Ci-e-alkoxy, C2_e-alkenyl, aryl, heteroaryl, CM-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more sub-stituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6alkoxy, C2^-aIkenyl, aryl, heteroaryl, Cs-a-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, Ci-e-alkoxy, C2_e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ci-e-alkoxy, C2.6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, Ci-e-alkoxy, C2^-aIkenyl, aryl, heteroaryl, C3^-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, Cs^-heterocydyl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy: and R6d, R7df R**, R", R10d, R11d, R12d, R13d and R14d are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6alkoxy, C2^-alkenyl, aryl, heteroaryl, C3^-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3^-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, Q^e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-i0-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-e-aIkenyl, aryl, heteroaryl, C3^-heterocyclyl, and C3_10-cycioalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e- alkyl, d-e-alkoxy, C2.e-alkeny!, aryl, heteroaryl, c1-c6-e-heterocyclyl and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d^-alkyl, d-e-alkoxy, C2-6-alkenyl1 aryl, heteroaryl, c1-c6-heterocyclyl and d-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitre, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6e-alkenyl, aryl, heteroaryl, dm-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy: wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R*. R5d, R6d, R7d, R*1 and RM; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R10d, R11d, R12d, R13d and R14d. 20. The compound according to claim 19, wherein R4d and R5d are H. 21. The compound according to any one of claims 19-20, wherein R6d, R7d, RBd and RM are selected from the group consisting of hydrogen, F, CI, d-ralkyl, d-e-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2l -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 22. The compound according to any one of claims 19-21, wherein R10d, R11d, R12d, R13d and R14d are selected from the group consisting of hydrogen, F, CI, d-e-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 23. The. compound according to any one of claims 19-22, wherein there are no covalent bonds between any of the substituents R4*, R5d, R6d, R7d, RBd and R9d. 24. The compound according to any one of claims 19-23, wherein there are no covalent bonds between any of the substituents R10d, R11d, R12d, R13d and R14d. 25. A compound of the general formula wherein R4& is selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, C2-e-alkyl, c1-c6alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c68-heterocyciyl and c1-c6io-cycloalkyl, wherein each of c1-c6r-alky!, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl, wherein each of the. hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2_e-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and c3-c10 cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Ca-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, (Walkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10cycloalkyl, perha-lomethyl and perhalomethoxy; and R56 is selected from hydrogen, F, cyano, c1-c6-alkyl, d-e-alkoxy, C2^-alkenyt, aryl, heteroaryl, C3-e-heterocyclyl and C3-10-cycloalkyl, wherein each of c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, CWalkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and CiMo-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6alkyl, c1-c6alkoxy, C2_6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C1^-alkyl, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyi, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, c1-c6-alkoxy, C2-6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, C3-icrcycloalkyl, perhalomethyl and perhalomethoxy; wherein R40 and R56 may be covalentiy bound to each other by a C-0 bond. 26. The compound according to claim 25, wherein R4e or R5e is selected from the group con sisting of wherein R6e, R7\ R8e, R9e and R10e are independently selected from hydrogen, hydroxy, sulfanyi, sulfo, halogen, amino, cyano, nitro, Chalky!, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyi, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyi, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-a-heterocyclyI and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyi, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyi, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6alkenyl. 27. The compound according to claim 25, wherein R4* or R56 is selected from the group con sisting of. wherein R6e, R7e, R8e, R9* and R10e are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkoxy, C2-6-aIkenyl, aryl, heteroaryl, C3-s-heterocyclyl and C3-io-cycloalkyi, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, CWalkoxy, CWalkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycIoalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Chalky!, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10 cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Cn-alkoxy and C2^-alkenyl. 28. The compound according to any one of claims 26-27, wherein at least one of the substituents R6e, R7e, R86, R9e and R10e are selected from the group consisting of F and perha-lomethyl. 29. The compound according to claim 25, wherein R4e and R56 are connected by a C-0 bond to form the compound wherein R11e is selected from hydrogen, hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2_e-alkenyl, aryl, heteroaryl, C3_8-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C1-C6B-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ct-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and Cs-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, ^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10 cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-e-alkenyl, aryl, heteroaryl, C3-8-heterocyclyI and C3-10-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and perhalomethoxy, and R12e is selected from hydrogen, F, CI, c1-c6-alkyl, d^-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 30. A compound of the general formula wherein R4f, R5f, R6f, R7f, R9* and R10f are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, Cswrheterocyclyl and C3-io-cyc!oalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Q^o-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2.6-alkenyi, aryl, heteroaryl, c1-c6s-heterocyclyl and C3-io-cycloaIkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Ci-e-alkyI, c1-c6-alkoxy, c1-c6e-alkenyl, aryl, heteroaryl, C3-B-heterocyclyi, and Qj-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocydyl, C3-10-cydoaikyl, perhalomethyl and perhalomethoxy: with the proviso that R* and R5f are not both methoxy; and R8f is selected from hydrogen, sulfo, d-e-alkyl, c1-c6alkoxy, C2.e-alkenyl( aryl, heteroaryl, CW heterocyclyt and c3-c10cycloalkyl, wherein each of sulfo, Chalky!, CWalkoxy, C2-6-alkenyl, aryl, heteroaryl, C«-heterocyclyl and C3_10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen,, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, (^-alkeny!, aryl, heteroaryl, C3-8-heterocyclyI, and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alky!, c1-c6-alkoxy, C2-6-alkenyI, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, perhalomethyl and perhalomethoxy, wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R4f, R5f, RBf, Rn and R*; and wherein there may optionally be a covalent bond between R9f and R10f. 31. The compound according to claim 30, wherein R9f and R10f are covalently bound so as to form a ring system with the C-atom to which they are bound. 32. The compound according to claim 31, wherein said ring system is a cycloalkyl, phenyl, heteroaryl, piperidine, piperazine, morpholine, orthiomorpholine. 33. The compound according to claim 30, wherein R4f and R8f are connected by a C-0 bond to form the compound wherein R11f is selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-10-heterocyclyl and C3-io-cycIoalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6alkenyl, aryl, het-eroaryl, c1-c6-heterocyclyl and C3_10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, ni-tro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, (^.eralkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyl, perhalomethyl and perhalomethoxy; and R17f is selected from hydrogen, F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2J -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl; and wherein there may optionally be a covalent bond between R9* and R10f. 34. The compound according to claim 30, wherein R8f is selected from the group consisting of wherein R12f, R13f, R14f, R15f and R16f are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, d-e-alkyl, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyc!yl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6 alkyl, c1-c6-alkoxy, CM-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, CWalkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C1-6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Q^rheterocyclyl and CS-K,-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyI, perhalomethyl and perhalomethoxy. 35. The compound according to claim 30, wherein only R9f and R10f are covalently bound. 36. A compound of the general formula IX wherein R49, R59, R69, R7g, R*9, R", R100 and R119 are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, c1-c6-alky!, c1-c6-alkoxy, (^B-alkenyl, aryl, het-eroaryl, CM-heterocyclyl and c1-c6io-cycloalkyl, wherein each of c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C-^-alkyl, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-a-heterocyclyl, and Cs-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6aHcyl. Ci_6-alkoxy, C2-e-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, c1-c6s-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and perhalomethoxy: and R129 is selected from the group consisting of -C(=0)-, -C(=0)NH-, -CH2-, -CH2CH2-, -: CHR159-, -CH2CHR15g-, -CHR159-CH2-, -NH-, -NR15g~, -NHC(=0)-, -NR15g-C(=0)-, -O-, -S-, - S(=OK -s(=o)r; wherein R15g is selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, d-e-alkoxy,. C2^-alkenyl, aryl, heteroaryl, C3^-heterocyclyl and C3-io-cycloalkyI, wherein each of hydroxy, sulfanyl, sulfo, amino, Ci-e-alkyI, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2^-alkenyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be one or. more covalent bonds between any of the substituents selected from the group consisting of R49, R5g, R6g, R7fl and R159; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R89, R", R10sf R11fl. and R159; and R13g is selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, c1-c6alkyl, d. e-alkoxy, C2-e-aIkenyl, aryl, heteroaryl, Cw-heterocydyl and C3-io-cycloalkyl, wherein each of C1-6-aIkyl( c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6alkoxy, C2^-alkenyl, aryl, heteroaryl, Cs-e-heterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, G|_ e-alkyl, c1-c6-alkoxy, C2_e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycIoaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6ralkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, Ca^-heterocyclyl and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalky!, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-e-alkyI, c1-c6-alkoxy, C2_6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and perha-lomethoxy: and R14g is selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, C2_6-alkyI, d. 6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of C2_e-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and d-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, d-e-alkoxy, C2^-alkenyl, aryl, heteroaryl, d-s-heterocyclyl, and d-10-cycloalkyI, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, C1r6-alkoxy, d-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and d-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Cve-alkyl, C-i-e-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloaIkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, d-e-alkoxy, C2_6-aIkenyl, aryl, heteroaryl, dwrheterocyclyl and d-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-eralkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Csj-s-heterocyclyl, C2-NH2l -NH-S(=OVOH, hydroxy, amino and perhalornethyl. 44. The compound according to. any one of claims 42-43, wherein there are no covaient bonds between R4h, R5h, R6\ R7h, R8h and R9h. 45. The compound according to any one of claim 42-44, wherein there are no covaient bonds between R10h, R11h, R12h, R13\ R14h and R15h. 46. The compound according to any one of claims 42-45, wherein R15h is hydrogen. 47. The compound according to any one of claims 42-46, wherein R11h and R13h are selected from the group consisting of hydrogen, F, CI, C2-6-alkyl, methoxy, c1-c6-alkoxy, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalornethyl. 48. A compound of the general formula Rs is selected from hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, CWalkyl, c1-c6 alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloaIkyl, wherein each of Ci-e-alkyl, c1-c6-alkoxy, CWalkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3.io-cycloalkyl may. optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6B-alkyl, d-e-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6alkoxy, C2_6-alkenyl, aryl, heteroaryl, Qj-s-heterocyclyl, and Cs.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, C-^-alkyl, c1-c6alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloaIkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, c1-c6-alkoxy, C2^-alkenyI, aryl, heteroaryl, (W heterocyclyl, and c1-c6^-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6 alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl, c3-c10cycloalkyl, perha-lomethyl and perhalomethoxy: and R6i, R71, R*, R9i, R101, R1* and R15i are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3.io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and Ca-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6e-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, Qj-s-heterocyclyU and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6ralkyl, Ci_6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3.8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci_e-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, perhalomethyl and perhalomethoxy: and R11i and R13i are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6alkyl, methoxy, C3-6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, wherein each of sulfanyl, sulfo, c1-c6-alkyl, CsMi-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-a-heterocyclyl and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Cj-e-alkyl, d-ralkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C*.10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, d-e-alkoxy, d-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and d-io-cycloalkyl may optionally be substituted with one. or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-e-alkyI, c1-c6-alkoxy, C2^»alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Ga-io-cycloalkyl, perhalomethyl and perhalomethoxy: and R12 is selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, d-e-alkyl, d^-alkoxy, C2-e-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and d-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-6-alkyl, d-ralkoxy, c1-c6-alkenyl, aryl, heteroaryl, d-s-heterocyclyl and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d^alkyl, c1-c6alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C&.10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyi, d-ralkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, Ci-e-alkyI, d-e-alkoxy, d-e-alkenyl, aryl, heteroaryl, C3_8-heterocyclyl and c1-c6Krcycloalkyl, perhalomethyl and perhalomethoxy. 49. The compound according to claim 48, wherein R6i, R71, R8' and R91 are selected from the group consisting of hydrogen, F, CI, d^-alkyl, d-ralkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)z-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 50. The compound according to any one of claims 48-49, wherein R101, R11i, R12i, R131 and R14i are selected from the group consisting of hydrogen, F, CI, Chalky!, d-ralkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2l -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 51. The compound according to any one of claims 48-50, wherein R1S is hydrogen. 52. The compound according to any. one of claims 48-50, wherein R10i, R11i, R12, R13i, R14i and R15i are selected from the group consisting of H, F and methyl. 53. A compound of the general formula wherein R4', R^', R6j, R71, R8j, R9j and R10j are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyi, c1-c6-alkoxy, C2_6-alkenyl, aryl, het-eroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ci-e-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloaIkyI, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, (Walkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6 alkyl, c1-c6alkoxy, C2-6-aIkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, CWalkenyl, aryl, heteroaryl, Qj-s-heterocyclyl, C3.10-cycloalkyl, perhalomethyl and perhalomethoxy: and wherein there may optionally be a covalent bond between the. substituents RBi and R73; and wherein there may optionally be a covalent bond between Rg and R8]; and R11Jand R1^ are independently selected from cyano, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6e-heterocyclyl and C3-io-cycloalkyl, wherein each of c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, CM-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-e-alkyl, c1-c6-alkoxy, C2_6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and Gs-io-cycloalkyl, perhalomethyl and perhalomethoxy; and with the proviso that R9j and R10j are both hydrogen, there may optionally be a covaient bond connecting R11iand R1^. 54. The compound according to claim 53, wherein R*j, Rs, R6j and R7* are selected from the group consisting of hydrogen, F, CI, d^-alkyl, C-^-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OHf hydroxy, amino and perhalomethyl. 55. The compound according to any one of claims 53-54, wherein at least one of the substituents R4*, R**, R6J and R73 are different from hydrogen. 56. The compound according to claim 53, wherein R8i is covalently bound to R^. 57. A compound of the general formula wherein R4* is selected from hydrogen, hydroxy, sulfanyl, sulfo; halogen, amino, cyano, nitro, c1-c6e-alkyl, Ci.6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci_6-alkyl, c1-c6-alkoxy, C2^-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalky!, C-^-alkoxy, C2^-alkenyi, aryl, heteroaryl, C3-8-heterocyclyl, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, d-e-alkoxy, C2.6-alkenyl, aryl, heteroaryl, CM-heterocyclyl and dt-10-cycloalkyl, perhalomethyl and perhalomethoxy: and Ra is selected from hydroxy, suffanyl, sulfo, halogen, amino, cyano, nitro, d-e-alkyl, d-e-alkoxy, C2^-alkenyI, aryl, heteroaryl, d-e-heterocyclyl and Cs-io-cydoalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, d-e-alkoxy, (Walkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-6-alkyl, d-e-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and Gs^o-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, d-e-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, d-e-alkoxy, C2^-alkenyl, aryl, heteroaryl, dwrheterocyclyl and C3-10-cycioalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, d-e-alkoxy, C2-6~ alkenyl, aryl, heteroaryl, d-e-heterocyclyl, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, d-e-alkoxy, C2.6-alkenyl, aryl, heteroaryl, C3_8-heterocyclyl and c3-c10cycloalkyl, perhalomethyl and perhalomethoxy: with the proviso that when R4k is hydrogen, then R5* is not C(=0)N(Me)2; and R6k, R7kf R8k, R9k, R10k, R11k, R13k and R14k are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, d-e-alkyl, d-e-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3_8-heterocyclyI and C3.io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, d-e-alkoxy, C2_e-alkenyl, aryl, heteroaryl, C3-e-heterocycIyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, d-e-alkoxy, d-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and d-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, d-e-alkoxy, d-e-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-io-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, d-e-alkoxy, d-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, perhalomethyl and perhalomethoxy: and R12k is selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, cyano, nitro, d-e-alkyl, d-e-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, d-e-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Ci-e-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C&r heterocyclyl and C3-io-cycloalkyl may optionally be. substituted with one or more substituents independently selected from hydroxy, sulfanyl, halogen, amino, cyano, n'rtro, sulfo, c1-c6alkyl, Ci_6-alkoxy, c1-c6e-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and c1-c6io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C1.6-alkoxy, C2-e-alkenyl, aryl, heteroaryl, C3. 8-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci_6-alkyl, c1-c6alkoxy, C2-e-alkenylr aryl, heteroaryl, C3-8-heterocydyl and c3-c10cycloalkyl, perhalomethyl and perhalomethoxy. and wherein there may optionally be a covalent bond between any of the substituents selected from the group consisting of R4k, R5k, R7* and R8k; and wherein there may optionally be a covalent bond between R5k and any one of the substituents R7* and R8k; and wherein there may optionally be one or more covalent bonds between R10k, R11k, R12\ R13k and R1458. The compound according to claim 57, wherein the substituents R4k and R5k are connected by a covalent bond. 59. The compound according to any one of claims 57-58, wherein the substituents R5* and R8k are connected by a covalent bond. 60. The compound according to any one of claims 57-59, wherein the substituents R10k and R11k are connected by a covalent bond. 61. The compound according to any one of claims 57-60, wherein the substituents R12k and R13k are connected by a covalent bond. 62. The compound according to any one of claims 57-61, wherein R6k, R7k, R8k and R9k are selected from the group consisting of hydrogen, F, CI, hydroxy, amino, methyl, methoxy, eth-oxy and perhalomethyl. 63.. The compound according to any one of claims 57-59, wherein R10k, R11k, R12\ R13k and R14k are selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, C-^-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH»S(=0)rOH( hydroxy, amino and perhalomethyi. 64. A compound of the general formula wherein R1 is c1-c6-alkyl, c1-c6-alkenyl or c1-c6io-cycloalkyl, each of which is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano and nitro; and R2 is c1-c6alkyl, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, or C3-io-cycloalkyl, each of which is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, c1-c6alkyl, c1-c6alkenyl, aryl, heteroaryl, 0*. s-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, amino, c1-c6-aikyl, Q2-6-alkenyl, aryl, heteroaryl,. C3_8-heterocyclyl and C3-io-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo,. halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3.10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, C3.8-heterocyclyl and C3-io-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, perhalomethyi and perhalomethoxy; with the proviso that when R1 and R2 are identical they are not methyl or benzyl; and R2 is optionally covalently bound to R1 by an ether, thioether or C-C bond, to form a ring system with the N-atom to which R1 and R2 are bound; and Ra, R61, R81, R9V R101 and R111 are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, d-e-alkyl, Ci_6-alkoxy, C2^alkenyl, aryl, heteroaryl, C3-8- heterocydyl and C3_10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, (1^.6-aIkoxy, c1-c6eralkenyl, aryl, heteroaryl, c1-c6rheterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alky!, c1-c6-alkoxy, C2.6-aIkenyl, aryl, heteroaryl, C3-e-heterocyclyl, and C3-io-cycloaIkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6 e-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C-^-alkoxy, C2^alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and CjMo-cycloalkyl, perhalomethyl and perhalomethoxy. and R41 and R71 are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, methoxy, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, wherein each of sulfanyl, sulfo, amino, c1-c6-alkyl, C3-e-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Ca-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3*-heterocyclyl, and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, c1-c6-alkoxy, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloaIkyl, perhalomethyl and perhalomethoxy: and wherein there may optionally be one or more covalent bonds between any of the substituents. selected from the group consisting of R41, Ra, R61, R71, R81, R91, R101 and R111. 65. The compound according to claim 64, wherein R1 and R2 are covalently bound so as to form a ring system with the N-atom to which they are bound. 66. The compound according to claim 65, wherein said ring system is a piperidine, piperazine, morpholine, or thiomorpholine. 67. The compound according to claim 64, wherein there are no covalent bonds between R1 and R2. 68. The compound according to any one of claims 64-67, wherein there are no covalent bonds between Ra and any of the substituents selected from the group consisiting of R91, R101, R11'. 69. The compound according to any one of claims 64-68, wherein there are no covalent bonds between R8! and any of the substituents selected from the group consisting of R4', R51, R61 and R71. 70. The compound according to any one of claims 64-69, wherein there are no covalent bonds between any of the substituents R41, R51, R61, R71, R8!, R91, R10' and R111. 71. The compound according to any one of claims 64-70, wherein R41, Ra, R61 and R71 are selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, Ci-e-alkoxy, -C(=0)NH2( -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 72. A compound of the general formula wherein R4m is selected from hydrogen, sulfo, c1-c6-alky!, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloaIkyl, wherein each of sulfo, C1^-alkyl, c1-c6-alkenyl, aryl, het-eroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, ni-tro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, (Walkenyl, aryl, heteroaryl, CWheterocyclyl, and c3-c10 cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalky!, c1-c6-alkoxy, c1-c6- alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6alkoxy, C2-6-aIkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6e-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and c3-c10cycloaikyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2^alkenyl, aryl, heteroaryl, CWheterocyclyl and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Cn^-alkyl, CWalkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy,, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-e-alkyI, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and perha-lomethoxy: and R5m, R6m, R7m, R8m, R9m, R10m, R11m, R12m, R13m, R14m, R15mand R16m are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, Ci_6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1_6-alkyl, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3.nrcycIoalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ci-e-alkoxy, C2^-aIkenyl, aryl, heteroaryl, c1-c6s-heterocyclyl, and C3-io-cycIoalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyi, and C3_io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-e-alkyI, c1-c6-alkoxy, (Walkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3.10-cycloalkyl, perhalomethyl and perhalomethoxy: and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R4m, R5n\ R6m, R7m and R8m; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9m, R10m, R1lm, R12m, R13m, R14m, R15m and R16m. 73. The compound according to claim 72, wherein there are no covalent bonds between any of the substituents selected from the group consisting of R5m, R6m, R7m and RBm. 74. The compound according to any one of claims 72-73, wherein there are no covalent bonds between any of the substituents R9"1, R10m, R11m, R12m and R13m. 75. The compound according to any one of claims 72-73, wherein there are no covalent bonds between any of the substituents R14m, R15m and R16m. 76. The compound according to any one of claims 72-75, wherein R4m is covalently bound to R6m.. 77. The compound according to any one of claims 72-75, wherein R5m, R6m, R7m, R8m, R9m, R10m, R11m, R12m, R13m and R14m are selected from the group consisting of hydrogen, F, CI, Ci-B-alkyl, d-e-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyi. 78. The compound according to any one of claims 72-77, wherein R14m, R15m and R18m are selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyi. 79.. A compound of the general formula wherein R4" is selected from hydrogen, sulfo, C2_e-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3.10-cycloalkyl, wherein each of sulfo, C2_6-alkyI, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyc!yl and Qj-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, Ci-e-alkyI, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyi, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alky!, d-e-alkoxy, C2_e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, d-e-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3. to-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, d-e-alkoxy, C2^-afkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6alky^ c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-hetero-cyclyl, c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, Ci-e-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and Cs-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyI, perhalomethyl and perhalomethoxy; and Z is selected from S, S(=0) and S(=0)2; and R5n, R6n, R7n, R8n, R9n, R10n, R11n, R12n, R13n and R14n are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C-^-alkyl, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heteroc1-c6clyl and CjMo-cycIoalkyI, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-aikoxy, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-^cloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ci_e-alkoxy, CWalkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^»alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6 alkyl, c1-c6alkoxy, c1-c6e-alkenyl, aryl, heteroaryl, C3_s-heterocyclyl and c3-c10cycloalkyl, perhalomethyl and perhalomethoxy: and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R4n, R5", R6n, R7n and R8n,; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R10n, R11n, R12n and R14n; and at least one of the substituents R5n, R6n, R7n, R8n, R9n, R10n, R11n, R12n, R13n and R14n are different from hydrogen. 80. The compound according to claim 79, wherein there are no covalent bonds between any of the substituents R5n, R6n, R7n and R8n. 81. The compound according to any one of daims 79-80, wherein there are no covalent bonds between any of the substituents R10n, R11n, R12n. 82. The compound according to any one of claims 79-81, wherein R14nis not covalently bound to any other substituent selected from the group consisting of R4n, R5n, R6n, R7nf R8nr plOn D"l1n p!2n 83. The compound according to any one of claims 79-82, wherein R4n is covalently bound to R6n. 84. The compound according to any one of claims 79-82, wherein R5n, R6n, R7n and R8n are independently selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 85. The compound according to any one of claims 79-84, wherein R14n is selected from the group, consisting of hydrogen, F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=O)-0H, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 86. A compound of the general formula wherein R20 is selected from sulfo, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocycly! and c1-c6no-cycloalkyl, each of which may optionally be substituted with one or more substitu- ents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, suffo, CLs-alkyl, c1-c6-alkoxy, C2,6-aIkeny[, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyI> wherein each of the hydroxy, sulfanyl, amino, suffo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-aIkenyII aryl, heteroaryl, C3-6-heterocyclyI, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, C3. 10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyciyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ci-e-alkoxy, c1-c6-alkenyi, aryl, heteroaryl, c1-c6r heterocyclyl, c3-c10cydoalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6alkoxy, C2^alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C-i-e-alkoxy, C2„6-alkenyI, aryl, heteroaryl, Q^s-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy; with the proviso that R20 is not methyl; and R40, R5°, R60 and R70 are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyi, c1-c6ralkoxy, C2^alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, Cve-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, CWheterocycIyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-to-cycloaIkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d. e-alkyl, c1-c6-alkoxy, C2_e-alkenyl, aryl, heteroaryl, C3-B-heterocyclyl, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, perhalomethyl and perhalomethoxy: and A10 is N or C-R80; A20 is N or OR90; A30 is N or C-R100; A40 is N or C-R110;. and A50 is N or C- R120; and wherein R80, R90, R100, R110 and R12° are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and Qwo-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl and c1-c6io-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d^-alkyl, C2-6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, Cs-a-heterocyciyf and c3-c10cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-e-alkyl, c1-c6alkenyl, aryl, heteroaryl, Q^rheterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6alkyl, C2„6-aIkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cydoalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, per-halomethyl and perhalomethoxy; with the proviso that when A1°, A20, A30, A40 and A50 are all CH, and R40, R50, R60 and R70 are all hydrogen, then R2° is not phenyl; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R40, R50, R60, R7°, R8°, R9°, R100, R110 and R120 87. The compound according to claim 86, wherein there are no covalent bonds between any of the substituents R40, R50, R60 and R70. 88. The compound according to any one of claims 86-87, wherein there are no covalent bonds between any of the substituents A10, A20, A30, A40 and A50. 89. The compound according to any one of claims 86-88, wherein R^is selected from the group consisting of cycloalkyl, phenyl, piperidine, piperazine, morpholine, thiomorpholine and heteroaryl. 90. The compound according to any one of claims 86-89, wherein R40, R5°, Reo and R70 are independently, selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, c1-c6alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)rNH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 91. A compound of the general formula wherein R4p is selected from hydrogen, sulfo, C2_6-alkyl, C2-6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of sulfo, C2.$-aIkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl rnay optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, Cn^-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6rheterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3_s-heterocyclyl, C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalky!, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyI, and Cs-io-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, (Walkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and Cs-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C-^-alkoxy, C2^-alkenyI, aryl, heteroaryl, c1-c6s-heterocyclyl, C3-io-cydoalkyl, perhalomethyl and perhalomethoxy: and R5p, R6p, R7p and R^ are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, F, amino, cyano, c1-c6-alkyl, c1-c6-alkoxy, C2-e-alkenyl, aryl, heteroaryl, C3-8-heterocyc!yl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6^-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-a-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, (Walkenyl, aryl, heteroaryl, C3^-heterocyclyl, and Cs-to-cycioalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C«- alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloafkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo( halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl,. c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, Cs-to-cycloalkyf, perhalomethyl and perhalomethoxy; and R9p, R10p, R11p, R12p, R13p, R14p, R15pand R16p are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, d-e-alkyl, c1-c6-alkoxy, c1-c6e-alkeny!, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cydoalkyI, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, Ci-e-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C3^-heterocyc!yl and Cs-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-e-alkyI, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6alkoxy, C2-e-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, d-e-alkoxy, C2-e-alkenyl, aryl, heteroaryl, Cw-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy: and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R5p, R8p and R7p; and wherein there may optionally be a covalent bond between R4p and R5p so as to form a chromen ring system; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R* R10p, R11p, R12p, R13p, R14p, R15pand R16p; and E is selected from the group consisting of -0-, -S-, -S(=0)-, -S(=0)2-, -NR17p- and -CR17pR18p-; and wherein R17p and R18p are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6alkoxy, c1-c6-alkenyl, aryl, heteroaryl, CM-heterocyclyl and c1-c6crcycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, Ct-e-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen,, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ci-e-alkoxy, Cu-alkenyl, aryl, heteroaryl, C3-8-heterocyclyI, and c1-c6trcycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d. 6-alkyl, c1-c6-alkoxy, d-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyciyl, and C3-io-cycIoalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2^-aikenyl, aryl, heteroaryl, C3-s-heterocyclyl, C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, d-e-alkoxy, c1-c6alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cydoalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, C3-e-heterocyclyl, c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Ci_e-alkyl, c1-c6-alkoxy, d-e-alkenyl, aryl, heteroaryl, Q^-heterocyclyl, and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6 alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy. 92. The compound according to claim 91, wherein E is selected from the group consisting of -O- and -CR17pR18p-. 93. The compound according to claim 91, wherein R4p and R5p are connected by a covalent bond so as to. form said chromen ring system. 94. The compound according to claim 93, wherein R4p and R5p are. connected by a covalent bond so as to form the chromen ring system i wherein R19p is selected from the group consisting of hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6s- heterocyclyl and C3-i0-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, Cve-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocydyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-e-alkyI, Ci-e-alkoxy, C2^alkenyl, aryl, heteroaryl, C3-rheterocyclyI, C3-io-cycloalkyI, perhalomethyl and perhalomethpxy. 95. The compound according to any one of claims 91-92, wherein R4p is selected from the group consisting of wherein R20*, R21p, R2^, R239 and R24p are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocydyl and c3-c10cydoalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyI, aryl, heteroaryl, C3-s-heterocyc!yl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6alkyl, c1-c6-alkoxy, C2-6-alkenyl, perhalomethyl and perhalomethoxy. 96. The compound according to any one of claims 91-92, wherein there are no covalent bonds between any of the substituents R4p, R5p, R6pt R7p and R8p. 97. The compound according to any one of claims 91-96, wherein there are no covalent bonds between any of the substituents R9p, R10p, R11p, R12p, R13p, R14p, R15pand R16p. 98. The compound according to any one of claims 91-96, wherein R10p and R11p are connected by a covalent bond. 99. The compound according to claim 91-97, wherein R9p, R10p, R11p, R12p, R13p, R14p, R15pand R16p are independently selected from hydrogen, F, CI, C-i.e-alkyl, d-e-alkoxy, -C(=0)IMH2, -NHC(=0)-OH) -S(=0)2-NH2| -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 100. The compound according to any one of claims 91, 92,95-99, wherein R5p, R6p, R7p and RBp are independently selected from hydrogen, F, CI, c1-c6-aikyl, c1-c6-alkoxy, -C(=0)NH2, -NHc1-c6OJ-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 101. A compound of the general formula wherein R4q, R6q, R7q, R9q, R10q, R11q, R12q, R13q, R14q, R15q, R16q, R17q,and R18q are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, Chalky!, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Ca-io-cycloalkyl may optionally be substituted with one or more sub-st'rtuents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, d-e-alkoxy, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, CW-alkenyl, aryl, heteroaryl, C3-B-heterocyclyl, C3.i0-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and C3_10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, C3*-heterocyclyl, C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d^-alkyl, c1-c6-alkoxy, CWalkenyl, aryl, heteroaryl, C3^-heterocycIyl, and C3-io-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C«-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy: and R5* and R8* are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, F, Br, amino, cyano, nitro, c1-c6-alkyl, d-e-alkoxy, CWalkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10 cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alky!, c1-c6-alkoxy, C2_6-alkenylr aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, suifo, c1-c6-alkyl, c1-c6-alkoxy, CWalkenyl, aryl, heteroaryl,'C3_8-heterocyclyl, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-B-heterocyclyl, C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.e-a!kenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perha-lomethoxy: and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of Ft4*, R5q, R6q, R7q and R8* and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9q, R10q, R11q, R12q, R13q, R14q, R15q, R16q, R17q and R18q. 102. The compound according to claim 101, wherein R^ and R6q are connected by a covalent bond. 103. The compound according to claim 101, wherein R^ is selected from the group consisting of substituted heteroaryl and substituted C3-s-heterocyclyl. 104. The compound according to any one. of claims 101 and 103, wherein R4q is selected from the group consisting of wherein R19q, R20q, R™\ R22* and R23" are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, het-eroaryl, c1-c6-heterocyclyl and c1-c6io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6alkyl, G^-alkoxy, c1-c6-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10 cycloalkyl may optionally be substituted with one or more substituents independently, selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloaIkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Chalky!, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, Cve-alkyl, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Ci_6-alkylf c1-c6e-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3_8-heterocyclyl and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, CM-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy. 105. The compound according to any one of claims 101 and 103-104, wherein there are no covalent bonds between any of the substituents R4^ R5q, R6q, R7q and RBq. 106. The compound according to any one of claims 101-105, wherein there are no covalent bonds between any of the substituents R9q, R10q, R11q, R12q, R13q, R14q, R15q' R16q, R17q and R18q. 107. The compound according to any one of claims 101-105, wherein R10p and R11p are connected by a covalent bond. 108. The compound according to any one of claims 101-105, wherein R11p and R13p are con nected by a covalent bond. 109. The compound according to any one of claims 101-106, wherein R9q, R10q, R11q, R12q, R13qf R14q( R15q, R16q, R17q and R18q are independently selected from hydrogen, F, CI, c1-c6 alkyl. c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=OyOH, hydroxy, amino and perhalomethyl. 110. The compound according to any one of claims 101-106 and 109, wherein R9q, R10q, R11q, R12qf R14q, R15q, R16qt R17q and R18q are all hydrogen or F. 111. The compound according to any one of claims 101 and 103-110, wherein R^, R6qf R7q and R8q are independently, selected from hydrogen, F, CI, c1-c6-alkyl, d-e-alkoxy, -C(=0)NH2> -NHC(=0)-OH, «S(=0)2-NH2, -NH-S(=0)rOH, hydroxy, amino and perhalomethyl. 112. A compound of the genera! formula wherein R^ is selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, d^-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3.io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C-j-6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10 cycloalkyl, wherein each of the hydroxy, sulfanyl, sulfo, Ci-e-alkyI, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C3-a-heterocyclyl, C3-to-cycloalkyl, perhalomethyl and perhalomethoxy: provided that R4ris not methyl or phenyl; and R* R6r, R7r, R8r, R9r, R10r, R11r, R12r, R13r, R14r, R15r, R16r, R17p and R18r are independently selected from hydrogen, hydroxy, sulfanyl, sulfa, F, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, whereia each of hydroxy, sulfanyl, sulfo, amino, c1-c6alkyl, d^-alkoxy, c1-c6e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Cs-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ci-e-. alkoxy, C2^-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-i0-cycloalkyl, perha-lomethyl and perhalomethoxy: and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R5r, R6r, R7r and R8r; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9r, R10r, R11r, R12r, R13r, R14r, R15r, R16r, R17r and R18r. 113. The compound according to claim 112, wherein R* and R5r are connected by a covalent bond. 114. The compound according to claim 112, wherein R4r is selected from the group consist ing of substituted heteroaryl and substituted c1-c6s-heterocyclyl. 115. The compound according to any one of claims 112 and 114, wherein R4r is selected from the group consisting of wherein R19r, R20r, R21r, R2* and R23' are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, d-e-alkoxy, C2^-alkenyl, aryl, heteroaryl, d-e-heterocyclyl and c3-c10cycioalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1BC-alkyl, d-e-alkoxy, d-e-a'kenyl, aryl, heteroaryl, c1-c6-heterocydyl and d-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, d-r-alkyl,. d-6-aIkoxy, C2-e-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and d-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-s-alkyl, c1-c6-alkoxy, d-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and CMO-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, d-s-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, d-a-heterocyclyl and c1-c6io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, G^-alkoxy, d^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and d-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, sulfo, Qt-6-aIkyl, d-e-alkoxy, C2^-alkenyl, aryl, heteroaryl, d-8-heterocyclyl, c3-c10cycloalkyl, perha-lomethyl and perhalomethoxy. 116. The compound according to any one of claims 112-115, wherein there are no covalent bonds between any of the substituents R5r, R6r, R7r and R8r. 117. The compound according to any one of claims 112-116, wherein there are no covalent bonds between any of the substituents R* R10rf R11r, R12r, R13r, R14r, R15r and R16r. 118. The. compound according to any one of claims 112-116, wherein R10r and R11r are connected by a covalent bond. 119. The compound according to claim 116, wherein R11r and R13r are connected by a covalent bond. 120. The compound according to any one of claims 112-116, wherein R9r, R10r, R1lr, R12r, R13r, R14r, R15r, R16r, R17r and Rn8r are independently selected from hydrogen, F, CI, d-e-alkyl, d-e-alkoxy, -C(=0)NH2l -NHC(=0)-OH, -S(=0)rNH2, -NH-S(=O)r0H, hydroxy, amino and perhalomethyl. 121. The compound according to any one of claims 112-117 and 120, wherein R9r, R10r, R11r, R12r, R14r, R15r, R16r, R17r and R18r are all hydrogen or F. 122. The compound according to any one of claims 112 and 114-121, wherein R5r, RBr, R7r and R8r are independently selected from hydrogen, F, CI, Chalky!, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0);rOH, hydroxy, amino and pertnalomethyl. 123. A compound of the general formula wherein A1s is N or C-R17s; A25 is N or C-R18s; A3s is N or C-R19s; A4s is N or C-R20s; and A5s is N or C-R21s; and wherein R17s, R18s, R19s, R20s and R21s are independently selected from hydrogen, hydroxy, sulfanyl, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3_s-heterocycIyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10 cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2^-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyi is. optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, c1-c6e-alkyl, C2^-alkenyl, aryl, heteroaryl, CWheterocyclyl and Cs-io-cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkenyU aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, amino, sulfo, C-^-alkyl, C2^alkenyl, aryl, heteroaryl, Oj-s-heterocyclyl and c1-c6io-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, Cs-io-cycloalkyl, perhalomethyl and perhalomethoxy; and R5s, R68, R7s and R8s are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, F, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cw-heterocyclyl and Cs-io-c1-c6cloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.e-alkenyl, aryl, heteroaryl, c1-c6r heterocyclyl, and C3-io-cycioalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, Ci-e-alkoxy, c1-c6alkenyl, aryl, heteroaryl, c1-c6s-heterocyclyl, and Cs-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^alkenyl, aryl, heteroaryl, c1-c6e-heterocyclyl, CiMcrcycloalkyl, perhalomethyl and perhalomethoxy: and R9S, R10s, R11s, R12s, R13s, R14s, R15s and R16s are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, F, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3_a-heterocyclyl and C3-io-cycIoalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Chalky!, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, c1-c6-alkoxy, C2.e-alkenyl, aryl, heteroaryl, c1-c6s-heterocyclyl, and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, Ci-e-alkoxy, C2_e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c1-c6^-cycloalkyl, perhalomethyl and perhalomethoxy: and E is selected from the group consisting of -0-, -S-, -S(=0)-, -S(=0)2-, -NR225- and -CR^R235-; and wherein R225 and R23s are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alky!, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, d-e-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, CWalkoxy, (Walkenyl, aryl, heteroaryl, c1-c6B-heterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfany!, amino, sulfo, d. e-alkyl, c1-c6-alkoxy, (W-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-i0-cycloaIkyl may optionally be substituted with one. or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-e-alkyl, c1-c6-alkoxy, c1-c6alkenyl, aryl, heteroaryl, c1-c6rheterocyclyl, C3-io-cycIoaIkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R58, R68, R7s and R8s; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9s, R10s, Rl1s, R12s, R13s, R14s, R15s, R16s, R18s. R19s, R208, R21s, R226 and R235. 124. The compound according to claim 123, wherein E is selected from the group consisting of.-O-and-CR^R235-. 125. The compound according to any one of claims 123-124, wherein there are no covalent bonds between any of the substituents R5s, R6s, R7s and RBs. 126. The compound according to any one of claims 123-125, wherein R5s, R6s, R7s and R8s are independently selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, Ci_e-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)rOH, hydroxy, amino and perhalomethyl. 127. The compound according to any one of claims 123-126, wherein there is a covalent bond between R10s and R11s. 128. The compound according to any one of claims 123-127, wherein there is a covalent bond between R13s and R228. 129. The compound according to any one of claims 123-126, wherein R9s, R10s, R11s, R128, R13s, R14s, R15s and R16s are all hydrogen or R 130. A compound of. the general formula wherein E is selected from the group consisting of -0-, -S-, -S(=0)-, -S(=0>2-, -NR18t- and -CR18tR19t-; and R41, R5t, Rm, R7t, R*, R91, R10t, R1tt, R12t, R131, R14t, R15t, R16t, R17t, R18t and R19t are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, nitro, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl and C3-io-cycIoalkyi, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyciyl and C3_i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, d-e-alkyl, c1-c6e-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl, and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, c1-c6-alkyl, d-e-alkoxy, C2-6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C3-B-heterocydyl, and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, c1-c6-alkyl, C-j-e-alkoxy, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl, and C3-i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, Ci-e-alkyl, c1-c6-alkoxy, (Walkenyl, aryl, heteroaryl, C3-8-heterocyc!yl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy; with the proviso that R4t and R5t are not both methyl; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9t, R10t, R11t, Riat R13t, R14t, R15t, R16t, R17t,R18t and R19t. 131. The compound according to claim 130, wherein E is selected from the group consisting of -0-, -S-, -S(=OH -S(=0)r and -CR18lR19t-. 132. The compound according to any one of claims 130-131, wherein R18t is hydrogen or F. 133. The compound according to any one of claims 130-132, wherein R10t, R12t, R4t and R61 are all hydrogen. 134. The compound according to any one of claims 130-132, wherein R6t, R7t, R8t and R91 are independently selected from the group consisting of hydrogen, F, CI, C-i-e-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 135. The compound according to any one of claims 130-134, wherein there is a covalent bond between R11t and R131. 136. The compound according to any one of claims 130-135, wherein there is a covalent bond between R13t and R19t. 137. The compound according to any. one of claims. 130-134, wherein R10\ R11t, R12t, R13t, R14t, R15t, R16t and R17t are all hydrogen or F. < 138. A compound of the general formula wherein R4u, R5u, R6U, R7u, R8u, R90, R10u, Rl1u, R12u( R13u, R14u and R15u are independently selected, from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkoxy, CWalkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c1-c6crcycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-8-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c1-c6Krcydoalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, (^-alkenyl, aryl, het-eroaryl, C3-8-heterocyclyI, and c1-c6io-c1-c6cloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, ni-tro, sulfo, d^-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-e~heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C-^-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycioalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, c1-c6Krcycloalkyl, perhalomethyl and perhalomethoxy: with the proviso that R4", R5u and R6u are not all hydrogen; and E is selected from the group consisting of -0-, -S-, -S(=0>, -S(=0)2-, -NR16u- and _CR16UR17US wherein R16u and R17u are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, Chalky!, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6e-alkoxy, C2_6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3_i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-e-alkenyI, aryl, heteroaryl, CM-heterocyclyl, and C3_10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d. 6-alkyl, C-i-e-alkoxy, c1-c6alkenyl, aryl, heteroaryl, c1-c6heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci.6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Ca-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, Ci-6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-e-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R4u( R5u and R6u; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R8u, R9u, R10u and R11u; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R12u, R13u, R14u, R15u, R16u and R17u. 139. The compound according to claim 138, wherein E is selected from the group consisting of -0-, -S-, -S(=Oh -S(=0)2- and -CR16uR17140. The compound according to any one of claims 138-139, wherein R17u is hydrogen or F. 141. The compound according to any one of claims 138-140, wherein there are no covalent bonds between any of the substituents R8U, R90, R10u and R11u. 142. The compound according to any one of claims 138-141, wherein R8u, R9u, R10u and R11u are independently selected from the group consisting of hydrogen, F, CI, d-e-alkyl, Ci-e" alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0}2-NH2, -NH-S(=0)2-OH, hydroxy, amino and per-halomethyl. 143. The compound according to any one of claims 138-142, wherein there is a covalent bond between R12u and R13u. 144. The compound according to claim 138-142, wherein R12u, R13u, R14u and R15u are all selected from the group consisting of hydrogen, F, methyl and c1-c6-alkyl. 145. A compound of the general formula wherein R4v, R5*, R6v, R7\ R8v, R9*, R10v, R11v, R12v, R13v, R14v, R15v, R16v, R17v and R18v are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C-i-e-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, Ci.B-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-s-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10 cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alky!, c1-c6e-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6e-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocydyl and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2_6-alkenyIf aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6e-alkyl, c1-c6-aikoxy, C2^-alkenyl, aryl, heteroaryl, CM-heterocycIyl, c3-c10cycloalkyl, perhalomethyl and perhalomethoxy; with the proviso that none of the substituents R4v, R5v and R6v are benzothiazolyl or benzooxazolyl; and E is selected from the group consisting of -0-, -S-, -S(=0)-, -S(=0)2-, -NR19v- and. -CR^R**-; and wherein R19v and R20v are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alky!, (Walkenyl, aryl, heteroaryl, CM-heterocyclyl and C3. io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^-alkenyI, aryl, heteroaryl, Cs-s-heterocyclyl, and c3-c10 cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-B-heterocycfyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci_6-alkyl, C2_6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy, and wherein there may optionally be a covalent bond between the substituents R7v and R8v or between the substituents R9* and R10v; and wherein there may optionally be a covalent bond between R6v and a substituent selected from R8v and R9*; and wherein there may be a covalent bond between any of the substituents selected from the group consisting of R4v, R5v and RSv; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R"v, R12v, R13v, R14v, R15v, R16v, R17v, R18v, R19v and R20v. 146. The compound according to claim 145, wherein E is selected from the group consisting of -0-, -S-, -S(=Oh -S(=0)2- and -CR19vR20v-. 147. The compound according to claim 145, wherein R20v is hydrogen or F. 148. The compound according to any one of claims 145-147, wherein there are no covalent bonds between any of the substituents R4vf R5v and R6*. 149. The compound according to any one of claims 145-148, wherein there are no covalent bonds between any of the substituents R7v, R8v, R9* and R10v. 150. The compound according to any one of claims 145-149, wherein there are no covalent bonds between a substituent selected from the group consisting of R4v, R5v and R6v and a substituent selected from the group consisting of R7v, R8v, R9v and R10v. 151. The compound according to claim 145-150, wherein R7v, R8v, R9v and R10v are independently selected from the group consisting of hydrogen, F, CI, Chalky!, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)rNH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 152. The compound according to claim 145-151, wherein there is a covalent bond between R12v and R13v. 153. The compound according to any one of claims 145-151, wherein R11v, R12v, R13v, R14v, R15v, R16v, R17v and R18v are all hydrogen or F. 154. A compound of the general formula wherein R4w is selected from hydrogen, hydroxy, amino, suifo, c1-c6alkyl, C2_e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, amino, sulfo, Chalky!, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyc!yl and C$.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, (^-alkenyl, aryl, heteroaryl, c1-c6-heterocydyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Ci_e-alkyl, c1-c6alkoxy, C2-6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and Quo-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, d-e-alkyl, c1-c6-alkoxy, C2^-alkenylf aryl, heteroaryl, C3.B-heterocyclyl and Cs-io-cydoalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Ci. e-alkyl, Ci_6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyciyl, and Cs-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfa, C1-6aikyl, C-^e-aikoxy, C2^-aIkenyi, aryl, heteroaryl, c1-c6-heterocydyl, Cs-io-cycloalkyl, perhalomethyl and perhalomethoxy: with the proviso that R4* is not methyl, morpholine or a 2-chromen derivative; and Z is selected from S, S(=0) and S(=0)2; and R*\ R**, R7", R*\ R*", R10w, R11w, R12*, Rn3w, R14w, R15w and R16w are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nltro, Ci-r-aJkyl, G>.6-aikoxy, C2-ralkenyl, aryl, heteroaryl, Cs^-heterocyclyl and Cs-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Chalky!, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, CM-heterocyclyl and c3-c10cycloalkyi may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and CM0-cycloalkyI, wherein each of the hydroxy, sulfanyl, amino, sutfo, c1-c6-alkyl, C-^-alkoxy, C2^alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and C3-io~cycloaikyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ci-e-alkoxy, C2.«ralkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and CMo-cycloalkyl, perhalomethyl and perhalomethoxy: and E is selected from the group consisting of -O-, -S-, -S(=0)-, -S(=0)2-, -NR17w- and. -CR17wRl8ws and wherein R17wand R18w are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyciyl and c1-c6io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2^-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Ca-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6alkyi, c1-c6-alkoxy, c1-c6B-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyi, and C3.10-cycloaikyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Cv e-alkyl, c1-c6-alkoxy, C2-ralkenyl, aryl, heteroaryl, Cs^-heterocyciyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2-6-alkenyt, aryl, heteroaryl, c1-c6-heterocyciyi, c3-c10cycloalkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be one or more covalent bonds between any. of the substituents selected from the group consisting of R4w, R5", R6w, R7w and R8w; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9w, R10w, R11w, R12w, R13w, R14w, R15w, R16w, R17w and R1Sw. 155. The compound according to claim 154, wherein the only substituents which are cova-lently bound are R4* and R5*. 156. The compound according to any one of claims 154-155, wherein there are no covalent bonds between any of the substituents R* R6w, R7w and R8". 157. The compound according to any one of claims 154-156, wherein there are no covalent bonds between any of the substituents R9w, R10w, R11w, R12w, R13w, R14wt R15w and R16w. 158. The compound according to any one of claims 154-157, wherein E is selected from the group consisting of -0-, -S-, -S(=0)-, -S(=0)2- and -CR17wR18w~. 159. The compound according to any one of claims 154-158, wherein R18w is hydrogen or F. 160. The compound according to any one of claims 154 and 156-159, wherein R5*, R6W, R7w and R8* are independently selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy; amino and perhalomethyL 161. The compound according to any one of claims 154,156 and 158-160, wherein there is a covalent bond between R10w and R11w. 162. The compound according to claim 154,156 and 158-161, wherein there is a covalent bond between R13w and R17w. 163. The compound according to any one of claims 154-160, wherein R9*, R10w, R11w, R12w, R13w, R14w, R15w and R16w are all hydrogen or F. 164. A compound of the general formula wherein R4x is selected from imino, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyciyl and C3-io-cycloalkyl, wherein each of imino, c1-c6-alkyl, C2^-aIkenyl, arylf heteroaryl, c1-c6-heterocydyl and C3_io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyII aryl, heteroaryl, Cs_ 8-heterocyclyl, and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^alkenyl, aryl, heteroaryl, Qwrheterocyclyl, c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, d-e-aikoxy, C2^-alkenyl, aryl, heteroaryl, Ca-s-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, CWalkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6e-heterocyclyl, Qj-io-cycloalkyl, wherein each of the hydroxy, sulfanyl,. amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyi may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, c1-c6alkyl, Ci-e-alkoxy, C2^-alkenyl, pertialomethyl and perhalomethoxy; and R5x, R6x, R7x, R8x, R9x, R10x, R11x, R12x and R13x are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-aJkyl. c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-i0-cycloalkyI, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl and Cwo-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl, wherein each of the hy- droxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-aikenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2-6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, c1-c6io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6alkyl, c1-c6-alkoxy, C2-B-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6s-heterocyclyl, C3.10-cycloalkyl, perhalomethyl and perhalomethoxy; and E is selected from the group consisting of -0-, -S-, -S(=0)-, -S(=0)r. -NR14x- and -CR15xR16x-; wherein R14x is selected from hydrogen, sulfo, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3.to-cycloalkyl, wherein each of sulfo, c1-c6-alky!, C2-e-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.eralkenyl, aryl, heteroaryl, c1-c6-heterocycIyl, and Cs-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, Cn-e-alkyl, Ci-e-alkoxy, C2_6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, C3-KrcycloaIkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, d^-alkoxy, C2-6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2_6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c1-c610-cycloalkyl, perhalomethyl and perhalomethoxy; and R15x and R16x are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, C-i-e-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6Krcycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, Cs-s-heterocyciyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-i heterocyclyl, and c1-c6io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6 alkyl, C-j-e-alkaxy, c1-c6s-alkenyl, aryl, heteroaryl, C3-s-heterocyclyI, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, d^-alkoxy, C2^-aIkenyl, aryl, heteroaryl, CW-heterocyclyl, C3-10-cycloaIkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be a covalent bond between the substituents R4x and R5x; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R6x, R7x, R^ and R9x; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R10x, R11x, R12x, R13x, R14x, R15x and R16x. 165.. The compound according to claim 164, wherein R6x, R7x, R8x and R^ are independently selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2»NH2, -NH-S(=0);rOH( hydroxy, amino and perhalomethyl. 166. The compound according to any one of claims 164-165, wherein R10x, R11x, R12x and R13x are independently selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and per-halomethyl. 167. The compound according to any one of claims 164 and 166, wherein there is a covalent bond between the substituents R6x and R7x. 168. The compound according to any one of claims 164-165, wherein there is a covalent bond between the substituents Rnox and Rm. 169. The compound according to any one of claims 164-165 and 167, wherein there is a covalent bond between R10x and a substituent selected from R14x and R15x. 170. A compound of the general formula wherein R4y and R11y are independently selected from imino, CWalkyl, C2-6-aIkenyl, aryl, heteroaryl, CM-heterocyclyl and c1-c6urcycloalkyl, wherein each of imino, c1-c6-alkyl, C2^-aIkenyIf aryl, heteroaryl, Cs-s-heterocyclyl and dj-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, c1-c6-alkyl, Ci-e-alkoxy, C2^-alkenylI aryl, heteroaryl, C3-8-heterocyclyl, and c3-c10 cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c1-c6io-cycloalkyl may optionally, be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, d_e-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3. 10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-i0-cycIoalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c1-c6 10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and QMo-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, nitro, sulfo, C-^-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, perhalomethyl and perhalomethoxy; and R5y, R6y, R7y, R8y, R9y and R10y are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, C-^-alkoxy, C2-6-alkenyl, aryl, heteroaryl, CM-heterocyclyl and C3-io-cydoalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6e-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen,'amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-icrcycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C,. e-alkyl, c1-c6-alkoxy, c1-c6-s-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyi, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, c1-c6-alkoxy, C2.e-alkenyl, aryl, heteroaryi, CW-heterocyclyl, c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Ci-e-alkyI, c1-c6alkoxy, c1-c6-alkenyl, aryl, heteroaryi, c1-c6s-heterocyclyl, and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyI1 aryl, heteroaryi, c1-c6-heterocyclyl, C3-i0-cycloalkylf wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyi, aryl, heteroaryi, CWheterocyclyl, and c3-c10cycloalk^ may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryi, c1-c6-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be a covalent bond between the substituents R4y and R5y; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R6y R7y, R8y and R9*; and wherein there may optionally be a covalent bond between the substituents R10y and R11y. 171. The compound according to claim 170, wherein R6y, R7y, R8y and R9* are independently selected from the group consisting of hydrogen, F, CI, C-^-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 172. The compound according to any one of claims 170-171, wherein there are no covalent bonds between any of the substituents R6y, R7y, RBy and R9y. 173. The compound according to any one of claims 170-172, wherein there is a covalent bond between the substituents R4y and R5y. 174. The compound according to any one of claims 170-173, wherein there is a covalent bond between the substituents R10y and R11y 175. A compound of the general formula '8z R wherein R4z, R82, R92, R102, R112, R12z, R132, R142, R152, R162 and R17z are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, d-e-alkyl, c1-c6-alkoxy, C2^-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ct-e-alkoxy, C2_e-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and C3_io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alky!, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.i0-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-e-heterocycIyl, and Ca-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and perhalomethoxy; and R52 is a carbon bound substituent selected from c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, CM-heterocyclyl and C3-io-cycloalkyl, each of which may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl, and CiMo-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-i0-cycloalkyi may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, Ci-6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, Cwrheterocyclyl, Cs-no-cycloalkyl, perhalomethyl and perhalomethoxy; and R62 and R7z are independently selected from hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, Ci-e-alkyl, c1-c6-alkoxy, C2-6-alkeny!, aryl, heteroaryl, c1-c6-heterocycIyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2-e-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-iQ-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C-^alkoxy, C2.6-aIkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloa!kyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6 alkyl, c1-c6-alkoxy, C2.e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl, and c3-c10 cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sutfo, c1-c6-alkyl, c1-c6e-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and perhalomethoxy; and E is selected from the group consisting of -0-, -S-, -S(=0)-, -S(=0)2-, -NR18z- and -CR19^202-; wherein R1Bz is selected from hydrogen, sulfo, c1-c6-alkyl, C2_6-alkenyI, aryl, heteroaryl, C3-8-heterocyclyl and Cs-io-cycloalkyl, wherein each of sulfo, c1-c6-alkyl, C2-e-alkenyl, aryl, heteroaryl, C3_8-heterocyclyl and C3-io-cydoalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, C-^-alkyl, c1-c6-alkoxy, C2^-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycioaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C-wrheterocyclyl, Ca-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, Q^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and perhalomethoxy; and R19z and R2te are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, Chalky!, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2-e-alkenyl, aryl, heteroaryl, C$s-heterocyclyl, and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6 alkyl, c1-c6alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c1-c6io-cycloalkyi, perhalomethyl and perhalomethoxy; and wherein there may optionally be a covalent bond between the substituents R4z and R52; and wherein there may optionally be a covalent bond between any of the substituents R7z, Rte, and R9*; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R10z, Rm, R12z, R13z, R14z, R15z, R16z, R17z, R18z, R19z, and R20*. 176. The compound according to claim 175, wherein there is a covalent bond between the substituents R4z and R5z. 177. The compound according to any one of claims 175-176, wherein R6z, R7z, R8z and R92 are independently selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2f -NHC(=0)-OH, -S(=0)2-NH2| -NH"S(=0)rOH, hydroxy, amino and perhalomethyl. 178. The compound according to any one of claims 175-177, wherein there is a covalent bond between R13z and a substituent selected from R18z and R19z. 179. A compound of the general formula wherein R433 is selected from hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyi, C2^-alkenyl, aryl, heteroaryl, Qwrheterocyclyl and C3_1crcycloalkyl, each of which may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2_6-alkenyl» aryl, heteroaryl, C3_8-heterocyclyl, and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycioaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2_e-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, CsMo-cycloalkyl, wherein each of the. hydroxy, sulfanyl, amino, sulfo, c1-c6-alky!, c1-c6-alkoxy, c1-c6alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perha-lomethoxy; and R5aa, R633, R7aa, R8aa, R933, R10aa, R11aa, R12aa and R13aa are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkoxy, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyciyl and c1-c6io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2_6-alkenyI, aryl, heteroaryl, C-^-heterocyclyl and C3-io-cydoalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C1-6-alkoxy, C2.$-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, and Cs-io-cycloalkyl, wherein each of the hydroxy, suifanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, ^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.no-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c1-c6trcycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-aIkenyIr aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl* c1-c6-alkoxy, C2-6-aIkenyl, aryl, heteroaryl, C3-e-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be a covalent bond between the substituents R5aa and R6aa or between the substituent R7aa and R8aa; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9aa, R10aa, R11aa and R12aa; and E is selected from the group consisting of -0-, -S-, -S(=0)- and -S(=0)2-. 180. The compound according to claim 179, wherein there is a covalent bond between the substituents R9aa and R10aa. 181. The compound according to any one of claims 179-180, wherein R5aa, R6aa, R7aa and R8aa are independently selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, d.e-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)z-OH, hydroxy, amino and perhalomethyl. 182. The compound according to any one of claims 179-181, wherein at least one of the substituents R5aa, R688, R7aa and R8aa are different from hydrogen. 183. A compound of the general formula wherein R4^ is selected from sulfanyl, sulfo, amino, c1-c6-alkyl, C2-s-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and Gs-io-cycioalkyl, each of which may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2_e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cydoalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C1^-aIkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, CWalkenyl, aryl, heteroaryl, C3-B-heterocycfyl, C3-«rcydoaIkyI, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C-j-e-alkoxy, C2^-alkenyI, aryl, heteroaryl, c1-c6-heterocyctyl, and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyi, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy; and E is selected from the group consisting of -NR13ab- and -CR14abR15ab-; and R5ab, R6ab, R7ab, R8ab, R9ab, R10ab, R11af\ R12ab, R13ab, R14ab and R15ab are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, d-e-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, C«-heterocyclyl and C3-io"Cydoalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cydoalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6a-heterocyclyl, and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2.6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-oycloalkyI, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-io-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ci-e-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be a covalent bond between the substituents R5ab and R6ab or between the substituent R7aband R8ab; and wherein there may optionally be one or more covalent bonds between any of the substituents selected from the group consisting of R9ab, R10ab, R11ab, R12ab, R13ab, R14ab and R15ab. 184. The compound according to claim 183, wherein there is a covalent bond between the substituents R9ab and R10ab. 185. The compound according to any one of claims 183-184, wherein there is a covalent bond between R10ab and a substituent selected from R13ab and R14ab. 186. The compound according to any one of claims 183-185, wherein R5ab, R6ab, R7ab and Rteb are independently selected from the group consisting of hydrogen, F, CI, c1-c6»alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=OK>H. -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and per-haiomethyl. 187. The compound according to any one of claims 183-186, wherein at least one of the substituents R5ab, R6ab, R7ab and RBab are different from hydrogen. 188.. The compound according to any one of claims 183-187, wherein at least one of the substituents R^, R10ab, R11ab,.R12ab, R13ab, Ruab and R15ab are different from hydrogen. 189. A compound of the general formula wherein R4ac is a carbon bound substituent selected from c1-c6-alkyl, c1-c6-alkenyl, arylr het-eroaryl, c1-c6-heterocydyl and Cs-nrcycloalkyl, each of which may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and Ca-nrcycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Ct-e-alkyl, c1-c6-alkoxy, C2„6-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alky!, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, (^-heterocyclyl, c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalky!, c1-c6alkoxy, C2^-alkenyl, aryl, heteroaryl, Cs-s-heterocydyl, and c1-c610-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perha-lomethoxy; and R5ac, R680, R7ac, R830, R9ac, R10ac and R11ac are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, Ci-e-alkoxy, (Walkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Chalky!, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-e-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkoxy, C2_e-alkenyl, aryl, heteroaryl, C3_g-heterocyclyl, c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C1fc6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.10-cycloalkyi may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano,. nitro, sulfo, Ci-e-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-10-cycloalkyl, perhalomethyl and perhalomethoxy; with the proviso that A3ac is not C-C(OH)(CF3)2; and R12ac and R13ac are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2-6-alkoxy, C2_6-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyi and C3.io-cycloalkyl, wherein each of sulfanyl, sulfo, amino, c1-c6-alkyl, C2-e-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyctyl and C3-i0-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c1-c6io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6alkyl, C-^-alkoxy, C2-6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alky!, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cydoaIkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c1-c6io-cycloalkyl may optionally be substituted with one. or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c1-c6io-cycloalkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be a covalent bond between R4ac and a substituent selected from the group consisting of R5ac and R6aa; with the proviso that A1ac, A230, A3ac, A4ac and A5ac are not ail CH; and wherein there may optionally be a covalent bond between any of the substituents R6ac, R7ac and R830; and wherein there may optionally be one or more covalent bonds between any of the substituents in A1ac, A230, A380, A430 and A5ac. 190. The compound according to claim 189, wherein there is a covalent bond between the substituents R430 and R6ac. 191. The compound according to any one of claims 189-190, wherein there is a covalent bond between A3ac and A4ac. 192. The compound according to any one of claims 189-191, wherein there is a covalent bond between A330 and A230. 193. The compound according to any one of claims 189 and 191-192, wherein R530, R6ac, R7ac and RSac are independently selected from the group consisting of hydrogen, F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)rNH2l -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 194. The compound according to any one of claims 189-193, wherein at least one of the sub- stituents A1aG, A280, A330, A430 and A5ac are different from CH. 195. A compound of the general formula wherein R43* is selected from hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2^alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, each of which may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6 alkyl, C-i-e-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl, and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, F, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ci_6-aIkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, CWalkyl, c1-c6-alkoxy, CWalkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c1-c6io-cycloalkyl, perhalomethyl and perha-lomethoxy; and R5ad, R5ad, R7ad, R8ad and R9ad are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkoxy, C2^-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-1CrcycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alky!, c1-c6-alkoxy, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and Cs-Kj-cycloallcyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Cv 6-alkyl, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-icrcycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkylv c1-c6alkoxy, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d.6-alkyl, c1-c6-alkoxy, (Walkenyl, aryl, heteroaryl, c1-c6-heterocycIyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alky!, c1-c6-alkoxy, C2-6-alkenyl, aryl, heteroaryl* Qj-s-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and perha-lomethoxy; and R10ad are selected from imino, c1-c6-alky!, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c1-c6io-cycloalkyl, each of which may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, Ci-e-alkoxy, C2-6«alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2_e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-to-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, Ct-e-alkoxy, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10 cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, CWalkoxy, C2^-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkoxy, C2-6-alkenyI, aryl, heteroaryl, C3-8-heterocyclyl, C3-i0-cycloalkyl, perhalomethyl and perhalomethoxy; and wherein there'may optionally be a covalent bond between R4** and a substituent selected from R6ad and R7ad; and wherein there may optionally be a covalent bond between the substituents R9ad and R10ad so as to form a 5-membered ring system. 196. The compound according to claim 195, wherein the substituents R0* and R10ad are co- valently bound so as to form a 5-membered ring system. 197. The compound according to claim 196, wherein said 5-membered ring system com prises at least one nitrogen atom in the ring. 198. The compound according to claim 196, wherein said 5-membered ring system contains 5 carbons in the ring. 199. The compound according to any one of claims 195-198, wherein there is a covalent bond between the substituents R4*1 and R7ad. 200. The compound according to any one of claims 195-198, wherein R5ad, R65"1, R7ad and R8ad are independently selected from the group consisting of hydrogen, F, CI, Ci-6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(-0)-OH, -S(=0)2-NH2l -NH-S(=0)2-OH, hydroxy; amino and per-halomethyl. 201. A compound of the general formula wherein E is selected from the group consisting of -0-, -S-, -S(=0)-f -S(=0)2-, -NR16ae- and - CR17aeR1Bae_; and p4ae p5ae p6ae o7ae pBae p9ae n10ae p11ae p12ae p13ae p14ae p15ae p16ae p1"7ae aprl Rl&as arft independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, Ci-e-alkyi, c1-c6-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl and Cs-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, suifo, c1-c6-alkyl, CM-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, suifo, c1-c6-alkyl, C2-6-aIkenyl, aryl, heteroaryl, c1-c6e-heterocycfyl, and Cs-icr cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, suifo, c1-c6-alky!, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocydyl, c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, suifo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, suifo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and CjMD-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, suifo, Ci-e-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, suifo, c1-c6-alky!, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be a covalent bond between any of the substituents selected from R4ae, R5ae, R6afi and R7ae; with the proviso that when R536 and R636 are covaiently bound they do not form a isoquinolin-3-yl or a substituted isoquinolin-3-yl together with the pyridine which they are both bound to; and . wherein there may optionally be a covalent bond between any of the substituents selected from R8a9 P936 p1°a® p11ae p12ae p13ae p14ae n15ae p!6ae p17ae a-j p18ae 202. The compound according to claim 201, wherein there is a covalent bond between R6aB and R7ae. 203. The compound according to claim 201, wherein there is a covalent bond between R5ae and R6ae. 204. The compound according to any one of claims 201-203, wherein at least one of R8ae, pfl* R10ae( pHa^ R12» R13ae R14ae an(j R15ae js se|ected from F> C|, c1-c6-alkyl, d.6-alkOXy, - C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 205. A compound of the general formula wherein R4af, R5*, R6af, R7af( R8af, R9af, R10af, R11af, R12af, R13af, R14af and R15af are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2. e-alkenyl, aryl, heteroaryl, C3-8-heterocyclyI and Cs-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, CWalkyl, c1-c6-aikenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, Ctj-s-heterocyclyl, CiMo-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyi, c1-c6-alkenyl, aryl, heteroaryl, CM-heterocyclyl and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6 alkyl, C2^-alkenyI, aryl, heteroaryl, c1-c6-heterocydyl, and C3-io-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2_6-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, c1-c6io-cycloalkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be a covalent bond between R6af and any of the substituents selected from R5af and R7af; and wherein there may optionally be a covalent bond between the substituents R9af and R10af; and R16af is selected from hydrogen, hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkenyl, C3-8-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2.6-alkenyl, c1-c6-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, Ca-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and Cs-10-cycioalkyl, wherein each of the hydroxy, sulfanyl*. amino, sulfo, c1-c6-alkyl, C2^»alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, QMo-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl9 C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl, and c3-c10cycloalkyl may optionally be substituted with one. or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3_10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalky!, Cae-alkenyl, aryl, heteroaryl, (W heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Cn-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and per-halomethoxy; with the proviso that R16af is not methyl; and wherein there may optionally be a covalent bond between the substituents R12af and R16af. 206. The compound according to claim 205, wherein there is a covalent bond between the substituents R" and R6af. 207. The compound according to any one of claims 205-206, wherein there is a covalent bond between the substituents R9af and R10af. 208. The compound according to any one of claims 205-207, wherein at least one of R8af, R9af, R10af, Rl1af, R12af, R13af, R14af and R15af is selected from F, CI, c1-c6alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2l -NH-S(=0)rOH, hydroxy, amino and perhalomethyl. 209. A compound of the general formula wherein E is selected from the. group consisting of -0-, -S-, -S(=0)-, -S(=0)z- and - CR16agR17ag-; and R4ag, R539, R639, R10ag, R1139, R12ag, R13ag, R16a9 and R17ag are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Ca-io-cycloalkyi, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2^alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cydoalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and CiMo-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C<\s-alkyl, C2-e-alkenyl, aryl, heteroaryl, Cs-a-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-icrcycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Ca.10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, C-^-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6rheterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and perhalomethoxy; with the proviso that R439 is not -CH2-N(CH3)2; and wherein there may optionally be a covalent bond between the substituents R5ag and R6a9; and R739 is selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, cyano, nitro, Ci-s-alkyi, CW alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sul- fanyl, sulfo, c1-c6-alkyl, C2-6-alkenyl, arylt heteroaryl, c1-c6-nexerocyuyi optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and Cs-^-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalky!. C2-e-alkenyIl aryl, heteroaryl, C3-8-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and Cs-io-cyoloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3.10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-alkenyl( aryl, heteroaryl, C3-8-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, c3-c10cycloalkyi, perhalomethyl and perhalomethoxy; R8*9, R9as, R14a9 and R15a9 are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2_6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3. 10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6io-cycloaikyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl, and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyi, C2.e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d^-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocydyl, Cs-io-cycloalkyi, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-alkenyf, aryl, heteroaryl, C3-s-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, C2_6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3-i0-cycloa!kyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6- alkyl, C2-6-alkenyl, heteroaryl, C3-8-heterocyclyl, C3-io-cycloalky[, perhalomethyl and perha-lomethoxy; and wherein there may optionally be a covalent bond between the substituents R9as and R10as; and wherein there may optionally be a covalent bond between the substituents R12a9 and R16a9. 210. The compound according to claim 209, wherein there is a covalent bond between the substituents R5ag and R639. 211. The compound according to any one of claims 209-210, wherein there is a covalent bond between the substituents R9a9 and R10a9. 212. The compound according to any one of claims 209-211, wherein at least one of RBa9, R9a9j plOag^ ^^ R12a9j Ria* R14ag an(j R15ag afe se)ected from F> C[i Q^-alkyl, C-^-alkOXy, - C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)rOH, hydroxy, amino and perhalomethyl. 213. A compound of the general formula wherein R4^, R5ah, R6ah, R7ah, R8ah and R9ah are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-to-cycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^-aikenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalky!, C2„6- alkenyl, aryl, heteroaryl, C3_6-heterocycIyl, and c1-c610-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10 cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6alkyl, CWalkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10 cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6alkyl, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2_e-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, Cs-io-cycloalkyl, perhalomethyl and perhalomethoxy; with the proviso that R53*1 and R6ah are not both CF3; and wherein there may optionally be a covalent bond between any of the substituents selected from R4*, R5ah, R6ah and R7ah; and wherein there may optionally be a covalent bond between the substituents R8ah and R9ah; with the proviso that when R8ah and R9ah together with the carbon to which they are bound forms phenyl then R5ahf R6ah, R7ah and R8ah are not all hydrogen. 214. The compound according to claim 213, wherein there is a covalent bond between R8ah and R9ah. 215.. The compound according to any one of claims 213-214, wherein there is a covalent bond between R6ah and R7ah. 216 . The compound according to any one of claims 213-215, wherein there is a covalent bond between R5ah and R6a217. The compound according to any one of claims 223-226, wherein at least one of R5ah, R6ah, R7ah and R8ah are selected from F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 218. A compound of the general formula R4ai, R**\ R6ai( R7ai, R8ai and R9ai are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2_6-alkenyl, aryl, heteroaryl, C3-e-heterocyclyl and C3-i0-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-e-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3.10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6s-heterocyciyl, and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, CM-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c1-c6io-cycloalkyl, wherein each of the. hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and ^o-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, C2.e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and per-halomethoxy, with the proviso that R4ai is not CHrN(Me)2; and wherein there may optionally be a covalent bond between any of the substituents selected from R4ai, R5ai, R6ai and R7ai; and wherein there may optionally be a covalent bond between the substituents RBai and R9ai; with the proviso that R8*1 and R931 together with the carbon to which they are bound do not form 4-methoxy-phenyl, 4-chloro-phenyl or.4-nitro-phenyl. 219. The compound according to claim 218, wherein there is a covalent bond between R8aj and R93'. 220. The compound according to any one of claims 218-219, wherein there is a covalent bond between R631 and R7ai. 221. The compound according to any one of claims 218-220, wherein there is a covalent bond between R5al and R6a'. 222.: The compound according to any one of claims 218-221, wherein at least one of R5ai, R6aif R7ai and R831 are selected from F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 223. A compound of the general formula wherein R4aj, R5aif R6ai and R7aj are independently selected from amino, cyano, nitro, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of amino, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^-aIkenylf aryl, heteroaryl, C3-s-heterocyclyl, and Qj-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6 alkyl, C2-6-alkenyl, aryl, heteroaryl, Qj-B-heterocyclyl, and Cs.io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, Qwrheterocyclyl, Cs-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and CsMcrcycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Gt-6-alkyI, C2^-alkenyl, aryl, heteroaryl, Qj-B-heterocyclyl, CsMo-cycloalkyl, perhalomethyl and perhaiomethoxy; and wherein there may optionally be a covalent bond between the substituents R4* and R5ai; and wherein there may optionally be a covalent bond between the substituents R6- and R7aj. 224. The compound according to claim 223, wherein there is a covalent bond between R6aj and R7aj. 225. The compound according to claim 224, wherein R6aj, R7aj and said covalent bond are selected so as to form a ring system selected from an optionally substituted piperedine, piperazine, morpholine and thiomorpholine. 226. The compound according to claim 225, wherein said ring system is selected from piperedine, piperazine, morpholine and thiomorpholine 227. The compound according to any one of claims 223-226, wherein there, is a covalent bond between R4aj and R5aj, 228. A compound of the general formula wherein R4*, R5ak, R8* and R7ak are independently selected from amino, cyano, nitro, c1-c6-alkyl, C2.e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Ca-i0-cycloalkyl, wherein each of amino, c1-c6-alkyl, C2^-aikenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyi may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, c1-c6-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and c1-c6io-cycioalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, Cs^-heterocyclyl, and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Ci-e-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloaIkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyi, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloa1kyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6alkyl, C2^-alkenyi, aryl, heteroaryl, C3-8-heterocyclyl and C3.10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and Cs.i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^-aikenylf aryl, heteroaryl, C3^-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy; with the proviso that none of R4akand R5ak are -C(=0)-0-isopropyl; and wherein there may optionally be a covalent bond between the substituents R43* and R5ak; with the proviso that R43*, R531* and the nitrogen to which they are bound do not form a substituted tetrazolyl moiety; and wherein there, may optionally be a covalent bond between the substituents Reak and R7ak; 229. The compound according to claim 228, wherein there is a covalent bond between R6ak and R7ak. 230. The compound according to claim 229, wherein R6a\ R7ak and said covalent bond are selected so as to form a ring system selected from an optionally substituted piperedine, piperazine, morpholine and thiomorpholine. 231. The compound according to claim 230, wherein said ring system is selected from piperedine, piperazine, morpholine and thiomorpholine 232. The compound according to any one of claims 228-231, wherein there is a covalent bond between R43* and R**. 233. A compound of the general formula wherein R481 and R5aI are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2_6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyctyl and C3-io-cycloaIkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2.a-alkenyl, aryl, heteroaryl, C3-B-heterocyclyl, and Cs-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Ct^-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3_10-cycloalkyi may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^-aIkenyl, aryl, heteroaryl, C3.s-heterocyclyI, C&.1Crcycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alky!, C2.e-alkenyl, aryl, heteroaryl, C3-B-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, d-e-alkyl, c1-c6-alkenyl, aryl, heteroaryl, Cs^-heterocyclyl and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, C2-6-aIkenyl, aryl, c3-c10cycloalkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be a covalent bond between R43' and R5aI; with the proviso that R43* and R5al together with the nitrogen to which they are bound do not form 2,5-pyrrolidinedione or an annealed ring system comprising 3 or more rings; and wherein E is selected from the group consisting of -0-, -S-, -S(=0)-, «S(=0)2- and -NR14aI-, -CR15a,R16aIs and Rea R7* Reaf R9d Rioa R«* Ri* R«^ R14* RiM and RiBa» are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-e-heterocyclyl and C3.10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Quo-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6alkyl, c1-c6-alkenyl; aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloaIkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, d-e-alkyl, C2^-alkenyl, aryl, heteroaryl, C3_s-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, CWalkyl, C2_6-aIkenyl, aryl, heteroaryl, C3-5-heterocyclyl, C3-io-cycloaIkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-«ncycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6rheterocyclyl and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Chalky!, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alky!, c1-c6-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl and C3-10-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3.1(rcycloalkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, Qj-io-cyctaalkyl, perhalomethyl and perhalomethoxy; and wherein there may optionally be a covalent bond between the substituents R7al and Rtol; and wherein there may optionally be a covalent bond between the substituents R10al and a sub-stituent selected from R14ai and R15aL 234. The compound according to claim 233, wherein there is a covalent bond between the substituents R431 and R5ai. 235. The compound according to any one of claims 233-234, wherein there is a covalent bond between the substituents R7al and R8al. 236. The compound according to any one of claims 233-235, wherein there is a covalent bond between R10al and a substituent selected from R14aI or R15al. 237. The compound according to any one of claims 233-235, wherein E is -NR14a'-. 238. The compound according to claim 237, wherein R14aI is selected from F, CI, d-e-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)rOH, hydroxy, amino and perftalomethyl. 239. The compound according to any one of claims 233-235, wherein E is -CR15alR16a1-. 240. The compound according to claim 239, wherein R16al is selected from F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 241. The compound according to any one of claims 239-240, wherein R15al is hydrogen. 242. The compound according to any one of claims 233-241, wherein at least one of R6al, R7a\ R8al, R9al, R10al, R11aIf R12al and R13aI are selected from F, CI, c1-c6-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH,-S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 243. A compound of the general formula wherein E is selected from the group consisting of-0-, -S-, -S(=0)-, -S(=0)2- and -NR14am-, -CR15amR16am~; and wherein A1am is N or C-R17am; A23"1 is N or C-R18am; A331" is N or C-R19am; A43"1 is N or OR20""1; and p6am p7am p8am pQam p10am p11am p12am p13am pt4am p15am p16am p17am p18am p19am «nf4 R20am are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, C1_6-alkyl, C2^-alkenyl, aryi, heteroaryl, C3-8-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6nrcydoalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2^-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, C2.B-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloaIkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocycIyI, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and c1-c610-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, c1-c6-alkenyl, aryl, het-: eroaryl, c1-c6-heterocyclyl and C3-io-cycIoalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl,. C2_6-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl, and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6e-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, c3-c10cycloalkyl, perhalomethyl and perhalomethoxy; with the proviso that R17am and R203™ are not both hydroxy; and wherein there may optionally be a covalent bond between R18am and a substituent selected from R17am and R19am; and wherein there may optionally be a covalent bond between the substituents R10am and a substituent selected from R14am and R15am; and wherein there may optionally be a covalent bond between the substituents R7am and R8am. 244. The compound according to claim 243, wherein there is a covalent bond between R1Bam and a substituents selected from R17am and R19am. 245. The compound according to any one of claims 243-244, wherein there is a covalent bond between R10am and a substituent selected from R14am or R15am. 246. The compound according to claim 243, and , wherein E is -NR14am-. 247. The compound according to claim 246, wherein R14am is selected from F, CI, c1-c6-alkyl, c1-c6e-alkoxy, -C(=0)NH2, -NHC(=0)-OH? -S(=0)2-NH2| -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 248. The compound according to claim 243, wherein E is -CR15amR16am-. 249. The compound according to claim 248, wherein R16am is selected from F, CI, d-e-alkyl, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 250. The compound according to any one of claims 248-249, wherein R15am is hydrogen. 251. The compoud according to claim 248, wherein there is a covalent bond between R15am and R16am. 252. The compound according to any one of claims 243-251, wherein at least one of R6am, pTam^ R6am( R9am( plOarr^ pllar^ R12am and R13am gre se|ected from Fj Q|f c1-c6-alkyl, c1-c6-alkOXy, -C(=0)NH2f -NHC(=O)-0H, -S(=0)2-NH2, -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 253. A compound of the general formula wherein E is selected from the group consisting of -0-, -S-, S(rO)~, -S(=0)r and -NR17an-, -CR18anR19an-; and p4an p5an p6an p7an p8an p9an p10an p11an p12an pl3an nUan p15an p16an p17an p18an anf4 R19an are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, Ci-e-alkyI, Cz^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, Ca-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloaIkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Chalky!, C2-e-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and Cs-io-cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6alkyl, C2_e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2-e-alkenyl, aryl, heteroaryl, Ca-s-heterocyclyl, C3-io-cycloalkyl, wherein each of the hydroxy, sulfanyl,. amino, sulfo, Ct-e-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, Ci_6-alkyl, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and Q^o-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, c1-c6alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocydyl and c3-c10cycloalkyl, wherein each of the hydroxy, sulfanyl, amino, sulfo, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, C3^-heterocyclyl, and c3-c10cycioalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano, nitro, sulfo, Cve-alkyl, (Walkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, C3-io-cycloalkyl, perhalomethyl and perhalomethoxy; with the proviso that R43" is not methyl or phenyl; and i wherein there may optionally be a covalent bond between RiaBn and a substituent seiectea from R17an and R1&an; and wherein there may optionally be a covalent bond between the substituents R7an and RBan. 254. The compound according to claim 253, wherein R48" is a substituted heteroaryl. 255. The compound according to claim 254, wherein said substituted heteroaryl is a substituted pyridine. 256. The compound according to any one of claims 253-255, wherein there is a covalent bond between the substituents R7an and R830. 257. The compound according to any one of claims 253-256, wherein there is a covalent bond between R13an and a substituents selected from R17an and R1Ban. 258. The compound according to any one of claims 253-256, wherein E is -NR17an-. 259. The compound according to any one of claims 253-256, wherein E is -CRlBanR19an-. 260. The compound according to claim 259, wherein R19an is selected from F, CI, c1-c6-alkyl, c1-c6alkoxy, -C(=0)NH2) -NHC(=0)-OH, -S(=0)2-NH2, -NH^S(=0)rOH, hydroxy, amino and perhalomethyl. 261. The compound according to any one of claims 259-260, wherein R18an is hydrogen. 262. The compound according to any one of claims 253-261, wherein at least one of R5an, R6an, R7an, R8an, R9an, R10an, R11an, R12an, R13an, R14an, R15an and R16an are selected from F, CI, c1-c6-alkyl, Ci-e-aikoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=OVNH2l -NH-S(=0)2-OH, hydroxy, amino and perhalomethyl. 263. A compound of the general formula wherein R4ao is selected from hydrogen, hydroxy, sulfo, halogen, amino, cyano, nitro, d-e-alkyl, d-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and d-io-cycloalkyl, wherein each of hydroxy, sulfo, amino, d-e-alkyl, d.«-alkenyl, aryl, heteroaryl, d-e-heterocyclyl and d-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, d-e-alkyl, d-e-alkenyl,. aryl, heteroaryl, d-s-heterocyclyl and d-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl* d-e-alkenyl, aryl, heteroaryl, d-e-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, d-e-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and d-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, d-e-alkenyl, aryl, heteroaryl, d-e-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, d-e-alkyl, d-s-alkenyl, aryl, heteroaryl, d-s-heterocyclyl and d-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, d-e-alkenyl, aryl, heteroaryl, d-s-heterocyclyl and d_10-cycloalkyl roay optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, d-e-alkyl, d-e-alkenyl, aryl, heteroaryl, d-e-heterocyclyl and d. to-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-s-alkyl. d-6-alkenyi, aryl, heteroaryl, c1-c6-heterocyclyl and C3.i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, d-e-alkyl, d^-alkenyl, perhalomethyl and perhalomethoxy; and wherein R5ao, RBao, R7a0, R8ao, R9ao, R10ao, R11ao and R12ao are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, d-e-alkyl, d-e-alkenyl, aryl, heteroaryl, d^-heterocyclyl, and d-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, d-s-alkenyl, aryl, heteroaryl, d^rheterocyclyl and d-to-cycloalkyl rnay optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, d-e-alkyl, d-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and d-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-s-alkyl, C2-6-a!kenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6alkyl, C2.6-aIkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyI, wherein each of hydroxy, sulfanyl, sulfo, amino, CWalkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocydyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2_6-alkenyI, aryl, heteroaryl, C3-8-heterocyclyl and C3-icrcycloaIkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-8-beterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, d-e-alkyl, C2-6-alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl and C3-icrcycloalkyI, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloaikyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2-6-a!kenyl, perhalomethyl and perhalomethoxy; with the proviso that any one of R6ao and R8ao is not methyl; and with the further proviso that R430, R530, R6ao, R7ao and R890 are not all hydrogen; and wherein there may optionally be a covalent bond beween R430 and R6a0; and wherein there may optionally be a covalent bond between R7ao and R8ao; and wherein there may optionally be. a covalent bond between R9ao and R10ao. 264. The compound according to claim 263, wherein R5a0, R6ao, R7ao and R8ao are independently selected from hydrogen and fluor. 265. The compound according to any one of claims 263-264, wherein R9ao, R10ao, R11a0 and R12ao are independently selected from hydrogen and fluor. 266. A compound of the general formula wherein R1ap and R23*5 are independently selected from Cnj-alkyl, C2^-aIkenyI, aryl, heteroaryl, CWheterocyclyl, and C3-io-cycloalkyl, herein each of Chalky!, C2_6-aIkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c1-c6io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6alkyl, C2^alkenyl, aryl, heteroaryl, C3.B-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, nitro, c1-c6-alkyl, C2„ralkenyl, aryl, heteroaryl, C3-8-heterocyc!yl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, CW-heterocycIyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2.6-alkenyi, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, perhalomethyl and perhalomethoxy; with the proviso that if R1ap and R28* are identical then they are not methyl or ethyl; and wherein there may optionally be a covalent bond between the substituents R1ap and R23*3; and wherein R5ap, R6ap and R7ap are independently selected from hydrogen and F; and wherein R4^ is selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, d^-alky!, C2^alkenyl, aryl, heteroaryl, Cs-s-heterocyclyl, and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6-aIkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Chalky!, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, Q^-heterocyclyl and C3. 10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2_e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyi, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alky!, C2^-alkenyl, aryl, heteroaryl, C3^-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, Cs-e-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, d-e-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6icrcycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6~alkenyl, aryl, heteroaryl, Qj-a-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, Ca-e-alkenyl, perhalomethyl and perhalomethoxy; with the proviso that R4^ is not methyl. 267. The compound according to claim 266, wherein R1ap and R2ap are not identical. 268. A compound of the general formula wherein R1aq and R2** are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-oycloaIkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alky!, C2.5-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, C3-e-heterocyclyl and C3-io-cycloaIkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C«-alkyl, (Walkenyi, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Ci_6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6s-heterocyclyl and C3. io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Ci-e-alkyI, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3_io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, d-e-alkyl, c1-c6alkenyl, perha-lomethyl and perhalomethoxy; with the proviso that R1aq and R23" are not both methyl; and wherein there may optionally be a covalent bond between R1aq and R2^; and wherein R4aq, R5aq, R6aq, R7aq, R8aq, R9aq, R10aq and R11ao are indenpendently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6alkyl, c1-c6-alkenyl, aryl, heteroaryl, Q^rheterocyclyl, and Cs-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocydyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Ct-e-alkyI, C2.6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkenyi, aryl, heteroaryl, Cwrheterocyclyl and C3. 10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C-^-alkyl, C2^-alkenyl, aryl, heteroaryl, C3-6-heterocyc!yl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c3-c10cycioalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6alkyl. C2-e-alkenyl, aryl, heteroaryl, c1-c6r heterocyclyl and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2.6-alkenyl, aryl, heteroaryl, C3_g-heterocycIyl and C3-«rcycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3. 10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2-6-aIkenyl, perhalomethyl and perhalomethoxy; and 1 wherein there may optionally be a covalent bond between R4*1. and R5aq; and wherein R3aq is selected from the group consisting of-C(=0)-, -C(=0)NH-, -CH2-, -CH2CH2-, -CHF-, «CH2CHF-, -CHFCHr, -NH-, -S(=0)2-NH-, -NH-S(=0)r, -NHC(=0)-, -0-, -S-, -S(=0> . -S(=0)2-; and wherein there may optionally be a covalent bond between two substituents selected from R**, R9aq, R10aq and R11a0. 269. The compound according to claim 268, wherein there is one covalent bond between the substituents R1aq and R2^. 1 270. The compound according to any one of claims 268-269, wherein R4^, R5aq, R6aq and R7aq are independently selected from hydrogen and fluor. 271. The compound according to any one of claims 268-270, wherein R3^ is selected from -0-, -S-, -CHr, -CH2CHr, -NH-, -NH-C(=0)-, -C(=0)-NH-( -S(=0)2-NH- and -NH~S(=0)2-. 272. A compound of the general formula wherein A1ar is N or C-R10ar; and A2* is N or C-R11ar; and A3ar is N or C-R12ar; and wherein R1ar, R23', R3ar, R48', R5ar, R6ar, R7ar, R8ar, R93', R10ar, R11ar and R12ar are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2. e-alkenyl, aryl, heteroaryl, c1-c68-heterocyclyl, and C3-io-cycloaIkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alky!, c1-c6-alkenyl, aryl, heteroaryl, C3_8-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, (^-alkenyl, aryl, heteroaryl, C3^-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Cn^-alkyl, Ca^-alkenyl, aryl, heteroaryl, c1-c6rheterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyt, C2-e-alkenyl, aryl, heteroaryl, C3_8-heterocyclyl and c1-c6io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Chalky!, (Walkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3. 10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2^-aIkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and c1-c6io-cycloalkyl may optionally be substituted with one or more, substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alky!, CWalkenyl, perhalomethyl and perhalomethoxy; with the proviso that if R1ar and R231" are identical then they are not methyl or ethyl; and wherein there may optionally be a covalent bond between R1ar and R23*". 273. The compound according to claim 272, wherein R9ar is S(=0)2-R13ar or C(=0)-R13ar; and wherein R13ar is selected from hydroxy, sulfanyl, sulfo, amino, Chalky!, C2-6-aIkenylf aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Ci-e-alkyI, C2^-a!kenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Ci-e-alkyI, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, Qj-s-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-aikyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl* sulfo, amino, c1-c6-alkyl, C2-e-alkenyl, aryl, heteroaryl, C3-a-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Ci-e-alkyI, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl and c1-c6trcycioaikyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloaIkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2.6-alkenyl, perhalomethyl and perhalomethoxy 274. The compound according to any one of claims 272-273, wherein R1ar and R291" are not identical. 275. The compound according to any one of claims 272-274, wherein there is a covalent bond between the substituents R1ar and R231". 276. A compound of the general formula wherein R1as, R285, R383, R4as, R5as, R6as, R7as, R8as and R938 are independetly selected from hydrogen and fluon and wherein R10as is selected from aryl and heteroaryl, which is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cydoalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Chalky!, Cs-e-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl and CsMo-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2^-aIkenyl, aryl, heteroaryl, C3^heterocyclyl and C3-1Crcycloalkyl may optionally be substituted with one. or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-aikyl, c1-c6-alkenyi, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Qs-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C1^-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6rheterocyclyl and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6»alkenyl, aryl, heteroaryl, c1-c6rheterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Chalky!, C2-e-aIkenyl, perhalomethyl and perhalomethoxy; and wherein R12as is selected from hydrogen, hydroxy, sulfanyl, sulfo, amino, cyano, c1-c6-alkyl, C2. e-alkenylr aryl, heteroaryl, c1-c6heterocyclyl, and C3_10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyi, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10 cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Ci-e-alkyi, C2^-alkenyl, aryl, heteroaryl, CM-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alky!, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxof halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and C3-i0-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Ci-e-alkyI, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and CsMo-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alky!, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^alkenyl, aryl, heteroaryl, C3-8-heterocyciyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-alkenyl, aryl, heteroaryl, C3-e-heterocyclyl and CsMo-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, c1-c6-alkenyl, perhalomethyl and perhalomethoxy; and wherein R13as, R14as, R15as and R16as are independently selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl, and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocycIyl and c3-c10cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, C3-a-heterocyclyl and c1-c6 10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6alkyl, C2^-alkenyl, aryl, heteroaryl, C3_e-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, d-e-alkyl, C2^-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and Cs-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d-e-alkyl, C2_6-alkenyI, aryl, heteroaryl, c1-c6-heterocyclyl and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Chalky!. C2.6-alkenyl, aryl, heteroaryl, Cs-8-heterocyclyl and C3-io-cycloaIkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, c1-c6-aikenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C$. 1crcycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Ci-e-alkyI, C2^-alkenyl, aryl, heteroaryl, C3_s-heterocyclyl and C3-io-cycioaIkyl, wherein each of hydroxy, sulfanyl, ilfo, amino, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl ay optionally be substituted with one or more substituents independently selected from hy-oxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, perha-methyl and perhalomethoxy; with the proviso that Rt2as, R13as, R14as, R15as and R16as are not I hydrogen; and herein there may optionally be a covalent bond between the substituents R13as and R14as. 77. The compound according to claim 276, wherein R13as, R14as, R15as and R16as are inde- endently selected from hydrogen and fluor. 78. A compound of the general formula wherein R5*, R6at, R7at R8al, R9at, R10at R11at, R12a\ R13at R14at, R15at, R16at, R17al and R18al are independently selected from hydrogen and fluor, and wherein R4at is selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, nitro, Ci_6-alkyl, C2.6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and C3-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3.10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, d^-alkyl, C2_6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-10-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, Q^e-alkeny!, aryl, heteroaryl, c1-c6-heterocyclyl and Cs-io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2^-alkenyt, aryl, heteroaryl, c1-c6-heterocyclyl and C3-i0-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, het- eroaryl, C-^-heterocydyl and Gs-io-cycloalkyi, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alky!, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl may op* tionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfb, oxo, halogen, amino, cyano, nitro, d-e-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6a-heterocyclyl and C3-to-cycloalkyl( wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nrtro, c1-c6-alkyl, C2-6-alkenyl, perhalomethyl and perhalomethoxy; and wherein R19at is selected from hydrogen, hydroxy, sulfanyl, sulfo, halogen, amino, cyano, C% e-alkyl, c1-c6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl, and CMo-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and Quo-cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, Ci-6-alkyl, C2-e-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and c3-c10 cycloalkyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2_6-alkenyl, aryl, heteroaryl, C«-heterocyclyl and C3.io-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2-6-alkenyl, aryl, heteroaryl, c1-c6-heterocyclyl and C3-io-cycloaikyl may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, c1-c6-alkyl, C2^-alkenyl, aryl, heteroaryl, C3-s-heterocyclyl and c3-c10cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, c1-c6-alkyl, C2^-alkenyI, aryl, heteroaryl, C3-B-heterocyclyl and C3-10-cycloaIkyI may optionally be substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, fluor, iodine, amino, cyano, nitro, c1-c6-alkyl, C2-e-aIkenyl, aryl, heteroaryl, C3-8-heterocycly! and C3-io-cycloalkyl; with the proviso that R19at is not methoxy. 279. The compound according to claim 278, wherein R5a\ R6*, R7at R8al, R9at, R10at R11at, R12at, R13at R14* R1S* R1M R17at and R18at ape aj( hydrogen. 280. The compound according to any one of claims 278-279, wherein R4at is an optionally substituted aryl or heteroaryl. 281. The compound according to any one of claims 1-280, wherein said compound com prises only one F. 282. The compound according to any one of claims 1-280, wherein said compound com prises two F and preferably three F. 283. The compound according to any one of claims 1-280, wherein said compound com prises a CF3 moiety. 284. The compound according to any one of claims 1-283, wherein said compound comprises a hydrophilic substituent selected from the group consisting of hydroxy, amino, c1-c6-alkoxy, -C(=0)NH2, -NHC(=0)-OH, -S(=0)2-NH2, -NHS(=0)2-OH, -NHC(=0)-R1am, -NHS(=0)2-R1an\ -N(R1am)C(=0)-R2am, -N(R1am)S(=0)2-R2aml wherein R1am and R2"" are independently selected from Chalky!. 285. The compound according to any one of claims 1-283, wherein said compound comprises a moiety selected from the group consisting of £ The compound according to any one of claims 1-297, which has an IC50 value of no greater than 5 μM as determined by the assay 3190.2 or 3180.1 disclosed herein. 299. The compound according to claim 298, which has an IC5o value of less than 1 μmt preferably less than 500 nM, preferably less than 100 nM, preferably less than 50 nM, more preferable less than 25 nM, more preferable less than 10nM and even more preferable less than 5 nM as determined by the assay 3190.2 or 3180.1 disclosed herein. 300. The compound according to any one of claims 1-299, which is ionized at pH 7.0 301. The compound according to claim 300, which has a pKa in the range from 8 to 12, preferable from 9 to 12, more preferable from 10 to 12. 302. The. compound according to any one of claims 1-301, which has a molar weight of no greater than 1000 D. 303. The compound according to claim 302, which has a molar weight of less than 750 D, preferably less than 500 D, more preferable less than 400 D, more preferable less than 300D and even more preferably less than 250 D. 304. A process for the preparation of a compound according to any one of claims 1-303 or its pharmaceutical^ acceptable salt, which comprises reacting the appropriate alcohol, Rz-OH, with the appropriate carbamovlating reagent, Lv-C(=0)-NRxRy, in a solvent according to the 306. The process according to any one of claims 304-305, wherein said solvent is selected from the group consisting of tetrahydrofurane, dimethylformamide and N-methylpyrolidone. 307. The process according to any one of claims 304-306, wherein said base is selected from the group consisting of triethylamine, N,N-diisopropyl-N-ethyIamine and DABCO. 308. A process for the preparation of a compound according to the general formula wherein R1 is selected from C1-8alkyl, C2-6-alkenyl and C3-1o-cycloalkyl, each of which is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, oxo, halogen, amino, cyano and nitro; and R2 is selected from C3-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, each of which is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6alkyl, C2-6-alkenyl, aryl, heteroaryl, C308-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C1-6-alkyl, C2-6-aIkenyl( aryl, heteroaryl, C3-C6-heterocyclyl and C3-10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C3-C6-alkyl, C3-C6-alkenyl, aryl, heteroaryl, C3-6-heterocyclyl and C3-io-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C3-C6 -aHcyl, C2-C6-alkenyI, aryl, heteroaryl, C3-C6-heterocyclyl and C3-C61o-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C3-C6-alkyl, C2-6-alkenyl, aryl, heteroaryl, C3-C6-heterocyclyl and C3-10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C1-6-alkyI, C2-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyI and C3- 1o-cycloalkylf wherein each of hydroxy, sulfanyl, sulfo, amino, C3-C6-alkyl, C2-6-aIkenyl, aryl, heteroaryl, C3-C6-heterocyclyl and C3-C60-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl,. sulfo, oxo, halogen, amino, cyano, nitro, C1-6alkyl, C2-C6alkenyl, perhalomethyl and perhalomethoxy; and wherein R2 is optionally covalently bound to R1 by an ether, thioether, C-C or C-N bond, to form a ring system with the N-atom to which R1 and R2 are bound; and R3 is. selected from hydroxy, sulfanyl, sulfo, amino, C3-C6-alkyl, C2.6-alkenyI, aryl, heteroaryl, C3-8-heterocyclyl and C3-io-cycloalkyl, each of which is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C1-6-alkyl, C2-e-aIkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-C10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-C6-alkyl, C2_6-alkenyl, aryl, heteroaryl, C3-8-heterocydyl and C3-C6io-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C3-C6-alkyl, C2.6-alkenylf aryl, heteroaryl, C3-B-heterocyclyl and C3-C10-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, C1-6-alkyl, C2-C6-aIkenyI, aryl, heteroaryl, C3-C6-heterocyclyl and C3-C10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C1-6-alkyl, C2_6-alkenyl, aryl, heteroaryl, C3-C6-heterocyclyl and C3-10-to-cycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Ci_e-alkyl, CWafkenyl, aryl, heteroaryl, C3-C6-heterocyclyl and C3-C10-cycloalkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C3-C6alkyl, C1-6-alkenyl, aryl, heteroaryl, C3-8-heterocyclyl and C3-C6nrcycloalkyl, wherein each of hydroxy, sulfanyl, sulfo, amino, Curalkyl, C2-6-aikenyl, aryl, heteroaryl, Cs-s-heterocyclyl and C3-1o-cycloaIkyl is optionally substituted with one or more substituents independently selected from hydroxy, sulfanyl, sulfo, oxo, halogen, amino, cyano, nitro, C3-C6-alkyl, C2-6-alkenyl, perhalomethyl and perhalomethoxy; and X is O or S; or a compound according to any one of claims 1-303; or a pharmaceutically acceptable, salt thereof; said process comprising the treatment of the appropriate amine, R1-NH-R2, with the appropriate acylating reagent Y-C(=X)-R3, in a solvent and in the presence of a base according to the reaction scheme P2 309. The process, according to claim 308, wherein Y is CI. 310. The process according to any one of claims 307-309, wherein R3 is an aryloxy group. 311. The process according to any one of claims 308-310, wherein said solvent is selected from the group consisting of diethyl ether, tetrahydrofuran and dichloromethane. 312. The process according to any one of claims 308-311, wherein said base is selected from the group consisting of trimethylamine, triethylamine, etbyl-diisopropyl-amine and 1,4-diazabicyclo[2.2.2]octane. 313. The process according to any one of claims 308-311, wherein said base is present as a functionality in one or both of the substituents R1 and R2, thus forming a salt with the acid H- Y. 314.. A pharmaceutical composition comprising a compound as defined in any one of claims 1-303 or a pharmaceuticaliy acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent 315. The composition according to claim 314, wherein said composition is in unit dosage form, comprising from about 0.05 to about 2000. mg, preferably from about 0.1 to about 500 mg and even more preferable from about 1.0 to about 100 mg of the compound according to any one of claims 1-303 or pharmaceuticaliy acceptable salt thereof. 316. A pharmaceutical composition for use as a medicament for inhibiting the lipolytic activity of hormone-sensitive lipase against triacylglycerols, diacylglycerois, cholesterol acyl esters or steroid acyl esters, said composition comprising a compound according to any one of claims 1-303 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent. 317 A pharmaceutical composition according to any one of claims 314-316, which is for oral administration. 318. A pharmaceutical composition according to any one of claims 314-316 for nasal, transdermal, pulmonal, or parenteral administration. 319. Use of a compound according to any one of claims 1-303 for preparation of a medicament for inhibition of the lipolytic activity of hormone-sensitive lipase against triacylglycerols, diacylglycerols, cholesterol acyl esters or steroid acyl esters. 320. The use according to claim 319, wherein a further antidiabetic, antiobesity, antihypertensive or appetite regulating drug is used. 321. Use of a compound according to any one of claims 1 -303 for the preparation of a medicament for the treatment of any disorder where it is desirable to modulate the plasma level of free fatty acids, glycerol, LDL-cholesterol, HDL-cholesterol, insulin and/or glucose; and/or modulate intracellular triacylglycerol and cholesterol ester stores, intracellular level of fatty acids, fatty acid esters such as diacylglycerols, phosphatidic acids, long chain acyl-CoA's. as well as citrate or malonyl-CoA; and/or increase insulin sensitivity in adipose tissue, skeletal muscle, liver or pancreatic (3 cells; and/or modulate insulin secretion from pancreatic p cells. 322. The use according to claim 321, wherein said disorder is selected from the group con sisting of insulin resistance, diabetes type 1 and 2, metabolic syndrome X, impaired glucose tolerance, hyperglycemia, dyslipidemia, obesity, abnormalities of lipoprotein metabolism and any combination thereof. 323. Use of a compound according to any one of claims 1-303 or a pharmaceutically accept able salt thereof for the preparation of a medicament 324. A method of treating a disorder of a patient where modulation of the activity of hormone- sensitive lipase is desired, the method comprising administering to said patient an effective amount of a compound according to any one of claims 1-303 or a pharmaceutically acceptable salt thereof. 325. The method according to claim 324, wherein said administration is carried out by the oral, nasal, transdermal, pulmonal, or parenteral route. 326. The method according to any one of claims 324-325, wherein said disorder is selected from the group consisting of insulin resistance, diabetes type 1 and 2, metabolic syndrome X, impaired glucose tolerance, hyperglycemia,, dyslipidemia, obesity, abnormalities of lipopro tein metabolism and any combination thereof.